10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-14-299064.txt : 20140807 0001193125-14-299064.hdr.sgml : 20140807 20140807060408 ACCESSION NUMBER: 0001193125-14-299064 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20140807 DATE AS OF CHANGE: 20140807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900031917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36457 FILM NUMBER: 141021626 BUSINESS ADDRESS: STREET 1: 7327 OAK RIDGE HWY STREET 2: SUITE B CITY: KNOXVILLE STATE: TN ZIP: 37931 BUSINESS PHONE: 865-769-4011 MAIL ADDRESS: STREET 1: 7327 OAK RIDGE HWY STREET 2: SUITE B CITY: KNOXVILLE STATE: TN ZIP: 37931 FORMER COMPANY: FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020417 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 10-Q 1 d754969d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2014

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-36457

PROVECTUS BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

90-0031917

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

7327 Oak Ridge Highway, Suite A,

Knoxville, Tennessee

37931

(Address of principal executive offices)

(Zip Code)

866-594-5999

(Registrant’s telephone number, including area code)

N/A

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ¨ Yes x No

The number of shares outstanding of the registrant’s common stock, par value $.001 per share, as of June 30, 2014 was 176,638,439.

TABLE OF CONTENTS



PART I FINANCIAL INFORMATION

Cautionary Note Regarding Forward-Looking Statements			2
Item 1. Financial Statements (unaudited)			3
Condensed Consolidated Balance Sheets			3
Condensed Consolidated Statements of Operations			4
Condensed Consolidated Statements of Stockholders’ Equity			5
Condensed Consolidated Statements of Cash Flow			10
Notes to Condensed Consolidated Financial Statements			12
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			17
Item 3. Quantitative and Qualitative Disclosures About Market Risk			20
Item 4. Controls and Procedures			20

PART II OTHER INFORMATION

Item 1. Legal Proceedings			21
Item 1A. Risk Factors			22
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			25
Item 3. Defaults Upon Senior Securities			25
Item 4. Mine Safety Disclosures			25
Item 5. Other Information			25
Item 6. Exhibits			26

SIGNATURES			27

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations and express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this Quarterly Report on Form 10-Q, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013, as supplemented by the risk factors disclosed in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, and elsewhere in this Quarterly Report on Form 10-Q), and the following:

•

our determination, based on guidance from the FDA, whether to proceed with or without a partner with a phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma and the costs associated with such a trial if it is necessary;

•

our determination whether to license PV-10, our melanoma drug product candidate, and other solid tumors such as liver cancer, if such licensure is appropriate considering the timing and structure of such a license, or to commercialize PV-10 on our own to treat melanoma and other solid tumors such as liver cancer;

•

our ability to license our dermatology drug product candidate, PH-10, on the basis of our phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed in conjunction with mechanism of action studies; and

•

our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to commercialization.

PART I FINANCIAL INFORMATION

ITEM

1. FINANCIAL STATEMENTS

PROVECTUS BIOPHARMACEUTICALS, INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30, 2014 (Unaudited)			December 31, 2013 (Audited)
Assets
Current Assets
Cash and cash equivalents	$	18,126,036		$	15,696,243

Total Current Assets		18,126,036			15,696,243
Equipment and furnishings, less accumulated depreciation of $432,763 and $429,331, respectively		26,681			30,113
Patents, net of amortization of $7,796,177 and $7,460,617, respectively		3,919,268			4,254,828
Other assets		27,000			27,000

	$	22,098,985		$	20,008,184

Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable — trade	$	479,857		$	348,869
Accrued consulting expense		104,042			61,282
Other accrued expenses		232,568			102,795

Total Current Liabilities		816,467			512,946
Long-Term Liability
Warrant liability		1,302,961			12,866,572

Total Liabilities		2,119,428			13,379,518

Stockholders’ Equity
Preferred stock; par value $.001 per share; 25,000,000 shares authorized; Series A 8% convertible preferred stock, 0 and 33,334 shares issued and outstanding, respectively, liquidation preference $0.75 (for 2013 in aggregate $25,001)		—			33
Common stock; par value $.001 per share; 300,000,000 authorized; 176,638,439 and 159,751,724 shares issued and outstanding, respectively		176,638			159,752
Paid-in capital		173,164,422			152,519,701
Deficit accumulated during the development stage		(153,361,503	)		(146,050,820	)

Total Stockholders’ Equity		19,979,557			6,628,666

	$	22,098,985		$	20,008,184

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Three Months Ended June 30, 2014			Three Months Ended June 30, 2013			Six Months Ended June 30, 2014			Six Months Ended June 30, 2013			Cumulative Amounts from January 17, 2002 (Inception) Through June 30, 2014
Revenues
OTC product revenue	$	—		$	—		$	—		$	—		$	25,648
Medical device revenue		—			—			—			—			14,109

Total revenues					—									39,757
Cost of sales		—			—			—			—			15,216

Gross profit		—			—			—			—			24,541
Operating expenses
Research and development		1,025,535			778,349			2,183,418			1,518,865			48,877,826
General and administrative		2,966,569			2,340,706			6,022,513			4,679,109			80,969,666
Amortization		167,780			167,780			335,560			335,560			7,796,177

Total operating loss		(4,159,884	)		(3,286,835	)		(8,541,491	)		(6,533,534	)		(137,619,128	)
Gain on sale of fixed assets		—			—			—			—			55,075
Loss on extinguishment of debt		—			—			—			—			(825,867	)
Investment income		1,443			256			2,816			283			657,358
(Loss) gain on change in fair value of warrant liability		3,515,025			909,206			1,227,992			(14,304	)		(7,530,937	)
Net interest expense		—			—			—			—			(8,098,004	)

Net loss		(643,416	)		(2,377,373	)		(7,310,683	)		(6,547,555	)		(153,361,503	)
Dividends on preferred stock		—			(73,024	)		—			(1,149,958	)		(12,026,710	)

Net loss applicable to common shareholders	$	(643,416	)	$	(2,450,397	)	$	(7,310,683	)	$	(7,697,513	)	$	(165,388,213	)

Basic and diluted loss per common share	$	(0.00	)	$	(0.02	)	$	(0.04	)	$	(0.06	)

Weighted average number of common shares outstanding — basic and diluted		175,554,000			127,114,868			172,225,322			123,926,235

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

(A Development-Stage Company)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)


	Preferred Stock				Common Stock
	Number of Shares		Par Value		Number of Shares			Par Value			Paid in capital			Accumulated Deficit			Total
Balance, at January 17, 2002		—	$	—		—		$	—		$	—		$	—		$	—
Issuance to founding shareholders		—		—		6,000,000			6,000			(6,000	)		—			—
Sale of stock		—		—		50,000			50			24,950			—			25,000
Issuance of stock to employees		—		—		510,000			510			931,490			—			932,000
Issuance of stock for services		—		—		120,000			120			359,880			—			360,000
Net loss for the period from January 17, 2002 (inception) to April 23, 2002 (date of reverse merger)		—		—		—			—			—			(1,316,198	)		(1,316,198	)

Balance, at April 23, 2002		—	$	—		6,680,000		$	6,680		$	1,310,320		$	(1,316,198	)	$	802
Shares issued in reverse merger		—		—		265,763			266			(3,911	)		—			(3,645	)
Issuance of stock for services		—		—		1,900,000			1,900			5,142,100			—			5,144,000
Purchase and retirement of stock		—		—		(400,000	)		(400	)		(47,600	)		—			(48,000	)
Stock issued for acquisition of Valley Pharmaceuticals		—		—		500,007			500			12,225,820			—			12,226,320
Exercise of warrants		—		—		452,919			453			—			—			453
Warrants issued in connection with convertible debt		—		—		—			—			126,587			—			126,587
Stock and warrants issued for acquisition of Pure-ific		—		—		25,000			25			26,975			—			27,000
Net loss for the period from April 23, 2002 (date of reverse merger) to December 31, 2002		—		—		—			—			—			(5,749,937	)		(5,749,937	)

Balance, at December 31, 2002		—	$	—		9,423,689		$	9,424		$	18,780,291		$	(7,066,135	)	$	11,723,580
Issuance of stock for services		—		—		764,000			764			239,036			—			239,800
Issuance of warrants for services		—		—		—			—			145,479			—			145,479
Stock to be issued for services		—		—		—			—			281,500			—			281,500
Employee compensation from stock options		—		—		—			—			34,659			—			34,659
Issuance of stock pursuant to Regulation S		—		—		679,820			680			379,667			—			380,347
Beneficial conversion related to convertible debt		—		—		—			—			601,000			—			601,000
Net loss for the year ended December 31, 2003		—		—		—			—			—			(3,155,313	)		(3,155,313	)

Balance, at December 31, 2003		—	$	—		10,867,509		$	10,868		$	20,461,632		$	(10,221,448	)	$	10,251,052
Issuance of stock for services		—		—		733,872			734			449,190			—			449,923
Issuance of warrants for services		—		—		—			—			495,480			—			495,480
Exercise of warrants		—		—		132,608			133			4,867			—			5,000
Employee compensation from stock options		—		—		—			—			15,612			—			15,612
Issuance of stock pursuant to Regulation S		—		—		2,469,723			2,469			790,668			—			793,137
Issuance of stock and warrants pursuant to Regulation D		—		—		1,930,164			1,930			1,286,930			—			1,288,861
Beneficial conversion related to convertible debt		—		—		—			—			360,256			—			360,256


	Preferred Stock				Common Stock				Paid in capital			Accumulated Deficit			Total
	Number of Shares		Par Value		Number of Shares		Par Value		Paid in capital			Accumulated Deficit			Total
Issuance of convertible debt with warrants		—		—		—		—		105,250			—			105,250
Repurchase of beneficial conversion feature		—		—		—		—		(258,345	)		—			(258,345	)
Net loss for the year ended December 31, 2004		—		—		—		—		—			(4,344,525	)		(4,344,525	)

Balance, at December 31, 2004		—	$	—		16,133,876	$	16,134	$	23,711,540		$	(14,565,973	)	$	9,161,701
Issuance of stock for services		—		—		226,733		227		152,058			—			152,285
Issuance of stock for interest payable		—		—		263,721		264		195,767			—			196,031
Issuance of warrants for services		—		—		—		—		1,534,405			—			1,534,405
Issuance of warrants for contractual obligations		—		—		—		—		985,010			—			985,010
Exercise of warrants and stock options		—		—		1,571,849		1,572		1,438,223			—			1,439,795
Employee compensation from stock options		—		—		—		—		15,752			—			15,752
Issuance of stock and warrants pursuant to Regulation D		—		—		6,221,257		6,221		6,506,955			—			6,513,176
Debt conversion to common stock		—		—		3,405,541		3,405		3,045,957			—			3,049,362
Issuance of warrants with convertible debt		—		—		—		—		1,574,900			—			1,574,900
Beneficial conversion related to convertible debt		—		—		—		—		1,633,176			—			1,633,176
Beneficial conversion related to interest expense		—		—		—		—		39,529			—			39,529
Repurchase of beneficial conversion feature		—		—		—		—		(144,128	)		—			(144,128	)
Net loss for the year ended 2005		—		—		—		—		—			(11,763,853	)		(11,763,853	)


	Preferred Stock				Common Stock				Paid in capital		Accumulated Deficit			Total
	Number of Shares		Par Value		Number of Shares		Par Value		Paid in capital		Accumulated Deficit			Total
Balance, at December 31, 2005		—	$	—		27,822,977	$	27,823	$	40,689,144	$	(26,329,826	)	$	14,387,141
Issuance of stock for services		—		—		719,246		719		676,024		—			676,743
Issuance of stock for interest payable		—		—		194,327		195		183,401		—			183,596
Issuance of warrants for services		—		—		—		—		370,023		—			370,023
Exercise of warrants and stock options		—		—		1,245,809		1,246		1,188,570		—			1,189,816
Employee compensation from stock options		—		—		—		—		1,862,456		—			1,862,456
Issuance of stock and warrants pursuant to Regulation D		—		—		10,092,495		10,092		4,120,329		—			4,130,421
Debt conversion to common stock		—		—		2,377,512		2,377		1,573,959		—			1,576,336
Beneficial conversion related to interest expense		—		—		—		—		16,447		—			16,447
Net loss for the year ended 2006		—		—		—		—		—		(8,870,579	)		(8,870,579	)

Balance, at December 31, 2006		—	$	—		42,452,366	$	42,452	$	50,680,353	$	(35,200,405	)	$	15,522,400
Issuance of stock for services		—		—		150,000		150		298,800		—			298,950
Issuance of stock for interest payable		—		—		1,141		1		1,257		—			1,258
Issuance of warrants for services		—		—		—		—		472,635		—			472,635
Exercise of warrants and stock options		—		—		3,928,957		3,929		3,981,712		—			3,985,641
Employee compensation from stock options		—		—		—		—		2,340,619		—			2,340,619
Issuance of stock and warrants pursuant to Regulation D		—		—		2,376,817		2,377		1,845,761		—			1,848,138
Debt conversion to common stock		—		—		490,000		490		367,010		—			367,500
Net loss for the year ended 2007		—		—		—		—		—		(10,005,631	)		(10,005,631	)

Balance, at December 31, 2007		—	$	—		49,399,281	$	49,399	$	59,988,147	$	(45,206,036	)	$	14,831,510
Issuance of stock for services		—		—		350,000		350		389,650		—			390,000
Issuance of warrants for services		—		—		—		—		517,820		—			517,820
Exercise of warrants and stock options		—		—		3,267,795		3,268		2,636,443		—			2,639,711
Employee compensation from stock options		—		—		—		—		1,946,066		—			1,946,066
Net loss for the year ended 2008		—		—		—		—		—		(10,269,571	)		(10,269,571	)

Balance, at December 31, 2008		—	$	—		53,017,076	$	53,017	$	65,478,126	$	(55,475,607	)	$	10,055,536
Issuance of stock for services		—		—		796,012		796		694,204		—			695,000
Issuance of warrants for services		—		—		—		—		1,064,210		—			1,064,210
Exercise of warrants and stock options		—		—		3,480,485		3,480		2,520,973		—			2,524,453
Employee compensation from stock options		—		—		—		—		870,937		—			870,937
Issuance of stock and warrants pursuant to Regulation D						10,116,653		10,117		6,508,571		—			6,518,688
Net loss for the year ended 2009		—		—		—		—		—		(12,322,314	)		(12,322,314	)

Balance, at December 31, 2009		—	$	—		67,410,226	$	67,410	$	77,137,021	$	(67,797,921	)	$	9,406,510
Issuance of stock for services		—		—		776,250		776		855,837		—			856,613
Issuance of warrants for services		—		—		—		—		1,141,593		—			1,141,593
Exercise of warrants and stock options		—		—		3,491,014		3,491		3,100,189		—			3,103,680
Issuance of common stock pursuant to Regulation S		—		—		559,000		559		418,691		—			419,250
Issuance of common stock and warrants pursuant to Regulation D		—		—		11,168,067		11,169		6,335,820		—			6,346,989


	Preferred Stock						Common Stock				Paid in capital			Accumulated Deficit			Total
	Number of Shares			Par Value			Number of Shares		Par Value		Paid in capital			Accumulated Deficit			Total
Issuance of preferred stock and warrants pursuant to Regulation D		13,283,324			13,283			—		—		4,204,107			—			4,217,390
Preferred stock conversions into common stock		(7,893,326	)		(7,893	)		7,893,326		7,893		—			—			—
Employee compensation from stock options		—			—			—		—		3,759,650			—			3,759,650
Net loss for the year ended 2010		—			—			—		—		—			(18,552,102	)		(18,552,102	)

Balance, at December 31, 2010		5,389,998		$	5,390			91,297,883	$	91,298	$	96,952,908		$	(86,350,023	)	$	10,699,573
Issuance of stock for services		—			—			350,000		350		332,400			—			332,750
Issuance of warrants for services		—			—			—		—		945,116			—			945,116
Exercise of warrants and stock options		—			—			7,185,522		7,185		6,616,126			—			6,623,311
Issuance of common stock and warrants pursuant to Regulation D		—			—			9,905,062		9,905		7,031,334			—			7,041,239
Sale of non-controlling interest in Pure-ific Corporation and warrants		—			—			—		—		443,500			—			443,500
Preferred stock conversions into common stock		(1,858,333	)		(1,859	)		1,858,331		1,859		—			—			—
Employee compensation from stock options		—			—			—		—		3,368,950			—			3,368,950
Net loss for the year ended 2011		—			—			—		—		—			(19,434,699	)		(19,434,699	)

Balance, at December 31, 2011		3,531,665		$	3,531			110,596,798	$	110,597	$	115,690,334		$	(105,784,722	)	$	10,019,740
Issuance of stock for services		—			—			550,000		550		455,950			—			456,500
Issuance of warrants for services		—			—			—		—		1,512,026			—			1,512,026
Issuance of common stock and warrants pursuant to Regulation D		—			—			6,227,647		6,228		4,784,316			—			4,790,544
Preferred stock conversions into common stock		(1,053,480	)		(1,053	)		1,053,480		1,053		—			—			—
Employee compensation from stock options		—			—			—		—		183,028			—			183,028
Net loss for the year ended 2012		—			—			—		—		—			(12,568,354	)		(12,568,354	)

Balance, at December 31, 2012		2,478,185		$	2,478			118,427,925	$	118,428	$	122,625,654		$	(118,353,076	)	$	4,393,484
Issuance of stock for services		—			—			750,000		750		525,250			—			526,000
Issuance of warrants for services		—			—			—		—		1,786,824			—			1,786,824
Exercise of warrants and stock options		—			—			6,319,594		6,320		7,829,150			—			7,835,470
Issuance of common stock and warrants pursuant to Regulation D		—			—			28,409,353		28,409		18,390,926			—			18,419,335
Issuance of preferred stock and warrants pursuant to Regulation D		3,400,001			3,400			—		—		1,248,650			—			1,252,050
Preferred stock conversions into common stock		(5,844,852	)		(5,845	)		5,844,852		5,845		—			—			—
Dividends on preferred stock		—			—			—		—		(29,063	)		—			(29,063	)
Employee compensation from stock options		—			—			—		—		142,310			—			142,310
Net loss for the year ended 2013		—			—			—		—		—			(27,697,744	)		(27,697,744	)

Balance, at December 31, 2013		33,334		$	33			159,751,724	$	159,752	$	152,519,701		$	(146,050,820	)	$	6,628,666
Issuance of stock for services		—			—			150,000		150		277,600			—			277,750


	Preferred Stock						Common Stock				Paid in capital		Accumulated Deficit			Total
	Number of Shares			Par Value			Number of Shares		Par Value		Paid in capital		Accumulated Deficit			Total
Issuance of warrants for services		—			—			—		—		1,350,319		—			1,350,319
Reclassification of warrant liability		—			—			—		—		10,335,619		—			10,335,619
Cash proceeds from exercise of warrants and stock options		—			—			14,703,381		14,703		4,333,183		—			4,347,886
Issuance of common stock and warrants pursuant to Regulation D		—			—			2,000,000		2,000		4,348,000		—			4,350,000
Preferred stock conversions into common stock		(33,334	)		(33	)		33,334		33		—		—			—
Net loss for the six months ended June 30, 2014		—			—			—		—		—		(7,310,683	)		(7,310,683	)

Balance, at June 30, 2014		—		$	—			176,638,439	$	176,638	$	173,164,422	$	(153,361,503	)	$	19,979,557

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)


	Six Months Ended June 30, 2014			Six Months Ended June 30, 2013			Cumulative Amounts from January 17, 2002 (Inception) through June 30, 2014
Cash Flows From Operating Activities
Net loss	$	(7,310,683	)	$	(6,547,555	)	$	(153,361,503	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		3,432			3,100			455,764
Amortization of patents		335,560			335,560			7,796,177
Amortization of original issue discount		—			—			3,845,721
Amortization of commitment fee		—			—			310,866
Amortization of prepaid consultant expense		—			—			1,295,226
Amortization of deferred loan costs		—			—			2,261,584
Accretion of United States Treasury Bills		—			—			(373,295	)
Loss on extinguishment of debt		—			—			825,867
Loss on exercise of warrants		—			—			236,146
Beneficial conversion of convertible interest		—			—			55,976
Convertible interest		—			—			389,950
Compensation through issuance of stock options		—			—			14,540,039
Compensation through issuance of stock		—			—			932,000
Issuance of stock for services		277,750			98,250			9,857,261
Issuance of warrants for services		1,350,319			1,341,295			9,333,712
Issuance of warrants for contractual obligations		—			—			985,010
Gain on sale of equipment		—			—			(55,075	)
Loss (gain) on change in fair value of warrant liability		(1,227,992	)		14,304			7,530,937
Change in assets and liabilities
Prepaid expenses and other current assets		—			(93,034	)		—
Accounts payable		130,988			(178,673	)		476,212
Accrued expenses		172,533			81,437			486,240

Net cash used in operating activities		(6,268,093	)		(4,945,316	)		(92,175,185	)

Cash Flows From Investing Activities
Proceeds from sale of fixed assets		—			—			180,075
Capital expenditures		—			—			(96,570	)
Proceeds from sales of investments		—			—			37,010,481
Purchases of investments		—			—			(36,637,186	)

Net cash provided by investing activities		—			—			456,800

Cash Flows From Financing Activities
Net proceeds from loans from stockholder		—			—			174,000
Proceeds from convertible debt		—			—			6,706,795
Net proceeds from sales of preferred stock and warrants		—			2,550,000			11,458,131
Net proceeds from sales of common stock and warrants		4,350,000			5,817,698			65,583,856
Proceeds from exercises of warrants and stock options		4,347,886			21,000			28,859,292
Cash paid for preferred dividends		—			(29,063	)		(29,063	)
Cash paid to retire convertible debt		—			—			(2,385,959	)
Cash paid for deferred loan costs		—			—			(747,612	)
Premium paid on extinguishments of debt		—			—			(170,519	)
Net proceeds from sale of non-controlling interest in Pure-ific Corporation		—			—			443,500
Purchase and retirement of common stock		—			—			(48,000	)

Net cash provided by financing activities		8,697,886			8,359,635			109,844,421

Net change in cash and cash equivalents	$	2,429,793		$	3,414,319		$	18,126,036
Cash and cash equivalents, at beginning of period		15,696,243			1,221,701			—

Cash and cash equivalents, at end of period	$	18,126,036		$	4,636,020		$	18,126,036

Supplemental Disclosure of Noncash Investing and Financing Activities:

During the six months ended June 30, 2014, the Company has reclassified $10,335,619 from warrant liability to equity due to the exercise of a portion of our warrants.

See accompanying notes to condensed consolidated financial statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ended December 31, 2014. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

2. Recapitalization and Merger

Provectus Biopharmaceuticals, Inc., formerly known as “Provectus Pharmaceuticals, Inc.,” “Provectus Pharmaceutical, Inc.” and “SPM Group, Inc.,” was incorporated under Colorado law on May 1, 1978. SPM Group ceased operations in 1991, and became a development-stage company effective January 1, 1992, with the new corporate purpose of seeking out acquisitions of properties, businesses, or merger candidates, without limitation as to the nature of the business operations or geographic location of the acquisition candidate.

On April 1, 2002, SPM Group changed its name to “Provectus Pharmaceutical, Inc.” and reincorporated in Nevada in preparation for a transaction with Provectus Pharmaceuticals, Inc., a privately-held Tennessee corporation (“PPI”). On April 23, 2002, an Agreement and Plan of Reorganization between Provectus Pharmaceutical and PPI was approved by the written consent of a majority of the outstanding shares of Provectus Pharmaceutical. As a result, Provectus Pharmaceuticals, Inc. issued 6,680,000 shares of common stock in exchange for all of the issued and outstanding shares of PPI. As part of the acquisition, Provectus Pharmaceutical changed its name to “Provectus Pharmaceuticals, Inc.” and PPI became a wholly-owned subsidiary of Provectus. This transaction was recorded as a recapitalization of PPI.

On November 19, 2002, the Company acquired Valley Pharmaceuticals, Inc., a privately-held Tennessee corporation formerly known as Photogen, Inc., by merging PPI with and into Valley and naming the surviving corporation “Xantech Pharmaceuticals, Inc.” Photogen, Inc. was separated from Photogen Technologies, Inc. in a non-pro-rata split-off to some of its shareholders. The assets of Photogen, Inc. consisted primarily of the equipment and intangibles related to its therapeutic activity and were recorded at their fair value. The majority shareholders of Valley were also the majority shareholders of Provectus. Valley had no revenues prior to the transaction with the Company. By acquiring Valley, the Company acquired its intellectual property, including issued U.S. patents and patentable inventions.

On December 16, 2013, Provectus Pharmaceuticals, Inc. was reincorporated in Delaware and changed its name to Provectus Biopharmaceuticals, Inc.

3. Basic and Diluted Loss Per Common Share

Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation at June 30, 2014 and 2013, respectively, relate to 58,311,418 and 50,358,525 from warrants, 13,718,334 and 15,097,206 from options, and 0 and 4,881,666 from convertible preferred shares.

4. Equity Transactions

(a) During the three months ended March 31, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $137,500. During the three months ended March 31, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $48,750.

During the three months ended June 30, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $140,250. During the three months ended June 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $49,500.

(b) During the three months ended March 31, 2014, the Company issued 733,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $900,317. During the three months ended March 31, 2014, 121,500 warrants were forfeited. During the three months ended March 31, 2014, 12,522,198 warrants were exercised on a cashless basis resulting in

9,100,824 common shares being issued. During the three months ended March 31, 2014, 3,036,218 warrants were exercised for $2,672,364 resulting in 3,036,218 common shares issued. During the three months ended March 31, 2013, the Company issued 1,924,973 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $409,640. During the three months ended March 31, 2013, 859,833 warrants were forfeited.

During the three months ended June 30, 2014, the Company issued 202,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $450,002. During the three months ended June 30, 2014, 315,000 warrants were forfeited. During the three months ended June 30, 2014, 1,594,082 warrants were exercised on a cashless basis resulting in 915,467 common shares being issued. During the three months ended June 30, 2014, 372,000 warrants were exercised for $372,000 resulting in 372,000 common shares issued. During the three months ended June 30, 2013, the Company issued 2,605,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $931,655. During the three months ended June 30, 2013, 1,051,500 warrants were forfeited.

As the fair market value of these services was not readily determinable, these services were valued based on the fair market value of the warrants, determined using the Black-Scholes option-pricing model.

(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $1,153,835 and $311,062, respectively. During the three months ended March 31, 2014, 858,825 of the Series A Warrants were exercised. During the three months ended March 31, 2014, 697,092 of the Series C Warrants were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $186,262 and $221,149, respectively. The Company determined the fair value of the Series A and Series C Warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the Series A and Series C Warrants exercised in 2014 of $3,911,370 was reclassified into additional paid-in capital.

(d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $211,422 and $446,698, respectively. During the three months ended March 31, 2014, 1,756,665 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $3,285,793 and $399,057, respectively. During the three months ended June 30, 2014, 133,232 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $2,377,133 was reclassified into additional paid-in capital.

(e) In February 2013, the Company had an issuance of Series A 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $921,776 and $165,750, respectively. During the three months ended March 31, 2014, 1,650,000 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $42,970 and $289,000, respectively. During the three months ended June 30, 2014, 200,000 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $4,047,116 was reclassified into additional paid-in capital.

Dividends on the Series A 8% Convertible Preferred Stock accrued at an annual rate of 8% of the original issue price and were payable in either cash or common stock. If the dividend was paid in common stock, the number of shares of common stock equaled the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends were payable quarterly on the 15th day after the quarter-end. The Company paid the dividends in common stock although was required to pay the initial dividends due in cash. The Company had a deficit and, as a result, the dividends were recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In 2014, the Company recognized no dividends because of the full conversion of preferred stock to common stock as of January 15, 2014.

(f) In January 2014 there were 33,334 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 33,334 shares of the Company’s common stock. As of January 15, 2014, there were no shares of Series A 8% Convertible Preferred Stock outstanding.

(g) During the three months ended June 30, 2014 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,000,000. The Company accepted subscriptions, in the aggregate, for 2,000,000 shares of common stock and five year warrants to purchase 2,000,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $3.00 per share. The purchase price for each share of common stock together with the warrants was $2.50. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $650,000 and issued five year fully vested warrants to purchase 300,000 shares of common stock with an exercise price of $2.50 to Network 1 Financial Securities, Inc., which represents 15% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

5. Stock-Based Compensation

One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750, 14,248 options at an exercise price of $0.75 per share of common stock for $10,686 and 600,000 options at an exercise price of $0.93 per share of common stock for $558,000 during the three months ended March 31, 2014. Another employee of the Company exercised 300,000 options at an exercise price of $1.10 per share of common stock for $330,000 during the three months ended March 31, 2014. Another employee of the Company exercised 189,624 options at an exercise price of $1.10 per share of common stock for $208,586 during the three months ended March 31, 2014. One employee of the Company forfeited 300,000 stock options on February 26, 2014.

One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. Another employee of the Company exercised 100,000 options at an exercise price of $1.25 per share of common stock for $125,000 during the three months ended June 30, 2014. A former non-employee member of the board exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. One employee of the Company forfeited 25,000 stock options on May 27, 2014.

6. Related Party Transaction

The Company paid one of the Company’s directors $6,000 as of March 31, 2014, all of which was paid as part of his overall compensation of an aggregate of $85,000 for board and committee service.

7. Fair Value of Financial Instruments

The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are measured and reported on a fair value basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. The fair value of certain of the Company’s financial instruments, including

Cash and cash equivalents and Accounts payable, approximates the carrying value due to the relatively short maturity of such instruments. The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. The warrant liability is a derivative instrument and is classified as Level 3. The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used at March 31, 2014 for the 2010 warrants include a weighted average term of 0.9 years, a 5% probability that the warrant exercise price would be reset, volatility range of 66.5% to 129.7% and a risk free interest rate of 0.13%. Significant assumptions used at June 30, 2014 for the 2010 warrants include a weighted average term of 0.7 years, a 5% probability that the warrant exercise price would be reset, volatility of 187.7% and a risk free interest rate of 0.09%. Significant assumptions used at March 31, 2014 for the 2011 warrants include a weighted average term of 1.8 years, a 5% probability that the warrant exercise price would be reset, volatility of 101.8% and a risk free interest rate of 0.29%. Significant assumptions used at June 30, 2014 for the 2011 warrants include a weighted average term of 1.5 years, a 5% probability that the warrant exercise price would be reset, volatility of 132.7% and a risk free interest rate of 0.29%. Significant assumptions used at March 31, 2014 for the 2013 warrants include a weighted average term of 3.9 years, a 5% probability that the warrant exercise price would be reset, volatility of 84.7% and a risk free interest rate range of 0.77% to 1.32%. At June 30, 2014 there are no remaining 2013 warrants and therefore no associated warrant liability.

The warrant liability measured at fair value on a recurring basis is as follows:


	Total		Level 1		Level 2		Level 3
Derivative instruments:
Warrant liability at June 30, 2014	$	1,302,961	$	—	$	—	$	1,302,961
Warrant liability at December 31, 2013	$	12,866,572	$	—	$	—	$	12,866,572

A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2014 to June 30, 2014 follows:


Balance at January 1, 2014	$	12,866,572
Issuance of warrants		—
Change in fair value of warrants included in earnings		(1,227,992	)
Reclassification to APIC due to warrant exercises		(10,335,619	)

Balance at June 30, 2014	$	1,302,961

8. Litigation

Kleba Shareholder Derivative Lawsuit

On January 2, 2013, Glenn Kleba (the “Plaintiff”) derivatively on behalf of the Company, filed a shareholder derivative complaint in the Circuit Court for the State of Tennessee, Knox County (the “Court”), against H. Craig Dees, Timothy C. Scott, Eric A. Wachter, and Peter R. Culpepper (collectively, the “Executives”), Stuart Fuchs, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, together with the Executives, the “Individual Defendants”), and against the Company as a nominal defendant (the “Shareholder Derivative Lawsuit”). The Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties, (ii) waste of corporate assets, and (iii) unjust enrichment, all three claims based on the Plaintiff’s allegations that the defendants authorized and/or accepted stock option awards in violation of the terms of the Company’s 2002 Stock Plan (the “Plan”) by issuing stock options in excess of the amounts authorized under the Plan and delegated to defendant H. Craig Dees the sole authority to grant himself and the other Executives cash bonuses that the Plaintiff alleges to be excessive.

In April 2013, the Company’s Board of Directors appointed a special litigation committee to investigate the allegations of the Shareholder Derivative Complaint and make a determination as to how the matter should be resolved. The special litigation committee conducted its investigation, and proceedings in the case were stayed pending the conclusion of the committee’s investigation. The Company has established a reserve of $100,000 for potential liabilities because such is the amount of the self-insured retention of its insurance policy.

On March 6, 2014, the Company filed a Joint Notice of Settlement (the “Notice of Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company, the parties to the Notice of Settlement are the Plaintiff and the Individual Defendants.

On June 6, 2014, the Company, in its capacity as a nominal defendant, entered into a Stipulated Settlement Agreement and Mutual Release (the “Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company and the Individual Defendants, plaintiffs Glenn Kleba and Don B. Dale are parties to the Settlement.

By entering into the Settlement, the settling parties have resolved the derivative claims to their mutual satisfaction. The Individual Defendants have not admitted the validity of any claims or allegations and the settling plaintiffs have not admitted that any claims or allegations lack merit or foundation. Under the terms of the Settlement, (i) the Executives each agreed (A) to re-pay to the Company $2.24 Million of the cash bonuses they each received in 2010 and 2011, which amount equals 70% of such bonuses or an estimate of the after-tax net proceeds to each Executive; provided, however, that subject to certain terms and conditions set forth in the Settlement, the Executives are entitled to a 2:1 credit such that total actual repayment may be $1.12 Million each; (B) to reimburse the Company for 25% of the actual costs, net of recovery from any other source, incurred by the Company as a result of the Shareholder Derivative Lawsuit; and (C) to grant to the Company a first priority security interest in 1,000,000 shares of the Company’s common stock owned by each such Executive to serve as collateral for the amounts due to the Company under the Settlement; (ii) Drs. Dees and Scott and Mr. Culpepper agreed to retain incentive stock options for 100,000 shares but shall forfeit 50% of the nonqualified stock options granted to each such Executive in both 2010 and 2011. The Settlement also requires that each of the Executives enter into new employment agreements with the Company, which were entered into on April 28, 2014, and that the Company adhere to certain corporate governance principles and processes in the future. Under the Settlement, Messrs. Fuchs and Smith and Dr. McMasters have each agreed to pay the Company $25,000 in cash, subject to reduction by such amount that the Company’s insurance carrier pays to the Company on behalf of such defendant pursuant to such defendant’s directors and officers liability insurance policy. The Settlement also provides for an award to plaintiffs’ counsel of attorneys’ fees and reimbursement of expenses in connection with their role in this litigation, subject to Court approval.

On July 24, 2014, the Court approved the terms of the proposed Settlement and awarded $911,000 to plaintiffs’ counsel for attorneys’ fees and reimbursement of expenses in connection with their role in the Shareholder Derivative Lawsuit.

Class Action Lawsuits

On May 27, 2014, Cary Farrah and James H. Harrison, Jr., individually and on behalf of all others similarly situated (the “Farrah Case”), and on May 29, 2014, each of Paul Jason Chaney, individually and on behalf of all others similarly situated (the “Chaney Case”), and Jayson Dauphinee, individually and on behalf of all others similarly situated (the “Dauphinee Case”) (the plaintiffs in the Farrah Case, the Chaney Case and the Dauphinee Case collectively referred to as the “Plaintiffs”), each filed a class action lawsuit in the United States District Court for the Middle District of Tennessee against the Company, H. Craig Dees, Timothy C. Scott and Peter R. Culpepper (the “Defendants”) alleging violations by the Defendants of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. Specifically, the Plaintiffs in each of the Farrah Case, the Chaney Case and the Dauphinee Case allege that the Defendants are liable for making false statements and failing to disclose adverse facts known to them about the Company, in connection with the Company’s application to the FDA for Breakthrough Therapy Designation (“BTD”) in the Spring of 2014 and the FDA’s subsequent denial of the Company’s application for BTD. The Company intends to defend vigorously against all claims in these complaints. However, in view of the inherent uncertainties of litigation and the early stage of this litigation, the outcome of these cases cannot be predicted at this time. Likewise, the amount of any potential loss cannot be reasonably estimated.

On July 9, 2014, the Plaintiffs and the Defendants filed joint motions in the Farrah Case, the Chaney Case and the Dauphinee Case to consolidate the cases and transfer them to United States District Court for the Eastern District of Tennessee. By order dated July 16, 2014, the United States District Court for the Middle District of Tennessee entered an order consolidating the Farrah Case, the Chaney Case and the Dauphinee Case (collectively and, as consolidated, the “Securities Litigation”) and transferred the Securities Litigation to the United States District Court for the Eastern District of Tennessee.

Hurtado Shareholder Derivative Lawsuit

On June 4, 2014, Karla Hurtado (the “Plaintiff”) derivatively on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the Middle District of Tennessee (the “Court”), against H. Craig Dees, Timothy C. Scott, Jan E. Koe, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, the “Individual Defendants”), and against the Company as a nominal defendant (the “Hurtado Shareholder Derivative Lawsuit”). The Hurtado Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties and (ii) abuse of control, both claims based on the Plaintiff’s allegations that the Individual Defendants recklessly permitted the Company to disclose false and misleading information and failed to implement adequate controls and procedures to ensure the accuracy of the Company’s disclosures.

On July 25, 2014, the court presiding over the Hurtado Shareholder Derivative Lawsuit entered an order transferring the case to the United District Court for the Eastern District of Tennessee. It is anticipated that an order will be entered by agreement that will stay all activity in the Hurtado Shareholder Derivative Lawsuit pending the resolution of an anticipated motion to dismiss the anticipated consolidated amended complaint in the Securities Litigation.

As a nominal defendant, no relief is sought against the Company itself in the Hurtado Shareholder Derivative Lawsuit.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion is intended to assist in the understanding and assessment of significant changes and trends related to our results of operations and our financial condition together with our consolidated subsidiaries. This discussion and analysis should be read in conjunction with the accompanying unaudited financial statements, our Annual Report on Form 10-K for the year ended December 31, 2013 (“2013 Form 10-K”), which includes additional information about our critical accounting policies and practices and risk factors, and the risk factors contained in Item 1A of Part II of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 and this report, which updates those risk factors. Historical results and percentage relationships set forth in the statement of operations, including trends which might appear, are not necessarily indicative of future operations.

Plan of Operation

We have implemented our integrated business plan, including execution of the current and next phases in clinical development of our pharmaceutical products and continued execution of research programs for new research initiatives.

Our current plans include continuing to operate with our four employees during the immediate future, as well as four primary consultants and various vendor relationships, and anticipate adding additional personnel if necessary in the next 12 months. Our current plans also include minimal purchases of new property, plant and equipment, and increased research and development for additional clinical trials as necessary and appropriate, including our planned phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma.

We believe that our prescription drug candidates PV-10 and PH-10 provide us with two therapeutic products in multiple indications, which have been shown in clinical trials to be safe to treat serious cancers and diseases of the skin, respectively. Also, important immunologic data with PV-10 has been corroborated and characterized by institutions such as Moffitt Cancer Center in Tampa, Florida. We continue to develop clinical trials for these products to show their safety and efficacy, which we believe will continue to be shown based on data in previous studies, and which we hope will result in one or more license transactions with pharmaceutical and/or biotech partners. Together with our non-core technologies, which we intend to sell or license in the future, we believe this combination represents the foundation for maximizing shareholder value this year and beyond.

Results of Operations

Comparison of Three and Six Months Ended June 30, 2014 and June 30, 2013

Revenues

We had no revenue during the three and six months ended June 30, 2014 and 2013.

Research and Development

Research and development costs of $1,025,535 for the three months ended June 30, 2014 included payroll of $260,901, consulting and contract labor of $501,191, legal of $113,758, insurance of $0, lab supplies and pharmaceutical preparations of $126,094, rent and utilities of $21,875, and depreciation expense of $1,716. Research and development costs of $778,349 for the three months ended June 30, 2013 included payroll of $389,821, consulting and contract labor of $291,055, legal of $54,460, insurance of $12,500, lab supplies and pharmaceutical preparations of $10,810, rent and utilities of $18,153, and depreciation expense of $1,550. The decrease in payroll is due to less employee benefit expenses. The increase in consulting and contract labor is due primarily to preparations for a phase 3 trial for the treatment of melanoma and FDA interaction with respect to PV-10; and increased liver and Moffitt Cancer Center mechanism of action feasibility studies activity. The increase in lab supplies and pharmaceutical preparations is due primarily to preparations for phase 3 melanoma drug supply.

Research and development costs of $2,183,418 for the six months ended June 30, 2014 included payroll of $753,159, consulting and contract labor of $735,449, legal of $140,229, insurance of $54,803, lab supplies and pharmaceutical preparations of $452,504, rent and utilities of $43,842, and depreciation expense of $3,432. Research and development costs of $1,518,865 for the six months ended June 30, 2013 included payroll of $723,976, consulting and contract labor of $555,025, legal of $81,024, insurance of $87,500, lab supplies and pharmaceutical preparations of $32,165, rent and utilities of $36,075, and depreciation expense of $3,100. The increase in consulting and contract labor is due primarily to preparations for a phase 3 trial for the treatment of melanoma and FDA interaction with respect to PV-10, and increased liver and Moffitt Cancer Center mechanism of action feasibility studies activity. The increase in lab supplies and pharmaceutical preparations is due primarily to producing phase 3 melanoma drug supply, as well as phase 2 liver and meeting requirements for filing New Drug Approval (NDA) application to the FDA.

General and Administrative

General and administrative expenses increased by $625,863 in the three months ended June 30, 2014 to $2,966,569 from $2,340,706 for the three months ended June 30, 2013. General and administrative expenses were very similar for both periods, except for legal expense which increased by approximately $500,000 primarily due to our NYSE MKT listing and the Controlled Equity Offering^SM Sales Agreement with Cantor Fitzgerald & Co., as well as investor relations and related travel expenses which increased approximately $150,000 for the three months ended June 30, 2014 versus the three months ended June 30, 2013.

General and administrative expenses increased by $1,343,404 in the six months ended June 30, 2014 to $6,022,513 from $4,679,109 for the six months ended June 30, 2013. General and administrative expenses were very similar for both periods; however, almost $600,000 in increased expense is due to the higher stock price during the three months ended March 31, 2014 versus the three months ended March 31, 2013, which resulted in higher noncash expenses charged to operations for the value of both stock and warrants issued for services. Additionally, legal expense increased by about $400,000 primarily due to our NYSE MKT listing and the Controlled Equity Offering^SM Sales Agreement with Cantor Fitzgerald & Co., as well as investor relations and related travel expenses increased approximately $300,000 for the six months ended June 30, 2014 versus the six months ended June 30, 2013.

Investment Income

Investment income was insignificant in both the three and six months ended June 30, 2014 and 2013.

Gain/Loss on change in fair value of warrant liability

Gain on change in fair value of warrant liability increased by $2,605,819 in the three months ended June 30, 2014 to $3,515,025 from $909,206 for the three months ended June 30, 2013. This activity results from accounting for the warrant liability described in Footnotes 4(c), 4(d) and 4(e) to the financial statements which is primarily attributed to a decrease in our common stock price.

Gain on change in fair value of warrant liability increased by $1,242,296 in the six months ended June 30, 2014 to $1,227,992 from a loss of $14,304 for the six months ended June 30, 2013. This activity results from accounting for the warrant liability described in Footnotes 4(c), 4(d) and 4(e) to the financial statements which is primarily attributed to a decrease in our common stock price.

Liquidity and Capital Resources

Our cash and cash equivalents were $18,126,036 at June 30, 2014, compared with $15,696,243 at December 31, 2013. The increase of approximately $2.4 million was due primarily to $4.35 million cash received from warrant and stock option exercises and $4.35 million net proceeds from the sale of our common stock in the six months ended June 30, 2014 offset by $6.3 million of operating cash expenses.

By managing variable cash expenses due to minimal fixed costs, we believe our cash and cash equivalents on hand at June 30, 2014 will be sufficient to meet our current and planned operating needs until well into 2015 without consideration being given to additional cash inflows that might occur from the exercise of existing warrants or future sales of equity securities, although we may, in our sole discretion, direct Alpha Capital Anstalt (“Investor”) to purchase up to an additional $30,000,000 of our common stock per an existing agreement with Investor. In addition, on April 30, 2014, the Company entered into a Controlled Equity Offering^SM Sales Agreement with Cantor Fitzgerald & Co., as sales agent (“Cantor”), under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $50,000,000 from time to time through Cantor, acting as sales agent.

Therefore, our ability to continue as a going concern is reasonably assured due to our cash and cash equivalents on hand at June 30, 2014. Given our current rate of expenditures and our ability to curtail or defer certain controllable expenditures, we do not anticipate needing to raise additional capital to further develop PV-10 on our own to treat locally advanced cutaneous melanoma, cancers of the liver, recurrent breast cancer, pancreatic cancer and other indications because we plan to strategically monetize PV-10 through appropriate regional license transactions, license PH-10 for psoriasis and other related indications described as inflammatory dermatoses, and also complete the spin-out of Pure-ific Corporation and the other non-core subsidiaries.

We believe that our financial position and corporate governance are such that we will continue to meet the relevant listing requirements of NYSE MKT, although there can be no assurance that we will continue to be listed on NYSE MKT. We believe our efforts to obtain regulatory clarity will be helpful to facilitate such transactions with potential partners. Additionally, the existing and forthcoming clinical and nonclinical mechanism of action data for both PV-10 and PH-10 are expected to further aid in both regulatory clarity and transactions with potential partners. The Company’s current cash position is sufficient to meet our obligations. In addition, management is returning $8.96 million to the Company as a result of the previously announced settlement of a shareholder derivative lawsuit (subject to a 2:1 credit to the executives, such that total actual repayment by the executives may be $1.12 million per executive which would total $4.48 million) and we further enhanced our strength by management’s recent exercise of options. In total, we have adequate funds to operate without a further injection of capital through well into 2015. We believe the existing cash position of the Company is sufficient to fund our operations through obtaining interim data from the planned phase 3 melanoma study as well as other planned programs including generating key liver data, and clinical mechanism of action data for both PV-10 and PH-10.

We have provided data on a confidential basis to both potential global and geographic partners for both PV-10 for oncology, and PH-10 for dermatology, via a secure electronic data room. We are encouraged by the number of companies doing due diligence on our technologies. For instance, we recently had a team in India meeting with potential partners and have two teams focused in China working with potential partners there. We also have begun to consider co-development transactions with one or more pharmaceutical or biotech companies to combine PV-10 with immunology agents such as those referred to as checkpoint protein inhibitors. Whenever we obtain a Memorandum of Understanding (MOU), definitive agreement or similar indication of interest from a potential partner, we will issue a press release and Form 8-K filing to notify the market. Furthermore, the strategy of the company for the benefit of shareholders is a series of partnerships followed by an acquisition of the Company along the lines of Celgene/Abraxis, although there can be no assurance that such partnerships or acquisition will occur. The Company is not in discussions regarding the sale of its business and there can be no assurance, however, that the Company will be able to monetize PV-10 or PH-10 in the manner described herein.

We have already signed an advisory agreement with China’s TriRiver Capital to help identify distribution and joint venture partners for PV-10 in China. This agreement is intended to enhance our reach into China and will bolster our efforts in developing partnering opportunities in various countries in Asia including China, India and Japan, where we have held numerous detailed discussions with pharmaceutical companies over the last year. We are already seeing the results of efforts to enter into partnerships from the activity in our electronic data room. The Company is not in discussions regarding the sale of its business and there can be no assurance, however, that the Company will be able to monetize PV-10 or PH-10 in the manner described herein.

The primary financial objective of the Company is to strategically monetize the core value of PV-10 and PH-10 through the various transactions discussed elsewhere in this report. Ultimately, the Company wants to leverage value creation through the sale of the business or a merger that may include upfront cash, acquirer stock, and/or a contingency value right (CVR) as part of the total consideration. A CVR represents the right for its holder to receive certain defined payments upon the achievement of a specified milestone and would be designed to facilitate potential upside for the Company’s shareholders on a post-transaction basis. A CVR could trade on an exchange. The Company is not in discussions regarding the sale of its business and there can be no assurance, however, that the Company will be able to monetize PV-10 or PH-10 in the manner described herein.

We believe our continued development of PV-10 with existing funds will yield proof-of-concept evidence to support expected best-in-class clinical benefit to treat a wide range of solid tumor indications due to its unique immuno-chemoablation mechanism of action. Likewise, we believe our development of PH-10 with existing funds will yield proof-of-concept evidence to support expected best-in-class clinical benefit to treat a wide range of inflammatory dermatoses due to its unique non-steroidal anti-inflammatory mechanism of action.

However, we cannot assure you that we will be successful in either licensing of PV-10 or PH-10, any equity transaction, or selling a majority stake of the OTC and other non-core assets via a spin-out transaction and licensing our existing non-core products. Moreover, even if we are successful in improving our current cash flow position, we nonetheless plan to seek additional funds to meet our long-term requirements in 2015 and beyond, even though we do not anticipate needing additional capital to develop PV-10 on our own to treat locally advanced cutaneous melanoma. We anticipate that these funds will otherwise come from the proceeds of private placements, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While we believe that we have a reasonable basis for our expectation that we will be able to raise additional funds, we cannot assure you that we will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to shareholders.

Critical Accounting Policies

Management’s discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe there have been no material changes to the items that we disclosed as our critical accounting policies under Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our 2013 Form 10-K.

New Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.

The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017. The Company currently does not have revenues but will consider any related impact going forward.

In June 2014, the FASB issued Accounting Standards Update 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (ASU 2014-10), which eliminates the concept of a development stage entity (DSE) from U.S. GAAP. This change rescinds certain financial reporting requirements that have historically applied to DSEs and is intended to result in cost-savings for affected entities, such as certain start-up or research and development entities. The new standard also changes one related aspect of the variable interest entity (VIE) consolidation guidance in Topic 810.

ASU 2014-10 is effective for public entities for annual reporting periods beginning after December 15, 2014 and interim periods therein. Early adoption is permitted. We are currently evaluating the impact of our pending adoption of ASU 2014-10 on our consolidated financial statements.

Contractual Obligations — Leases

We lease office and laboratory space in Knoxville, Tennessee, on an annual basis, renewable for one year at our option. We have a lease commitment of $30,000 as of June 30, 2014.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We had no holdings of financial or commodity instruments as of June 30, 2014, other than cash and cash equivalents, short-term deposits, money market funds, and interest bearing investments in U.S. governmental debt securities. We have accounted for certain warrants issued in March and April 2010, January 2011 and February 2013 as liabilities at their fair value upon issuance, which are remeasured at each period end with the change in fair value recorded in the statement of operations. See notes 4 and 7 of the interim financial statements contained in this Quarterly Report on Form 10-Q.

All of our business is transacted in U.S. dollars and, accordingly, foreign exchange rate fluctuations have not had a significant impact on us, and they are not expected to have a significant impact on us in the foreseeable future.

ITEM 4.

CONTROLS AND PROCEDURES.

(a) Evaluation of Disclosure Controls and Procedures. Our chief executive officer and chief financial officer have evaluated the effectiveness of the design and operation of our “disclosure controls and procedures” (as that term is defined in Rule 13a-15(e) under the Exchange Act) as of June 30, 2014, the end of the fiscal quarter covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective.

(b) Changes in Internal Controls. There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS.

Kleba Shareholder Derivative Lawsuit

Class Action Lawsuits

Specifically, the Plaintiffs in each of the Farrah Case, the Chaney Case and the Dauphinee Case allege that the Defendants are liable for making false statements and failing to disclose adverse facts known to them about the Company, in connection with the Company’s application to the FDA for Breakthrough Therapy Designation (“BTD”) in the Spring of 2014 and the FDA’s subsequent denial of the Company’s application for BTD. The Company intends to defend vigorously against all claims in these complaints. However, in view of the inherent uncertainties of litigation and the early stage of this litigation, the outcome of these cases cannot be predicted at this time. Likewise, the amount of any potential loss cannot be reasonably estimated.

Hurtado Shareholder Derivative Lawsuit

As a nominal defendant, no relief is sought against the Company itself in the Hurtado Shareholder Derivative Lawsuit.

ITEM 1A.

RISK FACTORS

There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2013, as supplemented by the risk factors disclosed in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, other than the additional disclosure of the risk factors listed below.

We may not obtain or maintain the benefits associated with breakthrough therapy designation.

On March 21, 2014, we submitted a request for breakthrough therapy designation (BTD) to the FDA for PV-10 in the treatment of metastatic melanoma in the United States. The FDA denied the request in May 2014, but stated that a new request may be submitted if we obtain new clinical evidence that supports BTD. Accordingly, we are not entitled to the benefits of BTD, including expedited development and review of PV-10 in the treatment of melanoma.

If we resubmit such request for BTD, we may not be granted BTD, or even if granted, we may not receive the benefits associated with BTD. This may result from a failure to maintain breakthrough therapy status if PV-10 is no longer considered to be a breakthrough therapy. For example, a drug’s development program may be granted BTD using early clinical testing that shows a much higher response rate than available therapies. However, subsequent interim data derived from a larger study may show a response that is substantially smaller than the response seen in early clinical testing. Another example is where BTD is granted to two drugs that are being developed for the same use. If one of the two drugs gains traditional approval, the other would not retain its designation unless its sponsor provided evidence that the drug may demonstrate substantial improvement over the recently approved drug. When BTD is no longer supported by emerging data or the designated drug development program is no longer being pursued, the FDA may choose to send a letter notifying the sponsor that the program is no longer designated as a BTD program.

We depend on the successful completion of clinical trials for our product candidates, including PV-10. The positive clinical results obtained for our product candidates in prior clinical studies may not be repeated in future clinical studies.

Before obtaining regulatory approval for the sale of our product candidates, including PV-10, we must conduct additional clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. The outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products.

In October 2012, we presented final top-line data from the Phase 2 trial of PV-10 for metastatic melanoma, and in March 2014, applied for BTD with the FDA, which was subsequently denied pending new clinical evidence that supports BTD. We (i) are conducting an expanded phase 1 trial for PV-10 for metastatic liver cancer, which is expected to be completed in 2014; (ii) have completed a phase 1 clinical study for PV-10 for recurrent breast cancer; (iii) are conducting a phase 1 trial for PV-10 in an investigator initial study to ascertain the feasibility of detecting immune cell infiltrates in injected melanoma tumors; (iv) are conducting a phase 2c clinical trial for PH-10 for psoriasis; (v) have completed a Phase 2 clinical trial for PH-10 for atopic dermatitis; and (vi) plan to conduct a phase 3 clinical trial to assess response to intralesional PV-10 versus that of systemic chemotherapy in patients with disease confined to cutaneous and subcutaneous sites. Meetings with scientific advisors, investigators and advocates in the field have led us to expect a starting date for the phase 3 study sometime in the second half of 2014. However, we have never conducted a phase 3 clinical trial. The positive results we have seen to date in our phase 2 clinical trials of PV-10 for metastatic melanoma do not ensure that later clinical trials will demonstrate similar results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed satisfactorily through preclinical studies and initial clinical testing. A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience, have suffered significant setbacks in Phase 3 clinical development, even after seeing promising results in earlier clinical trials.

We may experience a number of unforeseen events during clinical trials for our product candidates, including PV-10, that could delay or prevent the commencement and/or completion of our clinical trials, including the following:

•

regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;

•

the clinical study protocol may require one or more amendments delaying study completion;

•

clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;

•

the number of subjects required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate or subjects may drop out of these clinical trials at a higher rate than we anticipate;

•

clinical investigators or study subjects fail to comply with clinical study protocols;

•

trial conduct and data analysis errors may occur, including, but not limited to, data entry and/or labeling errors;

•

our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;

•

we might have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the subjects are being exposed to unacceptable health risks;

•

regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;

•

the cost of clinical trials of our product candidates may be greater than we anticipate;

•

the supply or quality of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and

•

our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators to suspend or terminate the trials.

We expect our research and development expenses to increase in connection with our ongoing activities, particularly if we commence a phase 3 clinical trial with respect to PV-10 as planned, and undertake additional clinical trials of our other product candidates. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds required to complete research and development and commercialize our products under development; however, we believe we have sufficient cash on hand to fund the planned phase 3 trial with respect to PV-10.

Negative or inconclusive results of our future clinical trials of PV-10, or any other clinical trial we conduct, could cause the FDA to require that we repeat or conduct additional clinical studies. Despite the results reported in earlier clinical trials for PV-10, we do not know whether any clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our product candidates, including PV-10. If later stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates, including PV-10, may be adversely impacted.

Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval.

Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. We may experience delays in clinical trials at any stage of development and testing of our product candidates. Our planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of subjects, or be completed on schedule, if at all.

Events which may result in delays or unsuccessful completion of clinical trials, including our future clinical trials for PV-10, include the following:

•

inability to raise funding, if necessary, to initiate or continue a trial;

•

delays in obtaining regulatory approval to commence a trial;

•

delays in reaching agreement with the FDA on final trial design;

•

imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities;

•

delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial sites;

•

delays in obtaining required institutional review board (IRB) approval at each site;

•

delays in recruiting suitable patients to participate in a trial;

•

delays in having subjects complete participation in a trial or return for post-treatment follow-up;

•

delays caused by subjects dropping out of a trial due to side effects or otherwise;

•

delays caused by clinical sites dropping out of a trial;

•

time required to add new clinical sites; and

•

delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.

If initiation or completion of any of our clinical trials for our product candidates, including PV-10, are delayed for any of the above reasons, our development costs may increase, the approval process could be delayed, any periods during which we may have the exclusive right to commercialize our product candidates may be reduced and our competitors may bring products to market before us. Any of these events could impair our ability to generate revenues from product sales and impair our ability to generate regulatory and commercialization milestones and royalties, all of which could have a material adverse effect on our business.

We are subject to securities class action lawsuits that could adversely affect our business. This litigation, and potential similar or related litigation, could result in substantial damages and may divert management’s time and attention from our business.

Beginning on May 27, 2014, three putative securities class action lawsuits were commenced in the United States District Court for the Middle District of Tennessee against us, and certain of our officers and directors, alleging violations by the defendants of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, together called the “federal class actions.” The federal class actions allege, among other things, that the defendants made false and materially misleading statements and failed to disclose material information regarding our application to the FDA for BTD.

On July 9, 2014, the plaintiffs and the defendants filed joint motions in the federal class actions to consolidate the cases and transfer them to United States District Court for the Eastern District of Tennessee. By order dated July 16, 2014, the United States District Court for the Middle District of Tennessee entered an order consolidating the federal class actions and transferred the federal class actions to the United States District Court for the Eastern District of Tennessee.

In addition, on June 4, 2014, a shareholder derivative lawsuit captioned Hurtado v. Provectus Biopharmaceuticals, Inc., et al., was filed derivatively on behalf of the Company in the United States District Court for the Middle District of Tennessee (the “Hurtado Shareholder Derivative Lawsuit”). The Hurtado Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties, and (ii) abuse of control, both claims based on the Plaintiff’s allegations that the Individual Defendants recklessly permitted the Company to disclose false and misleading information and failed to implement adequate controls and procedures to ensure the accuracy of the Company’s disclosures.

As a nominal defendant, no relief is sought against the Company itself in the Hurtado Shareholder Derivative Lawsuit.

We intend to defend these actions vigorously. We are currently unable to estimate a range of payments if any, we may be required to pay, or may agree to pay, with respect to the federal class actions and the Hurtado Shareholder Derivative Lawsuit. We believe, however, that the resolution of these suits will not result in a material adverse effect to our consolidated financial statements. However, due to the inherent uncertainties that accompany litigation of this nature, there can be no assurance that we will be successful, and an adverse resolution of any of the lawsuits could have a material adverse effect on our consolidated financial statements. Furthermore, these actions may divert management’s time and attention from our business, and we could be forced to expend significant resources and pay significant costs and expenses, including legal fees, in connection with defending the lawsuits.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the three months ended March 31, 2014, the Company issued 733,000 warrants to consultants in exchange for services.

During the three months ended June 30, 2014, the Company issued 202,000 warrants to consultants in exchange for services.

The Company intends to use any net proceeds from the exercises of these issuances for working capital, FDA trials, securing licensing partnerships, and general corporate purposes.

During the three months ended June 30, 2014 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,000,000. The Company accepted subscriptions, in the aggregate, for 2,000,000 shares of common stock and five year warrants to purchase 2,000,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $3.00 per share. The purchase price for each share of common stock together with the warrants was $2.50. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $650,000 and issued five year fully vested warrants to purchase 300,000 shares of common stock with an exercise price of $2.50 to Network 1 Financial Securities, Inc., which represents 15% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

The issuances of the securities were exempt from the registration requirements of the Securities Act of 1933 (the “Securities Act”) by virtue of Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4.

MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5.

OTHER INFORMATION.

None.

ITEM 6.

EXHIBITS


Exhibit No.		Description

10.1		Controlled Equity Offering^SM Sales Agreement, dated April 30, 2014, by and between Provectus Biopharmaceuticals, Inc. and Cantor Fitzgerald & Co. (incorporated by reference to Exhibit 10.1 to the Company’s Item 1.01 Current Report on Form 8-K filed on April 30, 2014)

10.2		Amended and Restated Executive Employment Agreement by and between the Company and H. Craig Dees, Ph.D., dated April 28, 2014 (incorporated by reference to Exhibit 10.1 to the Company’s Item 5.02 Current Report on Form 8-K filed on April 30, 2014)

10.3		Amended and Restated Executive Employment Agreement by and between the Company and Timothy C. Scott, Ph.D., dated April 28, 2014 (incorporated by reference to Exhibit 10.2 to the Company’s Item 5.02 Current Report on Form 8-K filed on April 30, 2014)

10.4		Amended and Restated Executive Employment Agreement by and between the Company and Eric A. Wachter, Ph.D., dated April 28, 2014 (incorporated by reference to Exhibit 10.3 to the Company’s Item 5.02 Current Report on Form 8-K filed on April 30, 2014)

10.5		Amended and Restated Executive Employment Agreement by and between the Company and Peter R. Culpepper, dated April 28, 2014 (incorporated by reference to Exhibit 10.4 to the Company’s Item 5.02 Current Report on Form 8-K filed on April 30, 2014)

10.6**		Stipulated Settlement Agreement and Mutual Release, dated June 6, 2004, by and among the Company as nominal defendant, H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Peter R. Culpepper, Stuart Fuchs, Kelly M. McMasters, and Alfred E. Smith, IV, as defendants, and Glenn Kleba and Don B. Dale, as plaintiffs (Exhibits Omitted)

31.1**		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

31.2**		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

32**		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 (Section 906 Certification).

101		Interactive Data Files.*

The documents formatted in XBRL (Extensible Business Reporting Language) and attached as Exhibit 101 to this report are deemed not filed as part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act, are deemed not filed for purposes of Section 18 of the Exchange Act, and otherwise are not subject to liability under these sections.

**	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EXHIBIT INDEX


Exhibit No.		Description

10.1		Controlled Equity Offering^SM Sales Agreement, dated April 30, 2014, by and between Provectus Biopharmaceuticals, Inc. and Cantor Fitzgerald & Co. (incorporated by reference to Exhibit 10.1 to the Company’s Item 1.01 Current Report on Form 8-K filed on April 30, 2014)

10.2		Amended and Restated Executive Employment Agreement by and between the Company and H. Craig Dees, Ph.D., dated April 28, 2014 (incorporated by reference to Exhibit 10.1 to the Company’s Item 5.02 Current Report on Form 8-K filed on April 30, 2014)

10.3		Amended and Restated Executive Employment Agreement by and between the Company and Timothy C. Scott, Ph.D., dated April 28, 2014 (incorporated by reference to Exhibit 10.2 to the Company’s Item 5.02 Current Report on Form 8-K filed on April 30, 2014)

10.4		Amended and Restated Executive Employment Agreement by and between the Company and Eric A. Wachter, Ph.D., dated April 28, 2014 (incorporated by reference to Exhibit 10.3 to the Company’s Item 5.02 Current Report on Form 8-K filed on April 30, 2014)

10.5		Amended and Restated Executive Employment Agreement by and between the Company and Peter R. Culpepper, dated April 28, 2014 (incorporated by reference to Exhibit 10.4 to the Company’s Item 5.02 Current Report on Form 8-K filed on April 30, 2014)

10.6**		Stipulated Settlement Agreement and Mutual Release, dated June 6, 2004, by and among the Company as nominal defendant, H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Peter R. Culpepper, Stuart Fuchs, Kelly M. McMasters, and Alfred E. Smith, IV, as defendants, and Glenn Kleba and Don B. Dale, as plaintiffs (Exhibits Omitted)

31.1**		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

31.2**		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

32**		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 (Section 906 Certification).

101		Interactive Data Files.*

**	Filed herewith.

EX-10.6 2 d754969dex106.htm EX-10.6 EX-10.6

Exhibit 10.6

IN THE CIRCUIT COURT FOR KNOX COUNTY, TENNESSEE


GLENN KLEBA, derivatively on behalf of nominal defendant PROVECTUS PHARMACEUTICALS, INC.,
		Civil Action No. 3-1-13
	Plaintiff,

v.		JURY TRIAL DEMANDED

H. CRAIG DEES, TIMOTHY C. SCOTT, ERIC A. WACHTER, STUART FUCHS, KELLY M. MCMASTERS, ALFRED E. SMITH, IV, and PETER R. CULPEPPER,

	Defendants,

and

PROVECTUS PHARMACEUTICALS, INC.

	Nominal Defendant.

NOTICE OF FILING

The Defendants, H. Craig Dees, Timothy C. Scott, Eric A. Wachter and Peter R. Culpepper, (“Officer Defendants”) who are currently serving officers of Nominal Defendant, Provectus Biopharmaceuticals, Inc. f/k/a Provectus Pharmaceuticals, Inc. give notice, pursuant to the deadlines established in the pleadings served by the Special Litigation Committee on May 7 and May 8, 2014, of the filing of settlement agreements signed by the Officer Defendants.

Respectfully submitted,

/s/ John S. Hicks

John S. Hicks (BPR #010478)

Baker Donelson Bearman Caldwell & Berkowitz, PC

Baker Donelson Center

211 Commerce Street, Suite 800

Nashville, Tennessee 37201

(615) 726-7337

(615) 744-7337 fax

Attorneys for Nominal Defendant Provectus Pharmaceuticals, Inc. and Specially Appearing for Individual Defendants

CERTIFICATE OF SERVICE

I hereby certify that a copy of the foregoing pleading has been furnished to the parties listed below via electronic mail and first class U.S. Mail, postage prepaid, on this the 12th day of May, 2014:

Al Holifield

HOLIFIELD & ASSOCIATES, P.L.L.C.

8351 E. Walker Springs Lane, Suite 303

Knoxville, Tennessee 37923

Eduard Korinsky, Esq.

Steven J. Purcell, Esq.

30 Broad Street, 24th Floor

New York, New York 10004

Robert J. Walker, Esq.

Charles I. Malone, Esq.

John C. Hayworth, Esq.

Walker, Tipps & Malone, PLC

2300 One Nashville Place

150 Fourth Avenue North

Nashville, Tennessee 37219

/s/ John S. Hicks

John S. Hicks

STIPULATED SETTLEMENT AGREEMENT AND MUTUAL RELEASE

This Stipulated Settlement Agreement and Mutual Release (hereinafter “Agreement”) is made and entered into by and between Provectus Biopharmaceuticals, Inc., f/k/a Provectus Pharmaceuticals, Inc. (the “Corporation”) and Peter R. Culpepper (hereinafter “Defendant”), and is consented to and approved by Glenn Kleba and Don B. Dale, derivatively on behalf of the Corporation (the “Plaintiffs”) in Plaintiffs’ shareholder derivative lawsuit. Where appropriate, the Corporation, Defendant, and the Plaintiffs shall collectively be referred to as “the Parties.”

RECITALS

WHEREAS:

A. The Corporation is a Delaware corporation with its principal place of business at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931.

B. On or about January 4, 2013, Plaintiff Glenn Kleba, acting by and through counsel, filed a case titled Glenn Kleba, derivatively on behalf of nominal defendant Provectus Pharmaceuticals, Inc., v. H. Craig Dees et al., Civil Action No. 03-1-13, in the Circuit Court for Knox County, Tennessee (the “Lawsuit”). Plaintiffs subsequently filed an Amended Complaint in the Lawsuit adding Don B. Dale as a party plaintiff.

C. On or about April 3, 2013, through a Consent Action By Directors of Provectus Pharmaceuticals, Inc. (“Consent Action”), the Corporation formed a Special Litigation Committee (the “SLC”) and charged the SLC, among other things, “to consider, investigate, review, and analyze the facts, allegations, and circumstances that are the subject of the Shareholder Derivative Lawsuit, as well as any additional facts, allegations, and circumstances that may be raised or put at issue in any related inquiry, investigation, or proceeding” and to “consider and determine whether or not the prosecution of any claims described or asserted in the Shareholder Derivative Lawsuit or any other claims related to the facts, allegations, and circumstances of the Shareholder Derivative Lawsuit is in the best interest of the Corporation and its shareholders, and what action the Corporation should take with respect thereto, including a determination of whether the maintenance of a derivative proceeding with respect to any such claims is or is not in the best interests of the Corporation.”

D. After thorough investigation and extensive deliberation, the SLC unanimously concluded that it was in the best interests of the Corporation and its stockholders to settle the Lawsuit on certain terms and conditions. Defendants agreed to compromise and settle the Lawsuit on such terms and conditions, and Plaintiffs approved and consented to the proposed settlement on such terms and conditions.

E. On or about March 6, 2014, the Parties filed with the Court a Joint Notice in the Lawsuit (the “Joint Notice”) providing notice that they had agreed to the terms, subject to additional definitive documentation, of a settlement evidenced by the execution of a Binding Settlement Term Sheet Agreement.

F. The Parties have agreed to settle the Lawsuit on the terms set forth in this Agreement, and in the associated Stock Pledge Agreement attached as Exhibit A and Option Rescission Agreement attached as Exhibit B (collectively, the “Settlement Documents”).

G. As set forth in Section 6 hereof, the settlement set forth herein and in the Settlement Documents is conditioned upon and subject to final approval of the Court in the Lawsuit, which approval shall be sought by joint motion of the Parties.

Settlement and Release Agreement

TERMS

1. No Admission of Liability. The Parties agree and acknowledge that this Agreement is intended as a compromise of matters involving disputed issues, and that nothing in this Agreement nor the negotiations for this Agreement (including all statements or communications related thereto) by the Parties or their attorneys may be considered an admission of liability or wrongdoing.

2. Cash Payments to the Corporation.

(A)

As Related to Prior Cash Bonus Compensation: Defendant agrees and obligates himself to pay to the Corporation TWO MILLION TWO HUNDRED FORTY THOUSAND DOLLARS AND NO/100 ($2,240,000.00) (the “Total Repayment Amount”), except that:

(1)

Subject to the satisfaction in full of the conditions set forth in Section 2(C) below and Section 2(A)(2), Defendant shall be entitled to a two-for-one (2:1) credit on the Total Repayment Amount such that his repayment obligation to the Corporation for the Total Repayment Amount shall instead be ONE MILLION ONE HUNDRED TWENTY THOUSAND DOLLARS AND NO/100 ($1,120,000.00) (the “Reduced Repayment Amount”).

(2)

To be entitled to the Reduced Repayment Amount instead of the Total Repayment Amount, Defendant must

(a)

make all payments of the Reduced Repayment Amount required in this Agreement timely and pursuant to the terms set forth in Section 2(C); and

(b)

remain employed by the Company until December 31, 2018, except that termination of Defendant’s employment prior to such date shall not affect Defendant’s right to the Reduced Repayment Amount if such termination is (i) a termination by the Corporation without “Cause” (or any substantively similar provisions as set forth in Defendant’s then-governing employment agreement with the Corporation); (ii) a resignation by Defendant “For Good Reason” (or any substantively similar provisions as set forth in Defendant’s then-governing employment agreement with the Corporation); or (iii) the result of Defendant’s death or disability.


Settlement and Release Agreement				Page 2

(B)

As Related to the Litigation Costs of the Shareholder Derivative Lawsuit:

(1)

Defendant shall also be obligated to pay TWENTY-FIVE PERCENT (25%) of the Litigation Costs incurred as a result of the Lawsuit. “Litigation Costs” shall be defined as (i) all fees and expenses of the SLC, including but not limited to the fees and expenses of the SLC’s counsel, PLUS (ii) the fees and expenses of the Corporation’s counsel, Baker Donelson Bearman Caldwell & Berkowitz, P.C., in connection with and directly related to the Shareholder Derivative Lawsuit, PLUS (iii) the fees and expenses of Plaintiffs, including but not limited to the fees and expenses of Plaintiffs’ counsel, MINUS (iv) any insurance proceeds offsetting or covering the foregoing costs. For the avoidance of doubt, the obligation to repay any portion of Litigation Costs is not entitled to any 2:1 credit.

(2)

No later than within thirty (30) days of the later of (a) Court approval of the settlement and (b) an agreement by the Parties and the other required defendants in the Lawsuit, or a decision of the Court, as to the amount of fees and expenses of Plaintiffs (including attorneys’ fees); the Parties, including the SLC, shall agree on a final Litigation Costs Settlement Statement which shall set forth the total Litigation Costs for purposes of this Agreement.

(C)

Terms of Cash Repayment. The “Cash Repayment Obligations” shall equal (i) the Reduced Repayment Amount (or the Total Repayment Amount if Defendant fails to satisfy the conditions set forth in Section 2(A) and this Section 2(C)) PLUS (ii) the Litigation Costs set forth above in Section 2(B).

(1)

Term / Annual Minimum:

(a)

The Cash Repayment Obligations shall be paid in full by Defendant within five (5) years from the date of this Agreement.

(b)

Defendant shall pay a minimum of $200,000.00 per year to the Corporation towards the Cash Repayment Obligations. Defendant authorizes and agrees that, so long as Defendant is employed by the Corporation, the Corporation shall retain from Defendant’s annual salary the sum of $200,000 per year to be applied toward the Cash Repayment Obligations, which amount shall be withheld from each salary payment on a pro rata basis in accordance with the Corporation’s payroll policies and procedures.


Settlement and Release Agreement				Page 3

(2)

Acceleration of Payment: All Cash Repayment Obligations outstanding under this Agreement shall become immediately due and payable by Defendant and shall bear an annual interest rate of ten percent (10%) or the maximum allowed by law, whichever is less, upon the occurrence of any one or more of the following: (a) Defendant materially breaches the terms of this Agreement and does not cure such breach within thirty (30) days after notice from the Company that failure to cure the breach will result in acceleration of all cash repayment obligations; or (b) Defendant’s employment with the Corporation is terminated prior to December 31, 2018 for any reason other than those set forth in Paragraph 2(a)(2)(b).

(3)

Security: Defendant agrees to grant the Corporation a first-priority security interest in ONE MILLION (1,000,000) shares of Corporation’s common stock beneficially owned by Defendant (the “Common Stock”) to serve as collateral for the Cash Repayment Obligations owing and due to Corporation pursuant to the terms and conditions set forth in the Stock Pledge Agreement, the form of which is attached hereto as Exhibit A.

(4)

Prepayment. Defendant shall be entitled to pay in full all Cash Repayment Obligations due and owing pursuant to this Agreement at any time prior to the expiration of the five-year period; provided, however, prepayment of such amounts shall not relieve Defendant of the obligations set forth in Section 2(A)(2) of this Agreement to remain employed by the Corporation until December 31, 2018. For purposes of clarification, even if Defendant has paid all Cash Repayment Obligations due hereunder prior to the expiration of the five-year period, in the event Defendant’s employment with the Corporation is terminated prior to December 31, 2018 for any reason other than those set forth in Paragraph 2(a)(2)(b), Defendant will owe the Corporation the Total Repayment Amount (minus any payments theretofore made by Defendant with regard to the Reduced Repayment Amount or the Total Repayment Amount).

3. Rescission of Certain Stock Options. Defendant agrees that the Corporation shall rescind FIFTY PERCENT (50%) of the Non-Qualified Stock Options granted to Defendant in both 2010 and 2011, pursuant to the Option Rescission Agreement, the form of which is attached hereto as Exhibit B. The Parties agree that the remaining Non-Qualified Stock Options, and all the Incentive Stock Options, granted to Defendant in 2010 and 2011 are valid and enforceable, according to their terms.

4. New or Restated Employment Agreement Between Defendant and the Corporation. Defendant agrees that, to the extent such has not already been completed in 2014, he will within ninety (90) days of the Effective Date of this Agreement enter into a new or restated employment agreement with the Corporation, which employment agreement shall be approved and adopted by the Compensation Committee of the Corporation’s Board of Directors acting with the advice and assistance of the Corporation’s legal counsel.


Settlement and Release Agreement				Page 4

5. Representations as to Corporate Governance. Defendant represents, warrants, and covenants as part of this settlement that he – in his individual capacity as an officer, director, and/or shareholder of the Corporation – will (a) take all actions necessary and proper for the Corporation to satisfy the SLC’s recommendations with respect to improvements in the corporate governance of the Corporation (as set forth in Exhibit C to this Agreement, and as approved by Plaintiffs) and (b) will not otherwise take any action contrary to the SLC’s recommendations or contrary to the governance of the Corporation in a manner consistent with his fiduciary duties to the Corporation and its shareholders.

6. Court Approval / Effective Date of Settlement. The settlement, and this Agreement, shall become final and binding upon the Parties only if it is approved by the Court in the Lawsuit. The effective date of the settlement and this Agreement (the “Effective Date”) shall be the date that the Final Approval Order shall be final and not subject to appeal pursuant to the Tennessee Rules of Civil Procedure and other applicable law. In the event the settlement is not approved by the Court, the settlement and this Agreement will be of no force and effect, and shall not be binding on any Party.

7. Plaintiffs’ Fees and Expenses. Within ninety (90) days of Court approval of this settlement or Court award of fees and expenses to Plaintiffs (whichever is later), the Corporation shall pay to Plaintiffs an amount of attorneys fees, expenses and other compensation (i) that has been agreed to by Plaintiffs, Defendants and the SLC; or, alternatively, (ii) that has been ordered by the Court. Pursuant to Section 2(B), such payment shall be part of the Litigation Costs to be borne in part by Defendant.

8. Dismissal of the Lawsuit With Prejudice. Pursuant to the terms of the Final Approval Order and the Joint Motion for Approval, the Lawsuit shall be dismissed with prejudice. The Parties acknowledge and agree that dismissal of the Lawsuit and the terms of this Agreement form good and sufficient consideration, and that none of the Parties is entitled to receive any money or additional consideration from any other party in connection with the Lawsuit other than as expressly provided in this Agreement.

9. Mutual Release. Upon the Effective Date of this Agreement and excluding causes of action that arise out of the breach of this Agreement, the Parties shall be deemed to have forever released and discharged each other and each of their related entities, predecessors, successors, affiliates, attorneys, guarantors, and past and present officers, directors, employees, agents, shareholders, members, and trustees (hereinafter the “Released Parties”) from any and all payments, damages, costs, fees, claims, counterclaims, demands, actions, causes of action, claims of appeal, obligations, penalties and losses, known or unknown, contingent or accrued, now existing or hereafter arising, which relate in any way to the issues alleged, or to compensation related issues that could have been alleged, in the Lawsuit. This release does not and shall not apply to or operate to release any claims arising out of the Parties’ respective obligations in the Settlement Documents.


Settlement and Release Agreement				Page 5

10. Reliance on Own Judgment; Authority to Sign. The Parties to this Agreement agree that: (1) no promises or inducements have been made except as set forth herein; (2) they are competent and authorized to execute this Agreement; (3) they execute this Agreement knowingly and voluntarily and accept responsibility therefor; and (4) they have been represented by competent legal counsel of such party’s own choice with regard to this Agreement, or have otherwise had the opportunity to consult with a legal counsel of such party’s own choice, and that all Parties fully understand the same.

11. Binding Effect. This Agreement shall be binding upon and benefit the Parties and their respective heirs, executors, personal representatives, successors and assigns.

12. Counterparts and Execution by Facsimile / Scanned Image. This Agreement may be executed in several counterparts, each of which shall be deemed an original, and all of which shall constitute one and the same instrument. Signatures by facsimile or scanned image shall be accepted as originals.

13. Entire Agreement. The Parties hereto acknowledge they have read this Agreement and freely and voluntarily agree to be bound by its terms. The Parties further agree that the Settlement Documents constitute the complete and the exclusive written expression of the terms of the entire settlement between the Parties and supersede all prior or contemporaneous proposals, oral or written, understandings, representations, conditions, warranties, covenants and all other communications between the Parties relating to the subject matter of the Settlement Documents.

14. Governing Law and Forum. This Agreement shall be construed and enforced in accordance with the laws of the State of Tennessee. The Parties hereby consent to the jurisdiction of the Knox County Circuit Court for the resolution of any and all claims or disputes arising out of the subject matter of this Agreement. The Parties irrevocably waive any right to bring or to remove any action arising or in any way connected to this Agreement to federal court.

15. Default by Defendant. In the event of any default by Defendant with respect to any term(s) of this Agreement, the Pledge Agreement, or the Option Rescission Agreement, the Corporation shall be entitled to recover all costs and reasonable attorney fees incurred in the enforcement of the Corporation’s rights in such agreements.

16. Amendments. This Agreement may only be amended by a writing signed by the Defendant and the Corporation, and written notice of such amendment shall be provided to Plaintiffs’ counsel of record in the Lawsuit and the SLC’s counsel of record.

17. Severability. In the event any provision of this Agreement shall be found to be unenforceable or invalid, such provision shall be severed from this Agreement and the balance of the Agreement shall remain fully valid and enforceable.

18. Construction. Each of the Parties to this Agreement represents that it has legal counsel representing it with respect to this Agreement. The Parties acknowledge and agree that each party has participated in the drafting of this Agreement and that the normal rules of construction to the effect that any ambiguities are to be resolved against the drafting party shall


Settlement and Release Agreement				Page 6

not apply to the interpretation of this Agreement. No inference in favor of, or against, any party shall be drawn by the fact that one party has drafted any portion hereof. The Parties also represent that they have had full opportunity to review the terms of this Agreement and have willingly consented to the terms set forth herein.

19. Waiver. Failure by either party to enforce any of its rights hereunder on any particular occasion shall not constitute a waiver of such rights on any subsequent occasion.

20. Actions Necessary to Complete Transaction. Each of the Parties hereby agrees to execute and deliver all such other documents or instruments and take any action as may be reasonably required in order to effectuate the transactions contemplated by this Agreement.

21. Tax Matters. Each of the Parties represents and declares that it has either received or has been afforded the opportunity to obtain its own professional tax advice. Each of the Parties shall be responsible for its own reporting to the tax authorities and shall be responsible for its own taxes that may arise as a result of this Agreement.

22. Notices. All notices, requests, demands or other communications required or permitted hereunder shall be given in writing and personally delivered or sent by certified or registered mail, return receipt requested, postage prepaid, or by a nationally recognized overnight courier service (e.g., Federal Express, UPS, etc.), to the Parties’ address set forth below:

If to Defendant:

Peter R. Culpepper

Provectus Biopharmaceuticals, Inc.

7327 Oak Ridge Hwy

Knoxville, TN 37931

Telephone: (866) 594-5999

With a copy to:

David W. Bernstein

K&L Gates LLP

599 Lexington Avenue

New York, NY 10022

Telephone: (212) 536-4029

If to the Corporation:

Provectus Biopharmaceuticals, Inc.

Attn: Board of Directors

7327 Oak Ridge Hwy

Knoxville, TN 37931

Telephone: (866) 594-5999


Settlement and Release Agreement				Page 7

With a copy to:

Tonya Mitchem Grindon

Baker, Donelson, Bearman, Caldwell & Berkowitz, PC

211 Commerce Street, Suite 800

Nashville, TN 37201

Telephone: (615) 726-5607

If notice required pursuant to Section 16 regarding amendments to this Agreement, with copies to:

Plaintiffs’ Counsel of Record:

Al Holifield, Esq.

Holifield & Associates, PLLC

11907 Kingston Pike, Suite 201

Knoxville, TN 37934

Telephone: (865) 566-0115

Eduard Korsinsky, Esq.

Steven J. Purcell, Esq.

Levi & Korsinsky

30 Broad Street, 24th Floor

New York, NY 10004

Telephone: (212) 363-7500

The SLC’s Counsel of Record:

Robert J. Walker

John C. Hayworth

Charles Malone

Walker, Tipps & Malone PLC

2300 One Nashville Place

150 Fourth Avenue North

Nashville, TN 37219

Telephone: (615) 313-6000

Notice solely by e-mail shall not be acceptable although a courtesy copy by e-mail is highly recommended.

23. Continuing Obligations. All obligations of the Parties under this Agreement which are not fully performed as of the expiration or earlier termination of this Agreement shall survive the expiration or earlier termination of the underlying agreement.

24. Section Headings. Headings are used for convenience only and are not intended and shall not be used in interpreting any provisions of this Agreement.


Settlement and Release Agreement				Page 8

IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day and year set forth below.


PROVECTUS BIOPHARMACEUTICALS, INC., f/k/a PROVECTUS PHARMACEUTICALS, INC.

By:		/s/ Jan E. Koe

Name:		Jan E. Koe
Its:		Chairman, Special Litigation Committee

Dated:		June 6, 2014


PETER R. CULPEPPER

/s/ Peter R. Culpepper

Peter R. Culpepper
Dated:


APPROVED AND CONSENTED TO:

PLAINTIFFS GLENN KLEBA AND DON B. DALE, DERIVATIVELY ON BEHALF OF PROVECTUS BIOPHARMACEUTICALS, INC.

/s/ Al Holifield

By:		Steven Purcell and Al Holifield, Counsel to Plaintiffs
Dated:		13 May 2014


Settlement and Release Agreement				Page 9

Exhibit A

STOCK PLEDGE AGREEMENT

Settlement and Release Agreement

STIPULATED SETTLEMENT AGREEMENT AND MUTUAL RELEASE

This Stipulated Settlement Agreement and Mutual Release (hereinafter “Agreement”) is made and entered into by and between Provectus Biopharmaceuticals, Inc., f/k/a Provectus Pharmaceuticals, Inc. (the “Corporation”) and Timothy C. Scott (hereinafter “Defendant”), and is consented to and approved by Glenn Kleba and Don B. Dale, derivatively on behalf of the Corporation (the “Plaintiffs”) in Plaintiffs’ shareholder derivative lawsuit. Where appropriate, the Corporation, Defendant, and the Plaintiffs shall collectively be referred to as “the Parties.”

RECITALS

WHEREAS:

A. The Corporation is a Delaware corporation with its principal place of business at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931.

Settlement and Release Agreement

TERMS

2. Cash Payments to the Corporation.

(A)

(1)

(2)

To be entitled to the Reduced Repayment Amount instead of the Total Repayment Amount, Defendant must

(a)

make all payments of the Reduced Repayment Amount required in this Agreement timely and pursuant to the terms set forth in Section 2(C); and

(b)


Settlement and Release Agreement				Page 2

(B)

As Related to the Litigation Costs of the Shareholder Derivative Lawsuit:

(1)

(2)

(C)

(1)

Term / Annual Minimum:

(a)

The Cash Repayment Obligations shall be paid in full by Defendant within five (5) years from the date of this Agreement.

(b)


Settlement and Release Agreement				Page 3

(2)

(3)

(4)

4. New or Restated Employment Agreement Between Defendant and the Corporation. Defendant agrees that, to the extent such has not already been completed in 2014, he will within ninety (90) days of the Effective Date of this Agreement enter into a new or restated employment agreement with the Corporation, which employment agreement be approved and adopted by the Compensation Committee of the Corporation’s Board of Directors acting with the advice and assistance of the Corporation’s legal counsel.


Settlement and Release Agreement				Page 4

9. Mutual Release. Upon the Effective Date of this Agreement and excluding causes of action that arise out of the breach of this Agreement, the Parties shall be deemed to have forever released and discharged each other and each of their related entities, predecessors, successors, affiliates, attorneys, guarantors, and past and present officers, directors, employees, agents, shareholders, members, and trustees (hereinafter the “Released Parties”) from any and all payments, damages, costs, fees, claims, counterclaims, demands, actions, causes of action, claims of appeal, obligations, penalties and losses, known or unknown, contingent or accrued, now existing or hereafter arising, which relate in any way to the issues alleged, or to compensation related issues that could have been alleged, in the Lawsuit This release does not and shall not apply to or operate to release any claims arising out of the Parties’ respective obligations in the Settlement Documents.


Settlement and Release Agreement				Page 5

11. Binding Effect. This Agreement shall be binding upon and benefit the Parties and their respective heirs, executors, personal representatives, successors and assigns.

17. Severability. In the event any provision of this Agreement shall be found to be unenforceable or invalid, such provision shall be severed from this Agreement and the of the Agreement shall remain fully valid and enforceable.


Settlement and Release Agreement				Page 6

19. Waiver. Failure by either party to enforce any of its rights hereunder on any particular occasion shall not constitute a waiver of such rights on any subsequent occasion.

If to Defendant:

Timothy C. Scott

Provectus Biopharmaceuticals, Inc.

7327 Oak Ridge Hwy

Knoxville, TN 37931

Telephone: (866) 594-5999

With a copy to:

David W. Bernstein

K&L Gates LLP

599 Lexington Avenue

New York, NY 10022

Telephone: (212) 536-4029

If to the Corporation:

Provectus Biopharmaceuticals, Inc.

Attn: Board of Directors

7327 Oak Ridge Hwy

Knoxville, TN 37931

Telephone: (866) 594-5999


Settlement and Release Agreement				Page 7

With a copy to:

Tonya Mitchem Grindon

Baker, Donelson, Bearman, Caldwell & Berkowitz, PC

211 Commerce Street, Suite 800

Nashville, TN 37201

Telephone: (615) 726-5607

If notice required pursuant to Section 16 regarding amendments to this Agreement, with copies to:

Plaintiffs’ Counsel of Record:

Al Holifield, Esq.

Holifield & Associates, PLLC

11907 Kingston Pike, Suite 201

Knoxville, TN 37934

Telephone: (865) 566-0115

Eduard Korsinsky, Esq.

Steven J. Purcell, Esq.

Levi & Korsinsky

30 Broad Street, 24th Floor

New York, NY 10004

Telephone: (212) 363-7500

The SLC’s Counsel of Record:

Robert J. Walker

John C. Hayworth

Charles Malone

Walker, Tipps & Malone PLC

2300 One Nashville Place

150 Fourth Avenue North

Nashville, TN 37219

Telephone: (615) 313-6000

Notice solely by e-mail shall not be acceptable although a courtesy copy by e-mail is highly recommended.

24. Section Headings. Headings are used for convenience only and are not intended and shall not be used in interpreting any provisions of this Agreement.


Settlement and Release Agreement				Page 8

IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day and year set forth below.


PROVECTUS BIOPHARMACEUTICALS, INC., f/k/a PROVECTUS PHARMACEUTICALS, INC.

By:		/s/ Jan E. Koe

Name:		Jan E. Koe
Its:		Chairman, Special Litigation Committee
Dated:		June 6, 2014


TIMOTHY C. SCOTT

/s/ Timothy C. Scott

Timothy C. Scott
Dated:

APPROVED AND CONSENTED TO:

PLAINTIFFS GLENN KLEBA AND DON B. DALE, DERIVATIVELY ON BEHALF OF PROVECTUS BIOPHARMACEUTICALS, INC.

/s/ Al Holifield

By:		Steven Purcell and Al Holifield, Counsel to Plaintiffs
Dated:		13 May 2014


Settlement and Release Agreement				Page 9

Exhibit A

STOCK PLEDGE AGREEMENT

Settlement and Release Agreement

STIPULATED SETTLEMENT AGREEMENT AND MUTUAL RELEASE

This Stipulated Settlement Agreement and Mutual Release (hereinafter “Agreement”) is made and entered into by and between Provectus Biopharmaceuticals, Inc., f/k/a Provectus Pharmaceuticals, Inc. (the “Corporation”) and H. Craig Dees (hereinafter “Defendant”), and is consented to and approved by Glenn Kleba and Don B. Dale, derivatively on behalf of the Corporation (the “Plaintiffs”) in Plaintiffs’ shareholder derivative lawsuit. Where appropriate, the Corporation, Defendant, and the Plaintiffs shall collectively be referred to as “the Parties.”

RECITALS

WHEREAS:

A. The Corporation is a Delaware corporation with its principal place of business at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931.

Settlement and Release Agreement

TERMS

2. Cash Payments to the Corporation.

(A)

(1)

(2)

To be entitled to the Reduced Repayment Amount instead of the Total Repayment Amount, Defendant must

(a)

make all payments of the Reduced Repayment Amount required in this Agreement timely and pursuant to the terms set forth in Section 2(C); and

(b)


Settlement and Release Agreement				Page 2

(B)

As Related to the Litigation Costs of the Shareholder Derivative Lawsuit:

(1)

(2)

(C)

(1)

Term / Annual Minimum:

(a)

The Cash Repayment Obligations shall be paid in full by Defendant within five (5) years from the date of this Agreement.

(b)


Settlement and Release Agreement				Page 3

(2)

(3)

(4)


Settlement and Release Agreement				Page 4


Settlement and Release Agreement				Page 5

11. Binding Effect. This Agreement shall be binding upon and benefit the Parties and their respective heirs, executors, personal representatives, successors and assigns.


Settlement and Release Agreement				Page 6

19. Waiver. Failure by either party to enforce any of its rights hereunder on any particular occasion shall not constitute a waiver of such rights on any subsequent occasion.

If to Defendant:

H. Craig Dees

Provectus Biopharmaceuticals, Inc.

7327 Oak Ridge Hwy

Knoxville, TN 37931

Telephone: (866) 594-5999

With a copy to:

David W. Bernstein

K&L Gates LLP

599 Lexington Avenue

New York, NY 10022

Telephone: (212) 536-4029

If to the Corporation:

Provectus Biopharmaceuticals, Inc.

Attn: Board of Directors

7327 Oak Ridge Hwy

Knoxville, TN 37931

Telephone: (866) 594-5999


Settlement and Release Agreement				Page 7

With a copy to:

Tonya Mitchem Grindon

Baker, Donelson, Bearman, Caldwell & Berkowitz, PC

211 Commerce Street, Suite 800

Nashville, TN 37201

Telephone: (615) 726-5607

If notice required pursuant to Section 16 regarding amendments to this Agreement, with copies to:

Plaintiffs’ Counsel of Record:

Al Holifield, Esq.

Holifield & Associates, PLLC

11907 Kingston Pike, Suite 201

Knoxville, TN 37934

Telephone: (865) 566-0115

Eduard Korsinsky, Esq.

Steven J. Purcell, Esq.

Levi & Korsinsky

30 Broad Street, 24th Floor

New York, NY 10004

Telephone: (212) 363-7500

The SLC’s Counsel of Record:

Robert J. Walker

John C. Hayworth

Charles Malone

Walker, Tipps & Malone PLC

2300 One Nashville Place

150 Fourth Avenue North

Nashville, TN 37219

Telephone: (615) 313-6000

Notice solely by e-mail shall not be acceptable although a courtesy copy by e-mail is highly recommended.

24. Section Headings. Headings are used for convenience only and are not intended and shall not be used in interpreting any provisions of this Agreement.


Settlement and Release Agreement				Page 8

IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day and year set forth below.


PROVECTUS BIOPHARMACEUTICALS, INC., f/k/a PROVECTUS PHARMACEUTICALS, INC.

By:		/s/ Jan E. Koe

Name:		Jan E. Koe
Its:		Chairman, Special Litigation Committee
Dated:		June 6, 2014


H. CRAIG DEES

/s/ H Craig Dees

H Craig Dees
Dated:


APPROVED AND CONSENTED TO:

PLAINTIFFS GLENN KLEBA AND DON B. DALE, DERIVATIVELY ON BEHALF OF PROVECTUS BIOPHARMACEUTICALS, INC.

/s/ Al Holifield

By:		Steven Purcell and Al Holifield, Counsel to Plaintiffs
Dated:		13 May 2014


Settlement and Release Agreement				Page 9

Exhibit A

STOCK PLEDGE AGREEMENT

Settlement and Release Agreement

STIPULATED SETTLEMENT AGREEMENT AND MUTUAL RELEASE

This Stipulated Settlement Agreement and Mutual Release (hereinafter “Agreement”) is made and entered into by and between Provectus Biopharmaceuticals, Inc., f/k/a Provectus Pharmaceuticals, Inc. (the “Corporation”) and Eric A. Wachter (hereinafter “Defendant”), and is consented to and approved by Glenn Kleba and Don B. Dale, derivatively on behalf of the Corporation (the “Plaintiffs”) in Plaintiffs’ shareholder derivative lawsuit. Where appropriate, the Corporation, Defendant, and the Plaintiffs shall collectively be referred to as “the Parties.”

RECITALS

WHEREAS:

A. The Corporation is a Delaware corporation with its principal place of business at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931.

Settlement and Release Agreement

TERMS

2. Cash Payments to the Corporation.

(A)

(1)

(2)

To be entitled to the Reduced Repayment Amount instead of the Total Repayment Amount, Defendant must

(a)

make all payments of the Reduced Repayment Amount required in this Agreement timely and pursuant to the terms set forth in Section 2(C); and

(b)


Settlement and Release Agreement				Page 2

(B)

As Related to the Litigation Costs of the Shareholder Derivative Lawsuit:

(1)

(2)

(C)

(1)

Term / Annual Minimum:

(a)

The Cash Repayment Obligations shall be paid in full by Defendant within five (5) years from the date of this Agreement.

(b)


Settlement and Release Agreement				Page 3

(2)

(3)

(4)

3. [This Section 3 intentionally left blank.]


Settlement and Release Agreement				Page 4


Settlement and Release Agreement				Page 5

11. Binding Effect. This Agreement shall be binding upon and benefit the Parties and their respective heirs, executors, personal representatives, successors and assigns.


Settlement and Release Agreement				Page 6

19. Waiver. Failure by either party to enforce any of its rights hereunder on any particular occasion shall not constitute a waiver of such rights on any subsequent occasion.

If to Defendant:

Eric A. Wachter

Provectus Biopharmaceuticals, Inc.

7327 Oak Ridge Hwy

Knoxville, TN 37931

Telephone: (866) 594-5999

With a copy to:

David W. Bernstein

K&L Gates LLP

599 Lexington Avenue

New York, NY 10022

Telephone: (212) 536-4029

If to the Corporation:

Provectus Biopharmaceuticals, Inc.

Attn: Board of Directors

7327 Oak Ridge Hwy

Knoxville, TN 37931

Telephone: (866) 594-5999


Settlement and Release Agreement				Page 7

With a copy to:

Tonya Mitchem Grindon

Baker, Donelson, Bearman, Caldwell & Berkowitz, PC

211 Commerce Street, Suite 800

Nashville, TN 37201

Telephone: (615) 726-5607

If notice required pursuant to Section 16 regarding amendments to this Agreement, with copies to:

Plaintiffs’ Counsel of Record:

Al Holifield, Esq.

Holifield & Associates, PLLC

11907 Kingston Pike, Suite 201

Knoxville, TN 37934

Telephone: (865) 566-0115

Eduard Korsinsky, Esq.

Steven J. Purcell, Esq.

Levi & Korsinsky

30 Broad Street, 24th Floor

New York, NY 10004

Telephone: (212) 363-7500

The SLC’s Counsel of Record:

Robert J. Walker

John C. Hayworth

Charles Malone

Walker, Tipps & Malone PLC

2300 One Nashville Place

150 Fourth Avenue North

Nashville, TN 37219

Telephone: (615) 313-6000

Notice solely by e-mail shall not be acceptable although a courtesy copy by e-mail is highly recommended.

24. Section Headings. Headings are used for convenience only and are not intended and shall not be used in interpreting any provisions of this Agreement.


Settlement and Release Agreement				Page 8

IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day and year set forth below.


PROVECTUS BIOPHARMACEUTICALS, INC., f/k/a PROVECTUS PHARMACEUTICALS, INC.

By:		/s/ Jan E. Koe

Name:		Jan E. Koe
Its:		Chairman, Special Litigation Committee
Dated:		June 6, 2014


ERIC A. WACHTER

/s/ Eric A. Wachter

Eric A. Wachter
Dated:		12 May 2014


APPROVED AND CONSENTED TO:

PLAINTIFFS GLENN KLEBA AND DON B. DALE, DERIVATIVELY ON BEHALF OF PROVECTUS BIOPHARMACEUTICALS, INC.

/s/ Al Holifield

By:		Steven Purcell and Al Holifield, Counsel to Plaintiffs
Dated:		13 May 2014


Settlement and Release Agreement				Page 9

Exhibit A

STOCK PLEDGE AGREEMENT

Settlement and Release Agreement

EX-31.1 3 d754969dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, H. Craig Dees, Ph.D., certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Provectus Biopharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 4 d754969dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Peter R. Culpepper, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Provectus Biopharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32 5 d754969dex32.htm EX-32 EX-32

Exhibit 32

CERTIFICATION PURSUANT TO RULE 13a-14(b) UNDER

THE SECURITIES EXCHANGE ACT OF 1934 AND

SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE

Each of the undersigned, H. Craig Dees, the Chief Executive Officer of Provectus Biopharmaceuticals, Inc. (the “Company”), and Peter R. Culpepper, Chief Financial Officer and Chief Operating Officer of the Company, certifies, pursuant to Rule 13a-14(b) under the Securities and Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act, and (2) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This Certification is signed on August 7, 2014.



By:		/s/ H. Craig Dees
		H. Craig Dees, Ph.D.
		Chief Executive Officer



By:		/s/ Peter R. Culpepper
		Peter R. Culpepper
		Chief Financial Officer
		Chief Operating Officer

EX-101.INS 6 pvct-20140630.xml XBRL INSTANCE DOCUMENT

33334

802

-1316198

6680000

6680

1310320

100000

2240000

0.25

1000000

100000

25000

4636020

1025950 1297950

3036218

176638439

300000000

3.00

176638439

372000

0.001

25000000

0.001

432763

816467

176638

-153361503

19979557

232568

22098985

7796177

173164422

104042

2119428

479857

18126036

26681

3919268

22098985

27000

18126036

1 1302961

1302961

1302961 1302961

0.75

0.08 25001

-153361503

176638439

176638

173164422

2000000

2.50

300000

11723580

-7066135

9423689

9424

18780291

10251052

-10221448

10867509

10868

20461632

9161701

-14565973

16133876

16134

23711540

14387141

-26329826

27822977

27823

40689144

15522400

-35200405

42452366

42452

50680353

14831510

-45206036

49399281

49399

59988147

10055536

-55475607

53017076

53017

65478126

9406510

-67797921

67410226

67410

77137021

10699573

-86350023

91297883

91298

5389998

5390

96952908

10019740

-105784722

110596798

110597

3531665

3531

115690334

4393484

1221701

-118353076

118427925

118428

2478185

2478

122625654

159751724

300000000

0.001

25000000

0.001

429331

512946

159752

-146050820

6628666

102795

20008184

7460617

152519701

61282

13379518

348869

15696243

30113

4254828

20008184

27000

15696243

12866572

12866572 12866572

0.75

33334

0.08 25001

-146050820

159751724

159752

33334

152519701

-4945316

123926235

-0.06

-6533534

-7697513

-6547555

283

93034

1518865

335560

3414319

3100

81437

8359635

1149958

4679109

-178673

1341295 2550000 -14304 -14304 5817698 29063 21000 98250

4881666

50358525

15097206

50860

<div> 3. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation at June 30, 2014 and 2013, respectively, relate to 58,311,418 and 50,358,525 from warrants, 13,718,334 and 15,097,206 from options, and 0 and 4,881,666 from convertible preferred shares. </div>

<div> A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2014 to June 30, 2014 follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="83%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,866,572</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Issuance of warrants </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Change in fair value of warrants included in earnings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,227,992</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Reclassification to APIC due to warrant exercises </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10,335,619</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at June 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,302,961</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

10-Q PROVECTUS BIOPHARMACEUTICALS, INC. Accelerated Filer

-6268093

<div> 6. Related Party Transaction The Company paid one of the Company’s directors $6,000 as of March 31, 2014, all of which was paid as part of his overall compensation of an aggregate of $85,000 for board and committee service. </div>

<div> (c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $1,153,835 and $311,062, respectively. During the three months ended March 31, 2014, 858,825 of the Series A Warrants were exercised. During the three months ended March 31, 2014, 697,092 of the Series C Warrants were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $186,262 and $221,149, respectively. The Company determined the fair value of the Series A and Series C Warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the Series A and Series C Warrants exercised in 2014 of $3,911,370 was reclassified into additional paid-in capital. (d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $211,422 and $446,698, respectively. During the three months ended March 31, 2014, 1,756,665 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $3,285,793 and $399,057, respectively. During the three months ended June 30, 2014, 133,232 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $2,377,133 was reclassified into additional paid-in capital. (e) In February 2013, the Company had an issuance of Series A 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $921,776 and $165,750, respectively. During the three months ended March 31, 2014, 1,650,000 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $42,970 and $289,000, respectively. During the three months ended June 30, 2014, 200,000 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $4,047,116 was reclassified into additional paid-in capital.   Dividends on the Series A 8% Convertible Preferred Stock accrued at an annual rate of 8% of the original issue price and were payable in either cash or common stock. If the dividend was paid in common stock, the number of shares of common stock equaled the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends were payable quarterly on the 15th day after the quarter-end. The Company paid the dividends in common stock although was required to pay the initial dividends due in cash. The Company had a deficit and, as a result, the dividends were recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In 2014, the Company recognized no dividends because of the full conversion of preferred stock to common stock as of January 15, 2014. (f) In January 2014 there were 33,334 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 33,334 shares of the Company’s common stock. As of January 15, 2014, there were no shares of Series A 8% Convertible Preferred Stock outstanding. (g) During the three months ended June 30, 2014 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,000,000. The Company accepted subscriptions, in the aggregate, for 2,000,000 shares of common stock and five year warrants to purchase 2,000,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $3.00 per share. The purchase price for each share of common stock together with the warrants was $2.50. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $650,000 and issued five year fully vested warrants to purchase 300,000 shares of common stock with an exercise price of $2.50 to Network 1 Financial Securities, Inc., which represents 15% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. </div>

172225322

2014-06-30

<div> The warrant liability measured at fair value on a recurring basis is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Derivative instruments: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Warrant liability at June 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,302,961</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,302,961</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Warrant liability at December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,866,572</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,866,572</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

false --12-31 2014

<div> 2. Recapitalization and Merger Provectus Biopharmaceuticals, Inc., formerly known as “Provectus Pharmaceuticals, Inc.,” “Provectus Pharmaceutical, Inc.” and “SPM Group, Inc.,” was incorporated under Colorado law on May 1, 1978. SPM Group ceased operations in 1991, and became a development-stage company effective January 1, 1992, with the new corporate purpose of seeking out acquisitions of properties, businesses, or merger candidates, without limitation as to the nature of the business operations or geographic location of the acquisition candidate. On April 1, 2002, SPM Group changed its name to “Provectus Pharmaceutical, Inc.” and reincorporated in Nevada in preparation for a transaction with Provectus Pharmaceuticals, Inc., a privately-held Tennessee corporation (“PPI”). On April 23, 2002, an Agreement and Plan of Reorganization between Provectus Pharmaceutical and PPI was approved by the written consent of a majority of the outstanding shares of Provectus Pharmaceutical. As a result, Provectus Pharmaceuticals, Inc. issued 6,680,000 shares of common stock in exchange for all of the issued and outstanding shares of PPI. As part of the acquisition, Provectus Pharmaceutical changed its name to “Provectus Pharmaceuticals, Inc.” and PPI became a wholly-owned subsidiary of Provectus. This transaction was recorded as a recapitalization of PPI. On November 19, 2002, the Company acquired Valley Pharmaceuticals, Inc., a privately-held Tennessee corporation formerly known as Photogen, Inc., by merging PPI with and into Valley and naming the surviving corporation “Xantech Pharmaceuticals, Inc.” Photogen, Inc. was separated from Photogen Technologies, Inc. in a non-pro-rata split-off to some of its shareholders. The assets of Photogen, Inc. consisted primarily of the equipment and intangibles related to its therapeutic activity and were recorded at their fair value. The majority shareholders of Valley were also the majority shareholders of Provectus. Valley had no revenues prior to the transaction with the Company. By acquiring Valley, the Company acquired its intellectual property, including issued U.S. patents and patentable inventions. On December 16, 2013, Provectus Pharmaceuticals, Inc. was reincorporated in Delaware and changed its name to Provectus Biopharmaceuticals, Inc. </div>

<div> 8. Litigation Kleba Shareholder Derivative Lawsuit On January 2, 2013, Glenn Kleba (the “Plaintiff”) derivatively on behalf of the Company, filed a shareholder derivative complaint in the Circuit Court for the State of Tennessee, Knox County (the “Court”), against H. Craig Dees, Timothy C. Scott, Eric A. Wachter, and Peter R. Culpepper (collectively, the “Executives”), Stuart Fuchs, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, together with the Executives, the “Individual Defendants”), and against the Company as a nominal defendant (the “Shareholder Derivative Lawsuit”). The Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties, (ii) waste of corporate assets, and (iii) unjust enrichment, all three claims based on the Plaintiff’s allegations that the defendants authorized and/or accepted stock option awards in violation of the terms of the Company’s 2002 Stock Plan (the “Plan”) by issuing stock options in excess of the amounts authorized under the Plan and delegated to defendant H. Craig Dees the sole authority to grant himself and the other Executives cash bonuses that the Plaintiff alleges to be excessive. In April 2013, the Company’s Board of Directors appointed a special litigation committee to investigate the allegations of the Shareholder Derivative Complaint and make a determination as to how the matter should be resolved. The special litigation committee conducted its investigation, and proceedings in the case were stayed pending the conclusion of the committee’s investigation. The Company has established a reserve of $100,000 for potential liabilities because such is the amount of the self-insured retention of its insurance policy. On March 6, 2014, the Company filed a Joint Notice of Settlement (the “Notice of Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company, the parties to the Notice of Settlement are the Plaintiff and the Individual Defendants. On June 6, 2014, the Company, in its capacity as a nominal defendant, entered into a Stipulated Settlement Agreement and Mutual Release (the “Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company and the Individual Defendants, plaintiffs Glenn Kleba and Don B. Dale are parties to the Settlement.   By entering into the Settlement, the settling parties have resolved the derivative claims to their mutual satisfaction. The Individual Defendants have not admitted the validity of any claims or allegations and the settling plaintiffs have not admitted that any claims or allegations lack merit or foundation. Under the terms of the Settlement, (i) the Executives each agreed (A) to re-pay to the Company $2.24 Million of the cash bonuses they each received in 2010 and 2011, which amount equals 70% of such bonuses or an estimate of the after-tax net proceeds to each Executive; provided, however, that subject to certain terms and conditions set forth in the Settlement, the Executives are entitled to a 2:1 credit such that total actual repayment may be $1.12 Million each; (B) to reimburse the Company for 25% of the actual costs, net of recovery from any other source, incurred by the Company as a result of the Shareholder Derivative Lawsuit; and (C) to grant to the Company a first priority security interest in 1,000,000 shares of the Company’s common stock owned by each such Executive to serve as collateral for the amounts due to the Company under the Settlement; (ii) Drs. Dees and Scott and Mr. Culpepper agreed to retain incentive stock options for 100,000 shares but shall forfeit 50% of the nonqualified stock options granted to each such Executive in both 2010 and 2011. The Settlement also requires that each of the Executives enter into new employment agreements with the Company, which were entered into on April 28, 2014, and that the Company adhere to certain corporate governance principles and processes in the future. Under the Settlement, Messrs. Fuchs and Smith and Dr. McMasters have each agreed to pay the Company $25,000 in cash, subject to reduction by such amount that the Company’s insurance carrier pays to the Company on behalf of such defendant pursuant to such defendant’s directors and officers liability insurance policy. The Settlement also provides for an award to plaintiffs’ counsel of attorneys’ fees and reimbursement of expenses in connection with their role in this litigation, subject to Court approval. On July 24, 2014, the Court approved the terms of the proposed Settlement and awarded $911,000 to plaintiffs’ counsel for attorneys’ fees and reimbursement of expenses in connection with their role in the Shareholder Derivative Lawsuit. Class Action Lawsuits On May 27, 2014, Cary Farrah and James H. Harrison, Jr., individually and on behalf of all others similarly situated (the “Farrah Case”), and on May 29, 2014, each of Paul Jason Chaney, individually and on behalf of all others similarly situated (the “Chaney Case”), and Jayson Dauphinee, individually and on behalf of all others similarly situated (the “Dauphinee Case”) (the plaintiffs in the Farrah Case, the Chaney Case and the Dauphinee Case collectively referred to as the “Plaintiffs”), each filed a class action lawsuit in the United States District Court for the Middle District of Tennessee against the Company, H. Craig Dees, Timothy C. Scott and Peter R. Culpepper (the “Defendants”) alleging violations by the Defendants of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. Specifically, the Plaintiffs in each of the Farrah Case, the Chaney Case and the Dauphinee Case allege that the Defendants are liable for making false statements and failing to disclose adverse facts known to them about the Company, in connection with the Company’s application to the FDA for Breakthrough Therapy Designation (“BTD”) in the Spring of 2014 and the FDA’s subsequent denial of the Company’s application for BTD. The Company intends to defend vigorously against all claims in these complaints. However, in view of the inherent uncertainties of litigation and the early stage of this litigation, the outcome of these cases cannot be predicted at this time. Likewise, the amount of any potential loss cannot be reasonably estimated. On July 9, 2014, the Plaintiffs and the Defendants filed joint motions in the Farrah Case, the Chaney Case and the Dauphinee Case to consolidate the cases and transfer them to United States District Court for the Eastern District of Tennessee. By order dated July 16, 2014, the United States District Court for the Middle District of Tennessee entered an order consolidating the Farrah Case, the Chaney Case and the Dauphinee Case (collectively and, as consolidated, the “Securities Litigation”) and transferred the Securities Litigation to the United States District Court for the Eastern District of Tennessee. Hurtado Shareholder Derivative Lawsuit On June 4, 2014, Karla Hurtado (the “Plaintiff”) derivatively on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the Middle District of Tennessee (the “Court”), against H. Craig Dees, Timothy C. Scott, Jan E. Koe, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, the “Individual Defendants”), and against the Company as a nominal defendant (the “Hurtado Shareholder Derivative Lawsuit”). The Hurtado Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties and (ii) abuse of control, both claims based on the Plaintiff’s allegations that the Individual Defendants recklessly permitted the Company to disclose false and misleading information and failed to implement adequate controls and procedures to ensure the accuracy of the Company’s disclosures. On July 25, 2014, the court presiding over the Hurtado Shareholder Derivative Lawsuit entered an order transferring the case to the United District Court for the Eastern District of Tennessee. It is anticipated that an order will be entered by agreement that will stay all activity in the Hurtado Shareholder Derivative Lawsuit pending the resolution of an anticipated motion to dismiss the anticipated consolidated amended complaint in the Securities Litigation. As a nominal defendant, no relief is sought against the Company itself in the Hurtado Shareholder Derivative Lawsuit. </div>

<div> 1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ended December 31, 2014. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued. </div>

0000315545

<div> 5. Stock-Based Compensation One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750, 14,248 options at an exercise price of $0.75 per share of common stock for $10,686 and 600,000 options at an exercise price of $0.93 per share of common stock for $558,000 during the three months ended March 31, 2014. Another employee of the Company exercised 300,000 options at an exercise price of $1.10 per share of common stock for $330,000 during the three months ended March 31, 2014. Another employee of the Company exercised 189,624 options at an exercise price of $1.10 per share of common stock for $208,586 during the three months ended March 31, 2014. One employee of the Company forfeited 300,000 stock options on February 26, 2014. One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. Another employee of the Company exercised 100,000 options at an exercise price of $1.25 per share of common stock for $125,000 during the three months ended June 30, 2014. A former non-employee member of the board exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. One employee of the Company forfeited 25,000 stock options on May 27, 2014. </div>

-0.04

<div> 7. Fair Value of Financial Instruments The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are measured and reported on a fair value basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. The fair value of certain of the Company’s financial instruments, including Cash and cash equivalents and Accounts payable, approximates the carrying value due to the relatively short maturity of such instruments. The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. The warrant liability is a derivative instrument and is classified as Level 3. The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used at March 31, 2014 for the 2010 warrants include a weighted average term of 0.9 years, a 5% probability that the warrant exercise price would be reset, volatility range of 66.5% to 129.7% and a risk free interest rate of 0.13%. Significant assumptions used at June 30, 2014 for the 2010 warrants include a weighted average term of 0.7 years, a 5% probability that the warrant exercise price would be reset, volatility of 187.7% and a risk free interest rate of 0.09%. Significant assumptions used at March 31, 2014 for the 2011 warrants include a weighted average term of 1.8 years, a 5% probability that the warrant exercise price would be reset, volatility of 101.8% and a risk free interest rate of 0.29%. Significant assumptions used at June 30, 2014 for the 2011 warrants include a weighted average term of 1.5 years, a 5% probability that the warrant exercise price would be reset, volatility of 132.7% and a risk free interest rate of 0.29%. Significant assumptions used at March 31, 2014 for the 2013 warrants include a weighted average term of 3.9 years, a 5% probability that the warrant exercise price would be reset, volatility of 84.7% and a risk free interest rate range of 0.77% to 1.32%. At June 30, 2014 there are no remaining 2013 warrants and therefore no associated warrant liability. The warrant liability measured at fair value on a recurring basis is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Derivative instruments: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Warrant liability at June 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,302,961</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,302,961</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Warrant liability at December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,866,572</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,866,572</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2014 to June 30, 2014 follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="83%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,866,572</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Issuance of warrants </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Change in fair value of warrants included in earnings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,227,992</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Reclassification to APIC due to warrant exercises </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10,335,619</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at June 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,302,961</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-8541491

-7310683

2816

85000

2183418

335560

2429793

3432

172533

8697886

6022513

130988

1350319 1227992 1227992 4327886 <div> 4. Equity Transactions (a) During the three months ended March 31, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $137,500. During the three months ended March 31, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $48,750. During the three months ended June 30, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $140,250. During the three months ended June 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $49,500. (b) During the three months ended March 31, 2014, the Company issued 733,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $900,317. During the three months ended March 31, 2014, 121,500 warrants were forfeited. During the three months ended March 31, 2014, 12,522,198 warrants were exercised on a cashless basis resulting in 9,100,824 common shares being issued. During the three months ended March 31, 2014, 3,036,218 warrants were exercised for $2,672,364 resulting in 3,036,218 common shares issued. During the three months ended March 31, 2013, the Company issued 1,924,973 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $409,640. During the three months ended March 31, 2013, 859,833 warrants were forfeited. During the three months ended June 30, 2014, the Company issued 202,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $450,002. During the three months ended June 30, 2014, 315,000 warrants were forfeited. During the three months ended June 30, 2014, 1,594,082 warrants were exercised on a cashless basis resulting in 915,467 common shares being issued. During the three months ended June 30, 2014, 372,000 warrants were exercised for $372,000 resulting in 372,000 common shares issued. During the three months ended June 30, 2013, the Company issued 2,605,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $931,655. During the three months ended June 30, 2013, 1,051,500 warrants were forfeited. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value of the warrants, determined using the Black-Scholes option-pricing model. (c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $1,153,835 and $311,062, respectively. During the three months ended March 31, 2014, 858,825 of the Series A Warrants were exercised. During the three months ended March 31, 2014, 697,092 of the Series C Warrants were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $186,262 and $221,149, respectively. The Company determined the fair value of the Series A and Series C Warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the Series A and Series C Warrants exercised in 2014 of $3,911,370 was reclassified into additional paid-in capital. (d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $211,422 and $446,698, respectively. During the three months ended March 31, 2014, 1,756,665 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $3,285,793 and $399,057, respectively. During the three months ended June 30, 2014, 133,232 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $2,377,133 was reclassified into additional paid-in capital. (e) In February 2013, the Company had an issuance of Series A 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $921,776 and $165,750, respectively. During the three months ended March 31, 2014, 1,650,000 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $42,970 and $289,000, respectively. During the three months ended June 30, 2014, 200,000 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $4,047,116 was reclassified into additional paid-in capital.   Dividends on the Series A 8% Convertible Preferred Stock accrued at an annual rate of 8% of the original issue price and were payable in either cash or common stock. If the dividend was paid in common stock, the number of shares of common stock equaled the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends were payable quarterly on the 15th day after the quarter-end. The Company paid the dividends in common stock although was required to pay the initial dividends due in cash. The Company had a deficit and, as a result, the dividends were recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In 2014, the Company recognized no dividends because of the full conversion of preferred stock to common stock as of January 15, 2014. (f) In January 2014 there were 33,334 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 33,334 shares of the Company’s common stock. As of January 15, 2014, there were no shares of Series A 8% Convertible Preferred Stock outstanding. (g) During the three months ended June 30, 2014 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,000,000. The Company accepted subscriptions, in the aggregate, for 2,000,000 shares of common stock and five year warrants to purchase 2,000,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $3.00 per share. The purchase price for each share of common stock together with the warrants was $2.50. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $650,000 and issued five year fully vested warrants to purchase 300,000 shares of common stock with an exercise price of $2.50 to Network 1 Financial Securities, Inc., which represents 15% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. </div> 4350000 4347886 10355619 1350319 277750 277750 4350000

58311418

13718334

-1227992

-10335619

-7310683

33334

2000000 150000 14703 14703381 150 2000

-33334

-33

4313183 10355619 1350319 277600 4348000 0.05 1.877 0.0009 P8M12D 0.05 1.327 0.0029 P1Y6M

300000

25000

6680000

1120000

2 0.70 0.50 911000 0

-5749937

126587

48000

12226320 27000 453 -3645 5144000

-5749937

400000

400

265763 500 1900000 25 452919 453 500007 25000 266 1900

126587

47600

12225820 26975 -3911 5142100

0.08

33334

0.08

6000

-3155313

601000

34659 281500 145479 380347 239800

-3155313

764000 680 679820 764

601000

34659 281500 145479 379667 239036

3049362

-11763853

1633176

39529 985010 144128 15752 1439795 1574900 196031 6513176 1534405 152285

-11763853

3405541

3405

226733 1572 6221257 263721 264 6221 1571849 227

3045957

1633176

39529 985010 144128 15752 1438223 1574900 195767 6506955 1534405 152058

1576336

-8870579

16447 1862456 1189816 183596 4130421 370023 676743

-8870579

2377512

2377

719246 1246 10092495 194327 195 10092 1245809 719

1573959

16447 1862456 1188570 183401 4120329 370023 676024

367500

-10005631

2340619 3985641 1258 1848138 472635 298950

-10005631

490000

490

150000 3929 2376817 1141 1 2377 3928957 150

367010

2340619 3981712 1257 1845761 472635 298800

-12322314

870937 2524453 6518688 1064210 695000

-12322314

796012 3480 10116653 10117 3480485 796 870937 2520973 6508571 1064210 694204

-18552102

3759650 3103680 4217390 1141593 419250 856613 6346989

-18552102

7893326

7893

11168067 776250 3491 559 3491014 559000 776 11169

-7893326

-7893

13283324 13283 3759650 3100189 4204107 1141593 418691 855837 6335820

-19434699

3368950 6623311 443500 945116 332750 7041239

-19434699

1858331

1859

9905062 350000 7185 7185522 350 9905

-1858333

-1859

3368950 6616126 443500 945116 332400 7031334

-27697744

29063

142310 7835470 1252050 1786824 526000 18419335

-27697744

5844852

5845

28409353 750000 6320 6319594 750 28409

-5844852

-5845

3400001 3400

29063

142310 7829150 1248650 1786824 525250 18390926

-4344525

360256

258345 15612 105250 5000 1288861 495480 793137 449923

-4344525

733872 132608 133 1930164 1930 2469 2469723 734

360256

258345 15612 105250 4867 1286930 495480 790668 449190

-10269571

1946066 2639711 517820 390000

-10269571

350000 3268 3267795 350 1946066 2636443 517820 389650

-12568354

183028 1512026 456500 4790544

-12568354

1053480

1053

6227647 550000 550 6228

-1053480

-1053

183028 1512026 455950 4784316

-92175185

2385959

36637186

55075

48000

96570

-153361503

-825867

2261584

7796177

18126036

456800

443500

455764

180075

14540039

3845721

486240

109844421

6706795

37010481

476212

9333712 11458131 310866 -7530937 174000 1295226 65583856 29063 28859292 170519 389950 373295 236146 9857261 55976 932000 985010 747612

-8098004

24541

25648

39757

55075

-137619128

-165388213

-153361503

657358

-825867

48877826

15216

7796177

12026710

80969666

-7530937 14109

75000

859833 -311062 1924973 409640 48750 -446698 -165750

29063

75000

0.08

121500 -1153835 12522198 2672364 3036218 9100824 733000 900317 0.0132 1.297 0.0077 0.665

1.10

189624

208586

0.95

25000

23750

1.10

300000

330000

0.75

14248

10686

0.93

600000

558000

137500

1756665

-211422 -921776

1650000

0.05 0.847 P3Y10M24D 0.05 0.0013 P10M24D 0.05 1.018 0.0029 P1Y9M18D 858825 697092

75000

127114868

-0.02

-3286835

-2450397

-2377373

256

778349

167780

73024

2340706

1051500 909206 221149 2605000 931655 49500 399057 289000

2000000

75000

175554000

0.00

-4159884

-643416

1443

1025535

167780

2966569

5000000 2.50 315000 3515025 186262 1594082 372000 372000 915467 1.00 202000 450002

0.95

25000

23750

1.25

100000

125000

0.95

25000

23750

140250

133232

3285793 2377133 42970

200000

4047116 3911370 P5Y

650000

0.15

25000

-1316198

932000 360000

-1316198

50000

120000 510 510000 6000 6000000 120

24950

931490 -6000 359880 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-01-18 2002-04-23 0000315545 us-gaap:CommonStockMember 2002-01-18 2002-04-23 0000315545 us-gaap:RetainedEarningsMember 2002-01-18 2002-04-23 0000315545 2002-01-18 2002-04-23 0000315545 pvct:NetworkOneFinancialSecuritiesIncMember 2014-04-01 2014-06-30 0000315545 pvct:FiveYearWarrantMember 2014-04-01 2014-06-30 0000315545 pvct:SeriesAAndSeriesCWarrantsMember 2014-04-01 2014-06-30 0000315545 pvct:SeriesConvertiblePreferredStockMember 2014-04-01 2014-06-30 0000315545 pvct:WarrantOneMember 2014-04-01 2014-06-30 0000315545 us-gaap:WarrantMember 2014-04-01 2014-06-30 0000315545 us-gaap:CommonStockMember 2014-04-01 2014-06-30 0000315545 pvct:EmployeeOneMember 2014-04-01 2014-06-30 0000315545 pvct:OptionsExercisedPriceOneMemberpvct:EmployeeThreeMember 2014-04-01 2014-06-30 0000315545 pvct:OptionsExercisedPriceOneMemberpvct:NonemployeeMember 2014-04-01 2014-06-30 0000315545 2014-04-01 2014-06-30 0000315545 pvct:WarrantOneMember 2013-04-01 2013-06-30 0000315545 us-gaap:WarrantMember 2013-04-01 2013-06-30 0000315545 us-gaap:CommonStockMember 2013-04-01 2013-06-30 0000315545 2013-04-01 2013-06-30 0000315545 pvct:SeriesCWarrantMember 2014-01-01 2014-03-31 0000315545 pvct:SeriesaWarrantMember 2014-01-01 2014-03-31 0000315545 pvct:TwoThousandElevenWarrantsMember 2014-01-01 2014-03-31 0000315545 pvct:TwoThousandTenWarrantsMember 2014-01-01 2014-03-31 0000315545 pvct:TwoThousandThirteenWarrantsMember 2014-01-01 2014-03-31 0000315545 pvct:SeriesConvertiblePreferredStockMember 2014-01-01 2014-03-31 0000315545 pvct:WarrantOneMember 2014-01-01 2014-03-31 0000315545 us-gaap:WarrantMember 2014-01-01 2014-03-31 0000315545 us-gaap:CommonStockMember 2014-01-01 2014-03-31 0000315545 pvct:OptionsExercisedPriceThreeMemberpvct:EmployeeOneMember 2014-01-01 2014-03-31 0000315545 pvct:OptionsExercisedPriceTwoMemberpvct:EmployeeOneMember 2014-01-01 2014-03-31 0000315545 pvct:OptionsExercisedPriceOneMemberpvct:EmployeeTwoMember 2014-01-01 2014-03-31 0000315545 pvct:OptionsExercisedPriceOneMemberpvct:EmployeeOneMember 2014-01-01 2014-03-31 0000315545 pvct:OptionsExercisedPriceOneMemberpvct:EmployeeThreeMember 2014-01-01 2014-03-31 0000315545 pvct:TwoThousandTenWarrantsMemberus-gaap:MinimumMember 2014-01-01 2014-03-31 0000315545 pvct:TwoThousandThirteenWarrantsMemberus-gaap:MinimumMember 2014-01-01 2014-03-31 0000315545 pvct:TwoThousandTenWarrantsMemberus-gaap:MaximumMember 2014-01-01 2014-03-31 0000315545 pvct:TwoThousandThirteenWarrantsMemberus-gaap:MaximumMember 2014-01-01 2014-03-31 0000315545 2014-01-01 2014-03-31 0000315545 pvct:SeriesConvertiblePreferredStockMember 2013-01-01 2013-03-31 0000315545 pvct:WarrantOneMember 2013-01-01 2013-03-31 0000315545 us-gaap:WarrantMember 2013-01-01 2013-03-31 0000315545 us-gaap:CommonStockMember 2013-01-01 2013-03-31 0000315545 2013-01-01 2013-03-31 0000315545 2002-01-18 2014-06-30 0000315545 2002-02-01 2014-06-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0000315545 us-gaap:PreferredStockMember 2012-01-01 2012-12-31 0000315545 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0000315545 us-gaap:RetainedEarningsMember 2012-01-01 2012-12-31 0000315545 2012-01-01 2012-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2008-01-01 2008-12-31 0000315545 us-gaap:CommonStockMember 2008-01-01 2008-12-31 0000315545 us-gaap:RetainedEarningsMember 2008-01-01 2008-12-31 0000315545 2008-01-01 2008-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2004-01-01 2004-12-31 0000315545 us-gaap:CommonStockMember 2004-01-01 2004-12-31 0000315545 us-gaap:RetainedEarningsMember 2004-01-01 2004-12-31 0000315545 2004-01-01 2004-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0000315545 us-gaap:PreferredStockMember 2013-01-01 2013-12-31 0000315545 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0000315545 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0000315545 2013-01-01 2013-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0000315545 us-gaap:PreferredStockMember 2011-01-01 2011-12-31 0000315545 us-gaap:CommonStockMember 2011-01-01 2011-12-31 0000315545 us-gaap:RetainedEarningsMember 2011-01-01 2011-12-31 0000315545 2011-01-01 2011-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0000315545 us-gaap:PreferredStockMember 2010-01-01 2010-12-31 0000315545 us-gaap:CommonStockMember 2010-01-01 2010-12-31 0000315545 us-gaap:RetainedEarningsMember 2010-01-01 2010-12-31 0000315545 2010-01-01 2010-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2009-01-01 2009-12-31 0000315545 us-gaap:CommonStockMember 2009-01-01 2009-12-31 0000315545 us-gaap:RetainedEarningsMember 2009-01-01 2009-12-31 0000315545 2009-01-01 2009-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2007-01-01 2007-12-31 0000315545 us-gaap:CommonStockMember 2007-01-01 2007-12-31 0000315545 us-gaap:RetainedEarningsMember 2007-01-01 2007-12-31 0000315545 2007-01-01 2007-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2006-01-01 2006-12-31 0000315545 us-gaap:CommonStockMember 2006-01-01 2006-12-31 0000315545 us-gaap:RetainedEarningsMember 2006-01-01 2006-12-31 0000315545 2006-01-01 2006-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2005-01-01 2005-12-31 0000315545 us-gaap:CommonStockMember 2005-01-01 2005-12-31 0000315545 us-gaap:RetainedEarningsMember 2005-01-01 2005-12-31 0000315545 2005-01-01 2005-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2003-01-01 2003-12-31 0000315545 us-gaap:CommonStockMember 2003-01-01 2003-12-31 0000315545 us-gaap:RetainedEarningsMember 2003-01-01 2003-12-31 0000315545 2003-01-01 2003-12-31 0000315545 2014-03-01 2014-03-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2010-03-01 2010-03-31 0000315545 2014-01-01 2014-01-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2010-04-01 2010-04-30 0000315545 pvct:SeriesConvertiblePreferredStockMember 2014-02-01 2014-02-28 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-04-24 2002-12-31 0000315545 us-gaap:CommonStockMember 2002-04-24 2002-12-31 0000315545 us-gaap:RetainedEarningsMember 2002-04-24 2002-12-31 0000315545 2002-04-24 2002-12-31 0000315545 2014-01-14 2014-01-15 0000315545 us-gaap:SubsequentEventMember 2014-07-23 2014-07-24 0000315545 us-gaap:ExecutiveOfficerMember 2014-06-05 2014-06-06 0000315545 2014-06-05 2014-06-06 0000315545 2002-04-22 2002-04-23 0000315545 pvct:EmployeeOneMember 2014-05-26 2014-05-27 0000315545 2014-02-25 2014-02-26 0000315545 pvct:TwoThousandElevenWarrantsMember 2014-01-01 2014-06-30 0000315545 pvct:TwoThousandTenWarrantsMember 2014-01-01 2014-06-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-06-30 0000315545 us-gaap:PreferredStockMember 2014-01-01 2014-06-30 0000315545 us-gaap:CommonStockMember 2014-01-01 2014-06-30 0000315545 us-gaap:RetainedEarningsMember 2014-01-01 2014-06-30 0000315545 pvct:SeriesConvertiblePreferredStockMember 2014-01-01 2014-06-30 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2014-01-01 2014-06-30 0000315545 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-06-30 0000315545 us-gaap:WarrantMember 2014-01-01 2014-06-30 0000315545 us-gaap:ConvertiblePreferredStockMember 2014-01-01 2014-06-30 0000315545 2014-01-01 2014-06-30 0000315545 pvct:SeriesConvertiblePreferredStockMember 2013-01-01 2013-06-30 0000315545 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-06-30 0000315545 us-gaap:WarrantMember 2013-01-01 2013-06-30 0000315545 us-gaap:ConvertiblePreferredStockMember 2013-01-01 2013-06-30 0000315545 2013-01-01 2013-06-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000315545 us-gaap:PreferredStockMember 2013-12-31 0000315545 us-gaap:CommonStockMember 2013-12-31 0000315545 us-gaap:RetainedEarningsMember 2013-12-31 0000315545 pvct:SeriesConvertiblePreferredStockMember 2013-12-31 0000315545 us-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember 2013-12-31 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2013-12-31 0000315545 2013-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000315545 us-gaap:PreferredStockMember 2012-12-31 0000315545 us-gaap:CommonStockMember 2012-12-31 0000315545 us-gaap:RetainedEarningsMember 2012-12-31 0000315545 2012-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000315545 us-gaap:PreferredStockMember 2011-12-31 0000315545 us-gaap:CommonStockMember 2011-12-31 0000315545 us-gaap:RetainedEarningsMember 2011-12-31 0000315545 2011-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0000315545 us-gaap:PreferredStockMember 2010-12-31 0000315545 us-gaap:CommonStockMember 2010-12-31 0000315545 us-gaap:RetainedEarningsMember 2010-12-31 0000315545 2010-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2009-12-31 0000315545 us-gaap:CommonStockMember 2009-12-31 0000315545 us-gaap:RetainedEarningsMember 2009-12-31 0000315545 2009-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2008-12-31 0000315545 us-gaap:CommonStockMember 2008-12-31 0000315545 us-gaap:RetainedEarningsMember 2008-12-31 0000315545 2008-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2007-12-31 0000315545 us-gaap:CommonStockMember 2007-12-31 0000315545 us-gaap:RetainedEarningsMember 2007-12-31 0000315545 2007-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2006-12-31 0000315545 us-gaap:CommonStockMember 2006-12-31 0000315545 us-gaap:RetainedEarningsMember 2006-12-31 0000315545 2006-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2005-12-31 0000315545 us-gaap:CommonStockMember 2005-12-31 0000315545 us-gaap:RetainedEarningsMember 2005-12-31 0000315545 2005-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2004-12-31 0000315545 us-gaap:CommonStockMember 2004-12-31 0000315545 us-gaap:RetainedEarningsMember 2004-12-31 0000315545 2004-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2003-12-31 0000315545 us-gaap:CommonStockMember 2003-12-31 0000315545 us-gaap:RetainedEarningsMember 2003-12-31 0000315545 2003-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-12-31 0000315545 us-gaap:CommonStockMember 2002-12-31 0000315545 us-gaap:RetainedEarningsMember 2002-12-31 0000315545 2002-12-31 0000315545 pvct:NetworkOneFinancialSecuritiesIncMember 2014-06-30 0000315545 pvct:FiveYearWarrantMember 2014-06-30 0000315545 pvct:TwoThousandThirteenWarrantsMember 2014-06-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2014-06-30 0000315545 us-gaap:CommonStockMember 2014-06-30 0000315545 us-gaap:RetainedEarningsMember 2014-06-30 0000315545 pvct:SeriesConvertiblePreferredStockMember 2014-06-30 0000315545 us-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember 2014-06-30 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2014-06-30 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2014-06-30 0000315545 us-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2014-06-30 0000315545 2014-06-30 0000315545 2014-03-31 0000315545 2013-06-30 0000315545 pvct:OtherDefendantsMember 2014-06-06 0000315545 us-gaap:ExecutiveOfficerMember 2014-06-06 0000315545 2014-06-06 0000315545 2013-04-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-04-23 0000315545 us-gaap:CommonStockMember 2002-04-23 0000315545 us-gaap:RetainedEarningsMember 2002-04-23 0000315545 2002-04-23 0000315545 2014-01-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-01-31 0000315545 us-gaap:PreferredStockMember 2002-01-31 0000315545 us-gaap:CommonStockMember 2002-01-31 0000315545 us-gaap:RetainedEarningsMember 2002-01-31 0000315545 2002-01-31 iso4217:USD shares pure iso4217:USD shares pvct:Directors

EX-101.SCH 7 pvct-20140630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited) link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Recapitalization and Merger link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Basic and Diluted Loss Per Common Share link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Equity Transactions link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Related Party Transaction link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Litigation link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Equity Transactions (Policies) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Fair Value of Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Recapitalization and Merger - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Basic and Diluted Loss Per Common Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Equity Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Related Party Transaction - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Fair Value of Financial Instruments - Warrant Liability Measured at Fair Value on a Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Litigation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 pvct-20140630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 pvct-20140630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 pvct-20140630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable Trade Current Accounts payable - trade Accretion of united states treasury bills. Accretion Of United States Treasury Bills Accretion of United States Treasury Bills Accrued Professional Fees Current Accrued consulting expense Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Accumulated depreciation on equipment and furnishings Additional Paid In Capital Paid-in capital Additional Paid In Capital [Member] Paid in Capital [Member] Adjustments to additional paid in capital beneficial conversion related to interest expense value. Adjustments To Additional Paid In Capital Beneficial Conversion Related To Interest Expense Value Beneficial conversion related to interest expense Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature Beneficial conversion related to convertible debt Adjustments to additional paid in capital employee compensation from stock options value. Adjustments To Additional Paid In Capital Employee Compensation From Stock Options Value Employee compensation from stock options Adjustments to additional paid in capital issuance of convertible debt with warrants value. Adjustments To Additional Paid In Capital Issuance Of Convertible Debt With Warrants Value Issuance of convertible debt with warrants Adjustments to additional paid in capital issuance of warrants for contractual. Adjustments To Additional Paid In Capital Issuance Of Warrants For Contractual Obligations Value Issuance of warrants for contractual obligations Adjustments to additional paid in capital repurchase of beneficial conversion feature value. Adjustments To Additional Paid In Capital Repurchase Of Beneficial Conversion Feature Value Repurchase of beneficial conversion feature Adjustments to additional paid in capital stock to be issued for services value. Adjustments To Additional Paid In Capital Stock To Be Issued For Services Value Stock to be issued for services Adjustments To Additional Paid In Capital Warrant Issued Warrants issued in connection with convertible debt Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Adjustment to additional paid in capital sale of non controlling interest and warrants. Adjustment To Additional Paid In Capital Sale Of Non Controlling Interest And Warrants Sale of non-controlling interest in Pure-ific Corporation and warrants Aggregate exercise price of warrants exercised. Aggregate Exercise Price Of Warrants Exercised Exercise price of warrants Aggregate liquidation preference. Aggregate Liquidation Preference Aggregate liquidation preference Amendment Flag Amendment Flag Amortization of commitment fee. Amortization Of Commitment Fee Amortization of commitment fee Amortization Of Debt Discount Premium Amortization of original issue discount Amortization Of Financing Costs Amortization of deferred loan costs Amortization Of Intangible Assets Amortization Amortization of patents Amortization of prepaid consultant expense. Amortization Of Prepaid Consultant Expense Amortization of prepaid consultant expense Amount reclassified from warrant liability to equity. Amount Reclassified From Warrant Liability To Equity Reclassification to APIC due to warrant exercises Reclassification of warrant liability Reclassification of warrant liability to equity due to exercise of warrants Annual cash bonus percentage. Annual Cash Bonus Percentage Estimated bonus percentage Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Common shares excluded from the calculation Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Assets Total Assets Assets [Abstract] Assets Assets Current Total Current Assets Assets Current [Abstract] Current Assets Attorneys Fees Awarded By Court In Legal Settlement Attorneys Fees Awarded By Court In Legal Settlement Attorney's fees and reimbursement of expenses Award Type [Axis] Award Type [Axis] Beneficial conversion of convertible interest. Beneficial Conversion Of Convertible Interest Beneficial conversion of convertible interest Business Combination Disclosure [Text Block] Recapitalization and Merger Business Combinations [Abstract] Business Combinations [Abstract] Cash And Cash Equivalents At Carrying Value Cash and cash equivalents, at end of period Cash and cash equivalents, at beginning of period Cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Net change in cash and cash equivalents Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Supplemental Disclosure of Noncash Investing and Financing Activities Cash paid for deferred loan costs. Cash Paid For Deferred Loan Costs Cash paid for deferred loan costs Cash paid for preferred dividend. Cash Paid For Preferred Dividend Cash paid for preferred dividends Class Of Stock [Domain] Class of Stock [Domain] Class Of Stock [Line Items] Class of Stock [Line Items] Class Of Warrant Or Right [Axis] Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Class Of Warrant Or Right Exercise Price Of Warrants Or Rights 1 Exercise price of common stock Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Common stock to be issued on exercise of warrant Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments Contingencies And Guarantees [Text Block] Litigation Common stock issued under recapitalization transactions. Common Stock Issued Under Recapitalization Transactions Common stock shares issued Common Stock [Member] Common Stock [Member] Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common stock unit beneficial conversion amount. Common Stock Unit Beneficial Conversion Amount Beneficial conversion amount Common stock unit fair value of warrants recorded on issuance. Common Stock Unit Fair Value Of Warrants Recorded On Issuance Fair value of the warrants Common Stock Value Common stock; par value $.001 per share; 300,000,000 authorized; 176,638,439 and 159,751,724 shares issued and outstanding, respectively Compensation through issuance of stock. Compensation Through Issuance Of Stock Compensation through issuance of stock Consulting costs. Consulting Costs Consulting costs charges Consulting costs relates to warrant issued. Consulting Costs Relates To Warrant Issued Consulting costs charges related to warrants Convertible interest. Convertible Interest Convertible interest Convertible Preferred Stock [Member] 8% Convertible Preferred Stock [Member] Convertible Preferred Stock Shares Issued Upon Conversion Preferred stock converted into shares Convertible preferred stock shares to be converted to common stock shares. Convertible Preferred Stock Shares To Be Converted To Common Stock Shares Converted preferred stock Cost Of Goods And Services Sold Cost of sales Current Fiscal Year End Date Current Fiscal Year End Date Depreciation Depreciation Derivative By Nature [Axis] Derivative, by Nature [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Name [Domain] Derivative, Name [Domain] Derivatives Policy [Text Block] Derivatives Policies Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-Based Compensation Dividends Preferred Stock Dividends on preferred stock Dividends on preferred stock Dividends Preferred Stock Cash Dividends on preferred stock Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share Basic And Diluted Basic and diluted loss per common share Earnings Per Share [Text Block] Basic and Diluted Loss Per Common Share Employee one. Employee One [Member] Employee One [Member] Employee Stock Option [Member] Stock Options [Member] Employee Three [Member] Employee Three [Member] Employee Three [Member] Employee Two [Member] Employee Two [Member] Employee Two [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Equity transactions. Equity Transactions [Text Block] Equity Transactions Executive Officer [Member] Executive Officer [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value, Hierarchy [Axis] Fair Value By Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Fair Value Inputs Level 1 [Member] Level 1 [Member] Fair Value Inputs Level 2 [Member] Level 2 [Member] Fair Value Inputs Level 3 [Member] Level 3 [Member] Fair Value Liabilities Measured On Recurring Basis [Text Block] Warrant Liability Measured at Fair Value on a Recurring Basis Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Measurements Recurring [Member] Recurring [Member] Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings Change in fair value of warrants included in earnings Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues Issuance of warrants Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Ending Balance Beginning Balance Finite Lived Intangible Assets Accumulated Amortization Amortization on patents Finite Lived Intangible Assets Net Patents, net of amortization of $7,796,177 and $7,460,617, respectively Five year warrant. Five Year Warrant [Member] Five Year Warrant [Member] Future payments ratio of contingent consideration. Future Payments Ratio Of Contingent Consideration Future payment ratio of contingent consideration Gain loss on change in fair value of warrant liability. Gain Loss On Change In Fair Value Of Warrant Liability (Loss) gain on change in fair value of warrant liability Gain loss on fair value of warrant liability. Gain Loss On Fair Value Of Warrant Liability Loss (gain) on change in fair value of warrant liability Gain loss on revaluation of warrants liability. Gain Loss On Revaluation Of Warrants Liability Gain (loss) on revaluation of warrants liability Gain Loss On Sale Of Property Plant Equipment Gain on sale of fixed assets Gain on sale of equipment Gains Losses On Extinguishment Of Debt Loss on extinguishment of debt Loss on extinguishment of debt General And Administrative Expense General and administrative Gross proceeds from sales of common stock and warrants. Gross Proceeds From Sales Of Common Stock And Warrants Gross proceeds from private offering of common stock and warrants to accredited investors Gross Profit Gross profit Income Statement [Abstract] Income Statement [Abstract] Increase Decrease In Accounts Payable Trade Accounts payable Increase Decrease In Accrued Liabilities Accrued expenses Increase Decrease In Other Operating Assets And Liabilities Net [Abstract] Change in assets and liabilities Increase Decrease In Prepaid Expense Prepaid expenses and other current assets Interest Income Expense Net Net interest expense Investment Income Interest Investment income Issuance of common stock and warrants pursuant to regulation D. Issuance Of Common Stock And Warrants Pursuant To Regulation D Shares Issuance of common stock and warrants pursuant to Regulation D, shares Issuance of common stock and warrants pursuant to regulation D value. Issuance Of Common Stock And Warrants Pursuant To Regulation D Value Issuance of common stock and warrants pursuant to Regulation D Issuance of stock for services. Issuance Of Stock For Services Issuance of stock for services Issuance of warrants for contractual obligations. Issuance Of Warrants For Contractual Obligations Issuance of warrants for contractual obligations Issuance of warrants for services. Issuance Of Warrants For Services Issuance of warrants for services Legal Entity [Axis] Legal Entity [Axis] Liabilities Total Liabilities Liabilities And Stockholders Equity Total Liabilities and Stockholders' Equity Liabilities And Stockholders Equity [Abstract] Liabilities and Stockholders' Equity Liabilities Current Total Current Liabilities Liabilities Current [Abstract] Current Liabilities Liabilities Noncurrent [Abstract] Long-Term Liability Litigation Reserve Reserve for litigation Loss Contingencies [Line Items] Loss Contingencies [Line Items] Loss Contingencies [Table] Loss Contingencies [Table] Loss Contingency Damages Paid Value Repayment under contingency Loss Contingency Receivable Damages sought to be receivable Loss on exercise of warrants. Loss On Exercise Of Warrants Loss on exercise of warrants Maximum [Member] Maximum [Member] Medical device revenue. Medical Device Revenue Medical device revenue Minimum [Member] Minimum [Member] Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Net Cash Provided By Used In Financing Activities [Abstract] Cash Flows From Financing Activities Net Cash Provided By Used In Investing Activities Net cash provided by investing activities Net Cash Provided By Used In Investing Activities [Abstract] Cash Flows From Investing Activities Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Cash Provided By Used In Operating Activities [Abstract] Cash Flows From Operating Activities Net Income Loss Net loss Net loss Net Income Loss Available To Common Stockholders Basic Net loss applicable to common shareholders Net proceeds from loans from stockholder. Net Proceeds From Loans From Stockholder Net proceeds from loans from stockholder Net proceeds from sales of common stock and warrants. Net Proceeds From Sales Of Common Stock And Warrants Net proceeds from sales of common stock and warrants Net proceeds from sales of preferred stock and warrants. Net Proceeds From Sales Of Preferred Stock And Warrants Net proceeds from sales of preferred stock and warrants Network one financial securities. Network One Financial Securities Inc [Member] Network 1 Financial Securities [Member] Non employee. Nonemployee [Member] Non Employee [Member] Number of non employee to whom consulting services paid. Number Of Non Employee To Whom Consulting Services Paid Number of directors to whom board and committee service paid Number of shares issuable on exercises of warrants issued. Number Of Shares Issuable On Exercises Of Warrants Issued Number of shares issuable on exercises of warrants issued Number of warrants exercised. Number Of Warrants Exercised Warrants series exercised Number of warrants exercised during period. Number Of Warrants Exercised During Period Warrants exercised Operating Expenses [Abstract] Operating expenses Operating Income Loss Total operating loss Options exercised price one. Options Exercised Price One [Member] Options Exercised Price One [Member] Options Exercised Price Three [Member] Options Exercised Price Three [Member] Options Exercised Price Three [Member] Options exercised price two. Options Exercised Price Two [Member] Options Exercised Price Two [Member] Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Basis of Presentation Other Accrued Liabilities Current Other accrued expenses Other Assets Noncurrent Other assets Other defendants. Other Defendants [Member] Other Defendants [Member] Payments For Repurchase Of Common Stock Purchase and retirement of common stock Payments Of Stock Issuance Costs Payment of fully vested warrants Payments To Acquire Investments Purchases of investments Payments To Acquire Property Plant And Equipment Capital expenditures Percentage of aggregate shares called by warrant. Percentage Of Aggregate Shares Called By Warrant Percentage of total number of shares of common stock sold to investors Percentage of common shares issuable on exercise of each warrant. Percentage Of Common Shares Issuable On Exercise Of Each Warrant Investors received five year warrants Period of life of warrants issued. Period Of Life Of Warrants Issued Expiration of warrants Preferred Stock Dividend Rate Percentage Convertible preferred stock The percentage rate used to calculate dividend payments on preferred stock. Preferred Stock Dividends Rate Percentage Convertible preferred stock EX-101.PRE 11 pvct-20140630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`2PA3]O@$``&`1```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/@S`4AN]-_`^DMP9* M4>AX:\X3V#T;*N M@@486RJ9$A;%)`"9*5'*:4H^)B]AGP36<2EXI22D9`66C(:7%X/)2H,-_&YI M4U(XIQ\HM5D!-;>1TB#]3*Y,S9V_-5.J>3;C4Z!)'/=HIJ0#Z4+7U"##P1/D M?%ZYX'GI'Z])#%26!(_KA8U62KC659EQYTGI0HH]E7"C$/F=[1I;E-I>>0Q" M.Q6:F=\%-OO>_-&84D`PYL:]\MICT&5%OY29?2HUBPX7Z:!4>5YF(%0VK_T) M1%8;X,(6`*ZNHG:,:E[*+?W`S@S2O%];^$2.!`G'-1*.&R0D@X[I!P])%PW"/A8#$6$"R.RK!8*L/BJ0R+J3(LKLJPV"K#XJL,B[$R+,Z: M8''6!(NS)EB<-<'BK`D69TW^RUF=SZ]`V^O?/].VS)$`9=VJ`GOFGYYUT6/* M!3<@WIWQ2?_L`#]K'^+P.7ALE+:^(V#@]%/81OYF=ZA](3"NA%WH[PK/.T7? M33A=<"^]0].O$"`ZM&G;'QE^`P``__\#`%!+`P04``8`"````"$`M54P(_4` M``!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/; MT?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W> M;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I" MRTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0`````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````"\ETUKPS`,AN^#_8?@^^K(_1Y- M>QF#7K?N!YA$34(3.]C>1__]3+>E*W3:)>@2L$/DET?2&WFU^6B;Y`V=KZW) M!(Q2D:#);5&;,A,ON\>[A4A\T*;0C368B2-ZL5G?WJR>L-$A?N2KNO-)C&)\ M)JH0NGLI?5YAJ_W(=FCBF[UUK0YQZ4K9Z?R@2Y0J36?2_8XAUA_K'!]L_MJB"5>.D._6'7R%&&)0[4H,F>BWO#R]68RB8B&O MBX$QLQH8DW*XX0!)1\V&I!-B#>$Y3Z>E/#V!8L*=(3)!"H8DTI?JF4J_]5V] MBF0S9U8SIQ(%BED-*%(.-QP@Z:@I,QTUI>APYXI.U:`^T[?0WUT%,Y)-_&>R M_J)42LGAMAS2<;@S128*V-&0;-2$NVXF5-UP&P[I-\"M!D@YBGNJ4/18,>C< MYROML'@.+L[\_FR"%]M4X0"W_P'M?TOFMH(E18>[RYT9#D@%N-$"R4>PS M#CGDJ$'G41^.3;RY][?>K_5/W*8DIR MX/W"?8\3;889,S3K^F<0RBU]]T&5Q6W).*Q>=L*.'_2J(N?*R^B*E-PLH;P] M.N@5G\;QN?VEE>*1T:VNDVSHO3PQDL*5MUICJ"SR/77% MX$6-L\@2QRAWL^E@.%T,!PF\+6:3\:"_A."V/^E/[X8()48H\?^A`(&*3`?! M.+T_06:Q!$[WF,PI0CD]0*8NY"UWNEPDLU&R6,X0%]"^$N;L`,HA8=[P<$GG M",89`Y=T2S33B5PELNC M(\)4\DAX2>UQC)@@(F6$0\]HHTJ,@ZT>M4PZ88:M6_2QKZ.6)0^(E\PE9RF# MV8J:`_LZ:EGR>`78DG;4U&JV3'G$5DD_0X0B["P(&L/CN+4PH0A["X(&T"%] M^AG,;9CQ!,9X/3YPNT0MDW[@,RC*8F$<7!B,Z0:?#^WFD#`.KBMNV?;XB8'/ MJL)B;#H(&H2.`X'Y:B#LQ+CEWN-`X+\:")LQ;EFZ;H,W=>U)51<0PNG@T1`[ M4P=N$[C/4L)3N&CMP]Y4[AR"_=^,WC\```#__P,`4$L#!!0`!@`(````(0!. M=FI;908``$4;```8````>&PO=V]R:W-H965T&ULE)EM;Z,X M$,??GW3?`?$^`1N,(6JZ6I[N5MJ33J=[>$T):="&$`'=[G[[&V,(C&EC^J9M MZ,]CSW_&XPE^^/2C.AO?BZ8MZ\O>)%O;-(I+7A_*R_/>_.?O=..;1MMEET-V MKB_%WOQ9M.:GQU]_>7BMFV_MJ2@Z`RQ--,4Y MZV#][:F\MJ.U*E]CKLJ:;R_735Y75S#Q5)[+[F=OU#2J?/?E^5(WV=,9_/Y! MW"P?;?BTC\"? MC7$HCMG+N?NK?OV]*)]/'82;@4?"L=WA9URT.2@*9K:4"4MY?88%P$^C*D5J M@"+9C_[W:WGH3GO3\;:,VPX!W'@JVBXMA4G3R%_:KJ[^DQ`93$DC=#`"(P8C M!!ZM'.P-@^'W.)BO78$EO>G%B;,N>WQHZE<#,@[6VUXSD;]D!X:%*@YH*WVX MZ?2>3*"/,/)96-F;W#1@>`NQ_?[HT0?K.X0C'Y#P#<3!2#0B0GQA-AX?3&8) M'I*,Q#@DE0_@Y[02]S;&`J=OGH/P<\_?SH/100$+!\=Y0OE@/H_B<+0D/'9; MB?1OB2A&DB6A&DF7R&0$.>Q\Q&$!0RK,=?3PZD.)N#-D4KKW+](2L99(M$1Z MCT`"P%+71US`>Q/$G1*)*P)(Y)X`6B+6$HF62"7A]_N.,L_U;^M$[D/16>^^ M@!7W)[-]=$.)P.0WA=3X:XE82R1:(I6$U[M/7&(';[L/U6V]^P)6W)_,2O# MC[@O8%S[^72DR.A+Y)[[6B+6$HF62.\12``"3`]EH(0TF<65=Z"V.&FQ1`HW4F"C&R(Z]B+NC`WLN',L0/GO3P0+=9,#HT, MLB%#,BB%*R3:MB[2([$>2?1(.B#C?K`#WYZ)A?-"-%OKA9"M&1)"B5-()#-, M[KG0_2@'2H01ZG#N<"6S8\QPA]APHN"\2C#C,9BAD"!XH'*3I90FK0 M#S64/8T/"W6)X<#F2F+'>B,)-D+@9`UFI:"O):G"4)MZG$RM M"%9":2G7U0LJ1BF**,Z$`R/?;&S>S`^,P#<@&[X#X]C'F'D[/Q3&@R_2:@.: M8H9`Q^'[=$9A52#SY[MEI2IBE***DJ8AE8Q498I)'[AH^&?0GR$;>VLK>RY> M`(KHR0)0MF0Z`&_G*=9`Z2]7:K#L,WUE#2'<%`B=Y$8@8B^[MKW0`D&40ZI# MKZDF!X(XA6\>#E5$2_!TU`FH1]6>5=Q>O-_#2%WD[81\`5\5S7,1%>=S:^3U MB[AY<"!HMZ>W6Y'/5+QU5IZ'9`>ORY?/8[*#=^+PW+H-@$N,:_9<_)$US^6E M-<[%$::RMQPZKD9>@\@/77WMKP.>Z@ZN+_H_3W!=5<"+>'L+\+&NN_&#F.!V M`?;X/P```/__`P!02P,$%``&``@````A``?JG#$A`P``[0H``!D```!X;"]W M;W)K&ULE)9=;]HP%(;O)^T_1+YO/B$0!%0M5;=) MFS1-^[@VB4.L)G%DF]+^^QW'0.+`''9#"+SGS>/W.+:7]V]5Z;P2+BBK5RAP M?>20.F49K7(4EW/*=)QI.<-865:47^G[L59C62#LL^"T>+,]I M2IY8NJ](+;4))R66P"\*VHB36Y7>8E=A_K)O[E)6-6"QI265[ZTIXH'3>IE1&(&*W>$D7Z&' M8+$)0N2MEVU`ORDYB-YW1Q3L$G3["NM":0-?5(=V#+VHJ1?,O43%'L7U<]M M![YS)R,YWI?R!SM$G172&CW%$:D!K;(WI^(2"%1L''#J7)*60D`\.E45$T- M2`2_M=<#S62Q0E'L3F=^%(#C"0SY MUN+H6`S7<[$;SJ?!-!Y'\/1PVG2>L,3K)6<'!Z8<`(L&JPD<+,!9Q3+[9RR0 MAZIY4$5M*:@%]/)U'I#)V;\=R*/63'J:CJ!5;&P*@Q$>U&>\/J].`2KQ"H%WCVV`IB7S-MT@ M\L,D#DS%QE"$\SB>SKJ(#388X.UL2CQ@2WSST8]:8\O-IC#8H(]]-C4!QWNK MBL9ZJS4V1IO"8(Q-1GMOE7B0W_#=T)(^6I0,NWNIZ::F`3?['S@E'L`EW:31 M+X76].FZ)^N7PJ8PV-3N.5A=QINKBL::JS4V1IO"8$Q,1GMSE7B0W["Y6M)' MNVSNI::+V(`+8*/K)VBG:]4#O"0:O+M'41^P>[CNKU5B\EW9/\8['.BE'Q:P MWOHW7)N/(BNG]KDN,3G5.MZ;B2,YZE7?NCZKG1NF@FV!-B775VA]8-%;S+O@OBG#%YNE$' MHO-!=?T7``#__P,`4$L#!!0`!@`(````(0`A'@C",`4``!<8```9````>&PO M=V]R:W-H965TZ1SDJKU7Y<$^(DJ(`CH$W[[W?,.("-ZT(ODI"\'A[/>/Q2K[^]YYGU1LLJ M9<7&)HYG6[1(V#$MSAO[G[^?'R+;JNJX.,89*^C&_J"5_6W[ZR_K&RM?J@NE MM041BFIC7^KZNG+=*KG0/*X<=J4%_')B91[7<%F>W>I:TOC8#,HSU_>\A9O' M:6%CA%4Y)@8[G=*$/K'D-:=%C4%*FL4U\%>7]%K=H^7)F'!Y7+Z\7A\2EE\A MQ"'-TOJC"6I;>;+Z<2Y8&1\RF/<[F<7)/79S,0B?ITG)*G:J'0CG(NAPSDMW MZ4*D[?J8P@QXVJV2GC;V(UGM`]]VM^LF0?^F]%;U/EO5A=U^*]/CS[2@D&VH M$Z_`@;$7+OUQY%_!8' MTK:2UZIF^7\H(B(4!O%%$'@70?R9,_/G830E2B"BP+N(0D:CN#BM)DM/<1UO MUR6[6;#T`+RZQGPADQ4$OJ<')],F[+-\0:)XD$<>96.'M@6IJ*#(;]L@]-;N M&Q0F$9H=:N"UU2P"6;(?2DBK<`&XI89$]JGUQ;S#<3&'X\7EM#O\HD\"U6QO MU&CV0TVGD%`@:>-1N'AC0^PV!T'831'I4#/K:68*FTDAL4&0\6Q<#*N[=]_` M5PJT0XV)S:20V*![QK-QL9JWKAZ8-]3TV8)0X=_K-%UV);[%%#XN5OGFTQZ>XRF_[S__7>*")AN?-RY6N18*%VKZ>>LR@KV`"D%.G"@,VQ`2&O?, MWEYB[DHN5M&ZN%A2U+0W]I?RW_<'M;[2@,B1Y4R'Q\]QY=?H)[O;P5JDM3 MB("!6XKG+!9SK__751,7JM#KYR/#\OV]!SNNX@1=089>*B47(CV$X,0X>HG, MR??Z'J=Y11)T!O,>+D3ZFPL^C*.7R'R@F<#'U6K+#(J.(E%TXOC+A=3'8_JV4+4YPLBY8%HKQ5UD63&21Y$=":D^/).B-I-:&#C\2?;2J-5.[B(W2VLG1(+.=R*IC[D= MJ_X]981,/\E\?(WY1`K+3HCZ:U/M;:-$YE/\QEQ['_W!W-M"9.0;[3,^W_%' M^TRC5JO?=:2H_M!$@FB0P:&HD\@9A(E.(.1JE5#M;!]%GW>V$.A3+---\A9^ M=#"@4WM;B%JZ:";[H-KI0C\&=I+1^&@0L)1:@PVB02I-+H)&(^+,\%FN=7$Y MC8K%C'LL\S56$PW2B2)]>@2A22)S3K(9'VWFBW9&D9'/))'Y)EF-K[.:P68N M&4GHA/T'<<_S-9LYCM#/2,+E_VOU>WMMP%QKD#T7M$T8`A59V>GY^RP.9`/%\%D\> MZ9YF664E[)6?O1+8$]IOVW/AQ^98V&U_@&/9:WRF?\3E.2TJ*Z,G&.HY(6RF M)1[LXD7-KLVYYH'5<"#;?+S``3R%HS_/`?&)L?I^P8^.VR/][?\```#__P,` M4$L#!!0`!@`(````(0!J.Z7UK@(``/<&```9````>&PO=V]R:W-H965TN39"-3F.@A`CWC!5B&:7XY\_ M'F[F&!E+FX+6JN$Y?N4&WZX^?E@>E'XR%><6`4-CD=,JSDMND.R)G$8ID12T6#/D.EK.%19"L;O%=M+WEA/HGE-+>@W ME6C-B4VR:^@DU4_[]H8IV0+%5M3"OG:D&$F6/>X:I>FVAKA?H@EE)^YN<4$O M!=/*J-(&0$>\T,N8%V1!@&FU+`1$X-*.-"]S?!=EFQ23U;++SR_!#V;PC4RE M#I^T*+Z(AD.RH4RN`%NEGASTL7`F.$PN3C]T!?BF4<%+NJ_M=W7XS,6NLE#M M*03DXLJ*UWMN&"04:()XZIB8JD$`/)$4KC,@(?2E>Q]$8:L<)VDPG85)!'"T MY<8^"$>)$=L;J^1O#XJ.5)XD/I(DH/ZX/PTF\70VOX*%>$5=@/?4TM52JP." MI@&?IJ6N!:,,F/\>$83BL'<.G.,91B#60!6>5TF:+LDSI(X=,6N/@><;)ER, M,9M+3-0C"`CKU4',UZMS8*?.Y=_)79\,`RE1W#OJ,!N/&8J0-VG>8 M%7[[>1.Y1CR'SO/TGG8P5KCYEW39:&83C>W@RWY]/A_DA>^C_RW*%S M>6<=O/:8]U)X0KA;RBYWO$-KVN#F-J[(1)#T+VUGV]WB6OL,_LZ MSM:=G?0;,'=:NN-?J=Z)QJ":ET`9!C/(F/:3RR^L:KO;OU46)D[W6<$/AL/% M"0,`ETK9T\+-QOZ7M?H#``#__P,`4$L#!!0`!@`(````(0#T`@_8F@0``,X2 M```9````>&PO=V]R:W-H965TK[ M1YH([R@O8IRM15521`%E$3[%V64M_OSA?EN(0E&&V2E,<(;6XB"W+VU*6B^B*TK"0\`UET'+&>1J6\#._R,4M1^&IZI0F MLJ8HIIR&<292A64^10.?SW&$'!R]I2@KJ4B.DK"$_(MK?"MJM32:(I>&^>O; M[5N$TQM('.,D+C\K45%(HV5PR7`>'A,8]XZ8+=F206FS.L4P`E)V(4?GM?BB+@^6*&]657W^B]&]:%T+Q17?O3P^_15G M"(H--A$#CAB_$C0XD1!TECN]WBM*G/Y/(?4A146TAPA\/T143=(6AFJ87U#1'RJS1D6#RXDI0+)T'*2" MS4"^G(/:U`,NGCH3"R+3XE9>.6$9;E8YO@LP_T&LN(5D-:E+8']&#L;N,9EDLLZT9,AV(L%,'GL*F MSO;9U4C=Q^4#'A_P^4#`!_9\X-`*R%"[IH`PLY@"]D_ONDZ$)G6J<[7KP'-\ MNL$-<$L9?5[5=:;.%R9;`8<"D&%3?:[VNRX!RXA5<2-&5M69P*SZV,,5L>= MP'@3&'\"$TQ@]GT,MYP//8RI-.-B+((-E;%HV!I",];P@2T-T*=!M9/P@5T= M>*Z:CGEN'\.M/J^/F3>#K+8Q?P(3]#$+5F??QW`3[C#,,$6'9Q-3=+(N9K]] M1M>;&.D%ZZ>UW>BFRB9J4P92:;8D+LWM*.&,$KM1PATEO%'"'R6"46(_2AR& M",8TL\>T\[57AN`ERLPD@7\-J`I"X/_`QHP0#?%?;M=54R^_Z'= M;AB+=@:,0=:7#"(T;Q`W,6S*T.VJ;[O9MH&>VCBT?<#AW2CACA+>*.&/$L$H ML1\EX+R`E+1_M-0I>AY`WS%3E%_0%B5)(43XC;SKSV`6-]'F&.)E1EZ(N+BM M+N%UL!MWX-BB+VYK2[O2D1LA.$ZXA1?T=YA?XJP0$G2&%!1I#H_:G!Y(T!\E MOE5OPD=&PO=V]R:W-H965T]P^ M/;]]>[B>3FJ?[JZO]H?UV]/Z9?NV>;C^9[.__L^7__^_S[^VNS_WWS>;PY54 M>-L_7'\_''[UT?Y']WWV[W/W:;]=/Q3J\O MMWXFD[]]73^_7<<5[G5D?9/S[[\\_]DFU MUT>7GV\;WY[V^[6?[S(/ M2>WC_Z3*OSX_[K;[[=?#C92[C0>:/N;B;?%6*GWY_/0L1Q`][%>[S=>'Z]"[ M#QM!<'W[Y?/Q$9H];W[MS_Y^M?^^_57?/3]UGM\V\G#+$Q4]!7]LMW]&M/D4 M;9([WZ;N73L^!8/=U=/FZ_KGRV&T_=78/'_[?I#G.R>'%!W9_=,_E?7Z')T;\I"L_S[^_/7\=/C^//_>'[>L\1IXJ%1?Q59%`1J]NS]UD_5SA[B-5LJJ*_$RJ2&''(RJ*K(SZ1* MX<-#\>1&=SK#Y"^JC)^_NAIA[I26*2L4Z3#>]W,H]OEI#D/G-SP\+!]>X&7T,[-\R1A'7DD;7Z]230N9".FF MEC;YG$[J:1)X1@LWTL8LTTP38RRM6)R?689HIT7JB#H.IILVQIYZ*/HH!FF1 M&NTP;4Y28]9 M->8Y2NU+->:Y.3\N+==D#JGE6C2YB*9!]GR+[J7EF[FA;&ZHF!NJYH::N:%N M;FB8&YKFAE:\03]R8P;0OF2,^.M<,GD](KN73$$WO4O&F'3UTZ9H=.B`R9#) MB,DX38*,<4P3!S.]9(Q?'S,',WS3)N<\72NF(2A@RDY&-4=YZ>I.9Q0 M-8S5J!XZ-X&?BI7T@-)(]9J]DNJ_WR$M5^1UBI8K]CR)M.3.^?32-TZ74FSD MS],4U&CL,HH*BBJ*&HHZB@:*)HH6BC:*#HHNBAZ*/HH!BB&*$8HQB@F**8H9 MBCF*!8HEBA6*,&3"71=RVX7<=R$W7LB=%W+KA=;>TR),K@II$>8V-8KN]7`M MT\]33`6^$52EV,BC?S*&**.HQ")_O)!3R&4RQI2A"K?7X/8ZW-Z(;[<<0Q-% M"T4;10=%%T4/11_%`,40Q0C%&,4$Q13%#,4C5A[3XLP>1M(BS#[+"S29G09+XQ*L;&,KHRB@J**HH:B MCJ*!HHFBA:*-HH.BBZ*'HA^+N^,O#'F;QL\9OS$&&I!WI,Q?*<-SD"VF;A]I MM\L[8\8.QO'MEG-G@F**8H9BCF*!8HEBA2(,F7"_A=QP(7=NT\))W`#X07I$VP\MXB5^*C>4$+*.HQ"*>=_D962QBG.75KGPBOZV6+!>#'UJ`14O4S#?N M^=IZ="\SR(Q+L*786$991E&)11QDV2B$C`N'U7-0S,AZ*F,4-0T$7CYG3!;K MYR";*>:S1E8V8F`YCB:*%HHVB@Z*+HH>BCZ*`8HABA&*,8H)BBF*&8HYB@6* M)8H5BC!DPAT7ZDP:3)I,6DS:3#I,NDQZ3/I,!DR&3$9,QDPF M3*9,9DSF3!9,EDQ63&31:-3`#]>69I-EI&P<.E)6EG*=JH-QZ$E9?E M'G.R+N,C,1=Q(^8"8XI4BC[Z8'_DRTPJBL0Q5_3D8Q/&*\FJ(3*2@\8[HC7> M3YU)@TF328M)FTF'29=)CTF?R8#)D,F(R9C)A,F4R8S)G,F"R9+)BHF$'+:: MA!P;AWZ4D.,Z24O:0M>A)R7D>%_VKM1#+EK7>WY-S?YB-/JD52KDC-7$)84L M1UIF4E%$O2`M7'AC0!>9(.][J9E>E)D<[\O>E7K(211I(>>VO#;ZM'IJ1F=W1!V;LH-)VE&JG:8YQC6BL.I0I^9@ M'%I2YG.VX]*C+EJD?#Z?&VS/J\S#KD4?0\'7:%#4E%5XB#S[O)^WI@_ M5C7QR?-RP5U@+/>H:4;>J/"RQMLF=4U\"CQ/OBU$?U>VH8CE:6XR:3%I,^DP MZ3+I,>DS&3`9,ADQ&3.9,)DJHGXU^G>Y0M'X+3W3R*?H=#$_NSC72%`L9G+& ME>.%)CYEL_F\^?;84A'+&;5B(EF';219QZ;L8))^M`Q9LB[>5_P(9_UBP;AX M'^K]^*GH>X6"L2)6)G7G5?P[6>=EEDDZ,M[1)UGF=;ZR6P^Z:$'S>=#!U;EX M_;,><$:HE#Q<)%UF4F%295)C4F?28-)DTF+25B1^XNYR=W>^\>!V-)&74ZAH MQ'&7=]-CTF5U*]=Q M:$B).*[CT)(RF;/5T3,N6O-\GG&.D[EXJ;2>=48:ESQ<3UUF4F%295)C4F?2 M8-)DTF+29M)ATE5$S5J*GA>8OU5[7*7/9,!DR&3$9,QDPF2J2/RX^$&AX)E+ M(6=<9;&_+;#&M>H M,VDP:3)I,6DSZ3#I,NDQZ3,9,!DR&3$9*_+;YWE"8,H[F3&9,UDP62KRVZ-9 M<0T)-VP@"3C'F[1$N(/A%N\XO@\W(+` MN!Y1BKYVEJ['(:EPE2J3&I,ZDP:3)I,6DS:3#I,NDQZ3/I,!DR&3$9,QDPF3 MJ2+QG$BF;[ZY1&"FBT(NGS>_67#.^UDP63)9:6.)UE*E+DN%&I&K4A>,0S>& M91Z-9!RVK%R/8^/0D9)Q7,?>DUK&15^L_8&,.W)S5;"Q2JVDD"7-RTPJ3*I, M:HJHTUJN@LKW4NCO*-2Y2H.K-+E*BTF;28=)ETF/29_)@,F0R8C)F,F$R93) MC,F]5EA2ZO/?C5]:7F5285)G4%%$I)]_=2PM)FTF'29=)CTF?28#)D,F(R9C)A,F4R8S)G,F"R9+)BLFDG)X\LJ7=;-Q M:,C0H2,EY7A?24]:\D%2CNLD77FYCIYR$E@?2;F(ZW.Y.^,]^)(?F\L[5R&' MI,)5JDQJBL0A5P@RYD?`ZERCH=6(%J`4<\;LM:D3^0JGO/P+//J4L<5[:C/I M,.DRZ3'I,QDP&3(9,1DSF3"9,IDQF3-9,%DR63&1C,,^DHR+3=P"?C&3^@=4 MRJFQWW:)9!J; MI!TO)T7\SYLXM&3HT).2<;PO>U?J&1>M(SZ?P47+XK*R MT;Y@)/JG-U-99ZQ!+2ED>>3*3"J*Q'%X?+?(?$^IRE5J3.I,&DR:3%I,VDPZ M3+I,>DSZ3`9,ADQ&3,9,)DRF3&9,YDP63)9,5DPD[>*&M/2:I!T;AX:4M.,Z M#BTI:<=U')I2WF^PU='3+EHN;*8=?[6O'Z\RUE^WIB[)V98BJTMR2"IJ5^I* MPO$-=.-:0%41RU-=8U)GTF#29-)BTF;28=)ETF/29S)@,F0R8C)F,F$R93)C M,F>R8+)DLF(B:8>-)&G'INQ@DHZTM)N\?N5].?2DS.VXCKTK];2+E@N?IQW, MZ>+5Q7K*&1?/2KYM";)*.205KE)E4F-29])@TF328M)FTF'29=*[0(*L\1&R M_@5D/-<#)D,F(R9C)A,F4R8S)G,F"R9+)BLFDG/82I)S;,H.QJ$G)>=X7PY= M*3G'=>Q]J>==K!K"Y>EJRGG/GI!Q_7+I>95!11 M'X$QWOFHA%N4C'=1Q:4B[2<1V'II2+=+8Z6L!%U^,^$'!';K[M M:BP>*REDF\8QJ2@2_UNB_L.Q0)^E`2Q^' M#HT8.G1BZ-"*H;T7]52+EA2?3]O<7J0&\4ID??IF?N1!(0WN5#E M"C4F=28-)DTF+29M)ATF728])GTF`R9#)B,F8R83)E,F,R9S)@LF2R8K)I)T M_+&`DH-Q:,8PZ49+3TO2\7@<>E*2CNO8NU)/.@DK+>GL+U"#B!OS-_.SH"6% M+(]&F4F%295)C4F=28-)DTE+D7BB=^FSU&TNTF'29=)CTF?\$1,ZX4E8*&E)>N7,>A)>6EJZU.G'6W^^^;S:&R/JR_?'[=[+YMRIN7E_W5X_;GF\27 M?/?FV>:KW>;KP[5\+\V_KUW:7O?OZY>V-_S[QJ7M3?^^>6E[*`=V:7O%NZ]?.MZ6=S^Z MM'WLW4\N;9]Z]XM+VU>RW]+QAMOW)^?+YQ_K;YON>O?M^6U_];+Y*D]4YJ8@ M*R1WS]^B2P[Q_QRV/^0)O+[Z8WLX;%^/?_V^63]M=A$0_'6[/23_(\_E[:_M M[L_CR?#EOP(```#__P,`4$L#!!0`!@`(````(0`Y7J&=#@,``.4(```9```` M>&PO=V]R:W-H965T?<>\UE??M:5^B%"LEX MDV#7;CA_6>BV=94JH0,#0R MP:52[=?>I+QN@6++*J;>.E*,ZG3U M5#1NXYMF,;F#;KC($#778D:)[@ M.W=U[[K8WJR[`OUF="\'OY$L^?ZS8-E7UE"H-O1)=V#+^;.&/F7Z%@3;9]&/ M70>^"Y31G.PJ]8/OOU!6E`K:'8`C;6R5O3U0F4)%@<;R`LV4\@H$P">JF1X- MJ`AY[;[W+%-E@OW0"B+'=P&.ME2J1Z8I,4IW4O'ZCP%UCGH2[T`"WP<2-[`6 M7A`M9[#81E%G\($HLED+OD+&V7Z"FZ0%S;S#PV6/<'F&#FEX2R!A*>K_(Q\P:K#/KHFLI M]^;&,(WW?AI_G.;H_'HZ'03=&YCPEW'/;Q08S&*`.95B9!0@0Z-:@0^S>5V! M#DHPN.S+Z$7^1('!++M&N(X?!*%[$CF2`*W^?PDZ:"S!CX.)!(.9483P7($> MP.M%T$'_:H/!S%``8SNLP?7,&CSU'DZ\&TQHRN\MPS"(+LR@7A"#TW<]M0:/ M4WOAJ:UF]@QF:-J/+QRS>)Q[WO3IH(F&R)G8-QAC_\;UO"B.+]AW8=J'_N=I MZ**F(J9'X``ZJG!\__(A@-4QDG&]#1UZG-Z/HTD-#J##$?0=+PZG;3#;QCR, M:RH*^HE6E40IW^E-XL+T]'?[+7?G=7NJ_P.63$L*^HV(@C42532'4,>*X``) MLZ;,A>)M]ZC?<@7KI?M9PNL$A0>F8P$XYUP=+_0B[%]0-G\!``#__P,`4$L# M!!0`!@`(````(0`^D>(]<@0``)<2```9````>&PO=V]R:W-H965TJ,USUFUL- M_>/OY,O"MGB35ONT8!7=V!^4VU^WO_ZROK#ZA9\H;2Q0J/C&/C7->>4X/#O1 M,N43=J85_')@=9DV\+4^.OQ64+A54]1H,=#GE&(Y:] MEK1JA$A-B[2!^?-3?N:]6IF-D2O3^N7U_"5CY1DD=GF1-Q^MJ&V5V>K;L6)U MNBL@[G?BIUFOW7ZYDR_SK&:<'9H)R#EBHO[;@WZ)Z<7?O._Q4_L\EN=[[_G%06W89UP!7:,O2#Z;8]-T-FYZYVT M*_!G;>WI(7TMFK_8Y7>:'T\-+/<,(L+`5ON/B/(,'`69B3=#I8P5,`'XM,H< M4P,<2=_;ZR7?-Z>-/9U/9D_NE`!N[2AODAPE;2M[Y0TK_Q40Z:2$B->)P+43 M(;.)[\V>%I]1F78J<.U5O`GQW?DG9N)W&G#M-+SYQ%O,R.PS*A!Y:PI<>Y6G MT6;,N\YP'3J/#,,1B].N=90VZ79=LXL%&PCLY^<4MR-9@>[CQ8551?89X8T- M$X9UXY"1;]OID;WC< MR8$`AR@A?<9'B3!&V0\4]`W7@:9W(=TSONO*84>"@6D/UMSIQ".8Y)[QW>DP MEA0X9/SXP!&6`E<;0K4A$@VW(?DN&:;2+F[\B/%D)GG$^`,CA00;<'Q(",.- MY\9RWYT-NNW\`L'`Y[`LUY%;(C02D9&(C42B(R0'X.8QW@&$-S:DS#4Z=ZXX M(!@8_\K(1"B(1;OGB8M_,A`9)6(CD>@(R0"X48TW`&'5@"=Y]H%@YFUXG@<[ M5XTO%(3&HLA(Q-(HL[LQ$IV"%#_<@B8Q$;"02 M'2%YL)0]T,>.L!([439P(!BQ!0B!6OMN"PA"EP5&(C82B8Z0'(!LE=)`;T%+ MJQXH3ZJ@@X9]X"F/BK`#=!Z8D=B,)%I$M@'+H$_O!B**)^FQ0)2'71CB"$O1#$E&W$MID2%0`2D-<*(1)W*K1'R M/28VCY-H$=D'K*EN?!AWFR2B$I/]4.JAH(.T?@@=#1)U*I#J>))P)\IFB\VC M)%I$=@-F\C_5^<`4M:'VE(BX);&7O%L_P4UF)H'=XS/$_Q,*2T!]XJ>-0>>BLX)P#O#!W@ MM<`Y/=(_TOJ85]PJZ`&&@C(#"KY:O%@07QIV;D^D.];`"X'VWQ.\`*)P1(3T ML*T#8TW_!0<87BEM_P,``/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL` M`!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6* MV+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5 M_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU M>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0 MVJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG M9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4- M?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC M>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG M%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>] M;=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM M&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P M68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/ MC^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9 MF]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP M$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/9 M9/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2C MLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1! MGS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I M!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW; MK"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,< M8[Z4%3]F\=%]`( M:-/^^QTS3L`FH?2F">7Q\/KU>`9G]>V]/%IO>=T4HEK;9.':5EYE8EM4^[7] MS]]/#Z%M-6U:;=.CJ/*U_9$W]K?-K[^LSJ)^:0YYWEH0H6K6]J%M3TO':;)# M7J;-0ISR"N[L1%VF+5S6>ZZ+G?*M*ALC+"LY\00NUV1Y8\B M>RWSJL4@=7Y,6]#?'(I32ZV[6%M,[[P`Y<1P*WGO&F?"AG2MK+7IA7E?P@1%0J# M4!4$/E40`E]G#F9J,'Q>!R]HZ!.??R[!P>ET[CRF;;I9U>)L0P/Y,(?$-1">2&X1W11R0=]4( M'@TU3FN3,,S!MGIM_C5L)S]&Q!L@_8,[(IDB-&GPG/G2)+RV(78OC1O2$`D[ M3TE(*'>9@20:XO.(4Z\W7Q,',YPO3L*&N,`0APB?$J\;&\S_>%'&3(B_3'QXB@/!:1B')C M`LF0\*COA;0GM.4-=(G3VT+"NC3F&M(04$A"?L=K8F+OB).PGHI8=3P#!'(^NN6[A^,I62* MT*01*+OSC>MHP[D^E;'.*0:M\P+PS=C1B48P+PQYGZ^Z.*-/3*\JP=H^K'3, M\"56#(HCKN=ZAK>)1G!"PQ[0M;5".(2X.H MCZ&+^U*'(.,68=;_6#$H+B3 M'1-DIC;$)*++D[5ZOKQQ MT20^V13C[L#ZW:;T#8L_)23R!L4?ZPD9(H0QR#S23U/W[TL=@F!]'RZO9[2` M6#&3RXMA;B.Z/*-3=*_D+MC_B8_CGN$9BQ@39&Z+4#Y>$/GZROK2J4LT^H64 MR#]_/<::/RQ_9G&+"3(JS0+.S5Q-=,*/`O].&M(O-8Z.UAO'X/T1TU`Q%W$, MBHQ'^Z>C@3KD4Y]$@=LOA.8C-=K'O&-&-\J0:K81Q:#4!^(SQHGO]LNIM&)# MNE`>=WTWI'UVZV*_U$_HN)]X?2]0?B*C_(PBV+.C5JSB(,.Y+#QWJC8,'O?VNU3U];2OF]LL6GL+QG'E*]_G/M-X756,=\QUL M('<1P":O\0R.%ZTX=>?)9]'"V;G[>H#?2G(X;+H+@'="M)<+>"]@")!$2:H3.ITYTCG2:'0N MSPXX"2I@A-VF_?>S[4U)[#0TZ0.7LKSZ>6W?NKA_K2OGA76BY,W2)5[@.JS) M>5$VNZ7[\\?CW=1UA*1-02O>L*7[QH1[O_KSC\6!=T]BSYATP*$12WY6Y]?8U;1[>F[O"T6A0E]$#%[G1LNW2_ MD'E&8M=?+71`OTIV$"?/CMCSP]]=67PK&P9I0YU4!3:ES)?_CAW]8N=M+*'<,/5(=FQ=O#TSDD"C8>*'&R'D%`'!UZE(- M#4B$ONK[H2SD?NE&B1>G041`[FR8D(^ELG2=_%E(7O]&$5%0@TG8F\"]-R'P M>&7CJ&\,]Z&Q%TYC$B>?(_C8'9W.`Y5TM>CXP8$A!\"BI6H`DSDXJU@B"/?C M6*`KJLT7U4@W!;6`6KZL)NG"?X'X\UZR/I>$IB+[0#$9)#[@#8R0T>V,JM'2 MA>N1<3K8ZVZL43+%#D1AFD2F(#,$X2R*R"`P`"&X4\#Q\)38`IL-M@B&DD2# MI>DL(:D5;V8H)DD`DL'#0)O<@J;$)EH<#+:(AI*91B-_W=F)7?QL0,&,N3XO M);:@CF5`*)1@7F$1-4DR0Q// MTIBDX=''P)O=@J?$%EYL#J8U2L;Q#,TX'H$%]S2^*Q=AU M5T%3DHU*C!2)M5>,5UFK+;SC&H5E[C43O9K8PZ__V(_1*(HN%%=MH:?I?8*% M:SIU_0CBHUM;.=8:'!YUC6IG!E4<]WA]@:^&N"&EQ1`B^U1F=V^;M9 M3K567SUI":[LI[DE5C3K7H,;JEJ'K74Z&Q&8:#=M$.H89TV$Q/K+ZUX#@UW7 MU`NLFJNSIS+Y2(!H>++$LU-+=^P[[79E(YR*;6$DJ3*X3H?G2GR1O-5GI`V7 MB+>YK5=77__'A9A2]2Z99 M.AE_\ZB[L?DH2L:#R3`=7WWSZ(?S%^M[CZ)L%H^'\6@R3KYY=)=DC_[CV?_\ M'U]GV2RB[SC[YM'U;';[Y=.GV>`ZN8FSC)A M=ITDLYO1T][FYL[3FS@=/XH&D_EX]LVCWDZW^RB:C],_SY-#]]-6=^?1LZ^S M]-G7LV='D\'\)AG/(N"(CL>S='87G8S=!,#]]=/9LZ^?JJEKOA.]FHQGUQE- MA\FP_O6[^7@CZF]VHMYF=ZO^,9_I8.%,T1\/+K+9-![,_JO>\W']AWRH\[O; MI/[Q<7=S_7?U'P]8X]#6^6(47]6_/KZ,1UECH'R6TV2:3H2=8704S]K;O4BS M03R*_I#$T^@%>,T:\RS%B^_N9UL\P.]Z]3']GKU-KE*ACYU\'=\T8'Q\^O;- M[X\/SW\XBYZ?O#G]]N#MJX/#XQ_.3PX/7IYUHI/7AQLM`Q]"'%-6=<*&?XB^ M3^[J[1YO\G_][O;VUG;]T^%\.A5ME1'3AL7'Z^O=WGJ_6Q_#K^]%.DJFT2'H MOYI,FS`<#`8)#?@\9#;^:AGF<')S,QE'9[/)X*=.='8=3Y,L>C.?&1_"F/5N MAV]>'QV_/CL^BOCK[,W+DZ.#<_[Q_.#EP>O#X^CLV^/C\[/HR0]G1]':%_7. M1\D`=N@:._3K'P-N#K(LF34HY3#.KHTE!_HC^?,\?1>/0&6CX?EDQN8L'^R8 M[KSM;/9V>GN+A_VS>P:"H@7HLMAH065G@A?IO%%.DIG:=)`(M0CR9A% MM_%=?#%*HO4(FA\VN(AVTSD4-IB,L_EH!@JCY`,BN2D[/+"^O6_4F+>Z>4L` M?#D97ZV?)].;*#1J8/W'>&K!8O>J^6[(MN[S>[NY.9Z>_U]GJ[QOW]SNYVM[/;>]"JZG"=QNEPG14, MXML425#_?)14\9>PI187HDLQ0E^T6;S(5%6V39V,3H0CE8Q]I!16*-(7*3:/5F-6;H%,RP MLJ6Q2)DAZCV\HC)Z6S)PM=D#1_7-'3,M!\`W+3%;O7V9GP]+_%P@R6@A^N.K MY.8BF3:,O**=7_-2Z-I:+P&PT:5%/.02K+["@UQ(+.Y9;U_&PFU5JC6:+C8S MSLZQ-EX=O\;$>/,B>G-Z_/;@_`0[!.(?Q_-ABK73R@C]I99Z=VM_Z?>R)=^O M0_L6J3&>-]7HF_-#Q/=D.!_,HJEK4^_Z*AF*?25X4D1Q2RLG2_S'AM8\G.`? M85=D6$2-C[^=3K!H@.(RG=4G?\/6H@T*K=WH_3;),-X'SO0J"A&@%ZO4B3#$M5HN^3#](\2VT M@EYJZ;1-/FB1=F,VN1XI8V?88G&N^+Z,I#,+B.QU>) MM.5EG`:ES]CO5QD>KS$#T_$LP6:.NFCN3G<98.;#.'Z6@N'T*PF"U3[EWO]F.27EVK=8SU M@O*,QG.)-FU3N1NP%S8*IN5%?;;ZN!57HRH#SL[?''[_[9N71\=OS[#1?O?# MR?D?[B,-C-3J\YSF0FFY:#XL.4WM\AM#1,1QZ`R1UG9E!1VLDS:=\!RG=CP6 MPSZ/1[%LMW@6?1<39)"S0*RCX0V?8!A:0S;^$IM>P19G-+9L_^OYSR.S-DJG$;T/8-.S2;F?.5T^=Y0^A23U,LR2Z2:9737]_1?,P M;7WC3N=(_YA1Y5I,L36G29"A"S=Z5?NV>1S#^<4(R?$`7R7#.W5N]^_CT2BY MBTY9]$T\2.9F]#;VZ^-&:8/I^$,R':2LO1#JC1D7M6D;SWND653L&8[>6&$# M%OD^G5U7'+]%.LHM4'OAM4P^V`*HJ_4]_4CQNE;5E5^A7=EN(\38E4 M;1X&7=G-P8Q`N$#E.IHO\V)]B2=![I7V#@%X/U8/RDH>?70[GTJ$SB2,""HJ M+*3M.ELV8[:T9UAS?81C+^JD+!5$<1-=3B2R'+$M(=#"NG2`%[R*$!\;FSK#7,*CCM=: MYZ='.#`E;E\P0MLZJL14)Z+M^L35YF'0!W:K-]_YN%E6=*O/LOMQLZSH5I]E M[^-F6=&M/LO^Q\W2Z%;F[HJ:^V2)>IL[3[^2B'XX>($ZZ[@J+_JCP&P;N,H< MM3WK;M;AJ#8/@Z[L%CRK\62\;F)T,AK)P<@%#L9_;NM%AY/I[40!%&R`\J8N M!Z8.Q(*T8]FI:8-]1;?Z+`UW]7X86M&M/LO'&3#=1K>WR6!$H$D6M4-O85N2 M6G')M$:"J+HB@58.)39T=K5Y&C MR?LL>B$+M(@5'BC-N3AM./S3W$70,EG+Y$TGXP')9TM\6@2)7Y4$M23N/"-2 M!.D6\3[,@Y:1CTI9V#HAER.*2S^BPZIP8FFT_OHN?I:-3HJ#BFBXNN=G`7FSU,Z,P7YU0$251' MWF$I[]'>IN3LS*ZGD_G5M>V)A:V8:+F95W:56GO7X:H'D55/8(FP>D/#U!-% M?+\0PK#V/R[D>YAW=)%JD\Q!9BQ(/9]ZN@F)\H8E*YKZ^ M(-&,,L5AX/IWQ8P?S)UU6>$BZ5)1[;+BM&+CWR>:'P*I!CJY'ORJ!F4W1X70 M+Y$R(;3?[.%]N%7MY_S4F96:0;`^$(TP#K M!7FC#J^Q:82%0L@)QOMP];WL1\MY6*E1-,0L@3`#-VCRP`SUI2IA9Z0$M654 MA9A]6F_D=8-$S^F$A*#*C=J*3*>JA>WZ&DC^H?^<\E_97U3=1/7NYJ.GS[X> M3$8P`6KIAG+=KGZ9OB#.XYJ`TNP7=/D\$#Q;@D$`*%7\GE,F%*-E;V[C\9UP M.0^E!Y(=Y&9EUO)7!HJIM>(?GD>@)$J*9D95671-CA0B3BBFD:Y7!1FVL`:> M#LWRL7R`_HU1JFEN*5(:I%!E%EVY;#N8Y'MRJSGHRS;4K$`(ACK?*>Z*A>#, M`DMO2O"D16%S:YQ[_3\W4.,""RA&=QW-0G,Z8=C.9#$#(BJG=I()3' M%&=<3B8SF@+V5,RNA:(Y?]6%:3-&"<5JBS"]`:<:8)-;RA*8`.\O^>7G4$H> M02^&_S"ON"HE+"_'%+KR6Q%&G5TC,&_B.^5.9#T-C"K]5'>JSG:3D+>Q6B0F M>M=E"C2-[0_A"G>@TR? MW6F47R,]728]5,Z*N%XMS'4^GV?I6(6\`'Z!@K)(\W)1U_L7$G4K,5D5>-AF M[R"9>88S.;FM)F"IE!\/-CJB6P0-1/C3>/(>,99%?__K_RDZGB[L]?>__M]E MS=S8:J2=9KRSTU<1Y4SS6S^K/KUG*AC*Q[Q@E#GL,F7C44PQ0FH4OY?C]BJ^ M^^5G:+J[O[NW$>4#10/<9#KY$`2,SV`TVJ>I)KV`YFZ0;N6ZT'6K"X7Y30%$ MR>6E$K@P'748_UW%)+3'#&"68PRA)>SMQ:>4L27XR03-726J>\?8V MN,!2>78GNO`4K;_A6Y?BQX*"Y<5H_"IU05D-@2C"$RX\!6HP'VQ^RT(%L1`& M*R^;0:^2R=4TOKVF\F&`16C<*`@;)EWG5%4 MR(FQD`IH2VBDNOG3I++'[-%KY-`PUFXY]>E6[(0O>2:2IVP*&V]:=!4ALL'` M_0Y$CN[6KY/1,#I/R,M34R9_H`BG/A'`IR?0W1<([WRUH;!#-!,=4#AMFL4( MZ)0J':'];<+1I'@<1-=%,GLOU=\&F.M[>F+D3?66.-#4IC;C_32=47YKZD?" ME^%CI/N?"&AQ5LF+_G*%5>8J1?C2-A\:GMI;E)RT4*>U&60F=@_Y=^JW]RKE M[,P`6^@\B?/3V)WD@X^9V-:4K`27PA>3M8!Z>F)081K9$FMDV`[D0RG-+RK( M&?:W8/OWN-F0!"(-]$O?I<-42KZ,2JE(;.\*T<%Y&`R83'3C;V&VIKPT`BNL MF^@0U6OV6E5S<-&^*Q@RDRM7PL:+LCD6E\1XV7A?DFX*[M/KR6R"A1D&PEB3 MN)&4$FZ<68Q]QB&6:=/'&44/L[6)Y>8II,H MHZ936R<19#SA2^",#<]J8"@:,S[`'`0`A<1,CX'(NR^.&QK!@A/"@#FUH M^_/J"TT'5A"M5K:$,+4H-S8P6#.+IZ`5JDRN$TS'HJ+4`9>S=QENK<43@0V# M4>K$?6OKG/\W0L?KF)U3J-Y5,&N)L@O=.!6:5GF2-A>;ZA;/9R-Z+BM>%KTV MVL'10JG"@)P/2KA<`0#[(]6&,X%-GJ/'7+RJZJXI]_M=K:Z>P;N]F:GST_;O6TG MQ4,<"XN\W]GMTKB_90V[G)';W^WT-G=<0X\`9XZ[DV];G;V];F=GQ[=HP839 M/`TQ<>PB:^>%A=A(")P3H(V>8P'_M)S5MOZ%6*T5;56V>A)_$1T5A^D(!V!` M5\(8KW28I`@O5/6%UP"[=DS25YF+(2HV);2EN(M+IIJ[5C$Q0R7W!GHJ/Y-J MV5,)<@JCAZ+.DK]GFG.MV]_M;&]N;CP(?,B_I!"#`OO_`?[6'DUUA8D\8^$L7=R-RT2%"A\Q'MJCU^GN[]6& M#.D1'$F9_\K-8(!G=JI(QIU$A=F7XVB_TV4U>QPP#B+%M`3^7F&`/A@PMJ2_ MT^FAZ/*=,)E2P"77=ZW7V=GM=?H[6U60BMY5D)PL?!@PB[F@V]GO;77V=_O_ M4++9VMSO[&RMY.(JV;"`/4Z![_7[-5P69%-GK$\6<3W"5/]HGMK"'"(\MFIW M*R)NJ\/-&4XS5NFLP,U#)";#P9_[6YW-O5X-V07AKF8H(-K:V?T$=FJL$2;1 M=E376(!DO-3WC2K,'7[\&#ZJ0+&8C>#?38?^?ZCT)1&SL[W]($H!_FYGDYL4 MEHG?.A\=."_$X@[$.'XBUZ]$3T@E$:T.EA5;0P27W)^N65(L9$CF;4KL1RZZ M61&5QLKHV$C$+\L>5-M,^2:YDX6>!0-GY%4! MX"#ZL>R6^5\/BU\SHO($E"]PJ7SQ*-/2OU3\I2BV\J'EQ._!V6&TU]VV4"2% MDF9H%G".(_)NI"AA4%3^++9`JZ_E$RYTD)Q;=")__$1[RSI]_M7&"ARE@`_- ML;)ERN8S`*[+B0)LZKX=^H2'(0F_F/B-YG5%:0J$$7P.4:]TS/'ON?*K>*MD M-D@HH!/]7+D#[$);93(+`.38N>.7K$P(%1IZQ=J3]<-X.II$9ZG=V".4&!5H M7BTIST/F:S/M'/3K>;'JTJ2*YUX38B@[+/2Q`0N-=M6[8V:V9#PP2#).=71C`L\>W(O$8H3,DN;N-;O[$-X_5UI;R/H0N!9LB`>4K4)@\8C*X8KW=+3%-G< MXW&BM"WA`ENC)18U%9?I:9D!PXI?DV(3.X=Z8>Y/PO?/[T\ZS07WF9W*M`1& M$`8.$6&PRG;!\J%5<.VMJV9??D43H8M_R_Q_RWRS'=IDT:?+_)["JSTOB[:V M2,;N[]5ET7+OJ"'QN7QKFW%V(ZN!3(_UZ/_`.%_W[G^K05FRRW_VUPS MNW*1FJF/GV5%LHK;DQK#W\+C&628]UC.,653BGAZQP/_9HR;<#&K5;)(6>,A MZ6(4>0;.730:+>MZNU1B,$IP)%Q67N7>U`)A/SMCBHDT4AU@&6W\SC($TG"" M/RC'>,S9=<&&$W61G$KG&MUKJW:@-L>L-9/; MZ#`O2,"](`GF:[X:;3D%4T`K'XH]5"OG$:Z&XT#.DXL!D1\$W8NNP8AO5$`= MQ)(KR9G?`D^`H6T].8[RZHS<+ZO(IGP@FP-7K(=?L[^]Z2'SH><5X#DG;I.[ M-NGI(%J\')7@6M5X#I41TE`U9T,.,;K;P11@8,BJ@G=Z$-?6U5S0'!8*/6AO MI727IZF$G1F*1)H#^M_._*<;=OOXE;N[.\YJZ>Y@PA`N%C5] MO"NO(**KU&//Q&(Y<9=IH?2AY#;^\QEV6SW2&:X68*VWAU5'4N=!^*E;==2J M6M#YTY%S#F[_^UAU9`>VL.JZ.T%\%NKKH0[]43B#%X3*?:TH.VZ!K%(8D3#I MF!KK4:1Z0`DXK#V_9[73W"ZJ*95KY!NNL4;@D7U$8UN:4)74@U*]*B=%''<$ MH6C+MO.!="RW=#&(XG;#S.41@:7<2L8)!RK-1B!@.Z&4VY7KBM&\7E(7G28+ M4Q+L-$SEU;XW+AA?"=/Z4Y!>IP:9SR+M:C8I62>-BT$K6/"12^P;KY:[V]3V M#3D?$E\Z19P`KD4WUSD8XL8*5.V.2[*`8O`:IS M9]*'-6\!>JHPFS-YBMS-MHN_-$.+E^9?^H8N>LF4 M[*`ANGJON@?'H_3O?_U;*?&SPM6TE$MA`9O`7#EX>47FR@!`8TF&T0`O6"RD MSWV%:JG$L(F?JU6E*E7U6:$YX+>3>,AK97MTI((MQ:B4&4"NJN0\2.#IFBH!3R$H:*V7;WFX0O"D\>(RF;)'""Y#QSUB@3+UJQ3JET_IO+2LOH MK0_?Z()T!+>HU.6/3YVIU'[\??:,FHO[0O!FS+':<' MR2NZ9UIX/:V$6M8_)`Q]YWGWQF&36 M=O:-2W1]Q;C;I)%5T3.$]7P-Q^I,.;J/2)J$QVK$!C99B=GN M1K'=8<*Q%\%VMXF-?5LV@-QNXQ@H2]7H2063WH<5[2<&;J3%"!5W^"Q%5"3]LS!*4-LGK MQ<'9<7'7XZ"'2CFH&[ONT`QX3K.1H^"&:9X`5:3H7R33W%S$0`*>8M9PWQIGZP MU."LO&`%XO12HXT>QE9)[`"7/F4=6*,%CJ.;.9&XBVH5+&!Y;-,<3[4D12XY M>#]Y[PQ&E54JH11UOXQ^1XB5@N0:-%4EU$ M06_HV!,281&01FD-#=G@YNA]&;WASIOI.SN-[.=Q'H7?0(:9CR=%&_^SQ8+D M(^.I3B<7NIX70-E*/P8AV[AESOZ7('_)B&,2S@\9%3I82V-5= MOKC[BS;-]JO(>*"-'!7T73"D1-OP^2"40U?1&^II?`8J"@07Q)%:WY,"#(7Z=&++KVE);$LA0*X0&+1L*C<42#*'0$? ML'L?RE(5Z)EUHG<348>I"-0&[W4Q_L[.!J.R]&YO?V/W-X94JBS2["+]C7X/$D^.]`:]4ZLV/%BK+AL'ZH\MYE5:'V*XBNC[R6OV'O__U?R]: MR,*ABXMQVMY>/\!0(%7)7?W%0^@ MBL2G+Z6',JMH:MWDZO.(JB/VE])U&R\NG)2.C@1]7L?V87Y[<=4&".V#XC8O MAC)2N[.G/L@32@.)9>WO-\CIBR9%OJV_-<':#TY/#@F_V=5Y?N9N,7E" M/+_?W^89^<8;,&7D5*X5K4/\DER9>Z>I_@5#RK^"P!%(V/V0DW@(`IX3EP=8 MQ$):KU"9/>,>QO;QOQ^1J7$9&W=)%V_*Y2;?R_A]QG'#.DQOQD6JG+-OKF[\ MMQC2X\@-]T0DK2O\1HBM67IYJ8O\L&/#P*X@YB*YCD<4850,>?+%SNUQR3@/ M4]'5@E(V+*1@)MAA.AT`))B98W;+.='L9X0QC!7.PP6#G>C[\>2#FHVQA`.( MUDO@8>7Y*I9ON=)D&J=78$+W/7*[,@F2N^@0TVLPF6'-'7.2,SK8X.CI@$=8 MI_1D8TYU.#=Z2]_YZ#:Y56":"V[M(BYL>G^=KY!R_`$I*CL_<].>\5(7@+_` M1V"V[[F[ZRYZM1&]&KR*N79B*O-3SLD(HW`8'0,$]'!-6O7WC?$;:>!B*N=G M,OL)%UE2NJK:+MY`Q47`*?.`:)J``Z$PV/#X8[KL30>/]7RR[Y1CT+)]K;2C M-3H/8WD[12:3*TCZ20J37A#7P66"-"Z!%8W&\80A2--^/$G5@MBEV]\B)>W< M58TH*[-EA8*CR M@#FSNM;3)48%U#A'M_YA[$100ZEN6075<#[3<%./`EY^6%0TV$QA:@PF7+JU8T*`5 MG1$H'J.D2OC,49Z3`"->Z/YDK0$^:1@N1%:*ZJQ*!,4P]]Q2,ZS]*`^*X\A/ MY$]!X-Q4:)XOFC;(7,D4F$HA:Z9VF76)8_[),LI$X!':0LIB&">:A(*;^"B-IKB>O+>AB1%(:!3G5_#W)B,*)1S'+(44*T+/G;,D=^F?2E^\ M#G$LX$L[H`^C/"V%JC]??$6TX(ZNBA&(@.PC9LF(X_\%;>9H,;06>*&)`S!( M"+NN.H\%"\GR>ZGX$`6NA8R>1/-M?B]:*0C(;KN:-!8M'044'J%L]'RS\<:MBB+L&Q;SQ)UQ_^=GG42M4DZN<[T0DW`M*P-)` M/TMF,_?D"X01\9.A1%M4M'?;FXFBU"*,:X5A@>V-'(:YF:0` MFS24HP5R9C<.?1DJ*;M4L#TPXL)UND-=8\+6\=#$FQ/+Q`"YJ)!]A3>Y7C1, M(N554G=!B!<`%S@SF&OCHAS;!]--(KK;%BN-:>QU=-.J1;H#45M6A&6TF4$@ M7)8TB5D'L2Z`'D9/#E#TH(@GF*WLN<)4*GZC!N05CW.5!9O"OX4BXI4%'P7W M58/PLH4+A03^X(YR7\+KCCA9M7D6[6[^1C@TH14&$Q91OR&8Z?6%57NOS^(/ M]B9;7G,'T#9OOK"O%&2T-X\ZTA%D"#`NS?"@RO)/)'A%"B$`[A`F$*4*4&8< M'D).F@E,E7F01[D(OEO-5].1YV)'TYH)'G9T>#WFP([A M!Z3)26;Q)-IT$[$(RQD3&3;^@+MOB/3H<:Z\##.,;:(*;N(FLF#\+!?(7S$X M)'3H`'9VC&.W():1;.ZT'WD;=_%WYHH;]0X$>Z`(+;CF'I!0Q9,?42@)=].@ M@](1B,A==8T19R1@1)3OC;;9Z4\6)"<"J4I&/G=N@D%7RC\$#!2&7<%#[(A9 MPT?3#,F&4V.+-F?&_GHUW?CEY\)M\7P%#"A:!*6P+3I!G5<-3>UD4.Z96_4% M:5S^Q,;FH\J;HFW')<(%[RE9HO122/?4!0K5_>B7QO2]]LS,=MGAWGTX>5/&X#5+`JM=M M!`"V,=`99I!2I\7-`$@,55I`5[G/$'8G'EI8CVD#%Q?NRY4H7B^6)4HBA!=H M-(P)#*6P16A"Y"5Z8)J4I6>!A0Y/=629=MH\2K?5Y:.@UA."HV MW80HDP28UWS-$'-C/^)YEF01+(@-*LD*(1L->[.MOG)O008SS66N,0?CNZ#> M\ODT6!X9L#$+9X2JX_R)^.HGFZ"H@A':*!C&CJ,:/)B:XM@`@3<4[7J6`GF. MA+P0=@ELQ+FY;^+)PFY@.AASSA-$5D^#'3^9CI,[/.F_<1>4YS#NNW;RSR@+ M*@QO`6H?$=KU$FTR^;7"0ZD@W4(6+C>)+F_8(6^(SLQ'=]`B5.AH MT0DBA4?R)P[TD],@GCM8M-[*J!AOPJ(MGI_7=.6,JGU:\2!Q\!D0@1$EV=(: M86@@X'!$),`>1(24O.'=B-J!I4K-6R?B=JN[Z(4BQHY5OJ.:)9/[^ZW*+++) MN!-]-]V0[@D1%`(U1F=E@I7H,UV%+N:!D)&==,]X0]$,XQ!U\M,<8@3+XG72 M`F@=2-QTY/8M2*_3>#XBY`8,T2$!TN3NUX'"C<7"RU!\!TLRSU$\YX$2#MC_ M.E/EP^6S.>._X"A']4G8`0'E+)82E%ZH)@5T-IRI2*PCB[.A`"[=T6H(5>XV MA%X.1?I@EZ$VA!HMD4WLQB39R`4]`SS5YUX)N,Z()=6CC:_2X1#&S;_"4WG< M<5%,K5,-JS2#C+;212%%OYRC$(:SY3C+76Y%'E\BKN6.`!8M91%Q,,,9BMU- MW90K\NUMZC9I+P6.PRLB!ZQ17]_.65=W\V*=6EMLL?E(<1%S)*:)V1H$)!50 M47D'D4NW9;EC:AHK4+%`+Q'^O7?7W!+9D#X`5UJ13%A)=V"4]"'D(B1<8@C( M5@%2I\FU$/()YGA!%4-7>(:#-T3ETE2^5.9?5.([@&)T6DF:8,[5_V*I';Z; M!D*^$H`PYT:"TI9\=&#`/2>F^1.11SNP>8X=$-_>88TI5>/:Z]&;Y^='%1=8 MEH"=YY)`R,G_Q=&!S5:Z)(]2#]TV[[?1@]P`24ABBFKT1F:LZO&$&2,KJ(@* ML,D\DX`+1SN1:]X=-?5$?`>V\_$NC(UO@[O"UWB'CB:-M%A@S M>D&/4EF"L?0R_2EYGP:I4H27Y%V4PE*Z(K`8C#U#&D)@5@QH%2K#AL)!ESB- MFPMN[7N)"41_^JE$N4[T_,D"3N07S'ESB/TH'F'O!L7E$3:9PXM-36PL0R@Z MPJ;IO63:L:4?T`1!Y+%GN5"S1TETQP&BY]YIFJ>@,5C9& MF)NL6*3X0I-\C$2I)&9$?2A@.5K%[1MN`3!D<9*ME$0S%BUC5JZH@%G8.@B" M>Z%C.=:_?CI[5GXB\UML.CV^MMQ"JOM4KA[F!^#V,%T=AM&"EY!1LZV6O M?8$:S("%4!CI6GDN)(-.S4I&6]&UD!F_GGX-X'Y,*H_,MW)JWT\P-CXE]08& M/DMR+6S)\@W6_CB9?K_VSEY`:JY(MIE@=K&#F+?L3.C")3.\%%[*DT/N5<)# M%D][11Z9E5?9+2%VN2 MU4%5^6.G0\7O2.[XE;AH",;-`&>6<(Y:B16QA8N+1$Z*9:O2&A M7NU*`?>YY(;A-.*&H:/TPIE4.Q:(S7//G6M(1'LZ2A9O$(B2^S61DXMPYSK* M"M!2ELN:Z(3`EI!#-B2]-2%O)E@NB]\35)7"#2!A<.;1$\9'^UH+I9I$<&9? MOU/@V>NY>Z[XMI2C`FT3/;&#^$$;`4D9.J=&/9%`%,[V+[;'Z;$[TY%P6=]88_T=?;O4R7+9&*"H6 M(Q%%H,"A-#(;%U%XXXO)GJL8O0X(GQ?42?DI[E#&H1;WT^9H>^DV6H\.BMM, M3DIRY8W5K\9J<:9=X2/15;UY1`?W(C"^Y7UC\@W'N_Q(5%3G#A.=HR] MWE*H&IA8/EKVNMG#H?>(Y4C5*SOG^%_UF0^0`^%]J[*=@\>HM[60M0K52U+/ M<;P\AQXO>%7MIPH6FO027<_FE`:T4<88X05V6+N9OPY]O6;IQ?$7+`R/Q^W=[H>3$'W`?J[V3:!\2%'SZ62-^N(*&.I\9'#V'"PC^_7>X9I#UHG=E%)M):CU#\N88-R MH23:J1`-6"928?Y)KCH,A^Z3[(#R.UP-R5H>_KU#EQD]'S&T5)VS#":AX+@Q M72Y9,#O<@?O_?*JWV1#<8$GD+KQ_D M4C/,:J$M.S52[Y^O)7,\&*9LJIVA"N`DG8MC6@58>H_08[P^@XB$;@&4^F=3 MYF0?J)%E.,GFMI;/EUP66A\5"L8<%K@8R+)I^R/;=1[OY[K/6/M2,F(L.AHB2RM+#",W&)FG"R[22GTK<_>9)^R\*JW M/B633]U8B=G*K=W9MK:93GT-`@M=>+E/8RZ('"\EA!4_\J:=^J@FR!?F.\6`G=]0HZJ:'-O46#*"P%]0EFRQ;UBB;I\:S]39`7>A_$[CU%@44M@K+ M6B_6LY3=F;(^K5_C\?$4FY?8UJ$*6%2L8?A;Y8-0R%! MVM!]98>SY4Z$CU^XS,=@;+8[33\N.EQ:7_-C1F*/Y3I2JL;MH`T3ZO%>:$"M MU:(&/WJKMTIOTG7AR&I]TM.*2"S.I];;O5U\'K7>;#$ZHO]%9=B8]Z)N6N5* M>\>8@]?+.W97;\#CKAUPC/9S!.XM1&!HM^/;+5A?_QZS]=UQ2A*F8;Z6'0T; MEH(K+1%BW%?(#-L'+157P\_>4)IEXW/DZMT;(=:_3&Y.@L0 M1Y,OV_+U97%\XZ-#,53!;T2;+?96.5+0")E@7[E#7-$;5V76NI5O<(ZFY!&D+C-CH^)W^NVV4E_)Q\*-FH,X?$EQFPKSUYS2D MIHM,>WWVH_@&VSD/9SN'%R;BCE5Y%_7FQYF[RX'R7!WV43+'F]_UEB^LD%%E M@%8B9YZ/*!Y_SBU`5ZZ,2950+2&GJ-[_;5Z./+<#37F_P5VS:;D83P&2)7`5 M9H@9983Z!_YR;3=/.ZI<=,?9@R$F`+X2;[PW5'O9\L0!*BQ4'RU1&DH70-27 M<^`K#A]C[ZVL-RPZ/\VRV;/_)P````#__P,`4$L#!!0`!@`(````(0`O8BV: MM0H``+M8```-````>&PO"U10+4)XFB M+,FQ')QDLSW@Z@8Y%RW0%`5%439COJ@D=6?W]2^!K7]PX\:)PI@_>]W7-#9UHY86/,_UO#];%1->2U`Y7 MMA^%[DQ_=1/]^YO?_N8Z25]]]_.3ZZ8:B`B3F?Z4IINK7B]QGMS`3MY'&S>$ M7]91'-@I',:/O603N_8JP4:!WS/Z_8'NAGDFX"AP9(8$=/V\W%TX4;.S4 M6WJ^E[XR6;H6.%^(#SXFC)%JG[T%<+UJO/8ZW`96D"::$VW#=*8;Y2DM^^7C:J9?ZEIF\B):`8@__&<;I=_] M+OOS[H_OWO7__>UW__S17?WKIV_V?_OI6[U7J"$R@8-ZF>_[M6+AYTQR+[?@ MYGH=A<00`,T<=/4<1E]#"W^#8`#S\+*;Z^07[8OMPYD!PG,B/XJU%%@&^]B9 MT`[<[(J%[7O+V,/+UG;@^:_9:0-/L,#(KPL\H`E/]C(-Y]6S1#2%31.$(=@T MQ#/4I@!,LO%DO4WVSP=L$G2-FG4=XS]!%[.BWJ[.=.W'Q9X/C]%5ALE@VMH37NU#(A%O=Y0X5#JTM7-BBT M/HQOS^;.[I5569>GX7/U`.QPW7K1@ZY;T[_'%G[.$2=G'M!.PQB3*B1]UO5X M;GSP`C?1[MVOVH]18(?H6#JHL:N%,5D(O.[%E]0CDCK@'/T+^[C!\6I0F$K^?[Y91\:.*D%<[<7,/J('7CT((#+?_^\+J! M*6L("QF,MEYV7S:>+[I$NIM.NA1H6?#H6^F&$GXZ%6O#?HC.?YD.5V17(4IZ6 M>KBP[;\?3Z?3R>!R,IE,S>'`-)F3EWE$>^'*?7%QK=N9F_81C`#!=#B97AH` MI&].F*JS(A@"@/%H-!D-IH8)_[,,?GH$7?MTI*MFE2!0Q"I!H(A5MK;J=9#Y M\YX"%1O%?94@4,0J0:"(U7''&7BLG%6"0!&K!($B5MGTNL.^"N5;Q7V5(%#$ M*D&@B-7.)I]Y!IXJ9Y4@4,0J07!N5HMEU>+NSF+UH?V96?7\F*WD8.VXC.(5 M['T5&SH#W-')SMU<^^XZA55B[#T^X=\TVL"_RRA-8:?HYGKEV8]1:/OPM5>T M*/[6M(2]--@VF^GID^<\@S*A$I'AS52<2D.9B4RL+2AQ;Z=#0T.6-G00M9& M,6X*=@7A93D!T_,!)#O^%BX_#L9.[LO3$FZ:9-LF%`V`:S>,%+;NP'^+DGS0 M@C'0<7W_,XY*_UB7`R'4>VZN7];D%@2X+P3WZ/$.!_P*1=7\:S;H90=@4%4C MH[*19F\V_NO]-EBZL<5N%F$JV%DLWO*C.1NM^?$'WWL,`Y=5K/1,S`]QE+I. MRFYF8<7F*CS#"CR#7)`,GF/TFQ7ZP4_2_CA&/U1$#I((?E&J'X)+6G^7\0"U MA,(?0`$-ZCH\72*`=6^!`$A0@0!O,\H[-H2G"@2PGB@00(!R!`"G)BJ.Z0<# MDLT@!KA*T'\JE9!C"BL%E2>TLBK]@OX:*RTA_1[E9I)O(="YF^&@!L!1*JM2 MK*H40VB'GL9=``5#_57M:-A=1!U:()>"^:9ZNG;.4(7+"U%%E*XX-==E$[U9ZBV/L%%IGX M@)<#Q50WUO&!P-1SZ)FOL;UY<%]@*9IMOKRLJVN]@*2H;^P&HXBP$A/7#\5[ M76NCO'/_'('E>$42E@6H,0,VI-3&#D.5(R-YU1U."[,H,5N>0#GB MD-)]BDR-BSDY[2>P'!?4[937;6["9*.=L!,%T'!W558701:KHS8&,TU^>-\` MG1WLCJ^;)5`&3H%;:2?LU&ED>*5.J\\6A\=XR9Y$X;,[/UK. MP5IWKH;^L(_G8'15.*HANF0\]8:^Z&(LSY^=!O M(%U2HX]H;.581*.D6,F\-0N)U$Q>#_=B9O`+F=)M-6(5=S M9T%=7WP[Y[3L(;_76\^%1(BP28IW7V29PQ_P\.YE7YNID09;*Z,"AE\J" ME-%6%DC(96'MG^""4:JM+%"?R1J"M406W(;:6A:$8BX+=V8X+A.J+VUQ09-< MENC[D:3OS4,\LCU,C@M-EL%%97$>P7/$QB&8W%86YQ&(H[+`Y+:R.(^`D,@R M04E;69Q'8('*@G!K*ZODT03BB*R1I.\O#_(HQBIN.,C@HK(XCV*L#B5CE#1GABR79AAK.?(E!>/N$C$&+)]=YUA;P M?$0I2.P/.(S*"+I[V?AV:*=1_*KA)EHI3B1])"GN3U%4^DB48,"A#*`_PVLX MX0V?&O@E\Y`8PSBC:B.F[`NB>P:2C!5HH'6&1HP_K%RT00.M,S%B4L7YDXR8 MC^%F6S(DYE(<]/$13.!%GVJ3OX/):!OA?MREQ([NUE<]Y<+$B(^3!2^$) MP*(3BS@`EI2("#:V2Q$[&452QM_M.,3>(G3=G1BML(C?)@"S_]4+?\**^3W% M%]6R9Z_*]0"X=^6N[:V?/I0_SG3^_2_LV5H(IORJ'[PO46<3'ISR<7YM`=74Q'\]N+D;F8W]Y: MT[[17_P77(9O];V"U\(>\=9<]G9?N%%@8%XE/KQ;-\Z-S<%_YN=F.CG(X+,G M%0$V[",41O22\JW#-_\#``#__P,`4$L#!!0`!@`(````(0`3&Y`M(@,``(L) M```8````>&PO=V]R:W-H965T&ULE)9=;YLP%(;O)^T_(-\W M8,A7HY"J7=5MTB9-^[QVC`E6`3/;:=I_OV,[,3AM)WH3`7G]/N<<'WQ87STV M=?3`I.*BS1&>)"AB+14%;WJ M8DQ'X-"J'%5:=ZLX5K1B#5$3T;$6_BF%;(B&6[F+52<9*>RBIH[3))G'#>$M M<@XK.<9#E"6G[%;0?<-:[4PDJXF&^%7%.W5R:^@8NX;(^WUW0473@<66UUP_ M65,4-73U>=<*2;8UY/V(IX2>O.W-,_N&4RF4*/4$[&(7Z/.<+^/+&)PVZX)# M!J;LD61ECJ[QZ@9G*-ZL;8%^+P4?+B"V\95!OV29/M#U8SJED! M.X[-TL_P*`&(L@(#47]/F.O44&*/&5Z?D'=VV[[)J&`EV=?ZNSA\ M8GQ7:2#-H`RF&JOBZ98I"ML`K$DZ,ZY4U&`!OU'#33]!&ZRE$V MG\P6289!'FV9TG?<6**([I46S1\GPC9`YV7#O"6:;-92'")H$E"KCIB6PRLP M?CD6",)HKXTX1PNH5HX4%.1ADZSC!TB9'A4W3@&_7H&](@:DYP)K/->(#=?4 MQ`1RXQX,,>G+F"S$F))GL-O_3],L`MT@B*J5<$:8)D?)I&;+?7 M%V_F71W7*8;V#NLDPW3Q*VUL#O31KX\1GY'[MG5D)PG(?>\% M.5^&Y'&=;1:=1=`WKHO`28((^BX,(L#P(HU/WJK/V'WS.O91$\#[5@SAYJ09 M77GLSB4X-ORKA?L./L*=)H#W_1C"WW1Z87=:#>C["G68(3U]I.9AK0>;C M=MZN"LN?GC??43.WKQM>S.?9C"\-:_]3/ MXN.0]'_`5.O(CGTET`0ZT24FC=S%U7I06KJ!J)AM7P)!>RHAHNY=95C60T:XNJT@T\+W8K MRFMB&.;R/1PBSWG*[D6ZJUBM#8ED)=6@7Q6\44>V*GT/747ETZZY2475`,6& MEUR_MJ3$J=+YX[86DFY*Z/O%']/TR-U>7-!7/)5"B5R/@,XU0B][GKDS%YB6 MBXQ#!VB[(UF>D#M_OO9]XBX7K4&_.-NKL]^.*L3^D^39%UXSQ_\SXMM`0=P0=86/S[/6>J10?/@?#8D%F^:_&M#J$U M)+E#EH1,B`/B%<3RO`R]8.$^@Y7I`;.ZQ/@V8GU$8`(@K],(W9UK_+O91RD( M1BEH/FI;F1O`W6GK*5M?(N*HDV8I`8?>KP3!"0'R;N'0"SM>(\Y@QF>8L8U8 M#R$L;4!RK@V3'+^Y-8]N81%LPK/U0Z^G8&4P0QJ'$)9&T-/7&,)+.)PH%O5] M/.5C?#28N-UZT33T_;$_[1EI0;PPFD;!B<52&=LJA]4AN*\NMI=>&,1==2-I@AC4,(2R-.N]XWY7K*6-3W\92/2=E@3,I^./&G8=C; MK&L+$GFS2>"=TK!4SOY')1;U54YZ:1O,D)-#"$NC#R]'W\KK<;=5U_(^@(9D M#D)LG?CI_N?(85)?NMG/_``:MZ^V9UN-LQX9S(X83Z=^'/?3-K/(NP#'1^_^"L\6[>F@>P"CO:%;]I7*+:^54[(<*+W1 M!#XUTAP.S(4633MI-T+#4&]_%G"(8S">O!&`&[_9DP@``/LG```9````>&PO=V]R:W-H965T;:W;WF8`37`.8 MPLYDYM]ORY9D28=QR-:\Y/+1.F[UL61)^/[+C^.A\CV\)%%\>JA:M4:U$IZV M\2XZO3Y4__[J_]6I5I)T<]IM#O$I?*C^#)/JE\<__[A_CR_?DGT8IA52."4/ MU7V:GGOU>K+=A\=-4HO/X8D^>8DOQTU*_UY>Z\GY$FYV6:/CH6XW&D[]N(E. MU5RA=[E%(WYYB;:A&V_?CN$IS44NX6&34O[)/CHG0NVXO47NN+E\>SO_M8V/ M9Y)XC@Y1^C,3K5:.V][X]11?-L\'ZOK=.2H_WNXAZP,I>N80O#]4GJQ?8=K7^>)\5Z)\H?$^4ORO)/GX?7J+= M+#J%5&WRB3GP',??6.AXQQ`UKD-K/W-@=:GLPI?-VR$-XO=1&+WN4[*[13UB M'>OM?KIALJ6*DDS-;C&E;7R@!.AGY1BQ6X,JLOGQ4+7IPM$NW3]4FTZMU6XT M+0JO/(=)ZD=,LEK9OB5I?/PW#[*X5"[2Y")W4L2NM:U&M]DFC9)V]&EV_>;M6[U"QS389( MUX!X0'P@0R`C(&,@$R!3(#,@4!++,V#\L*S:+WPG&3;LVR--0#B`O&`^$"&0$9` MQD`F0*9`9D#F0!9`ED!60-9``I5HA:>U\2<*SZ+UPG/BR.770!)U:NKH4Y.; M![&-J9R_.D:,)V/$].5+:4&&DA0Z=LL0&DDA-:BK9S2604)[(K4%F4JB"AE7 MFTDA)<@QUC]S&22T%U);D*4DBI#9MY444H(<8P.RED%".Y#:1+3[@;;%G[@? M6+1^/W!"]YLTUG9LO=8#'D1)%$%FSUP9))+V@/A`AI*42(]DD)`>`YD`F4I2 M(CV304)Z#F0!9"E)B?1*!@GI-9!`)9JO[-#B$\9FX;JS`M$E"M>+X(TK972A6R)VB@M.; MDI@)>:U#9A)S$56:Q$)$%4DL;TIB=37*3&(MY,L,"D20UA^E]/IM2H-'NTW_ M[^DBT\DF664FZ1J[N#X[,J:HTEUW$2-&@HO(0^0C&B(:(1HCFB":(IHAFB-: M(%HB6B%:(PHTI!M)=H.1=JM&D]5G#XJ9DO&\S)&^1W<,=P?LQ(6Y>R?G,!>1 MA\A'-$0T0C1&-$$T131#-$>T0+1$M$*T1A1H2'>.G:RH3XJ;-^T6:VDXE2-U MV\ZC%.0B\A#YB(:(1HC&B":(IHAFB.:(%HB6B%:(UH@"#>FVT,C1;/G@`<[" M#2\X4G;R[$M0%E4@%Y&'R->0GB<[B%!OGP_RS,\MZ'84TVN??2_&DM(7&L9> M<""B/EAH<"TMRGR.>5SK@X5&+D4/=.61\LOG&#L5$%6@AA\4@44;9G&D;PF, MG?6`U2CW[WI._#LQ'E6T"83BH9MV.OD#75SE;6FWGFV M%53,S3KOL%<'*ND^VG[KQW0EJNR54C1I*9NE^F3Q_:1ZXW.D>=Z&;2"/*MUF MN$*^&-D>1[9>:&-GZ(N&K#/RF]E?58+VCUHEKO28JB*ZG$7KYG-D=^3P'Q1( M20"<%E%=V=!#Y`N4R6L>LCO?]-!J92?3MWN8B1@=RI?]^N35-C8'`]ZP2>4K MBHQ]Y%K:/0^3%]<2D]?5K;R(N6GN(J72TGR-S[^ZO56SY0I<#,5^)DSSA&IV M'D6HM!!Y5#-_H88=_GM<2T&^)I^;G;\1E+^^<`POK^$@/!R2RC9^8V_[T+3_ M>"]Q_BI2O]4+LNG.Y$Z/CMBI*P9_LNS>$UT9/Z'=18\MD*]]TJ1/LH%OJ/6M M._HD6[`:G[B='IW:HM:HTZ/S5>2S3H].0I&O.CTZLT1.KV`]7<^5$KH2WZ?. M78VGKEWKV=-=[XEV@GCA/O4XZW!=]IA>O3IO7L/YYO(:G9+*(7PALQK9V+SD M+V_E_Z3\1GR.4WKI*KLG]_2274CW1X-M-%[B.!7_T(7K\K6]Q_\```#__P,` M4$L#!!0`!@`(````(0#?P;HSM`(``)8'```8````>&PO=V]R:W-H965T&ULE%5;;YLP%'Z?M/]@^;TXIB%I4$B5KNI6:96F:9=GQQBPBC&R MG:;]]SO&!(4F4MD+E\-WON_'?OQZN M;C"RCC4YJW4C,OPF++[=?/ZT/FCS;"LA'`*&QF:XB@2^% M-HHY>#4EL:T1+.^<5$WBV6Q!%),-#@RIF<*ABT)R<:_Y7HG&!1(C:N8@?EO) MUA[9%)]"IYAYWK=77*L6*':RENZM(\5(\?2Q;+1ANQKR?J5SQH_-C%-UN0%2L=[S%W`P'7`T`%!0'10 M!K7IRA[LE7UM?2AWP7`J$U^6N?X?&0^&YIP$']/%P!N4`V9^@ID/B%&"`)F> MH`=##\;2[VL;0!.D8:BF2WMP)ST4M[>,JDN7E[-'T8GIS655F,'3!+UJG"31\D-9[SB6[2UCV=5E6;_/3T[+=%GO.);M+2/9 M>'99=G4NF]`)R7J_L6IO&:N^/Z!A#X8UH80IQ1=1UQ9QO?<[+H:#/UB'];N- M_=E\;Y^GVVXMD^$#K,66E>*)F5(V%M6B`,I9EXL)BS6\.-U"Y+`;M8-]V#U6 M\/\3'5,V2P6#"%)<- M#0RIN89#%X44\*#%1D'C`HF!FCN,WU:RM2 M=F*@R.@R3N\GE"WFG3^_).SLV3>QE=Y]-C+_*AM`L[%,O@!KK9\]]#'W6WB8 MO3F]Z@KPS9`<"KZIW7>]^P*RK!Q6>XP)^;S2_/``5J"A2!,E8\\D=(T!X),H MZ3L##>'[[KV3N:LRFDRCV7@\FLRF2+,&ZU;2G-$I M)1BKQ2IL%TD^M#^4^;)S+)'T@ M%S+#_Y'QX(SBLP\^B5]X@W+`C,XPH_>5$7)]@AZ,-;B4?G$N2`?0%=+8#]=+ M>W`GW9M[W+EP-QZ^G^7D4LJ/1C*914CQ]U[RYRY5CSM8V3/W7WL;9C2TL`)3 MPB>H:TN$WOCY2[`I^]W^:E@FOF]>[X_297=EL/X'CFS+2WCBII2-)3442#F( M_(B:,/1AX72+D>/(:8>SVGU6>#<#]N7`)UYH[4X+%&;];;_X`P``__\#`%!+ M`P04``8`"````"$`[;[W?1L)``#%*P``&````'AL+W=OH"B:,^Y5F3:%B*) MAJC$R;_O+&>DW5E)2SHW<2P]',X[,[LO2?/^MQ_;S>Q[N^_7W>YA+FZS^:S= MK;JG]>[E8?Z__WZ^*>>S_K#+M;+/K5:[M=]K?=6[N#;YZ[_79Y@%_W+XO^;=\NGX:#MIN%S+)\ ML5VN=W.,<+>?$J-[?EZO6MNMOFW;W0&#[-O-\@#Y]Z_KM_X8;;N:$FZ[W'_] M]G:SZK9O$.++>K,^_!R"SF?;U=WO+[MNO_RR`=T_A%ZNCK&'7\[";]>K?==W MSX=;"+?`1,\U5XMJ`9$>[Y_6H,"5?;9OGQ_FG\2=-7*^>+P?"O3GNGWO@__/ M^M?N_1_[]=._UKL6J@U]#BZD9+%#-4!R[/"P?[_?=^PPF#O+MWY9N?L4=!'9545!;U'"JT[4R M07U13\^,.RCN0\'SK)&! M5$YJXSZ,$C9%,!4Y5Y'.WL&\#R(OH^R1R8=&**VB/C7L:Y%E_&@;?JV-*:XM M5-@CPN*GTW9PG';%3UPC0VDK8_(HLV8,L"%0%%4N"M]85G)W*1#LE>G<'1SE M7D2IUR=W"95/:CA$6"LA=9&>QM M+'D!GA36?MJB'8Z*942#71.4TC&.6$)0B9"5D=)OTUR*<[7)8R30`\,M5!1^ M8\-.$)24@'$2B*4H*`'2%Z;T^Q>7X+PND#"Q&^B07(H_`TE!*)%G(T812PA* MN5&%@H9<7A7"&5\@);VH!YH/5!'OH\0D%:3<=JB#I2BHH)2FS*]L2@).]`$! MCN8"1.%+0SU`**E@%+%#8@]S&B%,,!`R,DMHF5R`;S()0"B172-&$4L("E!E51GO M1%R!\\)`P<16H(-R)6?+`J&DDE'$"D10B=!&9YGR5P1:O8O`E*+8QQQ!)"PU2:3/A^<24P&-.'23HZ:D;I M(^,P$914@'$2B*4HJ.#&F"SP):X@LNR)O4#/9.CNY!SVZG)4*)0C?CB$TB7,(OF;=[ M9'8V5F<+8]29&XI#_:I4ILZ:D0K"E7S(O>4%]PXNEVF<$,+T!`Q"&>UC#84Y M#EP!EWE1&2Q#=)'+JWN4\\;)-B'12?EZB#;(FB`24$AXL,*WT(81)2P'/^I# M#2P#=)E+[;+J$@8XM(IKS MFJ"4A''$$D+C6&97+4)%=IV>I8&.%427$S5!207C]]@4A2:RRN$/"*=YY#UP MACEYC!3:*UO,E8^,JX&@I`*,DT`L14$%JH#K#!W8*-?@G'*Z!O15KB$V:(50 M(L%F'+&$4!=4GL.%7[!Y,(S:)<`F11T]LQ@6OKJ(+A5HAE*AT M,XY80K`9HH#;TVO-^)!9JPMF'=_-U`0E%6"RN$:'W"K>I9H@U#(,LBKR(#M0S)C2E5:7S5F!8=V?K*N)F[,T%)DEU!!*5H M[?:[TP1S);_DY?K)U[NLS\327U M!"',H4*P$(8HEB&B%#+/E#\3'[%?(M,05':K>,$;G*L^D7PW8&(:D M&V,B8Y^V8H:C^`-0F7G7PB$CZ')%2#0V\,CFV(R<1U()O3>*+@=MV_](V[6;3SU;=-_=&I(1W@DZ?GM[6 M_#2\K!E]7HN[9GCE<7'Z`EZB?%N^M'\L]R_K73_;M,\0,KLMP"?V^!HF_G+H MWH;7$;]T!WA]'OTLC``"!U0``&````'AL+W=O[I2=ZEA>S"Z[2ZP"RP6>WFNMLMVH5TN MHZIZ///O]U`1RF0$Y0AEOG1/3YT,BI^"Y"%%B>_^\O?';V_^=O_\\O#T_?U- M]O9X\^;^^\>G3P_?O[R_^9__G@_MS9N7U[OOG^Z^/7V_?W_SC_N7F[]\^.=_ M>O?SZ?F/EZ_W]Z]O$.'[R_N;KZ^O/WZ[O7WY^/7^\>[E[=./^^_XR^>GY\>[ M5_SG\Y?;EQ_/]W>?EA\]?KO-C\?Z]O'NX?L-1?CM>4^,I\^?'S[>CT\?_WR\ M__Y*09[OO]V]XOI?OC[\>%FC/7[<$^[Q[OF//W\/ST\O3Y]?WR+<+5UH6N?N MMKM%I`_O/CV@!@'[F^?[S^]O_IK]-F==>W/[X=U"Z'\?[G^^1/_[S;D%__G\YM/]Y[L_O[W^ MU]//?[U_^/+U%?>[0I5"S7[[](_Q_N4CD"+,V[P*D3X^?<,%X)]O'A]";@#) MW=^7?_]\^/3Z]?U-4;^MFF.10?[F]_N7U_DAA+QY\_'/E]>GQ_\C4<:A*$C. M0?!O#I)E%PCU)+`"N8B1%N^19?3SJ!(C_?$C_/EL%B+KC*N.ZAZ90 MH-.TDR#\2#&HY"WN26(QH3@Q2#&V.V%`($VG\,P@80Q`I`K0"0A"X^ MKY)+'^CON+Q?M9)Q582NIM()(,*7G?[[O/YX*[RH-_J__?4.8E5OW0>2Q*C7 MX"I&4A"[@$Y7WHTP6PI1_>:2Z@>QJK[JWWN2T*5W!=R;NO:!!`:?<54L]SU3 MOY]D`5FIQX9Y_;E[YX-GC49!.^.#6%5=C5L]28R:#:YB)`7?^6SCUKLA9DLA M;CW\P_[Z![&L/ZY.-7G2T,47H5-6@H$$!J%Q581[G^7J]Y,HH.K:5@GF]>?N MO<_0Q^^O_*+6M5>&HV>14;O!EXPL(8@@D$"<_""S*1$YD`6;M+L1+&K)H3V; M*G(_K*$*'+(BJS%?D8DRL,9`-?J2R9?,]L5($L$N[2=!Y@K_/`U?V3%!L3JP MQ2SK/P_9^N=S#.6D1I80S+K6^3Z)OX/U$3VN9#T+27(_)(+@FO8C((\E$6@O MG%E&;$F8P9>,+#ECV&@5;D&S69`$@:S2(D@&"?HDS89XO#.D$"0M6S9Y%1S\&7C"PA MG'E=-;7*O,D/,IL2R2/XJ8B'[14R6&&0&D^2T,,< M2CW@3JJ0!H.R[AYV.\4L&*N(PYW72L0^L,:"-)\EBI5,:NI2J M38'DEX/%5]3R5ZDJ M>.076)F M80\=>5#K-%#C>,\BHXJ#+QE90BS+*N\RU>PF/\AL2B0'92[W#1_YALG,M,]F MT=I;UI5>F!Y881`;?5'II86!-48]1Q&F*W.5=Y/X>]8V[1&#C"0^"\VA.=9U5IPO5X(( MUFL_"#)J$H2>A.66F^.6X4I&CD*9!0Y%W29#J1ME-J]%@`@/J/:#6-1J[,A4 MXO\D8-K+#RP9=,;CFS&41BN,A?%AO^,M/S+A81AJRLRD;=R($5 M)@8JR9!,;CFS68[$H`SFOH&CV#*:JK(]BPA'T1Z+4N7-P`JCKN-)$D;0=`E3 MEM%T=:W*F$\!W#&TN,IC+K]2#43/@WL6&14=?,G($@):-UTRWY[\(+,ID:F! MR[V@HPAJQ4%W`WU!(NXHB@[K5KJC(`7^>5H:5P/#R$%H'MO4ZL^3+N-8J'Y[ M/@78*D,B4/;2'CV+#5N9^&P6&14,BAUFD#C/QVJRAE#@46545>G8VL,;D0$49DLF/,ML7 M(TD$F[;;8A9DZH3%S/4DE$6$`L\(J^Q8J:096&/4T<2*`H+S*9BUJ-'7H^T+/(J.;@2T:6K$#;NJF.JL>9_#"S M*9$D+O*9Y1Z?R2*J`W8OX?&/O%4#*PQ6HR^9W')F,XC$<)7/+/?X3!81CJ9# M7Z$\X,`*$P>51$'RLDYR(OY[TV&F><[\9:HWFX5(%E<9S7)C,3,QFBPR:CKX MDI$E9QB8X\L,F_PHLRF10'"]^SO.,JA5;Y$\[&`152%=;AKX[P:H\20)4X^L M2`C095`))3H226@^_=QUF6'W]`75WW*9J@/HEY#O;_CBL%BE;^#`"A,`E<1& MN]!&6Y>!9R$:P1K`1Z`,IFVTRPUCJ?EO.4^',NOU*B1JY6!GD6,(V_;ME;SU8$E1F5'&:4K M5+Y;Q2"32PPD`V^I+)+6A81B@Z[MQOM1P:6F"2H*(J"((GU%,7D M19-E5:EZV5EH#G@<@Z7%YFSB)8F+[&>U83]U)]^SR*CFX$M&EIQ)P'BI/F?R MP\RF1)*XR(!6&P:T4"-FSR*N0U?C;5XY3QA88;`:3Y)E)T4Z@M"%K&5@1Z\: MS.93`'26,YM!)(ZKG&>]X3QU_]ZSB/.C++JFT_G!$I,' M%;5F63)CU:6TN5XEF]83NC'2R<'"0RJCIP'$,RLN1$(VM+-7I/ M?I39E$@@RGC:W4:]83CUPZ^>16L5\KQ-LL(UDR,'X?=@]*1GTF4<*V5[YU,` M=R2I<3_V6\U%K3H*[9YZ%ADW>O`E(TL()-X/P(*.[&XF/\AL2F0J**.Y;XY: M;QE.91UZ%JTIT21/QUA@`!M]R>05,YLQ)`SE-7?"V/"<>I+1UR0ZP<#KS<=3N>6#)]G4N_>\HH^"Q MIVXKLI1CW56J7YK-4B2-J]QGO;7RJ2QPSR*CJH,O&5E"25:#1EZI@B8_RFQ* M)!!E/W>FQX8-U1N!^II$5)6BPUL,\LX.+#"(C;YD\HJ9S1@"1G.5!5U^I486 M_9"T9Q'#.)9=4:OIR\`2"X>,DMCZ2?[]6%:=SI[9+$72N,J!-AL.-%GJ8Q%W MI76QT7.PQ*1!11F2R2]H-@N20*XRH;`<4P@%(5;'=I+5>KAQ8\RFQ()!!>SWY(V M02T[CF3UDS5K8F"$+=KDY4(6F22H+$,R^5%FYVHD"V5+[1E*^.Z;8I$5:L#H M6<3=1HG5NDS?SX$U1D5'$29O6CTOG80`'Y1K.[1(.7C-0G,(+P%CQ_!Y\5"B M")YO]]:UAAPBNHW3)EU\U4X6W[/(J.;@2T:6$-!`(N\:;3?\,+,ID224&W62 M8L.%ZN7-OHG]8=8657>^"XO#'%AAL!I/DF4WBEX.F709I9XYSJ<`YYMVSAB) MX"H+VFQ8T&0!E$5&10=?,K*$6UE7%LDLW@\RFQ+)0SE0)R4VG&>R`-H(YXF7 M"W4+'UAAD!I]R>26,YM!!(;V*N^Y_$H.(A^+C*H.OF1D"3/-2[RDIT:KR8\R MFQ()1'E/NY6T&YY3+U;T+*(JU'BF4ZIEJH$5!JKQ)`D=9Y.\IJ[+..J-Q_,I M@-MQMLIM.@@V7*;NM?LEY*^^&$&#AR\964(@P6"C;;AN=C;+D:F`^Q&[B7VN MNPV_4CV%7FOI6<19W=;(:]7,!Y:8.4%%&9+)+V@V"Y)`E-/<"63#<48&CAX. MM"0B(&56'/'!"=FI#2PQ:CN**'CMI%-3_TD(,/?#M\)4;S*;Q4@VV4NJDQ]F-B62B'*=.XELN4_5'/I6N,^Z3-[" M9(&!;/0EDU?,;,:0,*[RG^V6_U13A9Y%?&/#A[_THN#`$A,'%451L/U$E3+I M4K"TF#06"K%=BJ2AW.?.U-APH905/B>:;R@+%%< MY#Z[#?=9JB&O9Y%1S<&7C"PAH`N)(OGVHA]F-B62Q$4FM-LPH),ORA?S]I..K_G0^_=AUX!VNX7+GN?Q*]A'IWBT6&94L>=6")R8.*6J-H9SWI4K)&C["S68JD<975[+:L MIKKU/8N,J@Z^9&3)B4:;/"*<_"BS*9%`E-UT6LF&S4P6+G#&3IC*4A6P[)Z< M,#"PPD`UGB1+EZE?S)ET&H)]?ABZK'R`AZL!$%<#(*3Y MU14I),JKVB-Q=MPPJ?HA"3(D]I=9V>*3.LG[!:O(1A('P@ZQ3BUK`4BLJ#J< MLI+I!4<0B44'+`X<\5+0>=U2$5%^U2.R853UU@@0(9516>2(JT&.D&9M,P"2 MMVI(`1,W$)!8&@7D(K^:'3<,:S*M6U54D2K#1HNT6Z5`!C/P<#7`09I?%P4: M5AA%0UG7O8/-AH=-9GA2,=?M\*:A7+M`FKA&%UCB./B(A%I``9-8 M@(*P3*\>=0**59"$LASA$VWGV0F%3_[!2'_J%>/OJ=(#I\P\'XA6C7=H<$9/ M;%$!I4E>\L$A/99%79\X@"CKRAI?C]*]B'F\ MT)HAEN%<-&@PI"%TFV6!BQ5'<0'@F(N7)D$N#6OJT.1)0YA8X'V)1N42\H1" M&3<8>>)J`,35``AI"%KXLIV\(H4DV+DH53PDY/Y$BNC/)*#EQ!X1IK7"-P_3 M'"&1C20.5.%C&VH"!2"QHL9'BMM,3\E!)!8=L"FYJ>KC.90B$NSU=R@8)+ZM'$:4=YE>/K M&\HZ(5$L/[ER(0W5N4B^J0@HL0`%'>//22Q!`,4J2$$)=NX**.0")12]$)^9 M!PTMUPHHEI]8@<+5X&Q)TA!1H#CJ1U*@X88!#DNC<*!F5S08/F1(8$D]FCC/ M"!M`TM,]\+5FCQRHN!I@(0V1VRH*5*PPBDHP5L M>Y;:@`JI3&OB:Y`L%(<2(5"I:SUT(5OE7Q@#"0U].(< MHP-N$[ZCH8\10IY0*(,:B+@:`'$U`$(:(IM>D4(2C-T%2,@'QDB2)4[D"*GH M"CH\ZJM2MV:>9[2VG#@.-L#K*.`1*YH&7S\^ZNX-0&+1(2RU-%VD4D""L[L` M"!E!"41U$P!BV<6ELD@15X,4(0V!78#@^Q7)..P&`A)+HX`$5WIT+>6*YR;7AK)I@U2J]_Q9(9#'X"&H-*XSH!SUB`XNI+&3Q=(H+L'>79$LY`I1 MSMG)ZB];H0W%#K0N\(%_?0^1+):_7),ECH,%]^2@@#4*DPV5\#.5+;HC!152<5^;9PT>7\C,!I58@WO>JE$*N4(*_/-T!\[]Y,(-N1)' M"?-B//&4):$-67$4E6#P5*Z$[]$[=I9//!*Y4JE^'U10 MKL*J8O`]X31%UA!;J:9(!'\7D0@F94^*D"T41/3;"T@1RSRNW2QI^/:'AE/H M=TN1(VX@I(BK08I8&@4F&+T(C))"&H#5-G;@_ MX'##`(>E43B"RXMP[#2S?!J2P!+-J)8<0)[$+K-H\.4'W0FC*[%LYMIT7`VX MN&6!BQ5'365G9(3-/7>+&XVL`)-3`[+\`A#2< MD,D5*23!*$:YXB$A7RER1"\&HMD(]XD/#>+)N;)C0!*+JL31(4%B08>9L,I% MT!`*/"_).WWN#7#$HD.+-X'$9TP4CN#M+L!!5E#B4*82."S#N#89TM!-J[!O M!GL291(!2*P)0)I6NUPP<0L#$DNC@`1/=P$0LH`"2+JF)(YDZLH*GE/6%=EA M>+4F0O%+*"`HK^("G:#JFH,MAMN+&/ MWCRN:65B^44@5*XRB$JS=%53($0HJ^MU%4+%\XU(=I(JK08]"FG.J MX$7J)%O<..!B:1278.VNX$*.4'!)ET_$^4T-9N^Y_O0=N%C>FO M_B-78D&#HR(*W9X!Q2I(0EG.45)00K?DC,9\_)*`DJX3F('. MK6\+=H!RU%]>G58-QI=?K;',MD9Q"=XNXN+Q("LH>*3+!.*D)[A.O)LCP=+58UJ`,>J^<5&6%U,\H$"D%A#;-%2)%"I2T@$N5I72V?#YO%,:V90)!L% M::BYA"Y:0T=BN&&`P](H','418FQ<\SAXY=0SBD]L;5#WOT^$^;I*RU$!B:1228.^N2!5RA2)5TI?:_%.B@(0BG9%@A4W-AD`E M%H$*-"HO`88T-AA+H\`H,^MUKN0:8R#I;%@G0:BUE6D-0E#PLD&)A)/I-J^:[6Y+00G.3D'98>CY M'"9H2!A.<4U,UP-4)"&JEIM&GJ_*."PBE(X@J%3#2;L MX/&PA)\IXYH:>G&.%+YL?M3M'PE"@;;;]MJ)N!HD"6FX<]TH"E2L,(I*<'-7 M4"$3*)(EM?/F65!KLE`DJDXP"XEQE4=.)0(0L1SIVH-8&H4D^+DKD)`-E$C4 M*(#VXQI*9(HTE*AQ\A(.&E`L"M@2#<"XA2%7+(T"$]Q?!,9K.6068R"IG1=' M2F&#$>_Q/<"ESG2M3>A*],D&X&*921Z(11P<&)-8-2'`1T(Z+#K+ M)@@H5D$*"NH5-YN=4QP^_TE"40D-*"&XF0B`XFK&54-P\2TA?,Q9]4M(%C<. MN%@:Q27XNZCQ[.5"MA#EG+UL.O7CPZ(XL5MLL<=M\@74O'%AA=\M0988@V^X*>2 M'\E"`OSS=`O29(F#X.6M-MD4!BA6'`4E>#P%9<>4F(^'DE"2B0^KC/H`BF4R MUUPA390KR?>>T8K<0`!C:128X/$B,(YQXS.B!!!]@Y$EL0&M\CIY)`,>EK=< M>:R:Y4UBG6A`(8NIDGV0(+&&V$HU12*8NXA$Z$_VI`AY0D$DW0MK'BRU5!=( M8G<9V@U6:V67@Z9#&B/5@,75@(NE45R"R8NX>!E"GE#PT/5`AI#*J`=XN!KP M(`TUF?"=0YV,P.&&`0Y+HW`$>Q?AV#OLD"L46-*U`G$4%?;2X44:F0&@8MG+ MM>&X&F`A#??D&T6!BA5&4EG.A(JH.$G"1TC%-/1FLCX31U$=L+NN5O/_8948 M:33NT$RKAF!L%36ODNVB%(SK;"P?(Q5#P99U>?]!Q7*.W).PAJM3X2.N,@J@ M4!12I`(0<8L!$DNCD*!65[0:/E9*(E'S62`)P1T3*XZP.J#&^$B'VFT$*A3H M1"75`(Q;&,!8&@4F&+L+&@[Y0,0_6:=TX42<9'7`RCJ.@TR?7)A'57%'XFL` MQ+*F2QP`(-RJ!S_0B%4X)KB&B8Z_):EP!#-W08:0]XLS!,]( M9/L'#LLAKKT(:0@9=@WH*36(Q(J%""9PB97WRP(2ZWH4CV#I+N!!#E#R4"T? M/&(KB==DJVKCN^/F455KB[$,YZ)!EOB%@8@52!$)9NX"(N3]!)%T&4F>585] M59C4RRS"\&NYR!6(JP$0TE"FX4V^M"SPL.(H'L'-13QV6K3-P[%4-B-38L<9 M3E5M6_6L%EPL.[ERB>-@;^]1]3>@$BOP2+A`-RKO`*A8)2DJP=-L;`HVS[9:<5`8>G';!!U4)+.FDSSS.:L5" MKI+N_B'=Y'F*L>5ND1SKSW_9":&=6!J%(QBZ*W"0#Y0XD@F?>:S5BB/VIL"Q M85_%^5D;"D"Q;.E2$*!8&@4E>+H(BM=YD`6,8:23/7'NU:'!BA$>D\MFC<[4 M,I-+/=!D7`UXN!KP(`V-5,D%*2#!U%T`A#Q@#`3;?&1ET9N2JKT)B9YU^(I7 M5:EE%!"Q[.1*1`1JZEIOP080*2FPOZ:,MK.N*1*K#MA27]3HD\X7KJ`$3W[#NQ]W7^[_X^[YR\/WES??[C_#*1W?AN<G_WZ?XY""#^_/3TNO['[8=WMS^?GO]8ROCP_P(```#__P,`4$L# M!!0`!@`(````(0"LHPP^8`(``%4%```9````>&PO=V]R:W-H965T4K7R6(SHFRU;.OS2\+9]NZ)+?7YLY'95UD# M%AO;Y!NPU_K@I2^9?X2;V=WN7=N`;X9DD/-CY;[K\Q>01>FPVV,TY'TMLKBI)\,+`B_M/]GF;DRI<-)-)[&PP3E9`_6[:1'4B*. MUFGU.XB2*RI`!E<(_E\AR3@:#<;3V0,4%C)J#6ZYXZNET6>"0X,Q;T&LQG2W;"FHJK9A,T>.UIYIV&83Y= M4IA(/ZGWRWR+[<4^MB^[3V83'O0##>/X_4##_PGDQ=BYOH%DTG%#[*`9]32C M3O&7190\;M&+4XJ^NM(-XZ3CALA!,VF+/YG,8OQUBA`YC'?HO@)3P">H*DN$ M/OK137!G][0[5>M!>S"Z%SC5#2_@E9M"UI94D./6.)KB&)MP+L+"Z::=K;UV M.,_M;8F?+\#^Q!&*%/7O=!7/T!``#__P,`4$L#!!0`!@`(````(0`T M;D-F@`(``!$&```8````>&PO=V]R:W-H965T&ULE%3+;MLP M$+P7Z#\0O$>TZ$<:P7+@-$@;H`6*HH\S3:TDPJ(HD'2<_'V7HJW8<8VZ%T&D MAC.SLTO-;Y]U0Y[`.F7:G*;)B!)HI2E46^7TYX^'JP^4."_:0C2FA9R^@*.W MB_?OYEMCUZX&\`096I?3VOLN8\S)&K1PB>F@Q2^EL5IX7-J*NC;#'O\_FE8.L.WHFKS?:35<47U0*&C6T*#5@9LP[0 MQR)LX6%VU.1 MJ[=V+[Q8S*W9$FPWHETGPO"D&1+O/46&P>4YD^@ND"P#2TZO*4%]A\$^+3CG M<_:$:<@=YBYB\#E@T@'!T,U@"6T<6OI[/'OE``[*(:Y@Y2YN',J\&CF2&?^/ M3`!CW@?F.1\/]J-RQ$P.,),!<:2,D,L+#&!LSK'T:TE1.H(ND,9!.90.[>:S M,&YGIG`?[/(P1Y],W.<IKL?%.QX4W'3K'>VD\WL7^M<9?+^",CA(LO#3&[Q(/```` M__\#`%!+`P04``8`"````"$`\9^U?X<"``!I!@``&0```'AL+W=O50M>0!CI>X*FD0Q)=`)7#I=4R](XOF**RXX&AMR9O&]G;9S8ESJ%3W&QW_870JD>*C6RE>QI(*5$BOZ\[;?BFQ;H?DXR+9^[A M\(I>26&TU96+D(Z%1%_7?,VN&3(M%Z7$"KSMQ$!5T%62K^>4+1>#/[\D[.W1 M,[&-WG\RLOPB.T"SL4V^`1NMMQYZ7_H07F:O;M\-#?AF2`D5W[7NN]Y_!EDW M#KM]B07YNO+RZ1:L0$.1)DHO/9/0+2:`OT1)/QEH"'\L:(K"LG1-06=7T>4\ MGB4()QNP[DYZ2DK$SCJM?@=0,B05N(;4;KGCRX71>X+M1K3MN1^>)$?BT[E@ M$AZ[\N""SBE!&8O^/2S3+%ZP!RQ:'##K@,'?$9.,"(:BHS*JG:_LP5[9N^)3 M68?`L4QZ6F8VE?&FS[!U;Q?J+R'NJ(@T^UM&R"!@LB-,=CH#A)Q?J`=C+Z;2 M+ST.H#.D<2[.E_;@07HT^1"9N)S]P^>KJ93W.9T-D_P?K_W%J>PA@BT>9RC- M9J?-Q6$\KG#8J6N\^79__:VIYB$RU7S9T+#:87\4F!H^0MM:(O3.KVV*&S%& MQR_**O5#^S*>Y:MAF-GX`C>]YS5\Y::6G24M5$@91W/L@0G?BG!PNL?,<=^U MPQT?'AO\I`,N11PAN-+:/1]0F(U_$LL_````__\#`%!+`P04``8`"````"$` M7A.\:N0"``!T"```&0```'AL+W=OKFJ:G1(Y.*BS;%@>=CQ-I,Y+PM4_S[U_W5-49*TS:GM6A9BI^9 MPC?KCQ]6>R$?5,681L#0JA176G<)(2JK6$.5)SK6PIM"R(9J6,J2J$XRFO=. M34U"WU^0AO(66X9$3N$01<$S=B>R7<-:;4DDJZF&^%7%.W5@:[(I=`V5#[ON M*A--!Q1;7G/]W)-BU&3)U[(5DFYKR/LIF-/LP-TOSN@;GDFA1*$]H",VT/.< M8Q(38%JO<@X9F+(CR8H4;X+D-@@P6:_Z`OWA;*].GI&JQ/ZSY/DWWC*H-O3) M=&`KQ(.!?LV-"9S)F?=]WX$?$N6LH+M:_Q3[+XR7E89V1Y"122S)G^^8RJ"B M0..%D6'*1`T!P!4UW&P-J`A]ZN][GNLJQ>'2"Z^C(%H`'FV9TO?<<&*4[906 MS5^+ZE,:6<*!!>X#RVSA14M_%KQ-0FQ$?8)W5-/U2HH]@ET#DJJC9@\&"1!? MS@A2,=B-`:=XB1'$JJ`-C^LPGJW((Y0N&S"W%@/7$1.,"`*BHS*H35DOH MP^O?IG%T-0:+F\YQ-SNM"V`FGN9C=&.PO:[9>[FB!Y.K>GVYB#"SSU2G9=M[ MOE`>)H^K'+]0MC/>CL"&R9)]8G6M4"9V9GZ',-1&ZWBV;$+3II?V>;*Q9PX9 MW\#,[VC)OE-9\E:AFA7`Z??-D_;4L`LM.H@=!K_0,.S[QPI.=P:#S?>@TX40 M^K``93+^+ZS_`0``__\#`%!+`P04``8`"````"$`C#2N*Y$#``!(#```&0`` M`'AL+W=O4EC]Y5*]W;]^=/JR,63W%.J M'$`H9>SNE:J6GB>3/2V('/&*EO!+QD5!%#R*G27(H:*D,B*`Y47!^N6>5/*,5R1"X@HBG0W63\*("B"W+F7K5 MH*Y3),O'7:0]TLP(>`L/D-:KE$$& M6'9'T"QV-\'R+O1=;[W2!?K+Z%$VOCMRSX]?!4N_LY)"M:%/V($MYT_H^IBB M"8*]3O2#[L!/X:0T(X=<_>+';Y3M]@K:/86,,+%E^GI/90(5!9A1.$6DA.=P M`/AT"H97`RI"7F(W!&*6JGWLCF>C:>2/`W!WME2J!X:0KI,Z+(>B7XT8%^@[>L"-Z>8`G`E\\"AT#?#3K';N0Z0".A@,_K,)JMO&=( M.CGYW!D?^*Q]@MK#`]*:&=B&,Z,S,F-5\"AWQM"D"2_3C&T:+/H86O=^HA@$ M?HTDPBBJ\J.= M^Y=I48<;HZ+'=P83>(T5XVS6D\5F[1F319U$0=V"(VNH.Y-*[LM*>8'](>*%DG36.RYW+^ MID>6T.'+K)WFL/IB8"O-D\E.\TV#;6)4C\:=T:.Y@-`K;36B`T6N%2\XF6S: M'LD+6D)TA:VK/AH`7^-6+WM4+[B@/^%T.F0DNPJDP:#B5IZ+'N$++FA0,($Q MNY)P5X(T4H>V1_E@%^MT=0R8[[/J*/LNG4UVLFWE,WN;68X**G;T"\USZ23\ M@#M9".M.;:WWQ4V(5Z=MGRPW0`D_>/4OL,=59$=_$+%CI71RF@&FKWLGS"9H M'A2OX.RPS7$%&YS^NH>-G<+*X^.;)N-&PO=V]R:W-H965T;H'<%%*E6W6WTJZT6NWEV0$3K`)&MM.T?[\S MF-"8$(7V)0F3\3D^X_%A5K;N6U) M1:J4%+RBL?U*I7V[_OQI=>#B2>:4*@L0*AG;N5+UTG5EDM.22(?7M()_,BY* MHN!1[%Q9"TK29E%9N('G3=V2L,K6"$LQ!H-G&4OH/4_V):V4!A&T(`KV+W-6 MRR-:F8R!*XEXVMZ+GFA;MP`6F]2ADHP+);@F:QO?&7=_[,=M>KID!_&3W(D]^6 MS/GAJV#I=U91J#:<$Y[`EO,G3'U,,02+W;/5#\T)_!162C.R+]0O?OA&V2Y7 M<-P1*$)AR_3UGLH$*@HP3A`A4L(+V`!\6B7#UH"*D)?F^\!2E<.OA1,&T6SN M0[ZUI5(],,2TK60O%2__M5DMED8)6A3X;E$F4R>:>9,1(*[>42/PGBBR7@E^ ML*!K@%+6!'O07P+PL"*0@KD;3([MF6W!7B4W^2"8=;B:6>>$)SEA MEV$(A)3Q`C$9SL"D[M=6)XV@AJ8:3XW)#757W#9B5#>8#ZN`^N M-!,N-&G;"!SM2?D7P[30A*<*Q]/B0I.VC1BT$V^8%AW]Y+H@;3"=.U?%XCJ3 MM8V8K!>NRF*`-8J2?#1?;1 M0WI5#KV%`_UQQ9]P88^X#9G$%VZL#UD?(\:%/>(V9!)'%Q2CJ7Q(L78C\(WN M\J*'X%Y,XC

&ULK)M;<^(Z%H7?IVK^`\7["=@$2*@DISK@&U?C.C/S3(B34`TX!:33 M_>]GRY(L:R^W`U7]TDD^+VUO:4FR)+OO_OZYVS9^I(?C)MO?-YVK=K.1[M?9 M\V;_>M_\SS_^7S?-QO&TVC^OMMD^O6_^2H_-OQ_^_:^[S^SP_?B6IJ<&1=@? M[YMOI]/[H-4ZKM_2W>IXE;VG>[KRDAUVJQ/]>7AM'=\/Z>HY+[3;MMQVN]?: MK3;[IHPP.)P3(WMYV:S34;;^V*7[DPQR2+>K$^5_?-N\'W6TW?J<<+O5X?O' M^U_K;/=.(9XVV\WI5QZTV=BM!]'K/CNLGK94[Y_.]6JM8^=_0/C=9GW(CMG+ MZ8K"M62B6.?;UFV+(CWKC+&^B_F_3S6/J] M<7S+/H/#YGFZV:?4VN23<.`IR[X+:?0L$!5N06D_=R`^-)[3E]7']I1DGV&Z M>7T[D=U=JI&HV.#YUR@]KJE%*3_Y&Q&PVUA_'4[;[GU0Y*I:,XJHH]%-'Z5UU^^V. MH[[=M.GQ*IN3E=S:M`/RMN7E.PIPK23U7P]NK:[?9O\JQK M"O9501I$JN!YF=ZJJT>K@[ M9)\-FNJHM8_O*S%Q.@.'@NGQ*!TJ1NCO!BB-3!'EFPASWZ1ZT-`[TJSRX\&] MOKUK_:"98*TTCZAQ;,50*\2P%V%'''@<^!P$'(0<1!R,.9AP,.5@QL&<@P4' M,0=+#I(2:)$]A4$!](`"0$$@$9`YD`F0*9`9D#60")@2R!)&5BN49/ M5\NUZG6B?@P)=6Z.;M1'23J675W^W"E$NM@(B`?$!Q(`"8%$0,9`)D"F0&9` MYD`60&(@2R!)F5A>T`+'\D*L%=SN%>DO7"V(0+9-DG2H&YA1U7791%>("IN` M>$!\(`&0$$@$9`QD`F0*9`9D#F0!)`:R!)*4B643K<(LF^J'C%#;7DC"O.@P M+PI1X040#X@/)``2`HF`C(%,@$R!S(#,@2R`Q$"60)(RL;R@%?4%7@BU[84D MS`N^`"A$A1=`/"`^D`!(""0",@8R`3(%,@,R![(`$@-9`DG*Q/*"=K$7>"'4 MMA>2,"^Z;%P4HL(+(!X0'T@`)`02`1D#F0"9`ID!F0-9`(F!+($D96)Y(0X( M+#/$LZ1/.^Z+GR5Y)-LHA9A3/>:44156(?(0^8@"1"&B"-$8T031%-$,T1S1 M`E&,:(DHL9#MG-BEED\,ZA\OCMS4TGI9M_*C0LR>/K='%B25+C@R!37R$/F( M`D0AH@C1&-$$T131#-$=1X=A7H%&AI4WL'GP8Q->HXE!Y5CLCE,3JZ3JL6.MF5'I\',3 M7J.%0:58O(ZQB552]=@>?VE4.GQBPA.RNP@9=$D7$7*V!E&(=@:%TVZ/[VC% MFR]1D-:L1L4K.#(JG;J'R$<4&%03/C0J'3Y"-$8T,:@F_-2H=/@9HCFBA4$U MX6.CTN&7B!(+V5:+??0%LX'<=ENS@4*TV#4F]OB&6;P>DI-U28565ZEZ;,/G MJ5AN.W_3XG3:[BWO[[Z^'_4PDQ6_7Z!5]%3_O2K4*BL6SRK26='"S<3JL0W2 MV,32?DTTJDUBJE6U2*-X(FWFM3A75=V4O>FU^OVV03H:Q&M M9$R?*;5"_AHP4*KZ:3*LC,73BK3*.FK$7JJ2-P_]R5E)3'5XJT(\B9E6U28Q MURJ3Q.*L).)*%4]BJR]80_VAH5* M#]^1Z!O4VTK;10^1CRA`%"**$(T131!-$\-`8T<0!XB'U&`*$04(1HCFB":(IHAFB-:((H1+1$E%K)L MH<>X;4O]WC"7VXM-CZ/?$Q8N/TMEE_?\PH"+5M M15MT:*4C/X=RU0&!>7(_:F2YWN>[!*WZPG45WHQW3Q6D3S?+E60;!U^'MQ:= MI469W12DLIJBHLK4+$6=A9S9+Y%[8\Y)1#N2BE`I3QS<2G5;%/1T08-\C?+P M=NIB&\5==+KY*>@%+JK-6-E%A>QF9H-K*#HD5;)#$[OI<5A)%RVH=QKV^:?[/UW/;QLMPC#[);(LKM`U9FIN5RJ.O(C M77'.[(F.+)K0(%\A&5Y627YF+#]HW*6'UW28;K?'QCK[$)\0TZ/LX:[`\OMF M>OLP$,?G-(?`%9>NY$,*KMS0E;R7P95;NI)W27ZE.TCR29GSWH#>W%?6>Z<>5]G39EE'^#S>Y,AX\#<;:(]PCIBC@#Q"MTFC<09W5XA4[= M!N),#:_0%^3?JEN1$JO0/U*S5^H[@R0?>:P>WZXI?F5370^2/*%648*^'']? MO::SU>%ULS\VMND+=8MV/@TF);O)-\ MR;*3_H-JW"K^U\'#_P$``/__`P!02P,$%``&``@````A`)@X'KY\`@``,08` M`!D```!X;"]W;W)K&ULE%1=;YLP%'V?M/]@^;TX M$$):%%*EJ[I56J5IVL>S8RY@%6-D.TW[[W>-$Y2DT9:]`#;'Y]QS/[RX?54M M>0%CI>X*&D<32J`3NI1=7="?/QZNKBFQCGP.\'`ZIEB632<84EQT-#+FY MA$-7E11PK\5&0><"B8&6.XS?-K*W>S8E+J%3W#QO^BNA58\4:]E*]S:04J)$ M_EAWVO!UB[Y?XY2+/?>P>$>OI##:ZLI%2,="H.\]W[`;ADS+12G1@4\[,5`5 M=!7G=QEER\60GU\2MO;@F]A&;S\;67Z5'6"RL4R^`&NMGSWTL?1;>)B]._TP M%.";(254?-.Z[WK[!63=.*SV#`UY7WGY=@]68$*1)DIFGDGH%@/`)U'2=P8F MA+\.[ZTL75/0:1HEU[-XEB&>K,&Z!^DY*1$;Z[3Z'5#QCBNP)#L6?.]9LF@V MGTSC?Y.P$-%@\)X[OEP8O278-"AI>^Y;,,Z1^+PCM.*Q*P\NZ)P2C-5B%5Z6 M23I;L!=,G=AA[@(&GR,F'A$,14=E5+M8-RP*0'F'1$'!E$R.4&/1AK<"Q]FML`ND`:F^IR:0\>I,?D[G:. MLIO.S[O,CJ7\:&1IA`Q_;R5_[%ATMX.%'3LG2:]/1,.(A@Y68&KX!&UKB=`; M/WX)]N2X.]X,J\2WS>E^FJ^&&X.-/W!B>U[#$S>U["QIH4+*231'+R;,?%@X MW6/D.+;:X:@.GPU>S8!M.?'&*ZW=?H'";+SLEW\```#__P,`4$L#!!0`!@`( M````(0"/7<5UF0(``*X'```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``! M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````)Q5VV[B,!!]7VG_`>6] M#:7M:E695)2+6HD":M+NH^5U)F#5V%G;H+9?WW%2(.P:I.7-ESEGCN=F%-HLV0.MV8>ZZ(0'`::KY:@7-QIMW_$ M\.9`Y9"?E5O"J&:\6;M327/-O3[[DKV7*#@AO;*4@C.'KTP>!3?:ZL*UAF\< M)(F;EP35IH5:"%_L:,^$DV&DQ8\:%)%\W-5 M=+/3\V4XR5(Z'=$TFY[@):SLCEEAJ2[HS(#%#JCJ,F5=&`R%7#G(ZUM;2&1C:U\L@9/AGY7.6&:8LX[XS]NIMF[74:?Z* M_,B)5-C4]IALR;QS7U)[U$$%(^P5^L+D"GQ,1D(QQ0636$;8!JL@9"RGF,`M&(XM;8)\E.D[LD# MJ4)5'A:$/,&!C%6@(.1XS#HG8"Y/P%P%,;OZ^'JTC]5V+C4A>X/QKU$X%NK5 M/I>9'F`U;V;]_B%)%\Q`CE-P<[\[(/&>PMLBT[2LD3-3BXQ<6;& M&\*WC5@H`;3;OY=U79W1DT?ROCP\WTPAHQB\O2NF8;#P\^L:!CQI"ED@V,.DJM(W1,8R#W((1 MH4@-F\)UXXV(Z>@WV`GY+C:`1X1<80-1*!$%/@!S-Q!1CU1R0+H/7W<`)3'4 M8,#&@&E!\70R']B[HH=BV;=&..XWD3_'+ MXN&I&S77]K`K"8@?]E.+$!=IE6L-ZG;/=V^^SD+8EOAW5BK9V3'I041067J/ M'>U.R6I\=[^<(SXB=)*3:4ZNEY0P>L/(Y+7$IU9_GP]`TPO\FW@"\,[[YY_S M+P```/__`P!02P$"+0`4``8`"````"$`$L(4_;X!``!@$0``$P`````````` M````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U M53`C]0```$P"```+`````````````````/<#``!?&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A``?JG#$A`P``[0H` M`!D`````````````````NQ,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/0"#]B:!```SA(``!D````````````` M````7Q\``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`#Z1XCUR!```EQ(``!D`````````````````.CL``'AL+W=O M&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M M`!0`!@`(````(0`SF=Q,O00``,(1```8`````````````````*A&``!X;"]W M;W)K&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`+TP!"/1,P``(+X``!0`````````````````9T\` M`'AL+W-H87)E9%-T&UL4$L!`BT`%``&``@````A`"]B+9JU"@`` MNU@```T`````````````````:H,``'AL+W-T>6QE&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`,3AYXXW`P``6PH``!D` M````````````````HI$``'AL+W=O&PO M=V]R:W-H965T="NWX"```R!@``&`````````````````#$ MH```>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.V^ M]WT;"0``Q2L``!@`````````````````>*,``'AL+W=O_2R,``('5```8```````````` M`````,FL``!X;"]W;W)K&PO=V]R:W-H965T M&PO=V]R M:W-H965T$[QJY`(``'0( M```9`````````````````%78``!X;"]W;W)K&UL M4$L!`BT`%``&``@````A`(PTKBN1`P``2`P``!D`````````````````<-L` M`'AL+W=O&PO=V]R:W-H965TOAQN0D``+HP```9```````````` M`````+[B``!X;"]W;W)K&UL4$L!`BT`%``&``@` M```A`)@X'KY\`@``,08``!D`````````````````KNP``'AL+W=O

ZIP 13 0001193125-14-299064-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-14-299064-xbrl.zip M4$L#!!0````(`(TP!T70`?RDVWX``%B:!0`1`!P`<'9C="TR,#$T,#8S,"YX M;6Q55`D``RE/XU,I3^-3=7@+``$$)0X```0Y`0``W%U;<^.X7Y]N4+(IB;I:A+29 MAUU+O`A?H_&A&]U`__S7Y_&H]11E>9PF'R[H);EH1+:>Z%^2". M+UIY$2;#<)0FT8>+ERB_^.O'?_V7G__-\UJWMZUNFB31:!2]M'X?1*,H"XNH M]2G!)P817!Q,QU%2_&?K>YA'PU::M'YOWWYNL4O::CT6Q>3ZZNK'CQ^763:< MO^9RD(ZO6IXW_XE_E*V[;K74)8,65B[=IM-D>-WBE:\Z6106<'MK".VX;C%" MA4>,1^0WHJ\9NQ;D?ZIWIY.7+'YX+%K_/O@/N)E(#Y[@K=O+V\L*L+^TOJ9) M#G>/)V'RT@I&H]8M/I6W;J,\RIZBX>7LI<_?LU$+9)KD'RXJ\/#KRS1[N(*? MX%?Q3#H7Y9W7>'6TX?Y1G/P3Q?=Z/WZQ___WSU\%C-`Z]902@*0]A.'E]\C[,O]OG9A>NRGZ@'J?S M1X;1VP_9%N71X/(A?;J""S6W3YX&Q>O]^,&J"=Y'%">5=A0ODRBO;8B]4O-J M_/5AL=B8&69Y55Y:!)(P'>?T3]E(-ICAYBO*B_IGR6@VB M/!ZL$5P\J/F-)'J`H3YCR?"/"DJ\_R:$F+NOW[IWY`[>C7I" M[V"D3Y.X?&;&7'>_?NU>M(;1(!Z'(]!/N"4&;8B'=](W1A%]Q[DRW:"G/-GK M"T]0%7B!$<+KMU5/:-+C3*H[2N!.>O&1_'RUOLW-8+JC3"M!Z#-ERI?&-(E1 MG1ZC)H*Q)C'R,\#(#)%-8J1G@)';F;!%,?4/[ MS-?',(OR3WD^C8:_3M*DO!&MROV$`-2Y3$*Y?745[Z=?^BN(`9466G!/!Z+O MB7Z[[P6J9SQ)^X+J=K?3#?JOO]8+Q!ZN66>MG%1T.84XVV ML)RQ+[?L"S`]4")%?;,'UDI7OQOE,O_NIL*[0@3RY15)];9:!N65@P`GJ2CC;`^KGN(@?K!L^\X_WI%E.!">'$8[H4"69 MDEX_Z`>>`$EY[2#H>CV?=3D+J*:B=X<4_I&210U=:?02IC3/@6&+.'E`A^HV M&D3Q4PBDO/<4HH`&=L#FB15P[7ZG+W1;>TSUM"<$TY[I]#M>EPG1@PZE@=&H M*18?8V()X#H$)5!T#ZYOHWC\?9KE$2[:O-WQ)*@],7O"0A M)?C>-+L3>([@Y5R%*UV\!5/-I-+&93E5!TPBQ[@6?_$8ZF^\\)ZM`YHX+U"/Q'^YZ1BGD^Z?A2M(WOBP"M;P9V^L5'H;@BU=EN)S05#@5%&J>)'8*_ M0EO;41+=QX,X'+T9Z,$8U_,<2J`KVXP'@=?1A'NBT^]ZAG1]+^@9VB%!6\@> M*^T:G.X)D[XD,U;=&2@.6DVC(8W"9J$-E1PAL(` M9XPR7Z\5QD[`EH;&*,SSU]MO,AM'>&7J:##-P`R)\DXX&D7#]LO\M;,;\[UI M@Q_DKS+3U4:PML4%0!;H`;3XC'-XC_.KC\)JC59-J\VM'^'4=Y[ M!DLTSJ,O63RH,,9<[>F[15!AP+M)E-WM)A)XJU!4]6$ZY`;H4`OX2W:\`*R! M-C.FHV3_U>+DEPOR.`1F*:EA%%_WP)`H7LY`_Q7O]]J!#W07=$$K2-OW_!Y3 M7J]C#%&]3KO?]N^8M;C?U'\W!*=E_\/$T9-M2F30]CH^H9[H=\"'5G[/(U+Y MHLAL589Q$PUZ8)3!MY@OZ@`[G^?4<%QC*D9PK*DE%E;=#.6Y@ MP`54-'U\](2EWCT,<%,\1AF@S\#G^3.,1.A/AI&/BM)NAK"6;("1_@R]JC!* M0'SC&UE+/K4P%D'W8VA=]#E^BH:?$K!Y'S!.'>1Y5%3UODK=9R<&,&*U]A75 M%=7>'];2U#TB,AS=")8((MF!U;("P=GB?'S9Z+5U[6\^#N'`>`(]-90IPM5!08@WEV.-C?Q+='[] MC'.O4F;!8UK?_)WGH'.$"K,N]ZG/JG;&9@A+P]=^?7:P_#ICHFQKG5E88DN3 MP9D2#S*J7EC%J&UW7=><*Y?R.F)9:'(EAC=?L@.HO?%DE+Y$T;?TM\=TW$F3 M?#K"$/#7*'N*!U&.-L*[P79CX&1 MQ/1[6@9L%LU%(IT%[O9$4Y'#;(%R/IF>GQ5/-69H$086[`SL2OUUY# MF-TX'XS2?'KHVMH=ID\2;FP:)30/4Q48%=*FJ8%UB9^ET@P_"[(^/>\YCZ^3 M>/3AH@#+;#5Y(>CTE-':ZPM?@$PZOFH`+,#<+8[7P+@CO@ MFG$B3@N<58"_3BYSJ'^WV4$VK>6WN'C\-4F_8Z8;&E&?DLFTC%XG`Y"/=6GP M(_`"C(UVF,=OHGN'V505%CC:Y%!A;1HW6G?:@:+*$Z2G,+[?\8SI&<^T^UT= M"*J,DF\I5/.1TZBPG"MB4[+=50V%S9VH8Z6-P%W)Z61RH>^12WTLX7,,AO%P MMBJ.%Z+]LVDJDE&"D&-!F7L/E6V-6D&3MB%F_JQD_Q,$J&^6U8O"M1 M>0OR[8G+>Z#6-D!H9A2P$Z"*`(*'A\QN9W4^]H]AL5H!J#)./"?!S8B:B95+/81!/EA^)4J*<&IS7"%=B+YOV8*GA MU&971"_E-I11^/Y=F)0U>@Z%)#;_'NB6:L:EVQVF M)39GAI%$NPBQ>IHH1;ET8135H&S0*))V4PTP@2\8W._$(-H!X='[D=M^!)#B MI/K:K#$DT1:R8].`E\-\ZA`K;YAW-/(.]\OM7Y1(ER\HY%W$*L'8!F8 M3VZ.8EB%V2#Q:!R3PNYS-TI+XH9YMD,\>D_RF=8:Y=`/JP/:*/5HI!X$RJPE MQ5T.3]$P]?A(/5+"]$$5U<0EJPK'S&-7@A`JM$8JZ6LGZT`U,!MD'KLZ(G&O M/9ATW&CEA'FV0SQZ3W+;DXC2I=%3`[11YK$+0`B4<4VI%"X=$MDP\U![ZI_& M7A2@J=`$]^#?_:0PO:,.87TWJ;I!] MMF,\?E]RVY<( M5&L;YA][#!XBQ;@XX=(EV>JF^<>N-E."QKHPG$KJDH"T:P*RZ\T6K0=*2Q83 MH1MDH%6@33*078VE!(^R\KGOL^JFB@8I:#O(X_]:7&>5'$;)B&[!&VA*M!;W$CD$*W? M-`GYY2'D"H.81+DUA'S7'%0F)")83VGM:Y_ML_!U.`>M`FV2@\HT/?S>Y&5O6IPG5=R&.:C,1D2H6E.NR5YZ^][<2](P!S&[&DV%/:A` M^;[<*SIT)'3NLJ+M0Q^]-7O8FXG224%$'E(,:GD_*@DFESDKX)@[B>@?>G0J"6+T5&!EC;#$K\8"SN([5N^XFU#)6AKWM46I@Z"XN MX39'PDZW9[`RB*0P@Y@:U`3FAH9=;]&8`S4SH&X\&+COK%CESY@YU?PHN$./]."%ZY[ M_4]=\.(=6RMWE`]F+S.?5]W?9@I>+$K]H#J+C0N#(4?R=9I2XSR]NW9`\YAL M`@AEOJCX2`U7\7#0468V;;-:,G=1Q:-YD&45#Z&()*9:]=-Y%0\'4#%U1S&C MU!Z>_%&+>#@8B,+N8-=^Q?D[81$/!YVJRK-YP-\5M=QS#D4\FA<#%O&`0:SH MV17Q<*`"F#`BF:3^PC*E^R(>#H8W0%64&>#FPG')+*5TSP=P4.CEC$HWG0`A<_*%VP[4]2Q*-YJ+CKA$EA MF,LB'LW#\NN,B::*>#0/QWD1#P>3?1VQK"OB\<[B%0YF!@R6HT)U MC)U!+8.WLW_.HY8!G9\K_RK(1J75["']#H6[TZ']%(L9L'5:>L)J!I43J$XE M&/HNP=2O_QWC2//%P[EFEOJZL?F^#^TM4X#KE0@,EKZDAGM:^UU/R!ZX(3"?>YQP&C`>=/M*W0F; M5`#ZYS/%JL?('P9M43SS"/`\9^7X=3 M,DC'T>=D5)\"0#R;FL()"LX0O$,$^N#8(Y1PAVU,K\.0<*==`7@3T*7F*\@*7OLH[/@$B&%Y[+.VZ MPX:%=JH[Q->U?1GA((O"/.I&Y?\_H9,Q">-A[WD2)?D>KI.[&8Q=?/0!O:AB MW8QB.=4HC\)L@/&T;O04C5(;5CH!X!V[%A>ZX393W>:W$<-24**2I7!SOQQ> M.D.\/EJ?4JJ*1[@9PRY17YBRXG2XK"AGJ-X"/0Q!!:?^MO!O/:9%:50S1,\0 M+2YXT6J4K=K>;52UFIAUA@AQ.=-`=^I-=+6*9">7HQ\G83(X=Y<#S[TP7/J* MRZT>1PVB)7V>KP4N+A&>(8W9`"5(QY>50/^:YB]B_%N4@/DYPCSNX3A.XKQ` M8_0I.M\I"G?V*NW3:JV8+2AV&-PK63YGJ-RX9.]1;93F6P;X"IK*^K4M@YA4 MB_CUT^QKE#W%@[,)H M`)69O^0,L6,N-).RW+9S"*:*-/X6Q@FZ'3?):ZSS58`'I%ZXTWIB5^XY$3,1 M[`2D%GCG$6PY&"%G(H!=R5VL%<`.@+:.AXJ[?>:#`8]I-50KWVP<#/6`*G*P MQ@!X;,`:KP-G/EF>(V[,#_/A9V:H-S5_(5#[)IF:@K?SA/N;B4VE.4?<0/QX M^A5Y#=3N`ZAVQK,WG/ETAV>[&B;)RF2WW/@EUSLIXB&NC8+9\U9NMO<\&$W! MYD69P;B83(N97[N\O`I>[W2?/,)%>6`>E%%&E]$_I?>.B[6[@:][M./U:$^@ MA*07M%G;H\QHO]/I:-4.9L%K,/^,H0N[@XZ"_4S%B=E2S8@32Y."*G^4A$LC MJR>*_'^6)PPYOQEY!\]D[;VI.AH3Q"J@-N$ M30KM][HT$$KU[\H#.%'I3'71;2=?=5DNWP!H>W0(:C&G\24(?44Z.A`]K]/C MU!-*!EZ[1YA'B.JV#:6\:X"&<-#\953\-(R?_O)0_`1MQ$^35EZ\C*(/%^,P M>X@3KT@GU]1,BI]:LR^^IT61CJ\)?G4/#?;R^(_HFKY]O@_'\>CE^EL\AIGI ME^A'ZS8=A\E%Y3>^X]_\$O^\LG^_?5O&?D*P8.81/QL9`5FU2H.H967V]JC] M:[(%@#I>^]\:.)PU<(0-G$`#!V4#[5ALQ3@KXVB`.[Z#0SMLP:7B,8)7_)C% M25MA&2AM)392VDKO%UZ1M]*WH.EE*0?X&7A!^0M1.?!R?&LK'D_"08&OJ#S4 M2F=6$3;WQ]PDA@_P#M`U^/4"EX1;D[FV@NA0#T/[SI<6_DI8&?27K2]I$<$7 MX;;EM(]GW5.D?4(YSRJX"&0*\VR=;Q6NB MQ+)4EK+9/6\0,"21@``#@)+Y]ZOK>/=T-%[O^ M,(WJI,;/VU#\C[/>O/WVXZCUMMTR#>1@6`>!0Q$V#5AG(S"+)8(=_H0M@T8: M&=V!V;8LLV,-Z.%NRP15;X*NI\T0H_)LI@'+]"UXO-VA1ZVN"5K,!#7&<$F$ MF/3'ED1%QP1+;((IYF?V8(:.V:RPV_=2?/9?^6;RO:>X7DMARLIQ[SPLUH17 M2LB+%>2/KT&FXVFKVQMW&_W1;`:J;]IO#-IVN]$;SZU)=S*?3L;#>S7(V>C# MCZ?O&^/SJZOSLS<&2=C\_/U5X_+T_V9O#"O_Q7QT=OKNOV^,DLR]->025^<7 M\+R-SU_-_G/5.'T_G;V_>F-TOE-B.0)VT5&"DH!,*#EC9P19:+R62$:F7``1 MC!ND`JR!?(K+,.)1:D&(;_UT12MM$X&+)OXR]!>^"XN"<F5A$01#=)F_V:[?[D$O(TM$'3V0Z.-NR MLGZ*9U%['$FL\?F'Z>Q#8W+^[MWHXA)>&$P"*?WB!):LB?F%<1[$G8GQ*!S/6?_#4^X,V,P0= M*_6*S]S(A=D`Y'ON?^5Q?O]]$=CX0=@%/"P!G1$@XMO)9#:;SU_4GP[,W8LZ M?GF8X+V;S4',++$N"5X#?I5;Q``C.]+Q>WB]JC7O(0YA,N?2(K\>\.[+@SA` M_ABC.:;7+-L<]'IFMV\?]'X8W<;.YH<7_/]'`/TX+/%780`5VZ-Z5);X22E^ M#R$>L$*5-7*UB0S]9*!^[>?WW42?@VP9.DI"31:X<.$JCB].)X6TI&I"L`1&'3)Y^@>P` M$4R[:_:LX;/QP^;C'H+KYWP"7);Y2CJ1Y+)^RZ/^$%@CB0+?J\/^L83_K!O^ MW=6Y[@O6QC8/DU7X"Z9F:N`?R*AF+POB>\?P\D,]1[/=LLUASWI^Q_%+DNPV M")H7;2'F?"K1?OB.Q\GV]Q1)WYDH^AP9(,XQ><)_,XW<+5:X7NTVQU>S\:CX;AACZ;C1J&N/3\XN?1A_.1I/9KU>GD]&[2],X?3]I\B'JP"T?9NX' M(IXXJ5A&\?$5&)]XELZ+?XU<5P38A0'>,L&B@UX`[LFZLSJ?^:+9XNZLGMT; MM(;M3^_.^D`Y9^_"B=/=%=`Y<5Q*&.?C%#[';>YGKE8";XHV3K@S ML)_!B$*ADL'R]WD-XL1XV3/10C@)/`\KG6&W@.;!R%R6"<8_ MH!!UY;LKB$82WH?^/Z8KF)4/2^#=3B#O2;!\,TM+.Z'AJ%9U_/GEH$O[+J+8 MN(Z[-V M9]YOC'K3?J,SGXX:XQ;(=GL`\FP-[?%T,GF.2P7%.J_%^AW8#0&W]N M19*U-3B849$QM+&)@<'P`DZD>/T@G'0;T]4BG#L6?VY!2&BUT@O%6Y8$-L8+ M/>_W;8)JP2^(':,-;(B(:>\(IX,9@KN?^;+/HUL4L+#D,"081CA&$-W"<[P? M7K/235R3*)6EBS0@8(G\K@>E4R.C?A%KG"%;-R9.'$3&I;]65Y7KR!,HMK`W M/N71':1^1H!&2!9@*%1"(M_6IPO4$%:)!<%(ETW"`7V1;,&/`SK`\W\"]P!H M36,.DH];I*M8"``@3%>)(4*/\+%'#6G7IHA'04=U^#(:K\*6(Q&2AU MMV,:Y*B/+-/JMLU!NTM[O,2KUU;/-FF)_(*V:4RW=$]6#_E>]0G+#+H#4M(FN@]%5SCTV#-6JM6G;A/?CNSB(1-E)D;!YD MIG0CE?/-X6:J:*2(Z$>8J;*1T@3H`#.UQTC!(@>;J;U&"C%ZJ)G::Z247CO( M3%6,%+H@1YFI?0KXY)LCS=0QJM'&DB!;JL9.IV?VAH.R:F3#0:Q^E)$R+!-< M7+/7ZU:@*%Y)[:%HO4TA.(ZP*GML"BNX`U!7BSAX&_2E#4%'?]B6%GXX-%O= M?CWR*JB#!>X"'&NP8/VV79&Z$MYJ"5O&W%Y_G"T;K%$G7`?:,-U7U:S8,38, MG>6*A:V!0K=6-EBJO@E8^G*LE2!K-1?7,48\.5_>9:8R2_Y$]DK;KWXW]"XT MT_40PX7.:]%T?=7Q5=GF,[_J/":M`1N5'"G1!8+E18"D,$J-4#!7T<+7_F(;N[0*I5\*C.'DJD`AAIMX6'H% M3B'/%;$N!'7@D(Y;^'&"K.`$0>3JP-^A3C)6C\4:*.R1QU%9H+0=`UQ==:.) M!JSU=OJPQ`JJW$-]UKT>:R&CL\]GO[CD^L?+KC-80(OM_OL=ME]<`'Z[8.=+ON2PBAS]J#U3"5_!B>UYU)J:-] MUD_-275L<]AOR33(8(BG/#8AM<==I=3-06C;@S3TAP]V6.LUN[[$T4F76C$Y M(NE2#X7NL';,5@<<5JNG%/)>=Q4CX(<[K!^+#BO^7/)(\]*&_??VG\LAU@KH MI[J^/E*L- MS\0@;\X0/CEZKI.LX+6L+8?M[2DOEQF7[+H**41/*O//;EC>BJ1ZD!:%%=&9 M3E?MH0-J?C!(Y2+6%WPF#P'Y&'!#HM0SS3@_6;EME`>(]\@0Y-R)8,4 M@H?E2DH".>[D[0`0\A3X81JT_-KAMU3ABB@I;DE1$Z@)_EHCD-]MKSPI.:V`WT/ M@]AKO^]1=#UT_F8.I:2HS*W326IU^`$'D>87S..@UWK8021U#SE($X-EMLD: M8$7O(8RT#54\*85_L0T*CB/\NNJM`\\5.9-DM7HGV64[]TR)@P4E#B14LN^) M70/\3[M-G7JYJM'05;BEUR\&[E&Q%%+G<0P9*-[GY)L#=BKIS]%>K#);=DS] M/$#4?(?#\Q%ZG^?SD&GY^D'.4XF]L=(A$!1"HVJ_8:L&AZ5>U)(A*?2DIA@I MH'$4H,J(:CB*$XLRL"IB&5/OJXRY2251R03^KZ!0>1&Q(=F$>,"-?=7P*5VX MK/+"I)5MM4Q.MY-OJG`NP,$T=L*)=8B-S1;4*HY$O'\5U`CJ1'G"(%L5!7YG MX`.BC)1LD^T&][1:KA0@KX2R.4TE8R71Q$XY6 M3@TIN/A!1":'8=2;7"(V95F6@OR4+(F1QWT8?]O-;I&6V'#IR21"EFS!;6ZC M^`_Z*HO\0B@2B'-=2YZ?!EO'FXA\*H!R$R4"-/)[D>*+A@6KR)%Y\&0^QL`$ M"KE-*K7AP'P3."[K=F>)_UUDL62.PE/*](7"Y825.IEZH&B7I'_Q4@5I',=3 M#O-^3LCP#2NTR\Q69%@"HXZ4C&1FJPP==R##E(8RQ@&3":4*K.YWN;N61HC^ M>SU&,)?D(>6LB`;4]3D="9QZ""P'E#[MKV!ZE@GLU=+'1YO`WN8)['W;MKMM MVWZ<">QZJ2Z/29W!$RA$3UP\;.-G$:U.H]6#4Q=+B`MP/;R=_O%+VSK]WJ0S M:PT:O5YGTNC,QG!(N]-J].U9VY[-!ZWN]/X:SJ?LEZ^_$*YOC:]MC$?;DJ"> M_)NVJ@_M3VM5[W6.;U6_H[O]L7[_S];ZUM;C;;UO"WO?%@>T^@P>V-/YX%;& M3VD)0A$#N0KI^QI%P5$(H(+Q*_0J2O7CC]Z3^1D/R6@_[E&^]G;/W.76RPJJKL!G;\A^KN?^@?D?F+^R\0N_58O?'K>9^QG& M^CQ-<_;G'VISV/G_JK-L_L'/4^+GKR\O7[MW5*M)I\(5F)6K7L=^,=KTB8:D M_:,N_E&G?QW\?`$"\UD'D-1,&!E!M.=AQ#-2P[$;;8G#WP56]B)OXH4B22;2^]D.JA_FG; M^A<1D,*K\A)8?Q&QI;]\>7%F_!A'VTW=+MRXXH=998!G;+%_PIB@Z^AXD1$X MMWC/=>84I]=:P_Z@:61KPR*NX%KWO&S-#^&QH<5#Q;&4:RVHJB_[R&@C27', MNYL5J8C%@JN6:R?FPF*VF5<3A$"C2D4#5V8D0E`I1+1-#ONT=U4ZZ3-J/Q]_GLJBP@'#\A(B9$QF[F<(E M5B&E"9Q\+;ADXA`6W\.GL2BP'A5HOA:KPD$N3G5H7S=K,&2W%8H<^-LR%K(L M!@YV$3BX)-#X@XCBI1,J778MTEML==F'*'[[XE1*IK/9X(-9??!MC+-OJ+HF MD>65#G#`[U$L&P*HS":O:#C12_OV[5GJ/KH7IZHZIV?V!G=6W!`]Q4=F&R8A MCPA2W6"RJ4S_-(,&[L4I0G;R338_J"0OYGXLECGUA-K9CE#&%59%FB@=!JO= MKJ(`&`KTO"RI\ST?*SEU-&/9%K;EZ$RK-6XA>1GO)7LGS_X<.N`]@%Z,PJVA M8G*]9HNH@`41X"8'8O<(TED<*&IF$!(3+N;B2%19@2.@W M0'%5L@G>U8U_0V5Q^78%1OB/`QX7]?;?SPA%D(B:">LHV;Y#J_`S<%)W%8(9 M7>95=-0V%T9A`Z2Z`6\Y1K*!\*(1+1;(GTFTE@8,^98D`=@,S+'L/G/X.]O( M'T5`4!WX5!H'V`9F`"*S]J'662#5)M-,?O;%ZT1O#\4-L5;0V=#QD3=Y%-PN MKS[/"^RI4\V/M5H8!E!I(J5V)/0(B20/+03(C62[@]1!99@1?JHSX![]E[7@EPPT MK`D>(7\`QZMS"`KF8Y^O7$WI56+PP^*ETO?::38U<6/PHP;@WE_UIC`*L/YN#>0VT&K% M5&0%'OL[L)Q+Y]!1A(\,5*\(DX___B40UPY_O(KE7[\\?^?<)EL_)0#]YP+U M/*Q&([82HQ\#L&<&'^(5ZI."CQ$XH$G\Q:+@2I[@I`!U1&[)NA8K)UB4VB\@ MH/0#ZAG0M&/A96XLP#U4%?O$CUU`&"RQC;/2;.,RY8X#>#DSOZ;Q2QA]Q`?Q M*T`5T&F!`MAFUE?U4].8Q(Z/SN54H&T#3$;I:F=,(")T06N9QBR&4&?4-'YS MW%4J8@X!+[#MT_@`;V^#C=CP-[M>885A_G&K,ARSC\*E;VPE)6`N4^Q7,^9; M=P40_`+J&JW.6=,X<\\<,(6Q_)C5*%B@5I\!:*`;5J!__EW94R_!/^&^K'S? M*DRG(74H88/B5"Q$Z-&'/4JXXBDJ$F,%0Y.0#["F+D9/O5^EP&6!Z#5"40Q/ MT/S>+44G-!-!+('I7_G:G/SKF!H4@/D6<"B7W%AORP'R*U]_\A81JYHX5.#- M3@DC&Q[7G]^&V%MKB!"X885JF6>$JE%U+K#N.BGVR->(##8?$>`RGJ9&)C;O M&?K@B2V$Z3&UD`$DWV.LD76\<#,13\]`XT7]B_#ZC1\%A6``3RF#-1,:2;M]6@'L1+-00$&X5@==SSN=>U>LH MW"8B1WM.HHR=:%((AWIP%OP@WI/I:;U;ZS3,I\45>Q^+-!S3,%G`^#0;<0MQ M=H1.GT?!'?;.8[-%D!G+?.QLWK'A+]6D!IT[\X%]]<(XR50V(G[M_,$Y,6Z( MU]-+J^A6ZJ*UDZ;49*2F\T"`'`4WJJO^+FA)4D.0ZC3S;!7H%$"3Q\IM1/@! M&65&7&Q@DCW\$)GO,+`0')_+IE5P@Q--<+(-R]V)A?W*3;Z)`7\#5]E/5F3G ML)LFON&6'(N;>3@R-#;J^XJ%642J/30!(R`'8&B=UK)W&GB\`4J8RO=CD;(_ M3J-;"!WP!QIVLJ'6F.=AW/.PW(K<,ZM]LID[\#.R*H3J:=:)=BG2-.#L4\6. M9,]I3Q754S;\XF[[06U=JJ=:Q5V9K$K8*;&%UEZM&YOZB\NZ1%6023"-:;U MV8A2K.ZJHPGU3R(CN0ZV1J1%\ZY;*-.@XMIL-`08$7^SY?A;0TXAC8@.S19C M4.,#Z'N4R:J7<"=-C?N6`?Y63,,8[IC=D`7#D1R-U/EHA#0*1'9WX\`X M/%9VS+>[*]_AU<&QJ&(,?>,2IYA'[HR?LP.78OBM-5 MIC)*3*JAE;ZNC%_-"-CQ=`S[#?8-QG*:8&8#L3D]:[956[A1@OHHI-/`GS!3"`+B>N=FOU%S)J1D)+,Y&(Y";?V MI=08KA(%*OB07Y0K3C'(PY"<1=Z6(L0IIJHI]*`QU9@,4(8L;N:/90D`):1$ M;V)3(`VRV(THA4H+4D=6L<7[>IOB/P,ZP4(`#W:U,0!1B,+'\YBRD6]R.2(0 M;YQA2L,3`'(-+%,4;37%3O=E,),MQ]W($$D%TV65A`1F4Q`*].P%Q`'13C;2 M2Z.OC3+,'`SY.0W!LI=[$'1K4KZ1'&3?X@B]/&++V,^CD1RY4B@$\DL4F9"= M8;!;KK$)!U)!^$MN=(1BRU>>TM%7:.;S^!IY`3*SC`KK-5US51GA"Q90P8$ ML:)I[GQZD*:D^9L@0J*.EL\C[PUHJBW^`R6,I2[[8W&W_+LJ=/6Y6("''"?Z)#\%#H+!40EG M=TIL)W4_CP)Q9&9##L?(#+.^-]!Z&T(\1';^_]O[TB>WD2/?[XKH_Z%#SXZP M(YH]J`LHS/,J@N=:WAE+*\F[SY\45!/=P@Z;;//02/O7O\HJ'`42)$`2*!2Z ML8<](Y$@\I=9>5?F1KS"(OB1_BGO>$.PAU9 M0:9!2HB\!IW&HSJ;HM2D*FPW-;=7^O9S/9]+L\Y]^HJ1CY3)#$$]:+E6@VHT MIL`<.N"!^,H?8.X^""K(\'%F*,5VG!]EN0&%Z3Q^%!DQ@US@.36`(:=UXTC_3\H2]6$"&D!^=0`N[TF=_F\(3_WI[_5=0'FN0]K^M;F]D[B/V MPM5@WJP"D:T0X)4(+RQ\#.=R?.\Z%/X,V*6DAN)6BW3B"9$R=V MY/S(ZZB*/5?G0&6JX7G_6,@14+*8L[X>P<*]\&ZWU/-K.)N)4Y_\;;;HDU>0 MN$GJ.0>J.9%!V*_>[+/_0#E$A7VJ'2G)N:]CYUN+3V6B2"WF$H?W3U_^'/E> M?YK^..&(J$PY-]_V`J*D?.EQT`S/V[G468V/G)8#M6: MAC*ZALR^JGC#E%*8>0>C4N_$IU2+3)Q*$0'.%VA0W$U+Y4U@.C!#3IBZN;95 M6F(PZLMW':R"Z6^;KRLYW/&3[!#Y(4A;AP^+W,:YP:=1?B;J*9YVEDS$C7YF M]V6T@<6S8`$YWV/1C_[J\GT_C78W_T!LM5`1M/+)A!`^+`5%:U`Y\;!(&"VH M\A3JC=1YEZX4S^]*S4*;UI;A!]EN8-BCP M_Q;\'L:"J_Q?%13+65MI'AU&QZ6/$UP6JEE(Z(\D'S&SQ#?S===,.[2)8D[/ MF5*D_P/Y\2M8A954VZITSK2)X;;1E4AV)?AZZCNY55/P('\WH:%`1^5IZ M+(.>A:ZF4R4MFY7DQ!P((J0JRP*",IGH,F8!XN\]PZ"9A3BP%%&$_&&-Y*CF M(YYP!G[92OO5JV24JSXM=+_`G@XYT_M5LA9%VJ08_U7DI>=^,=9H^4!)/5&> M-\TZRG\5+PI-^;:WRV3J)DEH]1]"\TVO8QHLZ):IXNBWU?RR#J*MEOZ<%\CXENEH.=JUD:@(Y;GKYKA4P_KN_4U)&][I7Q+/*?;6@ MBP7#.U7&I M5C&+?OWW4'BD7U+;_$7:SZ0\K'8^P6>@04.ZKTG'=J3>S]H;*HU)>D1`((9Q1TX7VFT3#UYY8+\>7W M:G"M_-=W]\EXV8]))%KGW51OX%!W/(!-[A3WJ#,<]0;#T;!'Z638I^,1P6QR MRMW4"J]Y)JW2*/=JJKSQK>[XI/@U=RGUDU+?2@KA`&\7TZT:%`XU7D@0[YS' M^YC35Z_TM(.LWLL53.K.G:IK[^YY@W_?2B&4]B0I$47CI><_TI;+7`=+X-:' M>O_=-$IZRZ)G^)B^5<;"Z265#\%#O"SI8^__R45IZ2*7&U69%P<.@MEH=4'F MJEG6;LJ*]W(C/AQHNRJ^_-`(+"0O-R>7)3`9^Z[1EV(.G3?10Y9/X2+2MX*Y MTX<@;955VVD4D_X4W?*)TB@+(&FN/(MH`*W]LK8JI>O=/;!.8"]!^*!NJ`VAOT-:TP%X MYN]5/TD-5WF0-\2NC[R>A_"D1X>\+X@DDQZ;#"<3;SP9DP%M?&P"NU4=Z#T) MQK6.5W.VZ-TBB%H:@F`GE-"V9T7E^[@+0_F[\5]?O=)&\CNW/DMW*^Q=+0:E M\`=,U)XX$0-@RK7NCNQS,T_U"IXJGO('Y-RX7"VC<^,5:,5/]DGZ9)5QW7]C MQKA\W.R\77:WU_U%M+ZT".JK=!]"X;NC6^3DH7+U2G]W0ISB=\]Y\ZM7I[[[ M->+^C8NI]N8R=WC*NV?DQ.$WC+L0Q9[X[M&;[PAW7"5,>]*@]T@$-E`D6E= M6J8;@K7HU4V`:>!J:%-G56/`U0E+OP_*CF;I->DI+_=8OO?5JV-OCB(@BL[L MP5>/[K;+B]_)^S\&\7H0>.`7N))R]:HL^L>POWI5!OW32#@F,*GTJU=.E(8F M_KFM%*5VEUSF%V2=C/%TM8!;+N^#5?R=BC>9A.LEQ;(/_UFYYSZ]`4G`)Z#NP!22&MP7\:]X<#'XEOCAQ'$#,I MJ.IA&ZJ@'2KBZ;*2:(>))`(T37+S"I)?]ZOI8R"7#DF*J_ISE5V`M8]R3@2X>]&PDY6.EKG\\!XE^.?K=U^@>5ZV\434 MJ+O+D5"*5]TNENEGHC^&I`;0LY(C;U;++]$P#9AGHYXBXO]I@Y21GX7`YK]W MDL')?W/5H&#PW7>N^\8','9J9,NND#!(Y,R!MO7.JKE@!:=8W?*8P84#63)> M3.<_HL2N?$K^04WPB+=!J7X&N-^RE"LUY3HH[03+?5!R/:LL3:K/R>2B7-9+[BN^46S\ M+IN0UE''S6HE$]SJW;3K*7*$4=Q=LA96$/*'FVT\#DW=#$[?ZS:'S+1#($L# M%'VT3>52Z./L;-I1!VC"\#+ECLNI;Z'0_E!24V6Z<#63]_M^7*R%]LVA#X@%6[B1`DVV1OX*+UQM.5_/E]000Z,@4,/1#7[(]0T/X2V^BD^IZN?-$E7[7[LX'FYOK;[(+ M57YY)9M)Q2^X[JUX+BP3Q?ZM]\?H>$^O5^%:^$5@4I-;6O%B!$0\ M(8+D4(+\(CR\>O`0ST;<$P#LDA]7;+(`./YA`$Z3"'0B`NB6UX>`(YY>$@%< M#H%B$3@*0$P^^'<)`*PT`#ODBZ<4`$!PC@ADR5=9SG(`'!.`R`.'L1UE$$CH M)YI*$,\X#8%=^D'=91#@M!"`5'>(T^C]444DZ);@/Q[>RAXO^E:>E?CQQZER M8#+D1\I'?E0@)#\J4%W>A5-M`VYJ,,RZ8-WZS&Y]9MMW6';K,^?=^LSV$*(G M+[OUF;:3E:6I6Y_9K<\\D_?=.[_8=^[69YHZYW:O`^SVF77[WNS!Q_[S\MR] MHVY]9J=.6Z,N.GQ:?V`*UF8MKE-9_^4!=_?JU4M-=KO\LF0W/Y+#/908 M=>M.^SYW]V,PGA,-T&L!R5ZXB)U*ZK/_'D?\# M+WLMKT7GH7\JXVO]P9>NSG5?L,)4OO@;N,68WYIP7`3A>Z?(O8&73G$8+>]DO7LB/C6=OY=7!2;BS]:5 M7=+C9.A/7,?I^93Z/3H0_\&Q,^EYB'+'&_3IR(=+>O3UF__$:H+#P7?:F3@4 MCPQYNX#QI;_($:-57JK4;U+NTU7V)J7S^DV/,XJHC[2Q'/OOGB7N[\$F_:O^ MMVDX!XY_6@[E95LYD"%:8"SO8=I(.!>$>P0Y+B?>!NW^UI(&WG]!G/DIG0=>ODLB='=Z?=P)^53NC9['&T4F*R6C]H? MK_\[W'S5OU(?$F__/MG#8HB\_@#WW=Z`COJ@J]Q>?X*]7I\SAT_&'NOC_F?\ M&;U^(_[`<5(L+J1R%[)U`.WK<+E:W3<%D*-G62@:GI`,\2F*N`[($1JRY/8? MX:+:_T9CB-XF&^/[ZJ::??3ZK]^(`(NY&O^/T["S-WRZ!EC@O\;I]31EYL1) M@MG8P2A0_VV2^A&A?(+`1N.Q(_[#$X::N;CG.T.?T0'W?=H'0\T$NRGV/5_3 M<:?0M#.+*7A:P?6T:).H;=0*K4V*",?"XY0&/(3[]1]S'$\ M84J-N3$(#"$N'_7';H^-)[1'D=L77CREO25 M_K^82@TL\(4R`4$-0Y#1.Z`A;,02) MY@Y!4A!=ZQBE'SN_0^7\*26P_6ETSN"^S/`/Z-B1XG/M,7V'Z.[,MVCARW:^ MB0J2UT&\<$I=55Y':OCV>J@^!R\F-]!>B\^M'M1LH*7*)\$-:#D@]@^(>#H%0B2$]UL8]@VIM/2F_;HV!'W'N2'(.U+ M!R%\PS"^03Y/D5"[B)-)E;*/$F;[P'J3J(U2C?2&GY2CTOT;F,G),4V$,MK? M',B/J-G9QU_RZN`(D9MKP3;BWF!T^!VCP;[XQO7P#7%IY@6U[V=?;__%KG*' MEI;1V-'#`-(;'],;WR.&!8TZ_HU++S%`G/DWPI$Y(FAM-PC8P0VH`,I@8"T^ MTR#``4!*^9^M`0X\6$HK\^F-P_%%YU^\'W6]BT[_0=H]G*$]Y^A?_R'ZT-6K MG8,??;?HV&?>2#RDM'E.Y.K&==B>9`&;RLG6$.$S^_3M9QA",-&0SDH+A[KIL;-[7XMV/+ZVIF7_1 MGPZ3/[V2L_NB<4S9L7;Z2,21&//3O'THFW0 MD8Y=!9+4J5IE"_>!'A;A_X+&AWLX\7SA=.AB%K+KS(3?/Z`;Q(AP;IC\C3\0 M)-2>BV^4P7B*MRI>X$ASQH4#S.*WV#\86;.U_TM7KTJ&`Z[OW3@^WOFES&'; M_:W#S#BXV4>N4=KG!6Q'R^-%#B=2Z[?+"RZ<<1[P(3OD,J.U M=N=[9N#6U<_5JQ3]C#N3G`'Q[>3PRT%P\2E/1H_J1ER_D9MNIU+G)?GFWKM= MOV.5HP62J.,,%Z-_9+`2\I_/KIVDXZ\%.\.E3 MN)DV96MF?X:AO5)PU>Q7H>#F5]E#=(1I?DV[>I5OE5+;OWQ/X*92'[D*?D1E4511DH:F[/,E&ZD=.>O MK)G*&BG)]!/,U*Z1T@Y0"3-UP$A=O2IOI@X:J:M7YA[IQF/BB2[;>XOL MO9P#',VW*?D9D\-6Y8!-40JN!'2YP$'NA]Q@SFX\GT06WO=%8./E@W=BS`?8 M$?%\@O=.W0YNN8S=1>Z@/WY\+G,Y&Z;[JIH5.\6&7;W*L;`Y;Z%;*RPLE7># M9/*H)=8JD-8JWMR4$]OGF*G$DANR5]KOY?\:>!>:Z3K'<('SFC5=SSJ^VK7Y M2E[U<[A4^S(AZS*]@PVF@OZ[M=`4,-7WMU#>8(M>0=`*6PJ^;&ZOHC7#*O\4 M[ZP&CJVE\I(9@=W833Q(,BP0EO!'='KE]H]Y:I:C0?B[KYV='CQ;!NMH$Z>2 M*OG@+^']=G6G%C7#?/Z,8$RUX<(1,,L[\>WH]`9"86J*6#\$>:^C4D;A:BU7 M87?PN&;Y/!?"+X#Z,=B9H(C!]A)XF^6-@ZE9@-;9/RU3!'*!* M-]/)%Q/&9/17EB01]&(1*_IL+R^JOV3.*ZJ`V<$,OAO'8OG?@/VK`Q@F0UT\BWD'THK?:#T$&\\T*UI_%VY8&P'\ZM7,2\SZUNUK4*"A#15 MNN^QYMOIFI.B^,87X;U*@W`?J#PU(76XKH.= M4K`=`.WJU0D.:[YFUQ]Q5[1I[G5#6J)TM'^& M^';$D^4J?`C!_Y?Z,/+.0`+D,8VV`TEO[CH(I:,G-PJI3>M)J\OM]5OUN,2X M``.!0_#%[&);Y88MMO$JS@/-,P'LAHL$\%_;I?"5I1&,0NS4*,K72>V2^B>Y M.0@^IR]`2\U,M"MSD7WE)[7)4AX()^6P M!/%G>N+[V=,*L$1DI#^0P!2[DO/-5[DD79T$Z;A+;T>\1$1%N!"'07!.(WXK MQWP`)-F?E%&34!/@*\A51C?2)4AZ-4 M3X:FH),?O'JE`E:A;UT2;>""71UE?8]K*5Z'?8^LZZ'+MY)0F12-C/<7;N<9QU'\\;ZW+HOD MNF3*L[I?DV2'-LP:21S_#P^AY-O`5T3_-`AM"@VK\IJR:(A0?O&A)YV-..#["'PC@&LU!Q#;I"EBNU M^N]A!>GB..:6*DDVD,#_9Q2J>DCP),^FB`?N5J'J@;^)7;CI@PA>'\2+W<@G MX_@Q*=^N7NV_YSV,WX?M2ID>E:>M4*MP#;+X*:`18HK2A$'RU$,M5N!.Q3^R M?9+KV!PG\1'V;'7\V=C,2F,4_VP$0,R/3(2U5EFKWV3'C[)PDD$J MU_6@KH7!@LXGN9X3WO)IN896H;\'&[G3%XFGI,N,/\+(2YGPNQ$)[%D"N%;F>E;!'A2D<*22WS+OLC2I*9(D5W6;0;+^*7WD?"!)?>/PI/=BV7 MJ!NOQ.1?0I!&@[Z=^+K0>OT?MW.!2(;D?``":K= MB3J-)`V+O@Q9/FA!+3QB]X[9IV5T%1IA&B+11_8O MF&GW+JV^,>V0U*#[>-1+GT[@S"F6Q"6?A?`OIUM0^C[^K M$!J4"[@ZVTTT9V0>.Q`'R7'$C[Y^HP]/J8)J2X$DE.)Z M@,0`I//Z#>,$H>,IU#,?CUX$L`3@5GS$">$UHIG\QP>3D=<7.IB[[#,# MMI#7;WK)^`+C&-;*NK=12TFS;/J^#G]>A/-_>[U9;8,+&"5^X"?CGK]=LDI! M5AU"+HP3DGE3<0H[26JJC.;Y6'DN=9SOB#DNQ^Y9OM*$NQX9>#U&AYX`1*#B M"X(/2;6SH8ZBK3]!D]+D8:T0,!]%P!&.RHA8$='FTFJF10S2 M;*A5.3;CAQ`KC5YQPJUY/PQSA]5W"I'RPWK/V1';0;!Z\4/*$>O5X8DU;4") M^)-:P6/Q>$5$$*_8A!I++QB%JU6%1N/@5%)X-.@^&`%%5>G<(D_>6@_"B!:2 M53O*JW,B=/%+#N$HD&UYX;?@;7(-,$D9]\4O/BJE%GTOUFWOH8/H_6KY)7K, M!^BMN@!9[GG^=T0\PKE>R'O:K@(=4KP'*>-N?])GK.=.>+]'1WVGYPLT>[XS M$!\8#XD['G]VP2@*H7-N'98]AG7@4`':,+;\;B,LR!+8:!!@<@'`H.INQ>]< MB'`^[16`^B%<_S99!A%`+8^1;,^L)GG#X$ MGX+58W6`G@V:""#>\U\1'EUZU/>I:XLBI;XOHL_J%:DGHPO::=)BA,_4I`IA M!JJ4X!>F2@LQ/5.5*DR5_7?P2]*E,:+GHT:$,D7_='^M2YSZ?N#W*_6&O/_8&O8DG''S6YQ@-QY^97*Q(HA)/C43; MARK#GA))0C@1(LD(Y/A.17F"QH.QXTQZCMM'`F7.A,@2M]L/X:> M*`S--YB9@5D>"2T84R'L/V`.QX<@NHT2;5G3+R*WI4Z*J5RXE-6"51)MI6:]F*'11VFR6JT7P8ST) M@K5\!BRP&RZWJ\W;Q2_!PW3^,=ALYNKRW:D(>I@J!$5D*7ON"&%G9>]*`8EA MW::/4*I.3R$N8U:22DRV_TQ5O3XM!U'A1D"PP)H^P-1L-1?R)^P9&-=57054GW'6;*L"),4(WW+UQ' M;CQ[_:;'/.&)$Z]4KUU?SF61NOC3LI],<@#3\W8Q5#8X4T2PE&ZYPLUE7*/Z M9-)R2K**# M85(6U$)#[!*<4_+)4K!+95K@.%"^MI1D6#OL[32K%=*RGT=(BLEMH1O*5HQD MTP6'B2@NRZ<*E['A5,X^@.FN]1B%P7[]AB-+" M)LW\TFZE9MU84[T+/?4GF_ERBO]D9^X0!#6V3[JJXTV<^]WTU@DD&K?TQCH" M%3QQM$%HP$BZS',+&JURZ:O3'3(K'.`>L3R->=PSJK2QOSD9 M@+9^7[_[<&Y??VV>HF%I@$/!ZG`;6V-,8,\]9=C?;9H[0I4)S]FP'%3A26V=[ MGH:-C8'#(?-Y/BJX#&J/N3$`B6>C$1M@TN_WAIY#8&[*J,>=D=_KCSD:.OT!96.)OBM+FK>.-L:J#%%UPD`< M@,%Q:'9NRMYPM#(P#(9H.!P,>6_D.D(BW`'J]2D>]3"=3(9$_*]'1M`S@"^! MP6R9FT0=DF@G"UYAG5OV4D575ZNO=5FP:@K_2NG"PPI5S;)`V:(O/X`]]W>@([Z/3J@;J\_P9[0 MKLSAD[''^CCNP,LDSB^DL9)B"G'!+7)(S64C#F4CPL'2(L8(*C>/J(P?KQV^ M4?!%SCQ+;SI/U+X]2^'P0"!01B2JHECONBKQR/'CTWSY(PCT%C`Y5UJ[[WRB M_V(421A(1%V67$RNDN03H93?!Y6?!!5G.H!&`81N:H[2ZD0%E-9[W]LH.A@F MQC#JU7"Y.^\V[T>;L8#Y:=PA-"=E6XZN.H,FHT@(>XZ)SQOI@<@2:JP'@D-( M5-J,UU3#/$A[C9EZ#EE8@EZ_D0YT]:/)JE<#QA+4"AJA%EQ>@,LE.D%AFON$ M-DB.*^#Q_-RT8TDJS:E-PY+CR$-5=V6CSC#!6'*.0W+N)84-AI%]_F&$84!; M'E881JM5889A;"#L\'S7;4'881@9%88XI*!=XK@)-30N,0**U1R?P2U?[[/+ MX2H^]8F+*YV06$WH9@8#3\[]1YY+.+,\YVH($)C^ZQ(B(&GDP`:W/F7#W3\#V5-I/A#;M&GIWG\?&Z##8#*L'LR`H M19B?`.LI=%L32!D24YADQ3R&:XZW[!A<*3QQ"?I"ERS%O\ M@S:CYSE2\*A_4HA9GNQ244-LKMY/?\":+9OQ8C#%V7=%J%(8+>11=5Z@>>I$ M7K/G#U*S#"F'\#S*C*0D#*$![C$CE.[.?6QVD+79,R(WT&#,"Q1RG84]9KBP MAV2SX^G1HJE-%0=AJ;%R`YB0SZX/26&',8I:O:FB-(+5"Q91J1BI4PQMJKB\ MO-R`J#&!$L:N1TK=DVYR]56SPD2DSX>K=9=/KLB.VB!2+A0+,4:8%23.C]!Y MPFG;\1E;@1#DSUWBX5++P/9I-!XA&#YM$#'@$O5Y6\(%T\K(50>L@MCAJ.#I M.NRRU7L-'C4J%3?BU"]SUHI(-A=PF#YR'O@!!0K;PGJ>L<(GP,3B^A[SF5=+ M?:_I2IAA.%]D9'MB9[?NFB:%FB:7R'@BO',M[(4U@P$L_.YQ[CD,.NR+[BW:$:8:D@ZP M12Y-[O3:$);6Y\@;PA22G=S%E+G/R74W!!YB*E]5KJ09=#PX MKIPPO_C*1^.NHR%Y$5$R1<2AE11BZG,5#:&!X+*4XV!BH6=HZ(A`W5O$5K0@ MU*^SA\LUW<-%H8>KM)?34`O7/BIUUATIU-,X]-40SQ-!R7-HX2I&L'JY(C*" M`!!;U,+5@*AY0M0\Y&-:8)JM:>%J2)C`ORL$R<(6KB:T%\S^=APA4T4W1.SH MX6H"(LA%^Y04]4PTW\/5S''S5*ZY-=&":6W$HA/6NB:N)LX:D:J;<:@*M2T2;2]E32-E'B6GB,[]ZS]*J'*YI8%]B3MV]L@94/W@"D,&%R.%C_.7(*JZ1^HSQ\RA8DC[<7_$Y*(^$[3@DGK055[F($JYZ&#AO$"ZT)%HR;-11W;[6L MPMW$.?.EVN9^N9E)%E2X&SIQ<@[71<%'XRYEO6EEM4P[2I[*201-5+AKSS(: M!_199QT-HQEE(9&'S`S4J]'+,(&6RDJVX,YV4V=392F9Y]I]$Z@:5;_F?*WX""KC''%0]V+#1`ID"`/A^?%6:O#5@< M8W4S(-T]V0+55K/8)[_&K`[03@3;X6J>[SI%<8XU18MBD*J7$:*,"J%%N[PM MK%HT(508*F$.0JY;9((O*EM4;WB-2Q510+4O`]V(6"%U!FG1#AIK4M`-B178 M7:G"!N"IQ4Q MFG%09,Q&L7/1W8R+8C;AO=05N)^2X[9=BP M[2;+%'H$T$..^$;%0=W[57`?K%;![`0%_N[>;JR@0B.>2OP8JPN(-&&FC`'C MJ.XSYM=P8S`/PX]VPP%]PLC'1?TOARFKWUB;P@)S$4\PUT5G#=N3WX`/QW/A M'Q\%1/`$+92MSNLU)B!,>"R$NCZ/FU3.I[$&+\9"JW_5HW&XA`?)V!FS2F3Q[$*YYW?M'( M?+!B7#3OU.QA6+X%(.?6]>KSZHH3>89UX M8>[2J!P2H>2$W>1"#FG)3&8AX?UY>DB'TJ-`ZKHL)015GH%,F'.3!Q^E<'-N_+QSWD!LH3;'M#>>%]7.JLR,AU0(C)72'"*=8'EK8W+5P, M8?6B!2@2B6(-NX),]GHT(G](&"_?88Z+V]'JT01(5&@NTJ+!IDT=0RK7G!9= M3JSTCG#E?0R-R)>O<&.XU"7TYN]U-B9@3![$%OF8QBVAH_1YNROT.>#56!FE MLJX'GEA/N6+%U>5VNF+UED>_3.-ILH&(A?A MBI>,-Y\--"Z8SR,[:%P"6Y`M-(Z)RA[2\T9O6>#9&3EO,IM($"'4JFPBJ3N9 MRF4R%1:,]P3BON?1XS/*XK\:A=_"6;"8K;.M',/I^JNU1,(\?M]Q-0?T"!76 MN$:FT(%5P%3\U+/RA`R!YQ&X#D<8K7J/LLGN,%-8>7*<-W986V[[FP(&3J#' M79XT#]ODO9@"01ABAMTS!X6:]E9,@<+D@'?D$U)U[JD2]\1(O.;6S$91$$.*UJ=K9U#F$@84$FYR(7'FULQ'YHH`;\IEOZ-9V58ZE<0%S MY$%LD9=I'"$6*?1VESMST*NQW,EEG0Y\L=[S=L;J+7%<[ELS9P,@*23-<3W_&3 M1JC&T_5RJC^MN5R!Y+(WV>M)":5"3$HEY\N80LV?'P5?-O\=;KZF[OXDF&ZV MJY/DPR0>,#K$=<0?I&A41?*);M6'X&F[NOLZ70M!'`2+X#Z\"^,?TIYZ\FDS MB2;LKF6<4':"(W4*W39XJ@;QA.LWB+G)AKZZ_-(RS]6UY)[LQZK29C"A;1,Y MFGFLENI]=ROQ9/>2(98B1&%(9EK]*"3#U'(FDQ#`LB',Q?>LW<5D$@T8ZN.S M=/FE=2./3((A5^L15#3%IZD)1R:A0-`![_OXK`47E?K+QMI;@'*WO/]<6W7\ M`/$U5B^17"T)"RL\0KAWP;K@8Q;E]&Z*QI!@<@ZFZ_`2AG*O8Z(VY\!8"3)" M`>8W$%*=KU#1ZN.FI`)N*2"?.,@M5=QO=/%QDV+C*YCJ6WM)I_HTI8*X`\HK\C\:F^36 M$S2,[\O*$9H6WO;G#$V+HP@+*$_6IUF90S0-BJ*(9(#FAQ(<'K(XMG@1C&!P9<^ M=<79>"9->T;1@_Y0E_A>U;/!Z[-.II"!)BKDI5L(+&DL,XF!`YWI?O$].`.J MU5QY1]U>/E'5UE;@V2>_SJR:NE/D^.T9]EH2I.IEA"CE27"12V;M]T$7KQ4.H+EP0#7V/F^'T#B:RD%T*2THL5CG(!I' MJ@4.HVE,I`+CVG9+\PXDPG6/_W&EK^QZX#"*/X`)8Y;'YL8P<>4="P?SFC5Q M;JJ3;VZJF"OC M\O)JUOPDBP.XU#E/QI5Q@LMD=9+(VDFK!UF4A+!ZT0(4J4*QM5/%FI,_F`.% MX0>]2W24D:%BS8$$\4$]6;6J#+SI$P<&GUE_2[E1G83ER>(5F_[F;6*-4W5< M.10&;&+O>1O%>F?K1##2",9GM,SF$)[UCAUP94;D^83$QI%K0XAL&A05,C._ MM4;4B.3($)I3@FJ8]`%SL]ZOEC!3:S;X\8]U(([MNZ=@);ZS>.C?;<)O)^I[ MR@@!L*@CH#DOOS`21F^"J-^C>.R(__#\'F!N@TL\Q+7;#<>HR-+[[]-P`;F5=PNUP4I(AY"'S8_W<^CJ M%=]]@B_92#E208:G27@Y8O(9+C2I?BE!TQ\V$B^;:KF,.W#KI"XO#L`J$SAL%ZK^MI%].IT/"@26:N3Z%JE*.JC+WUCNJ!,G"(-?- M6'F*=LS9:GD7!+,UQ,^C4'X8;A!*@9);.-_":L[U0E).Z5(DC^.3X.Z25K%2$T(>-*(/5[KO[M/?>_YC1`Q=@%*[OEMO%YOTJ M>`RWCS:2"VM@.64>1H?L7@XA6;IW#<';1?_N;K4-9K^$TR_AW%HEC]6%44PU M35:&EE*&+O&.[#9TD$E@I;B[XO@CAZ>7 M%PZ_OD9DFM&<3,.5K%0D,QXOC).,U2M!P6^%^6T\4ZJ8Y^ M7U6_Y)&E(2+=0H"5,0:(+XP4_5E+.DWU$A>^? M6?F20A/?*%JGAG#GSI&5A,,L/\Z9C_W8H)]&5'8!#H1]@-MNKGMM;]H>YG0@ MSV'(3^@O(D,7]-3UC[-8-A()EP^)^)>D'R/GO74E+J+90*F]?XA7`C]FN@G6 MG\"IW:Y^#,+YW$IIEC$*PK?93N?OOLS#AZFU5AAQ*>I.LN#O M!'KRO:Y1Y+2`MVYM]9C"&F7JI;,ACQ&PFS>*2T;001"YXL)9/85,ZEU()O;P MA"%.>I[GCWJ4C;V>+P*G'G$(ZF/2'TU<]S.3HMWCCL\=A^JYHGP*=CHA5D*M M"X_L/K22--CR+'Y-RPAJ+[Q3VX'0X4/P+5AL@W]?+F=K6[D%XV!=RK6J3LZ; M'Z;-4K+``?0]YN63M2]WE??5&>,?JJ2O+FDK/:^WRABUD*="1.A0'V%-9G-> M_TC76/_;-)S+_/12"^U5;F<]F*[#.RMIYT"[RPCG&!UJ+"LFK:)N.F-4NR>W MTZ75%_6)-/@A6`?3U1VT8(V$.I\O MI3H[(]-JBF@/*NK<\SAV]1;W(U3L=-$)?_#=O33%D(V*8L"/XDS;2"W4SAE& M>K_OJS_2%*W^A?V1!Y;`VT@JDO4"![L>TCI##A"PHZE$5+^:S@7O^[/' M:^]$P7!;67A4@6S6+7]?;D(HCNB ML9;[)&!93V5?R'_"53:!S;O[]!ZNNB)8'@[?D;NZ';(S\Z;G]#)>.2@R0!_QI\A3<$REU6J(U6_`WKV0[4DT7T`>6Y3 M`&(^\CC%@QX>#DF/CH4H#2CQ>H3BD>,AEY-!7P`H1(F+KR3;V"JD-%?)"/$4 MQS"R./%7SM`OA\`IGPASV)"2B=L;#5S>HSX31TWX`CU_X-&!AY#KTKX2L!Y! MR''QGFXY3DJETF/V[)44';FU#E/?JTYV]@Y>5-./+ZE\".:R2K3,7.0V*#4E MH8';!$F4ZVF5TS&8;+/)#"Z->U<,GJDE!Y&CJ-HYAX[0+(Y9:!332@]B^K! M$`V'@R'OC5R']J@[0+V^X'`/T\ED2,3_>F0D]U?(&W24NJ[/S]A;-\'J[M`!+@/)SCTA\!YVJZ"PL%#I:0%H'%N M':ZW;1=38(=C>J[0E#*A2,8X&&F3/5OEF.Z#4ZUC*B6GAQ`CG+#S+<_>9'P1 M,4_77^?!6B;@3W8\:I8)Z'_%#&/D[^S//DB`WCGU\+`*'L1!BC_[?A7J9?PS M-B)5MDSCCVA???E0=R1_"]6^359!4"<&M.1.=SW)Z M-"80Y3&??YWQ&AX@_<(^X:W8.-<;<_Z0L7UIWPOO!C^XZPMNY8>&P# M\8'QD+CCL7+M,9(.&R(X:X`J@:("A"&_?R=4^+Y'\\W=YZ=@]7G?*\![C!$_TQ^/ M&>_Y7(1.E/O#7G_L#7H3CR*7]3E&0ZG"D;Q,=HMRDQ$FX#MAK'+N5J3ZX2_G MA)4'7,ZO]5U,=Z9QG$1V^4'*#:%6VDNJ;8A;]"32$!=Z#!.YLH;K^B."*S%2@*B1N&"V>RXM+I M"<"<84XX,J$G",!/.X_B./P5Z@D).-R8<)QGIBB."6T%BD("!_E44@JX9ZHI M1!S('+\ACP(KC$[N1Y%(?S5>A2J1XGBS)6QUBF*4V2V&H]"9B^0X[[!5>!15-#[2_1;` MNAL?99H`0?1UM/,Q`XXVF>D`3A4,WSN(2+FFR+SS5+8M4HH%O);,?U=%NKFV M'9,MI&H)`Q8G%U_08FX,D/I;2&5X)Y<,);-6SFLA;?RHE>TUS3MJI=#"QJ]XOUI^B1YS64&O;)%TWPCYJWNLW[\D_D?,KIJ-+97.? MP+:<_*+2_9DGWTVR-"TY^-4VHY1%]\SF$XDN5;TGB-C9>U++H8_P/!LS$9Z^ M?^$GGOJ^<'>J/_&>//%.BXY\3;:^$.`S;;T"&(+D6P=Q6VU]+7JT$-(S]:B" M%"M%BOV7HTAC0,\&S0=%^D__5\3KU:0'[RF<#P%W,.7"EOC4]_#)J=!RMXJB M=!9GG&-6=.7""+G4\PGUZR&71+T3KN\YR8SM`G(;O:R)U)76W?$BY2#I.WTT M<5"_YT`:D\)QZ7L3WAL3U\4C-N$>7"`P>%ESYP3%P,N?>[?=K#?3Q2QQJ$9JH9P0HMS5:HSG499%9SQ=+<1G8%=CS(!J83BG M@E42%HCL>\(V:?MW"LBI<,)C"7HKX;V<[TBP8#S1DMS-37J:F.QD@C%'G#73L*I9 M?Z:H]:$@(.AU&AKT9TQV@:W$T>\5F)WQ9XI0N`=`J.,Y9PWX:V9$Q$6NZI@- MD,/Z@][0=U"/3H:T-W#]<<]AKD_'F*#A1-'")!Q'=:J2_*7"DU):."2 M/$$N8V=>DC^_E4DGL(I6IE*1?S+#S2_H9#*A"TPVX+A`-?%]A^V/CVVR_R8? MC_K[;^1""LS]5"="Y(Y93%LTL3EH'K3!<,J32A MQQBC&<0L3!,>G5U=;9H010U`.B*FLX1UC^I&*DM($7R+VI,E-$`W9`E=2JB^ M7:&Y)*$!@MTB@NO)$1J@#`;R4$H:31+63R;,!7$P8WHVO[$L8?WD7I@EK#B) M5C^]BO,P329.:I__ M[W#SM18$#O@=%[CX,%#S-IE078XD.U*JY[KUI9(>LAN"H$K30<8SJ@8,(A4H M0=X9[X_>M2.E>LF"V%*=,_)B-7?Q)6LQ*AR_:N)H@!?$A#CPG=&/3OI31 M)'H7F^++T2DSP;^D*R&'_R12GGQ$/,]%!VH:I7..$S0>C!UGTG/).3UPX*+@\X.!*M6@(S^5"6X&BP/&$Y7(:]MEIB@K'H@X^O'6U@(M`A1.H? MOJ76@Q."":YE(%#-.6N3K7],MOYASCR?G)_'_A#()">Y!D"50+^[_R6\#RK*YVL@47`=SRQS1,[F M>_;/M-!Q\%5W=C*K:&?][C[Q3:>+N^!"%Y,C@C@<)8>X9T77I>C&4?IR=[[B M,9H.U+>2NJD*68;3^3R8#7Y<5M(Z`D3Q>*3R"*CQ2(CE%+F.DU4^!OM[\+O\ MFU-$PI6SRD6,0"*\'N3V>WU.:6\R<,?4<\8$,Q>6N7F@ M34_(KR2T5-/`:HY,F-+4$_+DR@7+1YI8CU6!/RW'41EO+=&PDE(/+G?IY0'\X;$%Q(F3GU?02,R@6!@#HOFS/;P:*X_44[-/8+!I+S MBXHUP1YIQLR`6<$09H&ARFV"0D_[GOV"P240)>5"HZR,7$R66WFO37XYNN_3 M'A$A:E-(D8P<)+*\N.0]PG[)H?$FE9*BDT>E,3?+K.CX4ME>XG.9,L%$1)=U M8L%D1`6C!BJWPC78G?K1D.$(HG[EIJ=>;5L_,+`*I&9U6X,JJ1\7B.#@6V=I MDXA`^>L7$"@?)AX7R,;;IY]_^NGW MWW^_70=WMP_+;S\-W_['ZS=@)@ABC+*__)1^+7W4.GB`/-N;OWS_LIK/PI^# M[T_S\"[<_!I`,_[U+!1_NPZ7BW][G6J1Z49V7(S_M15O!>T8RP6DZOK?P_7K M-\E5Q_Q`?&"^%@[WUJ'SM$:AU52/@O"GW\)'J;SL7P;)=/JPEBP^7VY M^NW=(IB$B^GB+IS.M4$WB[OZ!!Q1X(V#"E@('W-[Q#'#PDP1TBH6)D8$RKE) M+?/=Z@-T8&H,G83?@G\&TU7T@9?)/U5I;R7_A"N7Q);L-K`A))L^\^+Y&?4R]9*?L9'=A&\2-9%?9MM M8UTRQNXEVL-LBWM;66[2YW)STEI$>;TO&" M9,>J#)T]Z!R:3F[E2;(B""'E6$?,LZX+0EK,NBX(:1W[[#(I-J!S=`&LE<)= M+N,\-)(@0>4\`M(CR"3[HG7%+6;?]$6R+[MPVTKVY6WJAEWF&@<__;[\]'6Y M74\7L_$\^!8LS)1\+&4F\0CGWG-@YJ>7SDGJ,=_2XMV)G/P:KC;!BV5G5XM] MCOSLTB"M95V7!FDQZ[HT2"O9IZHRC"#QA^VHS9:NRI0ILK6K(FRK]&#"'/^Y M2<_ORTYVZI>=W7HPPYQPU'+9,=U-4"BJ+T-VGH7>,2P[G=[INI@L[F*R37I< M7S@[$.Y`#O!E9W=+O\`'&,2>C;=^#1?AX_:QDYV7G$_N!.A<`6(^Y9WR.5MV MIM\[V>F43R=`Y07(KH8I:]`A73&QHO;`,OPDYOG9%1-;R[JNF-ABUG7%Q-:Q MSRX7P0)T**.>K=>82@X:JO4:$V6$V(P/;OB:%W%A3A7""&O:L9L`>)ZVQ.7T M`>Z)_ZM)'QSF)^:.I56KDOPT%BE8S<86."T63'*TFH?=*,>!S> MN1"7B[O#2_%3?*P)?G:VI_4\[&Q/FQEIE>VQ"![:V9X*Q+UKT6;"Q!9L[%R(UO.PUK/P\[V MM)F15MD>B^#Q.MM3@;A[Y?CI-<+/SO:TGH>=[6DS(^VR/?;`XW:VIP)Q=\OQ MTVV$GYWM:3T/.]O39D;:97OL@8=UMJ<"<6?E^,D:X6=G>UK/P\[VM)F1=MD> M>^#I+JY4(>[ENHB=^KN(\_C9V9[6\["S/6UFI%VVQP9XD,T#GTG#`Y\5.D[> MJ%+7TMG[B1(X-JK4_+1GIQPSG=J92>'VDX6B7G*V.:H-'4>).H6QG)VH7R;J MM)RHT[JFB&*N1!V+?^@&U5^^EJ'D5%C?C(,3DPW%;8*IQ3#P<.TR.NJ M=A%B&UFI%6.H17P1%XS8I:!H]QA5`1.]#%6)S@>IDH%(.)Q M:98)L]4L;[^L@W]M00=\$_^1+A@]\(%Z'2NOATD)_GGR#-3'/]=Q%?]\2I09 M=BFQDW\?@KG`8/9>(/;CTVJZ6$_OY$[8P0_];[(L'7\/[K:P4NW=_7UX%ZSJ MY:G;R6D&GQ,:].MF%LXX''/5SFP&.)80W@((ZT?3OI#E#J^^(TV2G5I^T` M'<^#;Z4W@)K9SUG;>J!#W'R)VX"?'2N[G-[SY&AUUJ]ADP MLBMD/B.&NKY#9,:4N5PR&(MX.][C_%G^N8?AWR&^LY/AJ7\[^/'WZ6:[VDFH MEEOJ7/KG)M-P]5_3^5;\6O*/?Q4D3%=W7W_\(D*A>?;GDP^]73QM-VOY"5+# MR_P:3->"=@!OLI()Y+L?!]Y$^^CZ0W"W7:V$*GMI@L]=[BG!Q[Z=@MT7SYB% MX%$O51+L75UO1!+*ZWG1%/3L9TU7J;.5.%WU;SZ6NAM;6LE4S`M,58;LB[#.1 MYL8C1Y,T=_?!+Q=,W`"3NH#07MYT`:&=C.D"0NNX8Y.MK9WF;B?\Y8*)&F!2 M9VOMY4UG:^UD3&=KK>..3;:V=IJ[Y>F7"Z;3`),Z6VLO;SI;:R=C.EMK'7=L MLK5UT]QM&;]<,-.%O`:9U.ES.QG3Z7/KN&.1/J^?9M[I\XL%DS?`I$Z?V\F8 M3I];QQV;]'GM-.]O?>_T^:E,\AI@4J?/[61,I\^MXXY-^KQVFO7L8T^ESZ[ACDSZO_5YU.@F?(X(X#!=SB$OM MDLA9$/[\2_`PG8_EVVCCQ/X>;'Y?KGY[MP@FX6*ZN`NG\W2RZ]O%76V7(9*I MZP88XV`J&$,I1=PRQB3*60U[BZ8\O5M]"!^^;C0V3<)OP3^#Z:J6V M_$D]YELZB^_$S9]?P]4FJ&O]9T-,ZGS4%C&I\U'M9$SGH]K*G6X8K/5X$`=<-@;95F3!S:2;,A:4:=--*_*>^DV9`TXTZ:JY=F MBY+<)F@FEB7V@692[T!V^_A,#,BVXZJPRZ<$B>"8<0=9.A/M0S`7T?'L_72U M^?%)Z-SU]`X2?.O!#_UOM&CYW>9KL!J)`'DQJS\_Z[@&V80]QZ6D_6R*OS/^ M+NP$V-AW]_?A7;!J/:MLTB*UTRPB%0LU)ZU3?XC]4#X/O M[SQI_76Z"M9[#U%_7.+[3^)O][X-?UCBNQH5GP71GW?>919^$_BFV,'W_KY] M#%;3S3*5_C*4*USSOR\?.PH6R\=P<>C!>6BDS]S_\E]^TMX]E_11N`KNQ!?V MD9=IQ.2O#Z"HCJ#XA_\/4$L#!!0````(`(TP!T4D%99:BPT``&ZI```5`!P` M<'9C="TR,#$T,#8S,%]C86PN>&UL550)``,I3^-3*4_C4W5X"P`!!"4.```$ M.0$``.U=;6_;.!+^OL#^!YT7.-P!YS@O;7<;-+MPXJ0PD#2!X^X5]V7!2(Q- MK"QZ22'_Z[7GF.PO,.*'!6>?H MX+#CX,"E'@DF9YVO]]W^_<5PV/GMUQ]_^/2W;M<9C9P!#0+L^_C%^>9B'S,4 M8F>,GFE`9R_.!?+=R$G@X8\Y9='KATUG.ZW>5PO\>,G3H?#HZ!M[5O1C0*O%/G9.W1!C\P_TG-#Y\WP6*$V=T M,#I8P_AWYYX&'%K/YBAX].\0QU2_+;N#4GIUSV3L.7.3[K<#*;^[B3/)LR_'C6F2_<4$C^W>&'DT-!_].`NM$, M!P#5NPQ"$KX,@T?*9I+KCB/Z_3H:KM@7]'+:A,D<[(D6O=Q.>MNR.`+*/^Y# MF&=BC-O'*Q+`BR'(OZ.238,^;8L+NWY/T.,6PN\A)]AE,<$A?Y M]:,9@O*:X2H\)Y2UN73)SX,/,*P&U;!\+J3K?D<$.[ZE$<,Z%TT)R'RR7_E^@?QW&`V MP:SO>7)V(K^2BJDZ0(W0SA$G+@PW('X48N^:U`6QXD`U0HVG M]IBA@"-7=,[KPF;:J]UG8'E)S5\2IKU MK;(2W=<(ZPH1]COR([RVKPW!%&/2P*AM%E8:YNU@_ALQD'EX3=`#\6&YW&`D MJ+Q^J`B#/FC"B#%P'H2^X/5+H1(7;RX^<+#3$?TY685W8,OV43%"1&P`7L(]0GWM(BN&/@,()# M$LL_@UC!&./G\-P''6XL@C=D:="M]U(QG"@7>.]1"R` MU27,*6E(U0E1W_?.4;VRJ6K%E=.[161WL+A<@LW5]W:C[!JI6@W@H*T9DHDA M=D%YR.6TDJ;F'7J15'6^YVTYV+6$-";ICE1YF=%VC7QE(:C!:WWS^?U;13=& M#WXM:]QDE%TC%1X\"9,_@Q`V"QP(Y0+6P><("?L0U_MB2PZ8X'=57D&D%5)R M@+8X\$2D-7XJ&-@J/!P/V=L8,&$9]Y>`P/,@D-:0OHOF4I2=!,J(,V3\B M_B#C]A'O3A":]\3DZ&$_Y,LGW3A1D14<*U_F#A%O&%S$ MP48=`$UK*YQSCD.N8S3^TAY?!1,AU<8&ER(H#FI1_"?,P07R92`HO`#'_044 MI]P[--R;T5I!%<>,18@R%\!F,QN\@DHF(;XF"PP+"3:+"0&]%D^,+U@W<0J( M;.!8AGBD;Y+)]'H+RQS"M)6O/972*F8[F\PREGP5D]'0!K\R5YCL>\:\%Q#9 MPQ$O-!JX!NQOMK7!]1WTA6%XKU`E9K6TPS&=8_!![WRPUF'9B:4V%S:L7B?F MDMC`,,(A(@'VEA$RF,G1+)+^]0`_$I?HD!@0VL!CK#&WUI&O74SQY(_-S,S& M\-EM5B.ON55]EF8",7?9%_R9\JE>%R8E+7H\FL7.7!>VXMF2_I'1V2O[XX$0?FZ#PVOYN*+G_Y*K`G M^P"VR()3<-_M`US-%JA0OF\;R@TK9!VLH7^DP!^U!WR&Q;X./FGZM6=XM,:S.\K^.<"FR+3&LSL-H4A<+<(OO:#+-) M"$'!KV)X-RH'F3ZX88F_Y!"#C931C+(PJ:,3?*1]25T.*9_(3OJ%@QP_4^I) MNPRS!7$QOX?)KDW$:`EL\#\@"^+!%.+I_43#O*YU+2&OS[#\Q4&(V^!B"B\6 M#X.U(ER3>%BY#FQ(6W%X#][U[6,J=K0*'&F$;TAL"Q<7O&'@[O)9E*%$A$]C M)3/`#WF0\NFLH,$!9LB'Y=GW9B0@/&2@=(^#*V0-?N\YE:&1*O M:&*O2V1#9*V,DM<@!FTP3Q,W;_CFGN.1I!,'N6Z`IEAG/[`7AJHT>>_]0%^4 M1-!DOAL.7N-C_)R3GQ_,]!D3E=+Z#2M1M2)VBN<&4'-:V[E]%V*'^'J MB`/0HA0*S(`9B68;(,SI[*-)$NC!1-Y-8`1D@\0^!AO);:.9#J]YCH@GKK&) M_!#I0J=E*&OA\AR,&E'P@7P8(+E,5RPT\7OV]?# MT=IU*N,IH]%D.N0\$O<+P^Z?45)A2E43=T9KIRFK9(#!)'))#M?^E)ML*NUAD%7)KBTJ,")N#*Z-2NTRJ#9)FX$I,87RL\Z% M9+5HL(VM`S:[98HO2VWEM*Z9FT07/F/F$KXV4!8[VK:6RF:DS<6H,+*\\Y>O7)P87?EF?3<$\RM' M`Y3HH$'XXES<%OBR.F@0OE555]A[IA'/10],") M1Q#3;[K;]%C3#%,,+"U1KDS1Y[)22SQ-EG,H5Y&B3/`IK-U;%RT*(-#\>H6EL MM1"@2FIDHP;,V&59E0\>J9DV[*LLK",7(#%W)X^2[G"3%SK@24(LJUFH7D"Z^HJ33KNKUJM(I MZSTH^;1H%]]"/OE5#TH:+3O`M87VS37;E4#:5/A=S_S(J--1XFA3)?A6ZJ0X MW*6$TJ8*\?I,EM)Q)R6P%CD&6\K+(/:NQ/*Q_?,H)XNIFT>%42'E&K3K2-8V M\BF1'U#BV8.]JN+\,8JC*D&UZ![/FN>11B![L(/EU!>8'/=LT[FG[220KI!M MY8WZVPG`_.A?^WW#2B+)/`?4RNOYJTFE^&17*V_QKTT8^L,_K;PJN\ZELWGH MK)47:&\S48Q.;&HNT=EKPZ/,)3.'>^`)FLP6?8UR6^_;J2J)$N<6VWHU3U71 M%`CANS%;=54:;;VXI_I\*#XNJ;G%9W\U:=[YG>UNOF^S+#)/XVA^QN9[F!L& MIZF4=+Z?F%#IVP^/]M]L+7.N6(3=^.>%D@!(/_!N,)M@IGZ%:!@\4A;+]DTOIU),RCL/ MQ0U_Q(]"4=?`16%GDH,5EVLUB=GXAB]8)F#AQEFL)G$GC4N0)_;6K?`F<3C" M\F>?[A!+2;%)+*[MI:L?>1H&/&21S,NUB-5-4^!&1OFPUP\58=`')1$Q!@I2 M+$3>3"3`(X5G/DGBN.,I3L"]M`'=-75+8'\EDU0D.P4 MJDPHWC;`>N+0)AU&7R=68,?`U;DO_/QFP#J/.`DPYZ`2'^!;,6)SF5W^1![L M@'+O:QQ_K_:_%G%X!S/:%79<,SA5LU`F,%?[=;)'RA25G`1R1U_5BC1,WIH= MO<$*8;4]*!8;)]5<'L?"56O*+%:I=RZ"5J"\<.#&OV7].4)BB\9&XOW4$\P\ MP%2'#_\#4$L#!!0````(`(TP!T6*];5"Q1H``'&Q`0`5`!P`<'9C="TR,#$T M,#8S,%]D968N>&UL550)``,I3^-3*4_C4W5X"P`!!"4.```$.0$``.U=6V_C M.)9^'V#^@S<#+':!R;VJ9[K0-8-<:P*D8H_CZN[=EX(BT;:V92DM2JFX?_V2 MNIB215*D1)FD*R^-:H>7\QWQ@:S/W03]!@HWL__.W)@>"O(_Q?;X1^^O5R>C\Z.SH=C99)\OSA^/C; MMV]'<>R5(QZYT>IX='A8SO9S3M>'T0]'9XBTRE^F41IZ'T;GE9^N8N!D$WN( MH@^CLY/3=X3\[^=N'L[,/[T[^M]HZ>E['_F*9C/[+_6_4^.3](>IQ M/IH>38\J$/]S]!B%$+5>/3OA>G01!*,I[@5'4P!!_`*\HV+0H(`[0@P-X<># M"L+7IS@XBN+%,9KF_+AL>/#G/XWRQA]>H5_K\.V\;'YZ_.OG^T=W"5;.H1_" MQ`G=6D<\&*WKZ8\__GB<_;7:&M'A)9OF5;+>'^=_S%M#_P/,YKR/W(RG`G!& MS!;X_P[+9H?XI\/3L\/STZ-7Z!W\`T_X4QP%8`KFHXSB#\GZ&7P\@/[J.0`' MQ6_+&,P_'CR_N`G^3N].?C@_P?W_39CXR?HNG$?Q*J/Z8(3' M_3*]VY"/^V>++"D6[#%N<!PNZ1]XL1`G.428R9+D/BN$ZA'!D%'CKY;GY/T5*\"+TQXD",CR#T)Q!"_P5T)UQN`N7XKARXO`VB;_`N]/P8 MN$D7#,U!>M-Y[4,WB&`:H_ZN\^PG3N#_D>U_Q)[/(%Z`^,+SLM7I!)V.F*X3 M*(1VZ4#?1=-=^T&:`.\^@G"2??=5%&;K0A7$CA,IA)HO[5GLA-!Q\>!0%3;1 MD16">4PB][=++$3A/8HV:+YN%`&2&5WI/@O0AL8G?(V;ZG:9Q/`*8=TZ?ORS M$Z2@)_>^\^0':+M\!@[NY5TDI&-X@4[" M-(Z1IH'/"ZB>"YVHV!V3T,01^BWPLZ\SGL^6H*!XK9EQRBA3R,Q[M*`72@^^ MMA'5"#\/40+@+-JP>2/'P'&\<,)""+A"]T@4^%XI$4QBI%XBA23G/Z4S@3$# MK\EE@,YP81;LD*2A>7B90C\$$**KZPG]%=,V#&<$)QH:[XT3AVAW87$J$Z14 M0F2//3BJADRE%!=G=(W()FASN3X0/[[[S3(T4K(;D()6$20+0>PJ@@G,EE4F M:DZ<==9+Y7?N2\'0'&*(I`,=Y3*S#8U\(R&0R95^>?[X6M'-G*=`R1X7F65H MI%B#]Y/BGV&"+@L0XL,%20>?4@?+AT#MAY6%AQZ8.VF0R%'7[+X;6J.5 MXX>=20"Q)9JWK@#0NT1"QFSZ!PPUGY"BE#5#0ZVV>[_#K M78UFM,E`Z.$GBOQ7/%2O=Y5\QN/ZE(.0(?A88AI!]<>/C!!$"CKH:O,'^(DN MBJF+*5L"L@A8<+QWD^QB?^,0@26/YRF+^5GA9O&K?N$C7>0"0I#`R@E?/*_^!ZZT>$4S88VIHOE MEP7U`A#KJ..;U"D3N=%D>NI')'GT"G;6CTOP`&[I9`H.[C',Z6`*_>V'<5LO M)>?3(XA]@.T?+TC\Q6=B?=;/A;+:/)_$.NK@]D8!JLIU%Z_X+9/*9W9[K=0C M91#Q]&*JYJ4 MTT92"WL4Q1Z(,Z?FTY.3@]%S[*,#,EE_/#@[&*4041L]YZ^^@Z%M&NEHB%MW M`P;.8P\!>J(=:.V+*<6)-#[]2#,[,!=BB6>DY,"46[M^X`M_,#[ M>)#$*2`_1F$"7I.;(!OAXP$$B]R\HN&#M^]C,8:HLS&1I7&F:1.HXDD7C8J@ M/[<_Z4P=SN;18SY+D&(OAOVW,CM4)!XFLXBI+8AJ0`F-Z_8 M"Q5D=PG5A6"0B738&$605`QVU^`I^<5/E@32+7"2E/F"HVSXG:V/F]5S$*T! MJ'HBWZ)C+SNZQMF9!'NM"_$)=H897[$X0P'VOVY\BR*"J!]HB1DTH"X)N(UB M[*X:.VZ2.L'X*2CBC%1A%YQG9QR8@N&+ALA"WQ(D2Z%! M%^4%BP2GT]Q)<9F M.QW4;BPI=0,+3F;!H)O70P>"_%-C>2,*T4KG.FS2VUI)M;2G*6-/5F67S8*L M[/Q)&N,&Z`29@@5^X\'O8+EB3]N@?8;3AX=Y+?883<>J>@!)KC;CY":,U51O M,X"O8GX_7J%N7$A3QDZ/V>?.5&]A7KI>79_V^8YU: M5#]/P:Z[H9-Y+`OVU//5$6DU0SGSRS<:JN-JDR-(\2]5Q(FSQHN-SUWQ$0:F MNM4*(MIU2#KOPBG`UB.0Y]^3I97:?4AZY01J^4%V3?NC"MH?-9\:K-.66"9K MMNI'G"#+3_S&2:YHT"&_84Y#\T21^(+,(79"=WFT="%XTW=X2K<.%FEJM_L; MMS<>P+?L3YWV`.D\_)>@'I;2WX,^BA[J'Y50_[@#ZJOOF!4[T,TKB%T?-O0V M!0,.CVD6E:^V\F=0M>\N*+W%*?;1KU4GD@Y$4X<9DOX*GV3EBT;78>FDL4:> M9/8H!IW[&4&*12+!,4WC0L?+;ZOOD"NS/!G1(5D],S<'I>P:%1M/-2(DLUVX M2$7/T^JTD+O5>%A:6BPYG"[:UC+QOO#05YR"Q(\%K%.=AC`7(VW==QE!R>HJ M-M5F$XF9"@5Z#4X=\_AH[Z22MFYV*_'.^KS'N2_>[.B=1MCT>W,C.X0A4GQ$ M"#YS0SF$\;5X4!.LYL9S"&-EO382D+HB.B3C_'DO>E7`#,YH#X*7#/?O!?FO:GYP%K%AN6V/L.ECI[4](T-E<97^&@DZO\/:G M+.AN"+8_AT&WI\Y]268@&2"P)\D-E,3T[$_J`T$[M?W)#V0-/_N3!T'*M+D_ MN1%$_0^T9TG8W;DF'Z=*F+./8AW/)8T@MU6RZ_9\0W#OHU37=`T@>*V6YKJX M`1'H5DMTG!??#<(S6^4T28\B`MAJ.:V?6P)A@JVBFYCW`,%IJZRF/"Z?L,1J M8:ZG6R3A@M526Y_P8L("6\6W_M&^A`=6BW*]HN8)#ZP6[P2\:0C2?9'F!`TT MYU;+=@KBWPDGK!;Z1/S9"%1;1;L>R90(>*OE/?$8+0+8:FE.<;)`PA5;I3NA MA$@$IM42G&BT/(%KM;`FG,2`X+5:,%.=%).P91^E."&-[9W5\ER7:%("W6H! M;J"DR80[MLM\/4/C""-LE?]DA%^Q7-&$)WLO(LKEV"6,L5U*[)MD@W#"5D&2 MD7*0`-,D,@Y1WX$>*F!ZC0>LLMP&T3=X%WI^#-QDA^4>KGV(PP;0UI\"-S\J MBJ)P2`[/79/)B7(7SJ-XE9>,TT'BI0-]%]%U[0/DYM4-4B_WE<2+-$T*6UP9DE06#,K=*TO"MC-@*QE;2P[P M?I1?KND#<#(:#CFCA1QL7!!JV46&-X>CAIC[@5"S$VC&]FQRJK%CUJ"ISB@VF/(Z2'_`R*M!8;0K%%!:PJ M>[:N!1NBK[O`Y,@X-@1F=X'<*J!J#\X6MY8-(N,I/"7XMZ:1MCIB@-,*?X*3V70M8YE#.J' M%,L":&=OKJPKI"P![W*]3;0,?HE1][E((N,.K`S[!5WHM)=KZEN)9.%VQJV31<492M;YX$^-D+443[$A6V7_L3+A]A]3Q M)1D>TXROQ6K=G7((W*-%]((T-C\G&OUCFU;TT]<;I!\F:ZJ@U/BS4=2H*O5Z MBQ3C_P%.S'N'X#140L,GA`<[6(QQGCIT_13:?'D%;7(\T<@2[JN&TAC[@<21 M"X`'L[`')P"0%?!'I5=NA.'7W#U2W8-\95'T-5H+)9Q\`,FW*/YM'();/T1B M!1*5B%AZ%[KLA2C84PV5I<2\N36PI6H`LL$VV-,L5#JAU58_& M;(G>RJFM>-91M@@V[;I+0=)EAE*%`ZW"\?S>GP.1`X';7LM:KHE=I30V15^? M\)6UID6ZJN%RX51>6&\J%V8U/(G*;[&>2J@D>2K=0A3)7>:!1U&N[\*$Y41/ MPZ%L;+T.01GG+]>9B4K,NZ?90TW9&[0/`;S`67JR?UV5O&,+'VU=%-+EM(KD MU'8**9`S+$AT5$FC()>N^G!)82GW2YS9[E,4>3@ESD,4@O(%O`@FK[SW_1M' MX"&ANVJP;2\$KV8"-5^H,SV5M(]SX">,$HH*AS<$+UMF4#:VGJ)510!*]<&2 M\SK(;J^MY%9%*6<$1M9/.K890-FP!I4+K%I5<:K6+#$"&[78`$,6#LSG:VB5 MXQ#/'``([H4IJ\]U]^,[CA/ M4>#WV`M>G$$*]3L;_-I;&4-W]+#!EUT,FCI]SP9G]TZ?F^5?H]W)W:!%4#%R MV%"=3(PM[3*X#27)!)=`/QW3AOID8HP0?.:UH3"9&&")N`D;RI()BSJ]G99M M*$PFM@3$G9=LJ$W6?8AEIE M_?3W]E!K&XJ5"2X#06=B&TJ3B:MNW)`%&RJ0R>_QMB@(_=7(Q/+NM2;8:-W> MEB7,4P78B$QWXDN;E\%CRYMBVT'(^Z*#NGWF!%5U,H5 M32?\O<7,$2(*S&=[@YFZU@N4YX;N3^$`$.4M:FV4^.F7V5^Y(0+-1DKGGJ%6`K-7FZF=_ULD,/NFD9IL#,1! MC9-FH]%(R=Q%B=B-QT!N@.$M@)8>PU'5LC1:^PQ(&6_1M/30'/N]\9:L'83X M>EYD%P"\7),VA<$J/WK$(L5[CJ\W+IA!,XODA@6,&0_<>6"K^%&L_,*?-L56 M_9":6F;(F8SD&'/5DUL]]":!$[:6_1EDJC>>24^E*4=O=RA;U])FP_P"L$X& MO(L7$#N+NB.M`QF$-W,M4P"7,XX.M#,_P<(*KL'Y MXGNI$W#T+GI;(ZC&3Z59@`_FZ-)_GD63:+=N,T,-U>G[#)BT_OR>(\CV0?B M?0=1U8;P]H&XM6,%RH9H^YVN2YY*84,8OJ9EV<7F9D.0_Y!FH(U[2-NCAPVA M\/H857GML"%R7".CJ@]6^B.LQ;1.KBV$*^JV*>7:500QQ7(H!ABA.PKLEX[& MELU6H'@1V)!&115LZNEH;K"",MC4L\[@W!I]@5.<-F032NS8Z2G/_81NN+A6 MQI;C];1C`BO!ZQNWW;L0(@T_NZ:-<<^RLR3L-=("7AQ<>/DJ"I,8?7PLVG`M MYMPN>X!!TZ,M(8FL[JD/>1FXN5UT8/CLO/JK=,5-8EQOHX5*=%"U4EEKHX/* M*=9$.!^?_%T;=5P.5EL83Z$N1PWSRJT@276VC%+HA-Y-`%Y`V%YNI:V+:KIF MDD0UVRNG:.G'"9`EB]Y)97+U35XSVDVQ$:PN($Q7I:GB&;A('/PYPB(O[HES M1M&`*)Y!*VI\9]XB3>4N3$`,8*(:,W5\K8B+?K5GB$D*44/V5XC44FOO;M9#\[9P_QDXN)=W44FO'EY,<4(I[,>:EXW1^HYXN7YPL+.GT`MB MK;'>]\_64%UJ4QTT5Y4YD"DWY?+P`2P7"*XY4BR*O.Y47%LC#;5I"ZS:.6SE M$N]-3-WX6KESN=[\\U\^B-'!O%S?(V6*%W@M!=BX%B M]M2*Z"Y\3A.8L?>4^\+,ZV$*@C-I!&>&(3B71G!N`@+:VN9>>R(]34$$F\>1 M-#;V&,:@W-PI8DN0UU7C>Z"FHO.D[-J&040:YSR_\OL98E:B"=]T=="L,'L9 M.RD]](6QN+0_9S!?E0>1XJN<4"@`[_';]6"?0>+,T?X0)6R&4:Y441Y("8?YA9ST:X MT"[Z+?"+\M2S)2A$T?6`3TD,Q3LO>DMJ9@,/%\W_IUDQ]*8*+CF" MWH>DMP;RY!:GYCOW86HQY*9L1", M\24SMRC'KOR(C$S$?H\&7>152/JG-&?Y_X1AZ@17#EQ>1F$*)^AR1RQV%M1H M&W9C)4%`%PEJ&8(UO`4`9D55@'>YOHK2.+D+[\'""1Y!DN26"RIY,OUUV&AO M7M$>Q%++>#[W71!SC;6,QDHX?9MBF:FH80.G>#F-YSB-#3H>T"_H7]!'6R-? M9A1.2_77P6FR=:8`Z\,L^W^SG19JD>J]X9Z+Y..&+KI--KN#$?3SG'P8C?73 MO;YV5N@L@Q/']WAO1FV]#$""[GK@OPA_A&I[)>?+.%F"^!K,T>7'3WY-;ZB$ MABGP5T]I#+/CG@#DWW#MG;0DKJ]49.&Z45`:6D:O)M\.1LT;>+FN_H57>T%\ M`"6KNV_AQS+U*BD`B5.,\C?'X'-J*;C0$U0E:^E#RA'GU,^CA5OI$\S4S^3F M!;1X&]#;&D`USM/(VVMIE[3K3"+,ZO#.DMKE^^ZHE(Y_!<( M/`:*MEZ[]F5HURZJ!A.6++_'7@:2#&JJEC;$)/99!35]0KO3CC*P;08P&[PX M))#*&7UL<+/HM::;VKX-G@X2WUM``=;NJ:#\([=>V3;D1Y:#/(`&8\/3D,1. M&%Y9MJ&:@MED`.VN;))69XV(FWSD.4H(LUVN3Y>4S0]LL4['&\<$+_CTS4 MQ+IU%/A>+G>&W@2I(UATS!,`43H3)Z`9HNHR0,K,@0F@+E.(A$8L5ZR>T%_Q MC*:26D8P(#$]$^X-HRZ+%:B>[];0-T$K&8N31M!)5A^V91'EKK@'KR*8P(9N M9QBO63>^J3N+DB?7,(YR*8 MEB>TPM'__#]02P,$%`````@`C3`'1<.?UIFH5P``H+\$`!4`'`!P=F-T+3(P M,30P-C,P7VQA8BYX;6Q55`D``RE/XU,I3^-3=7@+``$$)0X```0Y`0``W7UM M<^0XU37,]()VEV[)MP3%!5D$1/B:PE M6>K6_OH#P'<2(`$21$)[<=Y12V0B,YG/@[=$XI__]=OS`;W@*/;#X,_?.=_/ MOD,XV(5[/WC\\W<_W[X_N_UX>?G=O_[+?_]O__P_WK]'-S?H(@P"?#C@5_3O M.WS`D9=@=.=]"X/P^15]\>[Q(49?_.#W>R_&[Q#]WST*`_3OYS=?D/N]@]!3 MDAQ_^/#AZ]>OWT?1/I?V_2Y\_H#>O\];^DNJTP]H];U+U*K\Y28\!?L?T+SR MJX\1]A+R--H3;7Y`[LQ9O)]MWL^6=[/U#Z[[PV+V_ZI/A\?7R']\2M`?=_]$ M'IXMWY,WYNCF^YOO*^;]+W0;!C%Y^OGH!:_H['!`-_2M&-W@&$/]])O20 MF8N(,X/XS]]5+/QV'QV^#Z/'#Z29^8?\P>_^^W]#Z<,_?(O]V@M?Y_GCSH=_ M__'+[>X)/WOO_2!.O&!7>Y$*X[WJ;+?;#^ROZ=.Q_T/,I'P)=\Q+$@HBX1/T M7^_SQ][37[UWW/=SY_MO\?Z[?Z$-_G,4'O`-?D!,AQ^2UR/^\W>Q_WP\X.^R MWSU%^(&OQ2&*/M#W/P3XD7S+/6UA2UMP5K2%_YG]FL79=X@^^?/-I="@;4U6 M^M*'5,D#_0>-TYJ:^%N"@SW>YXK2USOAP=_Y^/X M[#Y.(F^7Y*TQ&__\G<0+'PK]Z2LU"R(12U^.]S3EYX/Y!5* M/SAX__/M=\C?__D[?__;A%NUQ1\F./A=D3'W8A(9MC\K[V(1^B\%DJ MFO+V0VFG?(##3WSMO7KW!WP7>7O\\11%..@!$/<-\PCBJ2$;89O%VG5K$(I1 M)@XQ>2@3"`JA\1:Z-0N/F87O44(E6H">KN#CP$?H$#7\'%]V"4/%;#6?,4S0 MW]!&(DP'"%QE(I%X0,Z,<$H9I))3*6BT3V5_?TDR.'1PD3F.G5S MKQY0*ABEDE$N&C'9>JWEC=O,&+UH?615JZ=F$&6H4AY1CX=*(U>X&.$=S[K,3_XUPN\HB/'DY1X,=/A$]` M>NFI\->@''W?`82<]GL_851Y[?G[R^"C=_033QAV@J=-4@=?!85N;YDO7!62 M$!6%+@.4"0/"M`[+&$3I^^_]`.W$YA@#7W=\U;#48;]%T/@1/]_C2.T;9N_` MPR151'H1=+Z:S_K`@GY-A4(M]>HSM,`.\N6L`P91/1(EH%1QBI[5JOU_G>*$ M]E_Q72AH\QP'^,$G_>+A8QADNYPWF/68=^%E0+XOCI-/Z73C+][AA!O?><*& MC*^'36&%9(C/W=76=;(%M%(/E(3(*Z%]S((_ZSC0?:$-G1QFZJ`HU8>^ZV<: MY1-&]$)U,KWP!N]7I^G7NQ!U4&:I#2K509D^]-U<(Y2IA)A.9AG6%M\R6CY7 MC42X=<$I2;%<2)SLN\`,M?JM26U(_/L#OL#WR2]^\E2:]1E[R2EJ]AW:Q1L= MP.G167KZL"3?1I7'*@H@J@&B*E0I+5,":F@(X4(YNMI5/+Q>,* M+=A(Y/+JR^)FN5ULUJI,[F=JT%R/YL`(?:5#RJ^9+M9R^52>5"3S7`V:*\0? MG.>Z6$WG4WF3\?FE=+19S>CJY*9$Z8J?`(#30]Q4^BC'VO\%'$J=/7DSTXRUO9ZM%HYA? MJ0T;65_%`&E,K;>.\K@^*A2A^.-O)CZDRE@[L)_.F8K47RI"R9^_@Y@I,P7K MRYX'@'4I.SMP(Q]V5O/]$+)3XGKE#V&,Y]G"T5UXCFEWA/>D"[K%T8N_P^,& M]7UB;63S'IUE`;*>;S8;50)/US?),_>8#=_QG@V>XDP!:TE;J\\4>3I=-"?/ MG&.4-L\&Z+D"5H_(M?J-#0?\$\XN0QVX3/^$L;D]Q^]^.DZ"E_\/=Z?O_X<8V+%U9$6 M'O*#QS/R(5^(@?W%3Z9H"HH^-.DOG:&^6:X67(8I%$%$$Y2J@J@N](]4&Y2K M@\Y?$56(DE"A$BIU@B_;`NY@ES,^C@H'!\3!!^I9\EOZ\XYZ]Q2GG!86'O4* M):SA,;(I'I)Y!S+__2D,V"IG>"!"'_/LV+-@GW=?W6/JT=+A MIIYC59>>%:P7JV5S!MHW`24JT$6<(`S2)?M4BS+;FYXSS1?VP2:B9CW8Z`3Z MIJ/4@U9?.C:\C4U+S7HQG9V6X?6>&UXD%*]/$7[O/_@[ MXK[H&$9I^E MVS@O&H#@O6F,3S-6A=\:CJI4L5LRD9*C]!+-%_^O)W^?E6[`#X3:@AU_\Z'[ M#3!*X:HC&U';U<+=-'GD4$HDX96+A&(.#?8UZ*(B$94B(0E"@XVNS#>$YX9. MN+4)0>R8X0MI,=Y]_QB^?-AC/UU#(S\TE\[(KWX[(_C;4PQ^/GB/C<_7_KN! M1:I6H_*5;I>SO-/,WT=4@-F8'ZF_*Z?_U/$L#`T:O7P3]?18E2)#-&/W^=EG M@_?/F-]==3QNO*\2ZR)]3GPVG\VRCJI:MXLE>.?RT`,VWDWI,LUIF<;R^PO3 MB$"('DJ7>6[_EX/KG/J15?9,/0X!V=^IZ403^"_\F%4R)GWFLW]Z%JW%][YG ME3QGI;Z'O+5$-;S+1]JA4#$)-H`LC$VG&8=9 MB330V;`>B[DTF(E&I>R\C![X)%F/U7SZ$'YG2^;.?:`53*,[7::+6\ATX0;O M#EX<^P\^WM/:)=G^TA??N_=M++LCCHDA2L2)E85"W4.W%5)VLIS<+@I-WH`FWYV%PBJ^) M1VG?\,@?'`L?-MY'B321#;_%9C/+LQ68K#0]^YY*0\="G.EN1X]93L4LEM// MI*%2'`2!ZC$MS5B*$_^9U49M?B\X^/?AJ$1ZIR-`%LJ"Q-_[AQ,=!MSBW2EB MV?6?ONT.IWW*0[12WRG)AMB?O"B@M_00S6^?O`BGU"5:"-$BV^2RFPZ%I1=X M9DZ1HEUI%Y4-H[SE='18:9O.7?/6*;01:Q^E"@`MY9GW'>,#NG=*'!)3(31! M-?,8FU,D3YA0^V%'KUT2+`@:6R_3B;/:LIHVO[]!^CE_Y0LX^^8+%_DG;/'M M4%67&;(@7&U61=E)301V_HI$HGZEJD&=-K3%V6Z7L\4>>B,D)X-FC=37^UG> M("%^\0-\F>#GB=BO%/]VJ*[06>%\[V:AE]=^I4H@IL7;I+"!3NSDJT^UL5K5 MB>$@)[X1EFM!5".EU3^3/?SUD_>,+\)GSV\NZ$B_!LXWI2XJ7?:FFT>H4/1K M*M8J8AAJ;1?@W_6;"POA=I3V0[/A*!#(=>8TF<]=4DMS6:^W\PPD$R8BA8EW MZ$3!`*575.D[*KDCA\I81(OS;H;FU^B,SKYZ/_6'C$>K<@F8^6JUJ48M?$&< M$7:XW>@S&\*=!63:1L*%],=3%&'QVG?M&>,!G34L36B;C>/6XCD3`,G&@VRH MD'+VOC7DW`B8=F!7#0:/:RG&;CX+%>?*O%>YBK<6[Y;P^"BSTFT1.X._G]UY MINO)=DC(DP%^C3]C')]]]2)68.PC^83)9?`%/WJ'6YPD!_S<)G7U]XWG1"@H M)[OIOEFLEGD5KEP\/3\:HZP!NES/FJ!5I%@CJ&S%DE:Y= MSMHS)KOE:L/2_=9L[N2+`/1]1`7`[O@--\.5-L-8#\P+F%K/V[)62X_+NRBB M=DE<7@..1V;R+YON:Z4UD^;8]6J^2#M:_FW@C>L'\YJ#AA,4)[+;:=A=N:2F M<35E+A^@:YW(]HX;X`7?'*Q?509ST:FJ^0ZB1ST_Q7Z`X_AC^'SO!PSXM#3` M(8Q/$;[#WY)STOCO@JY"\F6#?;"<1@J3RG6V-I0+1A7)J!2-?J7"$9,.U&]/ M87I^3"&M99J?HZ.CWQ]Q](@CR*Y=+7*K?;Z"IRR!9-\F0NY0(P$QUKE+T>L:"#S1,P=GP9[^AQXC>O$.M(+`6?+1BZ)7/WCD M79:F]JY!A$DI)%^9Q5UE_1L[+T.KG+,?*J+168)RX1->RW7$D1_N/P7<2Q,G M-'Y1&$][-788"I>BWR$O09C\@1X=9QI.:/QMXD6)8?.7_>;?XT<_H*E6$SNA MEW95(JTK!\EZRAXNO651=!KL(>S&^P.E_E<)`(`*3/0[8[Q?@1W>!`*R)\/ MX=>?B#_(CY?!"X[9-47!OJB#5EY95$ZO>B8RH\4:!OP87176UO,)$<,^;1-E MC:*B5<8-9EM]>H)N5 MIZ*W_W)J8QK>]=!G7DE>[.8M>M5S+A%1D5.4.-VFU@7L%@3NM%*WD0NICPBV MC2$#M6+GHM3K.@R8G!:W6I<>LZYF3U11@0F@*`!,#?$INK$5N:5$H8Y&Q<;4PH&HC9;[U MT`CXTG/8G?\L$`Z^J)Z@7FW6Q;)7`PI?H$^3:S",BX@>PR!0T0HR$3"^@)^] MSK3)"@=>13?^XU/2D20J?MX\1MI*R->";!D[R0JI7$6+R0'-)-5E8!TQN M8=AOH6'4B,./@QR!4ZQ!C\P@B_L&-((4!RGNS%WU8LB&$=AX*_MP9,^HK"L4 M>[%DQSBMKI/@7M[LK[&C\NE[94$CL$]!Z:A=+ISF.+"%S8ZKJ_-G8N18A%R] MWA'<9;W+:D/2X9EU>)8%0R_2I5QI#0?\='J^QQ$9,QY,C6F>2!C0K5L<[)02+91DF"0.%<54 MAK_9-8L5^6DZ5;4%JW(EIG.$VW2$-]P1QO`_).AK:%?V)S"V:RH2E?_MY%'^ MP3CN.Y>E*`0&W1*:*71IBWD;WO6(IF`OV[#@P-:4OF`(_T*ZKT?P\N_#(EJ` M7%E'Z365V*\4P&915E=\== M9[Z:9_D-U<%F-LP\T7;HC6CU`X9)I273:0\3N\*IN"+=^4F;0:P=U#IK66T) MX/#WU.YH3T.RVRS2`('+EQ@,_3*+8ICKH`8=F:H_8CK]Z>BQZL\9'CK4&I=/ M!EZX+@=XOZ9B`'O_$>:X2N:8[.NY@=3LSMN6`\?]M1==1;<)31=C)Z3RLN+] M7T_X)@PV1.K(5Z]?K9<!"T+U(-#2(_5K=[H'3H2LU]$IUX! M8-47IP*@=?H'&'I,D?CLE#R%D?\WW$S\E7D#!FI--508G#<23.6A4B`XK,99 MR(%3-KKS.DT$@)4H!@5PXOK%"ABE0TW9+YL]#0F?5`7Y!+KBHD\>="Z%LP8` MV`RQ3`P9N`F19*QU0J7B"RM@:6N4$JZ:@FH^>W[$9J1E]M8-WH6T^O150$<-7K!K+L(,EP-,0%)*2B^@;^:N M(^*B!])2NFY12=^)Z4X+:XWF]_A9>[#4-(%+!"Q%6\K6K:HYHGEKZ"I`>7OP MI#6!6QA_?:[%!;TD/(\-6]A+B1!$1";O/N#92&?MP>9C,+,.M;)J[I:+P.D* M!ZI,+@:8TII0_*E<$D9_^'XVS=+_JZQQ_0DYZ]6[U7SS M;C'?LEPK9[E]MUXZ[];NHCZ_9W^M3%7>$\M@!%!CTJRK+[=++:SHO\OA!)29U*+_IT2 M/8M<\QV]5DN=EJ69U*+;+HX)P_3?6JUUY;\K9,\M"3:CQBG@UJ[ M`:^"$L1^!8=MDZ<`W0T^>`F.[\)L&,[=GE)X$1B@?*UD`V:U7:VV?-B281Z3 M3$_A9#.R;$0("V@=!G-ACC+)Z"XL#FQ![-Y-970G+61?>U_YVM9013=B1032 MX3)=M")SK-%6AIW-/Z"AYII;XY** MT/J25[^?K`);-1_GYV,8E#M]JI'0([ ML)4NU#,6&B02<$0]1%_9-`]G0P9Z[='WL1'EV7Y-6BZC#'GR[VK-G>PQN"'[ M])Z2)48RPS_'J&B7_IN3A0@[)YC>6]7Y`W%"(ZILF$2,H1?>A&.P3V'&2W%R M]?!O8;BGQ\IO0BX0 M48E00QD]%KJ%A73?S#M`CTSZPJT^`.GTP7"\Q'CW_6/X\F&/_10JY(.AU`T3/<8%)7[[S>:-7[B,&>X=JN_)W[6WS M^*^^#D/^PPUP90PPQ?:\$*GR>\M,F#B._!>/)IJ=O_[D);08EKA^NN!AH['- MTT"^#IJS6.91G@NBQ2!34:!%TW58YM8M>X?N)4PS!X>N2*L#0^@*6(C0.E2T M3MP=:;*S4'KG*R!P:>LA'5KSS6K5`DTN#U&!P)72]5GIBJRTH4BZ3!SR821P M"RR8+H,XB=@2X(T?_R[5ZW!>`0%36P_Y=?3U>ML"4RD/48&6]$-CK6R"J6*E M3;V1.`[Y8!*X!19,/WG/LCU2Y5$0\)3M*PQNMIL6:*@<:SJ>H4:U1FR]5ID' M2#NV^,!H^``6$/%U>/!WKWTU``%'4PN%XZK+0Y5H( M?%=W?]3Q`<-U!0ALBDK85P_5LQII?N>>Y7JRG9I[+\;[:^\UK:?=76M^I%"3 M\!NEJ7P`;_-R+)4RZU)VLS2Y^5 M_&6,([1`K,8CX[^#U5QS7E6[MQ\?*=5&MN&K*C\'V\S=(72#SAOX@1\\F/08 MHQR6F_`^=42UQ3?!(-W`&40A'8Z%X9#L9O5ZLHDP?/A/&\4\5P7IS:W-PLTG MP+FD9MX5%#0U&.;6#2.T))$G-=RV;6I;@!]ID$]NG;,88IXY5NF$4ITMQ-ZP MB`4^>O&3VO=D;\"S`55#);2V/8R`J$#+H#/`QK<(GVH,2D"H$J6W/&+++/Z M+-A_"A(_>;T,'L+HF?7L@CF[_'NFL\!EE)(]TC>?D5EEFNJ=BV65=S`3C/Q2 MLN$$;OU&.C4C:5)G*AA5)(.M)$QDLSO>9B/)URKX+#*LI=TU?5IHKDJ:C'>- M(S_,HR*%-IB(DSGQFJR3)WB&4F4D-[ MPRS/#>UVA&D\T.14.3243X)@H6A>(94XOY>]&2\LE]@*'`RTBHN";JO,8Z`5 M6GP$U%U@+OY3Y(G/"/"?,QS[M<:E8V2QV33'5!E%PIT,T&"1JVJ1R9CGAE,S MXMO&FXMWFDW7\5W8GPU'-VU3^NJ$[6;5'-C0]^$B65U[5TI[DU%;#8IFL!;V M0:R6??*BP`\>X_P.L)[=>^'C!M?)1#I(D]QRN5UX/OH>JQS!UEG M:GFL+^BJ:V.=_K`!,>=>[._(_/O"/YP2X6U;?6\!XJ>ABL*^Z&HFA!$3RE9; M,K%VH&F4K>FE'\PPNCZX3V6@0QC'K.YW7O)!=`DF%+P$$=J%,IZ?;`!;7\*' M^'E`@"FG'*PVVWQBP>-P\,P+308V$3%&OI"\43-S0N#V(:GSN2);M]HVBD"0BI-.":EIKL*_,",[-B*XI7]H9(A,&#F&DC?S;&9;YPF++^&T*`<9H9CU@Q)0`ZSQ56RQ2P8FUAH0[%F\_3[ M2VE^ST=,:S8<+H,]_O9_\"MGVX3_G*$=)V[C\JMLCI-/G-(4K4P08I(0$65^ M%TJ#1:ZJ129VICK#*=^B$AMO+-XEKDAO?ZVNE\PB0<-E]C0595Z'1;MB+KKJ MOM+>"$BT&>L*C'TG::U!`$G$9P--?5XR!2UN89#6GXW"1;4XDY/G-&>Q`E/W M8YS^KJ3^YF*Z7=6#:Z&I./WL'W#TT4OP8QB)!SSUIXQ&;:UIZ8_O+!VG%KQ, M#,KE0(7P"&-<)6/,Q3,W@.IAW;;:5'3?X$>?9C0$"2V4(_PLC<>,QG>];854 MK'5]-%_*8?6,H")\C#FNFCGF8IP?1O4@YQ@.LAWRUQ-1IB_1K/Z0R8V/6LOR MX3%SLKH*J0#X1+(1=KC2=AC;T.`&36T7HVTO7'33L@EA0.;-G=7W^,\:C_6& M`O*EZMSEIA;RA2#@`GP:S'*5S3*+!$&`M0'!\X*>70,F_HYT)S'!&]WY%"5G M]3YN?"=!K(OL/3X;=['([H?*HB2IB#.=JJ++GBJ8J^(`<\[T&N@*#(3;;^A' M4;GST.,%D.[N&]Z=:-7"JX<'?X>C[L06_L,F.SRN!O(7F*X6^4IL+@AEDJ#3 M6308YJH;9JS3ZPRS6J\G=@0$/CY[?O07[W#"9W&,$WICTQ??N_MLPB$:MBDO7CYDM MMAF(:?N(*8!2#=B!A8H.*%<"7=&B>%F[[*FJ(NRT`^DDJ2Z(*0/$`H`.=>L. M?9=[U!-Y-*QZU!OF45/T,PF*JZRE_\.]5;*[\^X/S650_?+?&,DQI:4[\[6[ M7$Q#<$R/-\QM`_S8X+7<8:SDY;LN!NMPUENBK1H>=5-6^3U`Z>K\M?CQ?_LX M(AY^>OV"7\B'$E\_(_DR!-%T:J2P$#S?M%CD_!55_E5(1TP\Z`4U4UC?&M.4 M!L-?5:,6O5SD]KL*&)85LOT<+![E<.D\$T80(K443ALLG9Y:*P(1H5D M6X"HQVJ&0E4[`5#8%ZP""'8Z"11_91WPODL].E^!0!Q'#_D:2#.GO3Y0$0B^ MLZO/RN;@5MY*X_CJ"$8NL$2^L051?94,NM\!QM2`2Q2V\U4WJ,"K&F@TM(FK M\`%]]@,OV/DL]3^_*1#T>BJIH.R#%OP&5*'597`\)3$;OCJ=NU!=;T#@JJV& M?*K"?-9>Z4GE95,R!WA?2IN5#%(R-AG'CSCPN.@1.,(6[+C*V''MP(ZK%E5D MAK]HKV_4L.-:B)U!5E:PTVT3)'9<->RX%F)GKHR=N1W8F2N7OMC,NK$SMQ`[ M@ZRL8*?;)DCLS-6P,[<%.]T[!ND6@>P\24D6!-Y4%%2(T6U[!-B_P9?OYUDS MYYK..0S`OW@1.ZB1-_-:^L5+JEL:88"\II^L0/L0J'!Y0-G3MC/$ST%X'^/H MA>XE,I(C?R:.)6^Q!&"=!"+=E*7\(JN_PO!RM1Q,/U5MTM$#JNOSQ@AJ&N\R M_FKX)7Q`R1-&&:N]_GW3FBJ^A[*>TN<#)47>EE'G02.9-R$H2ZR.0N;RMCT5 M$>P6@AY*TFYT*SM!W6KC<.^/7"YZ>UQF"QCC=CJ%,BS%,H`!*E1,)6J=+JC& M_-PB^V"KR17-72(YDR$QVQO@?>CM]IPU."X&!G(+>EVO0J.VH8]"?H#;3CBJ M@;4<3EJRU*?-['S(+6$>*!H%8=H+0IYS;,'>+W[RU!J)Q_6A>'W<7DQ^_HWP M"+T\X#+8'4Y[O+\,\F+\"I$S3?O`+#")4=+G@]Q-7J9+,$2GZG%6`^+FLN!#,'+[^$2>Q(@X[8%^DI<\2^5KNJ(0D[]D M;B2/X`XW0O+?I%311Z+3?I=PZ4XB;TQVWB18GE'EFR M:^CPHQ\$/4ZQG>NE2$L'U_=['X3K_ M@O=GSV&4^'_C%0<;(<@D2RMK)S_\6<_RG%C6"&*MH+*9HHQ`V1"JM@0T9IS8 M(VQ`6'V=[J'@@*^1P##O68;PG[#P<&+W2W8@EV@B'9.KQ6(FA5(B MU#I`*AO*P'>=@NT="G!"9V1>#8P/Z`_K=^OMZIVS7K-"'.2?B]7LWT8I@!Y`ZY&JQ*PG,W(M:*GE^)BW\!_:B+)U(?`<8_T'3U3NY6LC>`[<@ M0[[LBCXJ![T20?G\WG#53@UV.(4=5%">#P9Y(Y@&HUQUHXR4ZNR$25&D4^P` M/5@])62]4S,_E(]8`NGI`91.HU@8$?4SF M`K<=`?T!`,4I"J$[4P4[ZK=16DFXN70;&ZZ@TU&M+ON[5ETR!LRS%`3.L$IG,"V\:\"E.U17P;5 MM$!"5ZVS/``\-:$C&%']D0K_)_1(_:$2#V"$-0C]!6.INU,S90VF*CLI2D,P MDMGWS.50DZV$I,WD-A$9I9]M:G&`'^FJFP0!Z3.<;0TQH_](B>>?WAKS#&,< MPTQS@ZD/&8:+!F-)LNEY%XYONA63#K78<"@G*J77GW6W>J4BO M$$]LR1#[*Z6"M]Z!$.)U%!YQE+Q> MDX^8T.MGCI00!(O^DB\;W&^1TT@A?=99<6!*95-\YM(1$X\*^3!;,%/87L*4 M8#*F9A-@/OC?Z'%CMBUA>B@TZ8=>\*S%75_5U%:2&DRK6TH*CH+BGYCJAXF& MG[[1!:N3'S]1G:X>+O!]%_5TOV>8=3J5D8[#97&G*).)4J&4<^IB*?M0P7!, MH]%>MYB%$-CANIT$@'OM=JK1C,XONQAFJDF:D4)CDV'Z?01"+CC`D7TL[F[FF>+&+0!=,Q:0/33LW%DG&XYTE90 M3)MA49E/<$TO9DSH!:?T0MX"HDVP*5.<;CTS+[!F&`OE#4$L;4SH"5<4#\?( M?R'##A(1#YB=6.@*#92$R-OM(KSW$W8T\P63AR*XVVN'<42Y'J+N<9"!0Z;F M@R^,#D@*)N5[A*=39X\6@"3O#X-W,+$.W1V\T/U7]7@)-#?6"?>#H]: MA]TP$B*"+P/"*?B6](7LB$?/;2ZBIPU&MD`%^9+QBW6V5)=*0H4H\-M;M)CF M#C#-%!YZ@JV*C2Y?`.$DPEZ,+W#ZW\O@;+<+3Z3SN?9>Z6&HN\C;BV:*DB^; M19&$1M+4NYWEMY_G@E$NF6;IY+)1)APQZ6`@TVYY>@HH-_*8R@$&FD*T-G`G MZQYK8!B=@!()5?K[UJ$OE%&Y]AC]N%TJ0/T MZ)U*B/8BC^<:.W!WE3SAZ.K(DH6#1]Y-OS]AB>'D**F@:%5253JF9ZM5%Y!9 MHZAH571W-VG9AM&L.8\U2E>E>\YLA>3037EPK#`(0-V$H>Y@.[CD.L)'S]]W M;[?TO@;*!G5=Y,M,;-?;#KAG4J?9M MXLP1.-3R0[4;EAQGP>".<#:.DW1JG6DC/APO?-PHSO@Z**P)S@I\I:)0MC:2 M"8,[":_'-M;QT>[>S^W#8JXP!YON2*O#I<,-,#"A>R=TT2E5*5=0^!D%CQN% M"5\'>5Y>.IL<)KFH'"BY,"B4Z##-;9CF,UFP$.F.LCI$.GR@94<_+VDHVF"[ M/D7T@>0NO,&/M.J+'P87MT]>U%IM&2W.]%[_"%UE-WJ=V6(Y2S?^J[4CQ9NY MQZQ-NJL;%:VB"\,)`,98HQBR4/*HM(`J38!RB68'".^5Z/KZ%M"- M-+XY_"/GPND(26[^^GV#_FAN>M#?O7;%_SH'3X%B9^\GGWS MFX3`>\+`W@ZG6?F=P7F^G<,DH%0$^I4*,9P---H,5\&,J>.[(UAH0(MLA=C% M[,^'!4I['9+HN5@ZV?1R\@36OH-)@]5G!Y/NJ/B^+%Q36Y`]^:@VI)U6=#@+ M]FS&^A0>]H1L:$625E$TZ==@XIVKB_Q](V1(VP(!6^"M"D6I5'!P:+"5CQBV M7%L5_8\=)@-`J3-.!?@2.\M&T/4D=4N_;A$(E8_:+3=K1QJ,X*G8TYCO-LU_ MB\CL2K!6FONAH.S3`IX)S?(FDJWEKUOX8"P M$4X"5%3MMR/^Y?NFY@N@>%`_ZKU<=V"@TU9$.KBVSF+11D\IT"8`C34S*YH8/+Z_P]%S=X5H``R)0U`` M(X$_8)"49'M5-Y@NNXM.KK6?,XJ81N/RDW!GNY/M ME1P*>;!H$(11'0$\TT&B/HSCXLJH'4'D%S_`EPE^%BXTBU\PB0.A%O(GC=?; M?%N%UI>J24._4GF("83J-#19Z`ZTT!A>>@.P!IQNKUB!H#M:6$7VJZ8/0R*' M::`P"MFNQ:AALFP!S`##A&`1&P:&DUJ8=6*D=`0\/EXOO&?O$QR5-W#N8.?,=C?U1J6WYC?YO<%9N^C7U,)0%.L$5:X MLE:8ZKVXX5+ML=K&:NFE?L1[?^<=+C#-B;[!+SC@'Q[G/F>Z=^(I(9O>OG"( MZ6G/E(E!>R:'WOA(!1GND\;;XE1M2>6@3!!`3S3>'E?\;<#ZGRYX%'V/T'20 M?LKW`<[ZH-C[H/[5_10V.YUVFX* M@^K!706HHO_L1F]/JM``05:B63UC;;7>#$0U>+[1U&Y)$_FH2SX?PJ_956^R M_&8?QKM2E0:ZTB+,I^4F1_38/`'P&.=H)=U;K9;+K02VBR9L[;%'^T#<8_N% M[5;WV!W!+8%BD?_L1N^P'KM+D)5H5C_%M-W(C,-YJ+:UQ];F%FZ/+^3&PQ^8)@,=F+H'MRDTZ=O;8HWU0[[%/,;L=&(6% MW5;WUAV!+8%@D>_L1NZPWKI+D)5(5NZ6%O/%VMM;F%VUO+Y$@CSZ84--/-!'!F59\PBM6Q8/DUSL5Z7(,QN"*$2P'`UU(CBXIS#9-I+ M=/E#M5_U:6\0U.T8;^"U820X%,]>//_`[K(-*X6PL](.YU[L[V0^F(04*#CW MJZ82;2LNX%'1""TG7RTZGQ<_80U9@"S=WJAA#WG'X\'?,3\D85%8GMXRD;5@ M#3KEPUZ(7TE7:DE[(@V33GZ'\3ZFPYDOH1>P'RI-\I)<9%XSG10EH9-L'L[& M<"6F+;0 M>7<*+,]H]("`<%@+G3?LP)./1B$6*@_#FQA)"G`BZBIWY$305'$=X/ MIRFQ"#N82JB?="UT$J-.+UD=\V9LY2M-?NBCK*(9FUE+DR_ZB*LK)BSCKEXB MZ*&O;H_J8K"O8?3[58"S%"?O<(MWIX@MP9*9(S?+7>5-`+Z24$OV?A?2[FI1 MT!05C,(`Y_FMW@'%A6SS?*3=3J=J)Y&,"M&HE$U7D8".!TQFN%LUW.&;#7F6 M8`!4J]0BZR\]C$(`\GP\A*\8=Y!'ZR'C/-'40+:76J]73G:OZ4_T,&\FQ#3\ MQZGO9.KG,D`!/+*(HPCETU_:0/22Z6B^R.K;0%.MP,*ABG6P1?23.T MJ$W63G%A$SJ2EDR3P)1^<"I^(%.0&L+N0D2;064[Q>5X"(C[T(OV;"I"UU7$"%.RB*#!08<%0UC@Y*H!KA5*XVE-[ZS>\;N M#[@L0!&7%2CH'W$GD$&]S("2F6C5+A-_## M_*=O1QS$O<=-Q,\;3&X5*B%?J]M=9Z`J3T7DPL!/AV@RSZV;AS-AD/FGO=%6 MS33M=@,H6'J/A`#(@/,$<\=UFM"8_&!'7P+W:(,JM^R59QVA#TMTQ!,7 M"*,.3@@&FU='.FXK>Z7KR-^1J6O'5EO/&Z:'E]WJ2&?:KI9NECZ4":P,)H]4 M)-VG-SR0U&F:4S6M'#8RD6QK'G##3J>=[A@[C0PCY1!7C!\EG#,=$=R15U2I MH/J.%61044AZL:(L/2N*)29U6M2H$<-@,SNIP8"9`\AAL*V=]-!O*QQ!<)#8 M31%-%TU($E]#58HHWK"#(')U9&/)G2]GV^[10O(UM&&T,-"T;DKX&MI'",/L M[*:#'CL!R:")N!XJJ#D'9.80 M_`93+,<7?KPC4[53A._PM^25N]L[OVOS6>,`:B@@?PE?D1F?X88) M0J4D2+2,,JH*$B8('AJ"B&HC@F>XGLDQ%7^!'W"PIQN]'7-B[H/&I\(\+62G M3\O-+*\-D(;!OA!D>MH[WHP*1$M!H%/<\3:YRC:9F^VR(4B(A658IME,?1B M:)L:&^!',F?8=W5UVFU>,*-S*^GYC`@G?L1F+LTJ&)!]HGS,5CM(27=!@O#J M@>G!DJR)%SZ&<:L,AM0K`,#CZ2$=?DY1P+J`'#USP"H6Y!(1$PDSJ-1GI%LQ MDD+JX70XO"):?!W#%F90"44>JH2N@<3377BV^^N),%A:WY[]KN<3C3C$2VOKCWDU,$N\:H'LF=X.SVE98EEVM,OGF0>(]DE'KV^!BQ+YH> MP_OH'0ZT'GR6=\^;9BN\;7IQ1EXUV?0XUZ&!QU9L2N&T+_!R\?F)S1UK@%[B ME8VV#*_H3&6[T["=C)\+\?GIW;0!>H%$U@3`ZL]4]KOM;\\2KU'0/+/;+.<8 MAX<]+4V0#AM"F"+6`P%?+"HINE4[/V6S:,$9X:N'3][N29*L5$1!,I>"GM+U MM1:+U8I'8]52Z_Q3Y_0I3%JT@-8F8?^%L/T#^5_TBKT(ON[C2,+@DIVJ/W4QGQ_NKQZ^^`]8IK)*Y_,`'"94 M1K;/=1;.8ED0%1%'Z>=`!,+71=%GGE,QCY`(%6A'J1-])C+2^/3MZ$=IXEOE MZT&R1"^XJE30[0J019-:)=H+GU[>%>QOR(BL9"[1G%SF59,+)1+ZR)_9<,**242D::+E?N]'IG74AZ9VCQ*<#E$9=9M"%$85HK2V)R'I)3Y?+ M;2WN!)7"B\8[81FM9&-LNUZNLM[X[@G3NB#Y"#FB<&+WH-+[FKS#[G2@O]GG M<#OF2Y6$^QLA:;K;UN^03J:)8:EF*IMM)!IU_);=N[2')B"9=!11K61R?8KH M]F9R%][@1PHEEN;]%^]PDJ`>-7&PA*2DJ^R0<[7B$DE#=)-YK*1NDZ0*.9/_N%VL:BO1I+5UJ>;_*2'E)< MFJTPM>6+-EI/?'K]J]I@>EGV719^U;"M-3M*<*_<=X->FOOA_/66G M%],_X&`GMS3%?Q-L98JKCO0:C;L1C;LJS3`2H=SJ9C61N@I<=V?I]U),:_B,;D,'#KBUPQ`#L=!0_)=&Q[=DJ>PLC_ M6ROA0?(E,`@V-5'9R!,,$K/I8BG3!KB-LY,/LVP5P>LT%`9NHJ@4PXSK(%O@ MQS3DA!I-CHMJ\32G#7`\E'7Q^$K,JV256Z.B5QX@5[ M/WA4^+K5MX"!5%%%FKA7SDPP-LS05!%J#Z0&6]J)J[#;5$AP<6*S#V%-'\'# MC+=GT_4D&)Q45KWID=*E8(P'L.*OS2`>4OY4SIG0'[Z?S9QR@>]/R%V^F\UF M]/_:0[X_T\ M2_P7?'@5KD'^8?;]>HG^^!!&B$3I'/E!Y8#7'YC6SC_9@_?6WD'?%]6U%?OL MGY[I!:,T$9[>K7#RXZ?LE/X%ON>?P.E_"V`SM4B*F;>O6`J&33QX^G,7BA\'$A-R(EH5G= M:91Q%,R((-QAO(\_1^R"X[P?X#",S!M&1PA"->0K!3KK8CLCE8:H.%3-O=2/ M+ODA@R8+W9J%-)1K73X4FA1"L-[O=KL%&D47/CV^QVHE7#U5JH, MDQ'#Z3[V][Y'AV`2'U]5(A`*%=64CN%54?Z[CM)*>[0;S%LD/Z!JFZC:*#R2 M)_52>L$U3LAXNXKVV#NPS)\@#-X30"9$ZP/-E/)SEY$Q^#51Z+W_X.^(\Z)C M&(&7`=>`*1%M#/D&FH;UI1*#A?+]:S M?.A?#6S^=>UT7IJFMH5I.\8G`M,Y@<.#11.U@ZVT.E&ZZI&U`Y+I.)TC.(,: MR6@`G#D,07]E%J'L3>BQT"WI>'[T",_ZR2O1[R/I=^CZ$%&/\FYO.;\!DH#& M/I+J*8S;MVL>UFD[*&^(8;S25#H*FJ@NX)"QSB1>X0"?CF^LJAHX'`*B(8N* M*VU`_=6#O M_F'A;M_-YTY]ZP\8K+V1W$!GMV?US/NSTL;IUVHH_WY=[T_@\ M7THMZ>J/R^4Z+YF7WUR076G>J//XE4@OIG:FI_43V.S4;,[N`*_?3(&H]&)> M#S&+G\!N5_5;PTW:E:!;3M;EG0;1X=^0;X3/OOFBJ7?Y=X-=>=&H;)>VVB[= MK!@5>Q?]2M\&.H,T4'M71GM3O6.]LN9FXM M=D%/T`VVH!J_%^&SYP?P$2P^)=J\4H4T68UNPZ=:`(Q981S(N/"L)]+R72J0`R.3\%4QZ-7J=4W4[#_? MGTBD4*ZZ8>6T:7'I[FJ3_2^9)],>C>0+;ZU7;LZ2%9E9J7%6=[TL/6F<];1: MZ;2M+(7"%HW4;*G;MG07QDGE2P)RC20`*R0BXQN0Z0=F2Z+77I2\ID-=T6"Z M_:#)R4BK=841_7*9XR9=_F52.D?V!N8F(PURU0PR-E41AE-MQL(W'CK^[T@? M'GML!_H3O1PLQFR#J_+KF"YT55^1^+I#I`(A:X"J"CLURQ4/AA7A*&\TW3FN M-ILN&-?>A,?MY.ZJ72%V`!"MM:*0P*-G M^(TJY4"6P:?`538A]<*/=X
0)69FTUKA5^YZQRBD.A116-I8%?NRJ3R6DER1F"\$ M0?5CVJQT:U;2=9M]*1$621)A6,=2GU-@T)1X?H#WG[PHH+G>9V62]P5^\'>^ MN(_J?=$HKOJTD0Z[^&@ER(`",?Z4P6:XWO-"? M+.C#Q#O(!KVR(2MV;3-M(H]TT!/+@J@11;E%`=ZS]2MZ&B[@5;<^-XZS<`2! M#[Z_J\6V;!YO'0JZ-FR[#`=!Q>X)[T^T5L!9D/A[_W"B)ZMO\8[6__!Q_.G; M[G#:XWU:`_'Y>$JR?.M\`)=?-W-'4R=%7UMO(R8QJ%5S^1'_RLFRBG,%V.&( MB@JHU`'E2N0E10LUZ$O%%*BXW0G]RI2!0CZ@1]V:1T,)CSXT/1JJ>M08!TT" MY!IUZ?]RL(S'E#GW8KRGZN(@9OJ>T4,CCRPG/#Y_+9_),O[.OGK17H[LQLH' MX;F12DOO(=/PDK`9`J"D4!]KBNT7(B,[UXYHQ6*V4_?,7T:LTAQF%TB_K6[K2ZK9:N0\IB3\BM.8,A[2R`M>)KZ/#!K/P3!`70G9([O;Q7;M M5F'OY4`W?-QZO!%.U8A,#CRRZF;[]5?I> MA(%PCU:RY3]FJXV[JG7E'7?J@>&S3\,-MT@ M8TC"M4$A,F[3R2F2G?Y'&SK]CT-ZEP6]D'U;(XB/H+W^&"MJZ+>GVQ]CDLLS MR9INGX^/)F;'=ON:5K_Z5NU$BW9?_`!?)OA9=/)4@V"3:VFCM5780]OF(W&) M9?J>57K:/&+M0RW/&7:<6SBN9UV^9UF^QW'&5ORTP:^V,*CGH^@9,@S5);L7 MB1[#V-&*=&'T@-D5<#=>TE,0;O(VC0]E)C9(=F"]7,Q7RVQ8Q$@IQ=:NBD&O MCL&X\EQV9`UY#(/9]5X(9\K1*C"9=BBBEXN#%;:SR]V:^HI,-Y0KATKM$%4/ MML*>72YO]3*U"&_$*=QHTQ"UEB-7$Q_I38V",\-*@^++@-CCAWO=XZ6.EM[" M.%FLOG2.QGPV7^LFPXH^M`!RJM$;&TGK+Y)I"F;^&R`_M*#B,5JJS`^Z\D_3O^7*L2RD*A*B.H$7-H:WL'% MA9#T/NET+=."VMA38E2)U8;Z_VT16S&?SFZ5ST>;OV#_\8F,U<]><$3FT_G? MV:5VVB-ZD!)O@@R'6":_C;&>.=IHLES4RU0M9[$HUQ9EZA8/I?=6OC4"G?ZC MI-2:.XE=Y=LHM$;^J,;`&'1L5K+CW.X#)D66:&#P8H"*->@=M="K@,[ MRU*>1TW5@.8]LVYDG$9?]`+.E;UD1DPH*#X=$J@[>Z=#'Y_"M'A?\\:XJDYY MOM/G?&FV>T-MO'BX[>[1NDM?<[V:YU>:5W>V'QGIT+,A085TXIQTD@KI_#4G MG>KE@<7J.=@.MF$/ZJ+M(J?O<]?^@[%-:<->9*S]2RN(+-AIUL95G$UE/4ZV MA)RY0T&]LM\>+2N-8);N:K5T]'-RNAOPY@AYB.^TLS'$$!K0?ZW1V2O,IZ+R?8;@5[#Z&3^D^ M];EWH-AZE^:)3G-T/C7G-O&B9!J#EM2@<_SH!X&D34:GU7T38W"HDB$'6TAD M]2NR:A8=EYJ)GS<)8I$2\I?J+6;9!2R%K*P425&"!?)^,DT&LBXT-2OL-\L8 M+OI"K@:23D^`(B;="*;K\J1W)IVN#&JX[T`@AZ>(2G`Y3?1DV^*E1#L`--[. MZJ:_E'7&<=05B%PL"9T"BJ+ZN&Y]7:YW3;A8L'IP9$&N6H& M&4=%*YRX4/@RXM2=YOB_>J#WI'T^A%_[;G7N?`4"$QP]Y/-&76?11`>]"H_> M&<]B0* MTK&H/"@[WH5!I5@AE;YAR8%E57(^O[((E[H,;P.S*OD?Y2P'@&9_%`NPV>,X M4'!VUEZN/P0!-[7*XHOUO-7=P194'F%'<[YE0-;_#+Z26]A[ITM^ML_YZM^](]^VP'-3^3E]UB MFF[19!LFIK?FI[#:*:VFN^UYU;54.$JEYXGZM]-M??5LJD]ANG"+_W'_P=Y([9$$R7N^4*CC1#/G_Q#B=^;22Y-ZVC'J:6 M;!;=?+Y69)X7*MXVXAE@LPKO,/$VTLX`NT>PCKUL4P.Q/-F4[H,9QM?4BP7Z MU0O55IX7#EM'BC4Z51BGJ_3<=3%?B"`?=V"^5?VX^A[4K,2DRXJ\/KSOO+7# MW"Q&#V;J\QX-'@4CD-K21%?,U!\T#?):Z](Q.%_,G0ILZ\MK@!E](RWBY/6! MYO.--(>?U0=TV_5(6RH77O,6-L&YCPOW%INU'6`'/_7N'-BQ73!VJ7R]6CAS M(6]9L"V@QT"W::"=*.E>Z->XNM^U!-$>5'P.H\N`?"L<)]?>*UUR[5Z*D)<` MLB0AK9[L!0;SV7HQJRY-<)7[10<]_$+)4?8AI`3_57[>&EFEZRJ_:+ MN>NLI`BI.&)I%Q&-L%J&@8K#D?8QSPC+.R@G_\P64@T7LQ(!>4ERL4VS.MCVX;]W1!NH]_A!Z;DH.N3Q'E]N0NO,&/IP/#^84J M$W4(L82/Q!I*C\"7LYG;RTK'K!UZ[C\J6D(7-I&3+E_T453>#KH+T4W5%Y8Q ME2Y_"(9*M6WF:GQ4?6(;C_730A^;]7C5-*?=ZN"T6^LY[5:MGW7G58(Q,KJN!H@51K@VVL9$>5RCLQ=EQ7$$= M_7V#HDY'&J&M?+U^R-5DHW#FS!;28Z/6WHU- M]#/*`9(4U-JRLXV'1CE!9K?.;C(2(%R.D'B^LVY5*/T]X4Y:_6C(4D%=@"VK M/36MY"ORSA?2HX?L;W000=NPQ:>BOP1N2C"1*B+%M'J#!(V-R8>R>)72RA-Q<0>Q?&)*[U1(A MM_:3W*UT[KN[7DLO;(CR8VPG.45OC",Y;DZ(;22GZ!$!R8FR8MX>K]V.Y[5; M0[S&_IC=(UTI3I%?&GH M(6LK_576F%W4--X=\BR5MX6JC=G'6.-=4BW+IY58-`JYBN3UO9[IC^1YKSVDM/*`S0+FL7W=.&;>(_O4Z2 M9,+VTA.Z"E#>+F(-V\:*>AW%3U,LPB0/'CN)4997Y"A2RK%3DF5EN*EZ.K_U MJB4$V-1+>N:Q+7JJK3D%L.GT_SNH^[JI.,FT[9S_.4(593N&C?SI13[<"<3=C&1)F=(D!)W3FD?06ERB-S$ MTCZZZF6!?N;J]J!%^W%,*DO.FZO[,86K>&4_ MNBM^6+B)IP8@B?T\!4_;QB,##YLTWK6$%Y3/6VREC\QG$J6Y4H2^A8P:71[)CW.69?I>1%,2 M&_`[-F.FQVU3+C'D"ZAGP9ZK@.IB@YP\2Y8=I)25+2&P6&Q7V]X%"'&2:&73 MQZ+%B`EO1T^)?[..UA!&WR,\3B!XZ1I`9]N.BM]NNP5:\"?ZB.];KY= M+'D9Q,V`2A-8;&&"(3;V\D&6?V(3+0RQ6/E@;2,_JU6S]IF$I"5!3*9`$N8HRTJR@\15Y-ST@G M3U%X>GQBZ*KG1``.S>4BK[54P7<.&&1N\)$$P9-'AOADZ'^#$S_B)85U?6Y9 M$:;A):F7=*DE9[ZN)0!4Y+-Y==8"-\52+QJWJ0<"5G=MWXO':1RQ8#M[F6`V M6XZ89#J&LJ\.E6*APBP3HHJRP&N61"5U\SDT/R!.MCNH$\ MQ`U2.+8?OZW5KJ&>`T'OZ3[&?ST1CW]Z(?_S(Z;GGD61P'W6)")Y"BC4%EWF M5[<7AL-& MKH+*T&HC0`>5A7ZETNP`R##;^!#IL0T()K@,]OZ+OS]YAXZ1%?]9D_'/4T!A<+Z99QB@=^",-H*JK;`CO*P=X'':I/Y@^*R9G4B9#092N6COA*^$_T"`'6$O/D6O M;$DP+2YX]9`NW/]O?!#ET?>]91*XW:HHW!JRS1;A_.'@)_ZC)TI4,X9'N2"MX4_"55JRN.Z^AG=/ MX2GV@OVG`R83N#QME+MB+?6*Z2RN'GUD,W^V6])FFL5%)*(D$XDPDUED$1M. MW])JG),;EXM$J%CGNT([T)_\ M*,&J:.>_!`EYKD;29XC6R^V*A_M,J@W@UV`@AP%R`VVC`0W6YEPPMY0+.H'' M)02Q4[2P0B:W.!C6FRLJ^Y9I7NA723J2YNXVNQTG$UHY>,JK2FJ8('1;ZE0M M+<^/3I_W*D40NJUE#/&)IXT;P":3'1;WZH" M7%2FJ'YO:(:1!W&3:23]I9-QOOC>O7_PD]>.SU@^`\0?A0*R-WPLYQMG4:>) M0RX#A@@&FE##>R$##M$#S7"Y7P(:J*W8;^*Q;NTDL+L@,'\A\?^"+X,XB1@< M/GM^Q-!^1OC@.:\Z<\2[!.__$M(4`OKFC9=TC09TM0`-^7'JR_8OL_7"<6J$ M$9=QBAY(>Y"C"!!G\*D'E2J@4@=$E<@J"%;40+D>J%0$44TL(#"3KDPK_I)9 M!`W\1S9R>2G$6<.">JA(R*$:'`[*P#=^_/OG").G2*#A.-'-OUSY;X5]>J@6B:J!+>;['WYK!H7W)27[) M225G(Z_"25\;2_SI#>6T\&BN%X/F&^%Y[2[60?O-W07$U$(5O=Y:-Z#=S2YO MMZD=BF^N@U!@R]']A>Q'@>T^L/_X1"829R\X(K.N.QP]:PU,CO@WTSVT=9>^ M/'FYW&CJ#C(ED)=J@0B!/+\5\A_K0"UDGSLPTP)1-=X2M8]U8DKEO#!Z>^PM M)JOQ;"WP,\1YL\R&SG).]6<,GB6K-2Q_Y'BQ<.MXAJW:-,(*M[8(8T.5)FZ\ M5`]ZM:W5.>BX"K`XL;OU#%#W7R@@G:(SG\T:V9EG,!WO0-5K:",R(+.OQUE2 MFXV*F%BX_E&3I:[XB]:_)W0/V@O#9H_:[2"M#%&0:#%;O/#CW2&,3U'7CDKW M>U!,T:64['+"8KUT9]9N06LTL4X4Y;I3986I%`U(%OHLMC/U4`J"+8;H]0K( M.+R^NE2KM5(9YU`JVY$!T(5_."7""WH'"C,Y=A^DH7QIGHV;=^?-U=U&(:+J M$)]U[CLV_L\:!!KT&W`.?]$W*`H9[;(+?=-Z1F'%2>_9R&#'"OKOQ6XR-HL8 M!9S:_&*XVU/D9&[X0@23?Y-_D1^(KS#YQ_\'4$L#!!0````(`(TP!T6"*+ST4^/Q]/'BYN;H[_^Y;>_^?$_CH\G ML]GD,@I#$`1@/?F'"P(0.PF8S)VW*(Q6Z\E##"`($R=!PTUN_?#7)P>"/T[P M?[T)^M4_SF>WD[-W[R>399*\?#HY^?;MV[LX]LHQW[G1ZF1R?%Q^[^\Y99\F MW[\[0\15_C*+TM#[-/E0^=5%#/(/>XBF3Y.ST_1?'B!'WFPTG9\.BWOYGD MC3^]0;_6X=N'LOG[DW]\O7UTEV#E'/LA3)S0K77$@]&ZOO_AAQ].LK_FK:'_ M"6:CW$9NAI($@1-F"_Q_QV6S8_RKX_=GQQ_>OWN#WM%?\`=_C*,`S,#S)*/A M4[)^`9^/H+]Z"?N`@<"/UG'WC2%$L.MTO:'YP8R$.N,&:R!(GO.H%^;F[0 MZ;4";6@N>FJGZ'&).%Y&@8?.LJM_I6@I3D/O'B$0XT,%_0F$T'\%[0E7^X!V M_BX?%3YS`_W>V_Q$\7T&\ M`/'4\[+5Z02MCIBV']#(VKD#?1=][M(/T@1XMQ&$#]F\KZ(P6Q>Z6&SY(8VL MYDM['CLA=%P\.-3%F^S(&IEY3"+WUW,L%N$]BC9HOFXT,:0RNM9]%J`-C4_X M&IKZ=IG"\!K9NG;\^.].D(+*O7:#1+$X$S"TK<)6G]D=FS\[,<(\N?6=)S]` MV^4K<'`O;YJ0CN$4G81I'"/M`9\74#\*K:C8'4CHPQ'Z7>!GLW/_/%^"@N*U M8>"T4:81S%NTH!=:#S[1B'J$G[LH`7`>;6#>R#'P/EXX82$$7*![)`I\KY0( MJKIQ98Y(9\+&'+PEYP$ZPZ4AV"%)?6-XGD(_!!"BJ^L)_173U@\RDA_JF]\K M)P[1[L+B5"9(Z621/7;O7#5D*JU\<48WR-D#VERN#^2/[VY?Z9M3LAN0@E81 M)`M!["*"">Y*0=$,432GHYRE:_US?E&0B`?USKS_/&- MUSF*WUSBC5X/RE^#!-T68`0'RY(.OB2.E@^!'HG5O&#!?\O%4D% M^Q5J0*#&(/2PJ37_+::@DWTX^R;Z*J*@]J$`V\ZCN`YY\9W,0`Z!^VX1O9YX MP#_!LX!_.,X=$>\+\_COT*]^F:)/>_CSUX&S*(<+G"<0?#YJ_OVD=WHND(2/ MOX;6H1/\$SCQ5>A=HAFCD,9LJD9E_6:5RGU(G=\V9YE)8$9=`F((LI:XIQ_%B(+/1V='DQ0BYJ*7W&JT7_!LR1,$G[,# M/IR[A.#TX8`35RX@2'T\("60]`A6WQVP8M]2!*;O#S!Q1#B"TY\../&550+5 MGP]0,657@M(/!Y1D=9,-:$CB[!>T'T^VC5T]F+[_@)'O(]%@!.)\>3 M3>_:S]'S9#/6I!SLCY/*<*UUHF<'/F6XIO!XX3@ON6($@@26O]G6D(I?_S)U MW2@-$_C@K+%1=1X['B@.D2UE2:9'>ZVN$P=Q"KR'.'H&$&:KY1H`*&2"U\D( M'QNO_(/C>S?A11XVQV*`T=H(Y1""9-M`MO5'!;==_@?[#9^=8(L8"RY<.)XC6ZOS,?$X$*NKQ&NR'W,96"[F0E: MT9WG)^#6?P7HF$(RP$'MT:^0.X`:P$).IG@HPP%RV(8J$176QBF$"W;;-IK MH>]BLNG=ALB+X`"2[FZ8-_ZA3VDX#'KET1_"'5`AYRX*7546*'U,<)&]6BGD M5ND5).ADCH_\*-\@RR5_NZT)JA]*I59XZ=):FJ$X>@%QLGX(G%SE1P??"U9$ MV;&6L)EK)Z2K-(KTNP;/O^BQ.)#J:X(=G5A`<2%)=S?`D M*6<,1+)0EB6T20^,N)[M=QNT&)Y&&Q-&1+Y>C2V&`EW15M^T/##\0]E6W[0\ M/B)ET5:OM#Q"#/')5B>TZIG3U<4<)4ZP#T@P%+$J()*F+^*]LMX)6M9O2PFT1/9;@I9=H4?MT.(B=-8FSFBO#BJV MGP*#Q#`;$7SL-*](XT-UV1)TVAA7AK]Z5&S+3;6'(DR=V6EB:8N3O!!&$+33 M%J,F@%(]9[L+&=T'B)KA/`0?.X]R-7R8H9$$)CL-YFHPR7A+"6*VGN[=C`I5 MA-JO99\U$M!4,[.V"#596#1V97SLGHNJD=LLP;25GN8Y4CQZ)3N;YTOR`!9T&@H?W&.8TV$H](L/8U$O M+>?3(XBQ#3L*7Y$PB<_$^E>_@M43B&GGDUQ'HU&L5:EN^N:SWL6PVQNE'JE6 MX`;]*"2;-#S$#&OF*U=H$Y=O5`+=J.C,X$/72XD'\XO@AKBE]'UXLT1(%-V&EGJE,\A"U`4R@ M3RA\=`)$5,V>+8KKD^QLBB^(:4-"6WCUABMZI3YAGA!%]8^-TB,X%4M84)"O-+=G/O"AR] MK-9F*$>"#X!)3E,QR^R<8\SF9FA_1:1@"'-R2N*8M#.::SGWOP(/1V)?`GRG MS\`K"!LYY]CM3*"'9BW'`9]<#,CJ;8Q3.7UU_"![YQU5U.SB14!VF\OP(3&* MD4R+Z!IT\-U1["I1*FQV>Z/4"]<4K:69;(40()T4)]U!FQ$$429X\&]'?A\C ML3E(B(+%,9(I%NRSF]K4-,URY`Z$4E$`%Z.U"D_%(BFG.+4Z(3Y*_[<:;S&<@>#,^CTDA1W!NTPH`]?LA('6@) M3BII$+#)]&<_61*6KH&3I,QL/]J&W]GZN%J]!-$:`+Q=T=1DA\0U.OPRY?D^ M.V!@IW4A_X&=\8Q?Z#BA"^Z?*7-16#6[,:WP!0-4J2`.A#11CNNBLW7B7NE;^R,\VRSS:-SD#].0Q-2^JP[ M,2L:=J@G?+$PN4G"U,?1/)MLU#-OZ%T49ILJ"H),F40MS=IF!,.9-KD28[/=@%[!X$)\#+IY/8R\ALFF M&LL;48A6.C>U+[VMEK5=E0$V$UO900]IC!N@G3@#"YS"!Z=(RM_(TA9ZE^', M\<.\7CJ,9CSNNH?H<*G\L/D]324[I^9H'<9;B?\Y.M5,U?B M01>#(/)G;E=HX%+-:.QD;AE<4Y8XUE@%6G\YK%K#F/E& MPSVC5_F,YJV#YAQ>1W&IF!?U7OGK07Z$GJD6VIYDN_9)YTV(O7@Q!%]!O`"Q M*JW4[GW2JZ9^J0^R:]H?==#^:/B<8]T/Q!Y<\Q`\`AN`/?LC^UV@.D<_\S03TL ME>>#/HH9ZA^U4/^X`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`Q42!2&PZO`ZB;_`F]/P85#93403R.QQ;Q2L"B4>89$.HE7YDE1QR MW1CDGJV?0C_!%D[T,3B/@0/3>'WN!P&]=)),/^,%KV;`C4+7#T!-`IA'&,2' M.,+67>]\_1,$2$[=5`*>NHG_FLE/@ESRO7Q*5R&I2@EH'';@9W1>`WIQ,TYS M(W-8HP?K7I<^=/$SPX<8K/QTQ9H083_SW%S[H8/62;BXB&"C*IE4%_,\-&N* M2W#1Z-3#2D?3_(*43J0,P31(,N=T42%>M.B9/<=0V(U!-4U-KVF:I96.1K!\ M9R-%Z-"I/`T]_`]&[-4),M$LN4"`KM%.XZ6OD^MK)5>&RNS0:2L3U[A8Y@"7 M(/]7B3W&$*9XQ&+='9(BT(\W:)_`3$0(OE/!\Y(>T*%+?73='&N5^Z^P44-=OKH:@2E3%?QE&Z6!(79Z:- M4^D2]])$G=2I/Y3S_1(@+0Y=/ODS*>K.J#71@M$7QP^QT'\?7CM^GD)K\VYW M\(F8 M^G"9*^E8<>"PQ.]G@IOM"^PF1.HYEA=AD:AF'CL>ZV:4[#P8ON(470;%IF#G M09?J.@R>[I,EB(E)(%..T/5<(?0.)()KONNHPT"B4,+H2IMT-\WE?;-+5%`0 MA]-:,S7"-!!\\L3=^Z-7#D!:!RTTY3=1&:U./D0CA]G64+%EFA&1(KXS=HS" M`,/F3W`(MAAH0/P2U:SE?-(& _[>:3-]"`^*48^=7XI`TP;/[:S:<^;X@V M?DT4MT=#(F1<`#R(3;O8W@$WKS-R1SSMJI+IU@=]6*6#K">M$H3R^_=(*1RDV,2Y;=B`5(N(;"\CZ%>V[%80+PMN3@_3'%SZF;R# MHV,S+VIF5;W!J5-@%/@>#G5]3)^@[_E.S!8RNHRH:841`DK-"A+5:BOW$'VU M*8U@>M[P9?$5!S7CV+G0NXB"`+@9:1ATX9'68J0A<+QEYI4YZA1&,,$ANAN+ MP[CQU(S!$:^'F9)MS0`T@:S.[6*L[%R^M?&RX-L(&8U-QD/V&9=6>[-<\WQU M*GNS!U&FNT)5%/_4J5`..A^>H@/2TK%_G2KP'!:U..;3^F(]!A!FAR;:7N+' MS,FQ'6=K>U6@W2QIJ=<"[0H)[=/CS5TM:8DPE785B`Y@;ZULMG?8]GI%.X%7 M(93<]KI&.\%;@.Q!&>QR*K-,$;:73=K1RA6'0;Z$FIU0/2W$8?[M\DSNT\K=":ST-S^V9Z/<%;2-9T>V)Z-L'Y:_.5^E M0EIMKW#2#4>ID#;;RY_H7XKB6&#;RZ3TABDK(MSVBBD:`%4-D;2]NHH&2/EY M'MI56=DGR5//[<,-@6Q7?64\($ID0&E7;F5D$,H\4;"_*(M^<5+Y?8'MQ5PT M02SQ+*M=J9?Q+5>5)_#=:KU$B1/L):(2SZM9!X#PV8;M1:TU0:KPYJ]=76L+ M-G['92KUGLKVDM<]+5<&AB,3I!115$GFT:T6]M[>3(K>95:QCO>CLFVJQK[W MXH@F"W94-E!%[#M[H`C,H[*,JI\+TFEV"*)M#*/#/VEE'O2VPXZR*FVO$]<- M0ZZ\,)K:<-TPY%H#VI6"LQ=#M63HW0K`V7<22J;([U0B+B_VA2B+DQ&"-[HJ M<@K@=8M>[%2!;IBEL0B;2&G)"X46+W@1+%]!O``QJ2=Z$SY'\2K/;&$@`\EY M"OT00'@1K9[0A&66)T$6%6X7754#2G="7JKP)S0%\3:8\]@)H>,R,RNU&,7D MUI.9B>J#(F6$=I@[Z+M=>D'*;;211!+#P5,N.CE8';<-$Q\#U/I MOU:JVEZ]N4'JY;':^+58FA1/_J^<.$2'*.8FYR,+[V9L33UC&ZG%U8WR\S5] M@+PN91]8<;^XAPC>;I>-U0L7&7XXV-PY*W`9K1R?54U%V,U(3242JE2/]/P* M5D^-=+JRO4QPTCA^^'('L[D1VE,_5C\%;Y7X4TXUF"XODNQF(IVQ>9RN7""`,>R;!.MPK_"J&8, MJ1L?FL!TNMU.MY,3IQVF)1.E^GH4._=!:S-E$\3AN4BV\.[#,GN9!-ERX^@J M]8Y3E)/4V33BZDWZ^.X,!%ENZ:C@-W?>2E##Z'AP0/3"228VP\*S_A*%9%>I M396TA$VRI/OJH33&\2U="IVJFM1`Q2M@BVK;I+2=)5AM+%!UJ%]\^W_C.0 M.1"X[%%:=RH7YLY\L>7>N9$\M5)+\ MOVXABN2O:8%'4;IOPB0BAG*"@T%$GC9(H771!2=,. MR'RVZ!SROD21A]]PWT4A*`,^BE(.%1_:_R#I``O=54,N]5+IX0-Z9J@U/97Z M"\\`EX:C3JS&X0?"+UMFT#:VT9+152<@Q^/&;F^L6'1%*<^!K"H@V=7+2?_+ M8++CL,:P:%):M;;BFBD.7/*XEAM`SY[D?:^A5=Z'^,L!@!"_:Z(*D]T&W+-@ MZB[(ES[)$+#OYD8;G5]6FE;YF3-1JX09%U(/AFSX56W/.RX+C&R4J%+28=M@ M8H5G*V6_M044%37(]A2V$D@U#_MNF5/W"Y1;WH,2G6J?[:]*A*#28TIL?TDB M!XL^]=/VIR:MEADKA,CV)R:[6GP56P^!U,XL77*0BM48@I/](AIGZ753\0F( M]DMO;!`E/?0$+#OKJ\F!I?`$A0`V!1&`!NI MOB!\^T$0&K.2T/F%D.W%2N15AS;/Q6PO-R*I+B@^6+&]>HB:4"(9Z-*M0(@% MH$E$P=M>]4]-&U5X3]2NN)]MP+5^*F)[^;YN]C=QUHUVI?LLPD_I[4FWHGP6 MH"7W.H[`-&8%0>6Q'D',:EV`G9-)>)2-)?>M1/ZGK?BU[8=$)#++:AE?`:'M M1T0$(:N%506$.(_D"%A62UA28#&R:1"([+KO6)E5B+XCF>6!`&2G!DU/[T)/ MSDMY'FOKG<;)/X*Q:2XO6X%0>"1=-U(QW]6-*/NO%%0<`;.$:NRKBKH;2W#. M1@Z.0+7;97YGPQ4J66]X62CM_NPVD``[7SLX_!EG!`XY:27R]VDSO][]%$E_?--*3=HP\0>#DDVLTTO+MO'@+B3?,3<>\!2#H MT1]5@J4A[-,C9;Q%(^AA.,G1YCU,[4+`TN`B<4 MUB#MY5/[A=G6`;N9^I\!5IZ!-WT%L;.H/X+1CF8K(@:7&J=2SXV9B+7#0`/B M-PLYUL`N9QP3W,[]!%^[-Z&'HUY3)^!H4O2V@Z`:ARMDF@]&=.F_S".:_5[$ MCV`4HU4$:9HN/1V#SBO$=L.T'M6L#P# MLFP,E5_#S2HMNC"<,5U''1`2HM`]83>3IXPL3U4IJO.*L-VTI@)JNZ-D=V8O M`R=Y)>77YKW538B@2W-WW%#"D;GOH[<.`7I;(^')(/9?$6:O.&]3MARQFLGU MG'.[F.6!K(N9#WG%N+A=3/"P6>5DX8MN$FX7$SQ\==[\5;KBUF2JMS%"I1^* MJ:RU,2)=8)L09P&3OQNCCHM@M<6A,FMVK2,5?[Z,4NB$WE4`7D$HKLPJZJ*; MKKDB4 M=8?]',0KK?Q3AC=8CQ+7B,G3C-VG"4S06824-<:%P^TR@.0@F$Q=%';`VID[*NU&@I3VFQW`R:%6.H#$]:=N3O'##"SC8 MUG6_`@?W\J:5XF3A=(8SPN*W-'E!7J->\?/UG8,?C4CYPVN-S7KSA>E,J$V- M>N^G$(),7R^7AP]@N4!P==-B4>25Q./:&FE8`ECN?BW?V%>4>!Y,;1>=\ MO?GQ;SZ(T>F^7-\B/9V7G4.RLV&^BCG(K($Q^%<*0G@R%@S-E#LX&QL$'90X^#($#VO[D7MTR/8?"$6P>J;>U%N"?*Z&O3`D[``[_?,*R^-/V!;F\85?8HCIY" M<>(U;55V.C=[486V'"(4F$8D-''0UVDD$)&H^0T4`KMH$( M-W=#!;<]<*V5N84*(\V.:7M4>2_HG371LS-@O!?T/C31ZSLP?'@NAW M@9]]^_YYO@2%XK[NT6W.,-!-5U$:)FA@',S@/_O`PRDIMKWX\R@O9THSU2F. M8-9I?G#V[X,;^^#L/SC[#\[^@[/_X&@^.)H/CN;]3;IBX'S[9NYT)N_(+FYC:"\"9T@Q1)Y#?AE1.'J)GPI.S]^Q:@FZ6UWQ&2 MQ;?V"37(8"4;2S-J_&\=4&OQK5_.]BW4YA#(,C@[6.=`%LO-@[H#67H^?3H9 M'E_R2DB)$R>'V>E##CF$?PUK7GC2]R&,K$NHGJK=O9.K\R6"/K[!1@IXWT)F MM_?F^:5R%7KVS\XAJG(0$$O%_UDKT!N-73U$51ZB*@]1E7L)Y"&J\A!5.3AH M^XVJM#-?T*XBVRRL&W:+]N(BGZO>2H5-PS!U@@L'+L^C,(4/('8Q-POJ.U%V M8RW/5Z<):AF"-;P&Z.S"94:!=[Z^B-(XN0EOP<()'D&2!-D2HI*GTM^$K^(B M6JW\)"\5%'HX(2$Z"-`A@DY<,NN"@`ZU,4QP>?6&SC@LE-\_/_LNB+FN&49C M+>OI.L4J05&[%L[PIKE_WB"6X`I6/CH^\LU$64]*_4T@30Z(&<`F%9:_K]G. M"+41A+7UVC`?;9/-[C`(^GDA@8S&YNE>7SHK=&)GU=IX/F)1KP%P@F0IX+]* M3T*UO9;SY3Y9@O@221RAQR\'0V^HA889\%=/*9)CLL2*&P;Y][BXD^DBEMQ0 M,TI#T_16:RF>KZM_X=7-DA]`RUH1UGQGE7S?U''/ZPY<1_$S\/'=B'/D\Y=: M[]\T4M"K(U.5U/EY?4W&`M'_'2-HI4\P4Y:3JU<@B-2AMQT`U3AK.&9S9"=99HM>R^FRVRN'?`#$R;/$@ZF6TQ$8;K:]J`6$)GK;; MW<0*0PVEIC)D^YM;18#8TK/M\7-R0(D,8K;75U)`2+O7_K`XMCV_BA'+6TP.*#MU=SXZ//\2 M0<9.-53=K$ZJL82^R>P50MNNQ&CQ#Z6&$X+LO?Z-I3M+-[L+DK0%19M.&$_K^S3V&+3A3X7CYAH?=0(:.2>(UT)J;M.:+J/$#JJ(G*8U/7 MQ4^_T`W\@,C'=[`@OHK3P80[1/L0J1 M4(OEW-43^BO^XD"VOB1E]`TAV=G$D4`A372H<;N8W*HRO%0WJ^RUQ;*'OY7ML<;O[ZVA,V-!.647Q?LYF8[DQN!2?7&PL*=EL,&R)$HA6BSA:-A1L9:="1S M.APVCI:-(S,UH]HZ1`#%(3#$SUE8(B\BF,"&F[/M_:)I6\F2_%0E6;"&.PYJ M).5[QZGK"`1C5*,)^+2LC-HYT17C41TF+.?'0&PJ+/($1X.PVY#>[\@;B51& M&*)'C;=ME=`9U1:E9=HPNBFM*@M`!56>B6%LN-;)6.C<'[97B446:F-$$[5J MD_%3_>2Y?60WG])80^>ZD9RRGIM2)RC2G]K+@TQMA=G^4*M/&.67[.Y>>0W@ M&JF\NJR%8$Y#[TOJX+R_P+#8-HYL0(KS(&139I"]?NVK"IAAX?#'$\P!M@:A M__E_4$L#!!0````(`(TP!T5C9-#02A```-&M```1`!P`<'9C="TR,#$T,#8S M,"YXC&R(PD)^'^^FO)-I:Q;&Q( M=NP4+S.`NEO]ZVY+K9;DO/_Y<>E:]YAQXM&KQMG):Q8'K7^N![=6NF5_!\2G;YK`<6&-3D8G&JI_6F./KA!=6VW7M4:2BULCS#&[ MQ\Y)*)0KL!98D/*KAH;OX>+$8_,6=''6^N/C;6"4QK??6`'MY>.4N23!(7^) M>"Y:A'*!J(TU%I?0SSDL>7&6Y!+K%>9&-M5BYEO=VV+#([^H,)"DIV\O3C5""F[QEV;@CF`M MV4<+B)I`A1FQ==;=?"D>2>/$FNDV?M,*&C5J&R)2L'62G&/[9.[=M$&">HB MA=_V&8/'+(LU;#7;SL'$S`8-9@[\:"_,+++%S$/H/>;"S!6TF9%11&QN9E-- MDNLLQ<6);>:!A@P.L6(9+-"RS2,0FV-QAY:8KY"-=X0>C&I+3,6-QY9=/$.^ M"W;XXB.7S`AV&A82@I&I+W""P*+3DAT^C?EH[$0ZO+4G1ZGJV+_5#U.E10<2Z#S+94O74L(ASU]>_@&:%$Z7EV>F8UK8A=_PBBK$"6I0E[W]J6L"W\@<4N0QKAB,O%3LP1EKELT7_AJYX4#OC$%-%3Z#V0VA,(H3Y`X]KG3H MN(CS,(JDGT;`\%=!AGRWP:QH;03!Y\[@KMN[&_>Z\M-X<-OOMB?PY;I]V[[K M]*SQ+[W>9'STWI[>&R(8G\4""P)&*>U*Q;W#GZ_W\:?U*J'8=T?_YOFW#VGN M$IN]%[;E^^A-,1^-)_#?Q]X=^&=P8PV&O5%[T@<"Z]4GBGR'".P_WMVF_9WE[/!ET_OW+ MX+;;&XW_9?5^_=2?_'GT>U&_=Q!?W+C>`^]3AS!L"[-OTV3Y_OMAG^>VTQ[_ M8MW<#GX_NB_7?7>>P'SB;::_C:'Y@,T1)?]3*#JPPO9$F5HJ?<2PX&1'1Y=P=`\Q M2NB<#S%3LW4YWV9SY[KS[-3TQ-K*AUWBPB+?L6X]SBV0*TN"2_"ODG]T;1G7 MJHQKPA#ER)8J\9+.S>'/=^_9MGL#498NZ^C*$JZ,C0F)%Z3.D#1L&/MY`836H0K0=1ZF$W/1&\;[<^4Y.E<%R M:B30&G>A[RU;K[I8('+TK)CX)4 MI:Q@:>48$0=%1'HF+A0"1=ER?7Z>*J>9)O&C?P_QKRI7J&J%7JPHY.,RK/E^ M3M75LHHH1V,))?3%C$C;4/>[3-&Z%SM0Y<, ME+VZR(^C?+B!33WXS27A:8G) M`H=.63]G"#Y9M_EAF2HF%@O+I':24BQP%*SK8[0^7[3&Q=Y",^(N\OSH2!4F M8W''.0Y^EO_(NT;OFJL')68TE! M_'L+N6ZC55WD23<6``X,!N#=C9B:X';1%+L%(0.M`?*ME%`3M-N/>0'0P&(` MK1]'-&%_W]+O*L&WY%VF]P#=8\*BJ1M5.9<9K>"^Y*UG*T$Y+/);,^)KRI^: M9^?-B[.31^Z$*I;1(+9T.0TBOK(:Y%Z"S-)!]6^\==G"KN`;6O"<2$%(A[YX;#.MZXN M%^L]8E*?,OH/KS0K!:X:;=MF.%A1?Z+R)HO:X><3IM:IZVOBNN%*7>82?Q4C M#Y(B]6J#RZ5'8?G#UGV!EW+%T+#0%%;.2-[ZGR%7)3V*$)(AXCD3Q>KX+%R] M!6U3Y,KY_ZH!O<,:JV%1Z$@>!+AJP")OHNY!QV4&_ M/@_.($V\>.DV1,3ITTZP1WV-*63!Y`R>VN,]2VB&^8MU?;18*7V!_>Q:0FY+\:6?*_(W"FM9H&8#12Y$"9WZB*H8)X+R_MY--VVJ1,]ET;S'2ZT'E:8V`0\@_!@M$$%3#PK MV"4L2\)#F>JR57A"_P8GD.91U6)430``)ZW@&9;WP7U76CA,MC,19S/4!+Q/ MQ0C;FS?0R,QX>W=_X@5']9)&*,58C\>;4DBWY#LCKCWJRV.NMBR$SQ/>SZ8) M,%)_*167O^X)\"F0".$QBM<<'D/>?D#,P<[UNN/Y3/3I+8Q,[A@+$;#HX$JQ MU2'`39E?8NT23XD9479754.>3U>+YU2`$ MDRV([I)[XF#JF)$:R.J!-#A^+]/S(#7_1!W,MJ]2Z">K=?Q[,.M6X?(D/O]Z M@YNFOZPYFA[78'HR8][%4X?<;`N.=E0J2JWE`20Y?`]H5%[(MD9!]IH89E/D MFRR`9[Z(RRL*<-(,.XEK,ARH[!/6EZE1?;NE%C-64NF@`,XG7AB*;*5<]8.I6%Y04#`NHJ,,862DV?>A:`=_7\]@'L+6\ M@3R@G04"5?LTG21OREP:WI)\M<@N8TQE;?"2L(_P/2`)J[[1,BD?_BZ6>EB` MR1O_S+,Q=K@Z-X%7A+H)O* M80^24J7\=2\@VQO1APBIQ1.T55/0=M&-5D@3U>O)V'F(Q8BZ`%?-G*TARO6W MD:X66(-9+MK$CY%H,+-)ZA#4'\%4-G*[6'H%9G-,$R.7N;D6KKO#0I^:Y4X/ MWQR*#/X8@@:T$'4='+H%I&@J4XZMOH9(5M3*V"*'LR;F>/#8YP'%\9OMY.5K M(J_C]:F=6K$79:C2$OX.C!^6?M)XTFV54MV7.JG#=)OJE??[PEO&I?]H[I0[ MNSJPLIQZN!(J\!RS_3:YGA!VD/NKE`$$QO,ICR?4U*;('KP'+BV>`WG>Z<(< MFBHMDC+5[/JR.#]4_1:!E:2O$L3P%L5&T^"8IZ'HOXNP2F..45?S=L!NTNH# M,VP4["*L%"CY![ODP27JR(51O'!,T'"5 M80K!5N&`HJZV]BY1PSPUF/60O<@'7DI"M:P`@@>S6S+#.5-Y/ID^$43:?45( MB85`=*Q.[OQ@XWG:@O2'.>TI,Y.DPH$3])G95*X9LRB7TG<4T"(JX:&!8A;>KH M-W(3%BC'6(>"PS"\FQA>B-)*2?I%6MT(!1D2`Z5Z+KY>G,?70^SP80QNS6'' M<.*T3T7613K-#$\GLA;/S`B3Y12&-?4;8,?D7DHTSJ0%:*LSBXY!+N9M^>RJ M3YW(9ZG$?2=EE5+X0$64=<['W%P]`)F'+#,0[:2O(,1\'VTW5PK`YN_;)5[5 M+O6=*[KK=>I/X*G+7)OU_`K;0EWGGF$BSV=E9N?/WU6%5F,QD@^>Y\B\0JN* M1T5B[<3AKS+9)&*=V,*5,!.+MR>56J4L]G!@J87NTXFLE*&26V)9RQ?=#D4Y M:@5S>U57E*$6F5K&RA2>W>BF!@R/L@^C%4HPUMP:6:\C*2040XH> M_'VK@C8P<]79#H7.!>[!^])L,C[`)N,78)-@FDL/A;LMDLU9N2DS1WG#N<'B M++4!NC6^%06;8JL-8.,05A1V!G.MP8\/`3^N$7B]4*T=DC.=;CE03FU,,O&B M2!,_D].#9;`K.9NS;P4S$ZH/)%+"[F7/OS/[L-L5M. M#4RB17#!%"_-4>?$SAS-A4V1PUQGJV3L:&XBO:!]"HJIFZ4@N6W;7WS"2="I MR0S;-/7&:*X+YE%6:>B;/'B3A>=S1)V>*R_'9&[Q[:2LTNZ+INRD&"8#654! M+0@3N""J#-HJ00MU,YZ@3CU<18BK]'SEZ;L]4Q2@K<50F;E5D%-9+L%3)QN8 M7CWP#"]9^!O>V;:M=1>ZOPTP8W+Y.;R;YXL!$A.N;F<8XY# M!5=HKWI?:"/"/]\PO'E]V!-9S"SV!=AK:^!4I^^&S)N&8I[(?(5Z>0G6Q&2^ M@`>K?8\9FN,)9LNGL)Y)JC[P??U3\2$TTY6H=%,%,Z@B59MZ%692K^/91%;\ M]WP-X/+)*SC;OF\%?R@,/OX?4$L!`AX#%`````@`C3`'1=`!_*3;?@``6)H% M`!$`&````````0```*2!`````'!V8W0M,C`Q-#`V,S`N>&UL550%``,I3^-3 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`C3`'1205EEJ+#0``;JD``!4` M&````````0```*2!)G\``'!V8W0M,C`Q-#`V,S!?8V%L+GAM;%54!0`#*4_C M4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`(TP!T6*];5"Q1H``'&Q`0`5 M`!@```````$```"D@0"-``!P=F-T+3(P,30P-C,P7V1E9BYX;6Q55`4``RE/ MXU-U>`L``00E#@``!#D!``!02P$"'@,4````"`"-,`=%PY_6F:A7``"@OP0` M%0`8```````!````I($4J```<'9C="TR,#$T,#8S,%]L86(N>&UL550%``,I M3^-3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`C3`'18(IR[S:)P``NM<" M`!4`&````````0```*2!"P`!`'!V8W0M,C`Q-#`V,S!?<')E+GAM;%54!0`# M*4_C4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`(TP!T5C9-#02A```-&M M```1`!@```````$```"D@30H`0!P=F-T+3(P,30P-C,P+GAS9%54!0`#*4_C F4W5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``#).`$````` ` end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Litigation - Additional Information (Detail) (USD $)
0 Months Ended 0 Months Ended 0 Months Ended

Jun. 06, 2014

Apr. 30, 2013

Jun. 06, 2014

Executive Officer [Member]

Jun. 06, 2014

Other Defendants [Member]

Jul. 24, 2014

Subsequent Event [Member]

Loss Contingencies [Line Items]

Reserve for litigation $ 100,000

Damages sought to be receivable 2,240,000 25,000

Estimated bonus percentage 70.00%

Future payment ratio of contingent consideration 2

Repayment under contingency 1,120,000

Reimbursement cost percentage 25.00%

Number of shares acquired under litigation 1,000,000

Stock option issued to employees 100,000

Share-based compensation forfeiture rate 50.00%

Attorney's fees and reimbursement of expenses $ 911,000

X

- Definition

Annual cash bonus percentage.

+ References

No definition available.

+ Details

Name: pvct_AnnualCashBonusPercentage

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Attorneys Fees Awarded By Court In Legal Settlement

+ References

No definition available.

+ Details

Name: pvct_AttorneysFeesAwardedByCourtInLegalSettlement

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Future payments ratio of contingent consideration.

+ References

No definition available.

+ Details

Name: pvct_FuturePaymentsRatioOfContingentConsideration

Namespace Prefix: pvct_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition

Reimbursement receivable percentage.

+ References

No definition available.

+ Details

Name: pvct_ReimbursementReceivablePercentage

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Share based compensation arrangement by share based payment award options expected forfeiture rate percentage.

+ References

No definition available.

+ Details

Name: pvct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRatePercentage

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LitigationReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of damages paid to the plaintiff in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

+ Details

Name: us-gaap_LossContingencyDamagesPaidValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248

+ Details

Name: us-gaap_LossContingencyReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares held for each class of treasury stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

+ Details

Name: us-gaap_TreasuryStockNumberOfSharesHeld

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Basic and Diluted Loss Per Common Share
6 Months Ended

Jun. 30, 2014

Earnings Per Share [Abstract]

Basic and Diluted Loss Per Common Share

3. Basic and Diluted Loss Per Common Share

Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation at June 30, 2014 and 2013, respectively, relate to 58,311,418 and 50,358,525 from warrants, 13,718,334 and 15,097,206 from options, and 0 and 4,881,666 from convertible preferred shares.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\W-F8Y,3=E.5]D,S4W7S0V.#%?.6)C-%]E,SEA M,6%E,3,P86,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E137T]&7U-4 M3SPO>#I.86UE/@T*("`@(#QX.E=O#I7;W)KF%T:6]N7V%N9%]-97)G97(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E M;%=O#I7 M;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D5Q=6ET>5]4#I7;W)K#I%>&-E;%=O#I%>&-E M;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D5Q=6ET>5]4#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E;&%T961?4&%R='E? M5')A;G-A8W1I;VY?061D:3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?;V9?1FEN86YC:6%L7TEN#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/DQI=&EG M871I;VY?061D:71I;VYA;%]);F9O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I!8W1I=F53:&5E M=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF M72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U M;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T M7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!);F9O M'0^)U$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^)RTM,3(M,S$\2!&:6QE3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)T%C8V5L97)A=&5D($9I;&5R/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-F8Y,3=E.5]D,S4W M7S0V.#%?.6)C-%]E,SEA,6%E,3,P86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-S9F.3$W93E?9#,U-U\T-C@Q7SEB8S1?93,Y83%A93$S,&%C M+U=O'0O M:'1M;#L@8VAA'0^)SQS M<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO3PO'0^)SQS<&%N/CPO2P@;&EQ=6ED871I;VX@<')E9F5R96YC92`D,"XW M-2`H9F]R(#(P,3,@:6X@86=G7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\W-F8Y,3=E.5]D,S4W7S0V.#%?.6)C-%]E M,SEA,6%E,3,P86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S9F M.3$W93E?9#,U-U\T-C@Q7SEB8S1?93,Y83%A93$S,&%C+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO65E'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!0:&%R;6%C975T:6-A M;',L('-H87)E'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!O9B!W87)R86YT'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E(&-O;7!E;G-A=&EO;B!F'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO6%B;&4L('-H87)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES M92!O9B!W87)R86YT'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`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`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!O9B!W87)R86YT'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M)SQS<&%N/CPO&5D(&%S'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!F:6YA;F-I;F<@86-T:79I=&EE'0^)SQS M<&%N/CPO2!T;R!E<75I M='D@9'5E('1O(&5X97)C:7-E(&]F('=A'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQD:78^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CXQ M+CPO8CX@/&(^0F%S:7,@;V8@4')E3I4:6UE2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E2!F;W(@82!F86ER('!R97-E;G1A=&EO;@T* M(&AA=F4@8F5E;B!I;F-L=61E9"X@3W!E$$P.S,P+"`R,#$T(&%R92!N M;W0@;F5C97-S87)I;'D@:6YD:6-A=&EV92!O9B!T:&4@65A$$P.S,Q+"`R,#$T+B!4:&4-"B!#;VUP86YY(&AA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78^#0H@/'`@2!K;F]W;B!A#(P,4,[4')O=F5C='5S(%!H87)M M86-E=71I8V%L#(P,4,[4U!- M($=R;W5P+"!);F,N+"8C>#(P,40[('=A28C M>$$P.S$L(#$Y.3(L('=I=&@@=&AE(&YE=R!C;W)P;W)A=&4@<'5R<&]S92!O M9@T*('-E96MI;F<@;W5T(&%C<75I#(P M,4,[4')O=F5C='5S(%!H87)M86-E=71I8V%L+"!);F,N)B-X,C`Q1#L@86YD M(')E:6YC;W)P;W)A=&5D(&EN#0H@3F5V861A(&EN('!R97!A2UH96QD(%1E;FYE#(P,40[*2X@3VX@07!R:6PF(WA!,#LR M,RP@,C`P,BP@86X@06=R965M96YT(&%N9"!0;&%N#0H@;V8@4F5O2!T:&4@=W)I='1E;B!C;VYS96YT(&]F(&$@ M;6%J;W)I='D@;V8@=&AE(&]U='-T86YD:6YG#0H@&-H86YG92!F;W(@86QL(&]F('1H M92!I2UO=VYE9"!S=6)S:61I87)Y(&]F(%!R;W9E8W1UF4Z,3!P=#L@9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!/;B!.;W9E;6)E$$P.S$Y M+"`R,#`R+"!T:&4@0V]M<&%N>2!A8W%U:7)E9"!686QL97D-"B!0:&%R;6%C M975T:6-A;',L($EN8RXL(&$@<')I=F%T96QY+6AE;&0@5&5N;F5S#(P,4,[6&%N=&5C M:`T*(%!H87)M86-E=71I8V%L#(P,40[(%!H;W1O9V5N+"!) M;F,N('=A3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\W-F8Y,3=E.5]D,S4W7S0V.#%?.6)C-%]E,SEA,6%E M,3,P86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S9F.3$W93E? M9#,U-U\T-C@Q7SEB8S1?93,Y83%A93$S,&%C+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6QE/3-$)VUA3I4 M:6UE6QE M/3-$)VUA2!A7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA2!4 M6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0G/@T*("AA*2!$=7)I;F<@=&AE M('1H$$P.S,Q+"`R,#$T+"!T:&4@ M0V]M<&%N>0T*(&ES&-H86YG92!F;W(-"B!S97)V:6-E$$P.S,Q+"`R,#$S+"!T:&4@0V]M<&%N>0T*(&ES&-H M86YG92!F;W(-"B!S97)V:6-E$$P.S,P+"`R M,#$T+"!T:&4@0V]M<&%N>0T*(&ES&-H86YG92!F;W(-"B!S M97)V:6-E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q M,G!T)SX-"B`H8BD@1'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@36%R M8V@F(WA!,#LS,2P@,C`Q-"P@=&AE($-O;7!A;GD-"B!I2!V97-T960@=V%R$$P.S,Q+"`R,#$T+`T*(#$R+#4R,BPQ M.3@@=V%R&5R8VES960@;VX@82!C87-H;&5S$$P.S,Q+"`R,#$S+"!T:&4@0V]M<&%N>2!I M2!V97-T960@=V%R$$P.S,P+"`R,#$T+"`S,34L M,#`P('=A&5R8VES960@;VX@82!C87-H;&5S$$P.S,P+"`R,#$S+"`Q M+#`U,2PU,#`@=V%R6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M)SX-"B!!2!D971E2!R96QA=&5D#0H@:6YS=')U;65N=',@ M870@82!L;W=E2!W87,@9&5T97)M:6YE9"!B87-E9"!O;B!T M:&4@36]N=&4M0V%R;&\@4VEM=6QA=&EO;B!M;V1E;`T*(&%T('1H92!D871E M('1H92!W87)R86YT$$P M.S,Q+"`R,#$T(&%N9"`R,#$S+"!T:&5R92!W87,@82!L;W-S(')E8V]G;FEZ M960@9G)O;2!T:&4-"B!R979A;'5A=&EO;B!O9B!T:&4@=V%R$$P M.S,Q+"`R,#$T+`T*(#@U."PX,C4@;V8@=&AE(%-E&5R8VES960N($9O2!R96QA=&5D(&EN M2!W97)E(&5X M97)C:7-E9"X@1F]R('1H90T*('1HF5D(&9R;VT@=&AE(')E=F%L=6%T:6]N(&]F('1H92!W87)R86YT(&QI M86)I;&ET>2!O9@T*("0S+#(X-2PW.3,@86YD("0S.3DL,#4W+"!R97-P96-T M:79E;'DN($1U$$P.S,P+"`R,#$T+"`Q,S,L,C,R(&]F('1H92!W87)R86YT2!W97)E(&5X97)C:7-E9"X@ M5&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&4@9F%I<@T*('9A;'5E(&]F('1H M92!W87)R86YT&5R8VES960@;VX@=&AE(&1A=&4@;V8@97AE6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q,G!T)SX-"B`H92D@26X@1F5B2!R96QA=&5D#0H@:6YS=')U;65N=',@870@ M82!L;W=E2!R96QA=&5D('1O('1H92!P2X@5&AE('!R;V-E M961S#0H@2!IF5D(&9R;VT@=&AE(')E=F%L=6%T:6]N M(&]F('1H92!W87)R86YT(&QI86)I;&ET>2!O9@T*("0Y,C$L-S&5R M8VES960N(%1H92!#;VUP86YY(&1E=&5R;6EN960@=&AE(&9A:7(@=F%L=64@ M;V8@=&AE('=A&5R8VES960@:6X@,C`Q-"!O9B`D-"PP-#2!T:&4@;6%R:V5T('!R:6-E(&]F('1H90T* M('-T;V-K(&]N('1H92!D:79I9&5N9"!P87EM96YT(&1A=&4N(%1H92!D:79I M9&5N9',@=V5R92!P87EA8FQE#0H@<75A2!A9G1E2!H860@82!D969I8VET(&%N9"P@87,@80T*(')E M$$P.S,P+"`R,#$S+"!T:&4@0V]M<&%N>2!R96-O9VYI>F5D M(&1I=FED96YD0T*(')E8V]G;FEZ960@;F\@9&EV:61E;F1S(&)E8V%U28C>$$P.S$U+"`R,#$T+CPO<#X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/ M4#H@,3)P="<^#0H@*&8I($EN($IA;G5A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q M,G!T)SX-"B`H9RD@1'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@2G5N M928C>$$P.S,P+"`R,#$T('1H92!#;VUP86YY#0H@8V]M<&QE=&5D(&$@<')I M=F%T92!O9F9E65A2!U2!.971W;W)K(#$@1FEN86YC M:6%L(%-E8W5R:71I97,L($EN8RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-F8Y,3=E.5]D,S4W7S0V M.#%?.6)C-%]E,SEA,6%E,3,P86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-S9F.3$W93E?9#,U-U\T-C@Q7SEB8S1?93,Y83%A93$S,&%C+U=O M'0O:'1M M;#L@8VAA6QE/3-$)VUA3I4:6UEF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX- M"B!/;F4@96UP;&]Y964@;V8@=&AE($-O;7!A;GD@97AE2!E>&5R8VES960-"B`S,#`L M,#`P(&]P=&EO;G,@870@86X@97AE$$P.S,Q+`T*(#(P,30N M($%N;W1H97(@96UP;&]Y964@;V8@=&AE($-O;7!A;GD@97AE65E(&]F#0H@=&AE($-O;7!A;GD@9F]R9F5I=&5D(#,P M,"PP,#`@28C>$$P.S(V+`T*(#(P M,30N/"]P/@T*(#QP('-T>6QE/3-$)VUA3I4:6UE M2!E M>&5R8VES960@,C4L,#`P(&]P=&EO;G,@870@86X@97AE$$P M.S,P+"`R,#$T+B!!;F]T:&5R(&5M<&QO>65E(&]F('1H90T*($-O;7!A;GD@ M97AE&5R8VES92!P$$P.S,P+"`R,#$T+B!!(&9O2!F;W)F96ET960@,C4L,#`P#0H@3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-F8Y,3=E.5]D,S4W7S0V.#%? M.6)C-%]E,SEA,6%E,3,P86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO-S9F.3$W93E?9#,U-U\T-C@Q7SEB8S1?93,Y83%A93$S,&%C+U=O'0O:'1M;#L@ M8VAAF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)SX-"B`\8CXV+CPO8CX@/&(^4F5L871E9"!087)T>2!4F4Z,3!P=#L@9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@0V]M<&%N>2!P86ED(&]N92!O9B!T M:&4@0V]M<&%N>28C>#(P,3D['0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#(P,3D[2!E2!A;F0@2!M87)K970@9&%T82X\+W`^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!);B!D971E2!P97)F;W)M M6%B;&4L(&%P<')O>&EM871E0T*(&ES M(&$@9&5R:79A=&EV92!I;G-T65A$$P.S,P+"`R,#$T(&9O&5R M8VES92!P2!O9B`Q.#65A$$P.S,P+"`R,#$T(&9O$$P.S,Q+"`R,#$T(&9O<@T*('1H92`R,#$S('=A6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4 M+4E.1$5.5#H@-"4G/@T*(%1H92!W87)R86YT(&QI86)I;&ET>2!M96%S=7)E M9"!A="!F86ER('9A;'5E(&]N(&$@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E M;G1E$$P.S$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1E6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE2!A="!*=6YE)B-X03`[,S`L(#(P,30\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#,P,BPY-C$\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M(%=A$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($ES$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XH,2PR,C$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q M,"PS,S4L-C$Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#,P M,BPY-C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-F8Y,3=E.5]D,S4W M7S0V.#%?.6)C-%]E,SEA,6%E,3,P86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-S9F.3$W93E?9#,U-U\T-C@Q7SEB8S1?93,Y83%A93$S,&%C M+U=O'0O M:'1M;#L@8VAA6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T M)SX-"B`\8CXX+B!,:71I9V%T:6]N/"]B/CPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T)SX-"B`\:3Y+ M;&5B82!3:&%R96AO;&1E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`V<'0G/@T*($]N($IA;G5A#(P,4,[4&QA:6YT:69F)B-X,C`Q1#LI#0H@9&5R:79A=&EV M96QY(&]N(&)E:&%L9B!O9B!T:&4@0V]M<&%N>2P@9FEL960@82!S:&%R96AO M;&1E<@T*(&1E#(P,4,[26YD:79I9'5A;"!$969E;F1A;G1S)B-X,C`Q1#LI+"!A M;F0-"B!A9V%I;G-T('1H92!#;VUP86YY(&%S(&$@;F]M:6YA;"!D969E;F1A M;G0@*'1H92`F(W@R,#%#.U-H87)E:&]L9&5R#0H@1&5R:79A=&EV92!,87=S M=6ET)B-X,C`Q1#LI+B!4:&4@4VAA$$P.W=AF5D(&%N9"]O M28C>#(P,3D[#(P,4,[4&QA;B8C>#(P,40[*2!B>2!I2X\+W`^#0H@/'`@#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`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`T*(&]F(')E8V]V97)Y(&9R M;VT@86YY(&]T:&5R('-O=7)C92P@:6YC=7)R960@8GD@=&AE($-O;7!A;GD@ M87,@80T*(')E2!A(&9I28C>#(P,3D[0T*('5N9&5R('1H92!3971T;&5M96YT.R`H:6DI)B-X03`[1')S+B!$ M965S(&%N9"!38V]T="!A;F0-"B!-6UE;G0@86=R965M96YT2!T:&4@0V]M M<&%N>2`D,C4L,#`P(&EN(&-A28C>#(P,3D[7,@=&\@=&AE($-O;7!A;GD@;VX@8F5H86QF M(&]F('-U8V@@9&5F96YD86YT('!U#(P,3D[(&9E97,@86YD#0H@#(P,3D[(&9E M97,@86YD(')E:6UB=7)S96UE;G0@;V8@97AP96YS97,@:6X@8V]N;F5C=&EO M;@T*('=I=&@@=&AE:7(@2!&87)R86@@86YD($IA;65S($@N($AA#(P,4,[1F%R0T*('-I='5A=&5D("AT:&4@)B-X M,C`Q0SM#:&%N97D@0V%S928C>#(P,40[*2P@86YD($IA>7-O;B!$875P:&EN M964L#0H@:6YD:79I9'5A;&QY(&%N9"!O;B!B96AA;&8@;V8@86QL(&]T:&5R M#(P,4,[1&%U<&AI;F5E M($-A#(P,4,[1&5F M96YD86YT#(P,40[*2!A;&QE9VEN9PT*('9I;VQA=&EO;G,@8GD@=&AE M($1E9F5N9&%N=',@;V8@4V5C=&EO;G,@,3`H8BD@86YD(#(P*&$I(&]F('1H M90T*($5X8VAA;F=E($%C="!A;F0@4G5L92`Q,&(M-2!P2P@:6X@8V]N;F5C=&EO;B!W:71H M('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@87!P;&EC871I;VX@=&\@=&AE($9$ M02!F;W(@0G)E86MT:')O=6=H(%1H97)A<'D@1&5S:6=N871I;VX-"B`H)B-X M,C`Q0SM"5$0F(W@R,#%$.RD@:6X@=&AE(%-P2!I;G1E;F1S('1O(&1E9F5N9"!V:6=O6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q,G!T)SX-"B!/;B!*=6QY)B-X03`[.2P@,C`Q-"P@=&AE M(%!L86EN=&EF9G,@86YD('1H92!$969E;F1A;G1S(&9I;&5D(&IO:6YT#0H@ M;6]T:6]N2!O#(P,40[*2!A;F0-"B!T#(P,4,[4&QA:6YT:69F M)B-X,C`Q1#LI#0H@9&5R:79A=&EV96QY(&]N(&)E:&%L9B!O9B!T:&4@0V]M M<&%N>2P@9FEL960@82!S:&%R96AO;&1E<@T*(&1E6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX- M"B!/;B!*=6QY)B-X03`[,C4L(#(P,30L('1H92!C;W5R="!P0T*(&%G2!A;&P@86-T:79I='D@:6X@=&AE($AU3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W M-F8Y,3=E.5]D,S4W7S0V.#%?.6)C-%]E,SEA,6%E,3,P86,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S9F.3$W93E?9#,U-U\T-C@Q7SEB8S1? M93,Y83%A93$S,&%C+U=O'0O:'1M;#L@8VAA2!4'0@0FQO8VL@6T%B'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q,G!T)SX-"B`H8RD@5&AE($-O;7!A;GD@9&5T97)M:6YE9"!T M:&%T('=A&5R8VES92!P M2!IF5D(&9R;VT@=&AE#0H@2X@1'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@ M36%R8V@F(WA!,#LS,2P@,C`Q-"P-"B`X-3@L.#(U(&]F('1H92!397)I97,@ M02!787)R86YT$$P.S,Q+"`R,#$T+"`V.3F5D(&9R;VT@=&AE M(')E=F%L=6%T:6]N(&]F('1H90T*('=A&5R8VES92!A;F0@861J=7-T960@=&AE(')E;&%T960-"B!W87)R M86YT(&QI86)I;&ET>2!A8V-O2X@5&AE(&%D:G5S=&5D(&9A:7(@ M=F%L=64@;V8@=&AE#0H@4V5R:65S($$@86YD(%-E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`Q,G!T)SX-"B`H9"D@26X@36%R8V@@86YD($%P2!D971E M&5R8VES92!P2!IF5D(&9R;VT@=&AE(')E=F%L=6%T:6]N M(&]F('1H90T*('=A$$P.S,P+"`R,#$T(&%N9"`R,#$S+"!T:&5R92!W87,@82!G M86EN#0H@&5R8VES960N(%1H92!#;VUP86YY(&1E=&5R;6EN960@=&AE(&9A:7(-"B!V M86QU92!O9B!T:&4@=V%R&5R8VES960@:6X@,C`Q-"!O9B`D,BPS M-S2!D971E&5R8VES92!P2!I2!T:&%N(&1E8G0N#0H@07,@82!R M97-U;'0L('1H92!C;VYV97)S:6]N(&]P=&EO;B!W87,@9&5T97)M:6YE9"!T M;R!B92!C;&5A2`R,#$S(&ES$$P.S,Q M+"`R,#$S(&%N9"!I2!W87,@9&5T97)M:6YE9"!B87-E9"!O;B!T:&4@36]N=&4M0V%R;&\- M"B!3:6UU;&%T:6]N(&UO9&5L(&%T('1H92!D871E('1H92!W87)R86YT$$P.S,Q+"`R,#$T(&%N9"`R M,#$S+"!T:&5R92!W87,@82!L;W-S#0H@2X@1'5R:6YG('1H92!T M:')E92!M;VYT:',@96YD960-"B!-87)C:"8C>$$P.S,Q+"`R,#$T+"`Q+#8U M,"PP,#`@;V8@=&AE('=AF5D(&9R;VT@=&AE#0H@2X@1'5R:6YG('1H92!T:')E92!M;VYT M:',@96YD960@2G5N928C>$$P.S,P+"`R,#$T+`T*(#(P,"PP,#`@;V8@=&AE M('=A2!W M97)E#0H@97AE2!D971E&5R8VES92!A;F0@861J=7-T960@=&AE(')E;&%T960@=V%R M2!A8V-O2X@5&AE(&%D:G5S=&5D(&9A M:7(@=F%L=64@;V8@=&AE('=A#L@34%21TE.+51/4#H@,3)P M>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*($1I=FED96YD2!O;B!T M:&4@,35T:"!D87D@869T97(@=&AE('%U87)T97(M96YD+B!4:&4@0V]M<&%N M>2!P86ED#0H@=&AE(&1I=FED96YD2!T:&4-"B!I;FET:6%L(&1I=FED96YD MF5D(&YO(&1I=FED96YD28C>$$P M.S$U+`T*(#(P,30L('1H97)E('=E0T*(&-O;7!L M971E9"!A('!R:79A=&4@;V9F97)I;F<@;V8@8V]M;6]N('-T;V-K(&%N9"!W M87)R86YT0T*(&%C8V5P=&5D M('-U8G-C65A2!V M97-T960@=V%R2!T:&4-"B!I;G9E&5R M8VES92!P65A2!V97-T960@=V%R&5R8VES92!P7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQD:78^#0H@/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG M;CTS1&-E;G1E$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG M;CTS1&-E;G1E$$P.S(\+V(^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`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`R+#DV,3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,BPX M-C8L-32!,:6%B:6QI M='D@365A'0^)SQD:78^#0H@/'`@ M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO M<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($ES$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XH,2PR,C$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q,"PS,S4L-C$Y/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#,P,BPY-C$\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\W-F8Y,3=E.5]D,S4W7S0V.#%?.6)C-%]E M,SEA,6%E,3,P86,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S9F M.3$W93E?9#,U-U\T-C@Q7SEB8S1?93,Y83%A93$S,&%C+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO&-L=61E9"!F'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`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`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES M92!P'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)S4@>65A M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES97,@;V8@=V%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M&5R M8VES92!P'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!V97-T960@=V%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M7,\'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M&EM=6T@6TUE;6)E'0^)SQS<&%N/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`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htm IDEA: XBRL DOCUMENT v2.4.0.8

Recapitalization and Merger
6 Months Ended

Jun. 30, 2014

Business Combinations [Abstract]

Recapitalization and Merger

2. Recapitalization and Merger

Provectus Biopharmaceuticals, Inc., formerly known as “Provectus Pharmaceuticals, Inc.,” “Provectus Pharmaceutical, Inc.” and “SPM Group, Inc.,” was incorporated under Colorado law on May 1, 1978. SPM Group ceased operations in 1991, and became a development-stage company effective January 1, 1992, with the new corporate purpose of seeking out acquisitions of properties, businesses, or merger candidates, without limitation as to the nature of the business operations or geographic location of the acquisition candidate.

On April 1, 2002, SPM Group changed its name to “Provectus Pharmaceutical, Inc.” and reincorporated in Nevada in preparation for a transaction with Provectus Pharmaceuticals, Inc., a privately-held Tennessee corporation (“PPI”). On April 23, 2002, an Agreement and Plan of Reorganization between Provectus Pharmaceutical and PPI was approved by the written consent of a majority of the outstanding shares of Provectus Pharmaceutical. As a result, Provectus Pharmaceuticals, Inc. issued 6,680,000 shares of common stock in exchange for all of the issued and outstanding shares of PPI. As part of the acquisition, Provectus Pharmaceutical changed its name to “Provectus Pharmaceuticals, Inc.” and PPI became a wholly-owned subsidiary of Provectus. This transaction was recorded as a recapitalization of PPI.

On November 19, 2002, the Company acquired Valley Pharmaceuticals, Inc., a privately-held Tennessee corporation formerly known as Photogen, Inc., by merging PPI with and into Valley and naming the surviving corporation “Xantech Pharmaceuticals, Inc.” Photogen, Inc. was separated from Photogen Technologies, Inc. in a non-pro-rata split-off to some of its shareholders. The assets of Photogen, Inc. consisted primarily of the equipment and intangibles related to its therapeutic activity and were recorded at their fair value. The majority shareholders of Valley were also the majority shareholders of Provectus. Valley had no revenues prior to the transaction with the Company. By acquiring Valley, the Company acquired its intellectual property, including issued U.S. patents and patentable inventions.

On December 16, 2013, Provectus Pharmaceuticals, Inc. was reincorporated in Delaware and changed its name to Provectus Biopharmaceuticals, Inc.

X

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)

Jun. 30, 2014

Dec. 31, 2013

Current Assets

Cash and cash equivalents $ 18,126,036 $ 15,696,243

Total Current Assets 18,126,036 15,696,243

Equipment and furnishings, less accumulated depreciation of $432,763 and $429,331, respectively 26,681 30,113

Patents, net of amortization of $7,796,177 and $7,460,617, respectively 3,919,268 4,254,828

Other assets 27,000 27,000

Total Assets 22,098,985 20,008,184

Current Liabilities

Accounts payable - trade 479,857 348,869

Accrued consulting expense 104,042 61,282

Other accrued expenses 232,568 102,795

Total Current Liabilities 816,467 512,946

Long-Term Liability

Warrant liability 1,302,961 12,866,572

Total Liabilities 2,119,428 13,379,518

Stockholders' Equity

Preferred stock; par value $.001 per share; 25,000,000 shares authorized; Series A 8% convertible preferred stock, 0 and 33,334 shares issued and outstanding, respectively, liquidation preference $0.75 (for 2013 in aggregate $25,001) 33

Common stock; par value $.001 per share; 300,000,000 authorized; 176,638,439 and 159,751,724 shares issued and outstanding, respectively 176,638 159,752

Paid-in capital 173,164,422 152,519,701

Deficit accumulated during the development stage (153,361,503) (146,050,820)

Total Stockholders' Equity 19,979,557 6,628,666

Total Liabilities and Stockholders' Equity $ 22,098,985 $ 20,008,184

X

- Definition

Warrant liability.

+ References

No definition available.

+ Details

Name: pvct_WarrantLiability

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableTradeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited) (USD $)
6 Months Ended 149 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Cash Flows From Operating Activities

Net loss $ (7,310,683) $ (6,547,555) $ (153,361,503)

Adjustments to reconcile net loss to net cash used in operating activities

Depreciation 3,432 3,100 455,764

Amortization of patents 335,560 335,560 7,796,177

Amortization of original issue discount 3,845,721

Amortization of commitment fee 310,866

Amortization of prepaid consultant expense 1,295,226

Amortization of deferred loan costs 2,261,584

Accretion of United States Treasury Bills (373,295)

Loss on extinguishment of debt 825,867

Loss on exercise of warrants 236,146

Beneficial conversion of convertible interest 55,976

Convertible interest 389,950

Compensation through issuance of stock options 14,540,039

Compensation through issuance of stock 932,000

Issuance of stock for services 277,750 98,250 9,857,261

Issuance of warrants for services 1,350,319 1,341,295 9,333,712

Issuance of warrants for contractual obligations 985,010

Gain on sale of equipment (55,075)

Loss (gain) on change in fair value of warrant liability (1,227,992) 14,304 7,530,937

Change in assets and liabilities

Prepaid expenses and other current assets (93,034)

Accounts payable 130,988 (178,673) 476,212

Accrued expenses 172,533 81,437 486,240

Net cash used in operating activities (6,268,093) (4,945,316) (92,175,185)

Cash Flows From Investing Activities

Proceeds from sale of fixed assets 180,075

Capital expenditures (96,570)

Proceeds from sales of investments 37,010,481

Purchases of investments (36,637,186)

Net cash provided by investing activities 456,800

Cash Flows From Financing Activities

Net proceeds from loans from stockholder 174,000

Proceeds from convertible debt 6,706,795

Net proceeds from sales of preferred stock and warrants 2,550,000 11,458,131

Net proceeds from sales of common stock and warrants 4,350,000 5,817,698 65,583,856

Proceeds from exercises of warrants and stock options 4,347,886 21,000 28,859,292

Cash paid for preferred dividends (29,063) (29,063)

Cash paid to retire convertible debt (2,385,959)

Cash paid for deferred loan costs (747,612)

Premium paid on extinguishments of debt (170,519)

Net proceeds from sale of non-controlling interest in Pure-ific Corporation 443,500

Purchase and retirement of common stock (48,000)

Net cash provided by financing activities 8,697,886 8,359,635 109,844,421

Net change in cash and cash equivalents 2,429,793 3,414,319 18,126,036

Cash and cash equivalents, at beginning of period 15,696,243 1,221,701

Cash and cash equivalents, at end of period 18,126,036 4,636,020 18,126,036

Supplemental Disclosure of Noncash Investing and Financing Activities

Reclassification of warrant liability to equity due to exercise of warrants $ 10,355,619

X

- Definition

Accretion of united states treasury bills.

+ References

No definition available.

+ Details

Name: pvct_AccretionOfUnitedStatesTreasuryBills

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amortization of commitment fee.

+ References

No definition available.

+ Details

Name: pvct_AmortizationOfCommitmentFee

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amortization of prepaid consultant expense.

+ References

No definition available.

+ Details

Name: pvct_AmortizationOfPrepaidConsultantExpense

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount reclassified from warrant liability to equity.

+ References

No definition available.

+ Details

Name: pvct_AmountReclassifiedFromWarrantLiabilityToEquity

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Beneficial conversion of convertible interest.

+ References

No definition available.

+ Details

Name: pvct_BeneficialConversionOfConvertibleInterest

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Cash paid for deferred loan costs.

+ References

No definition available.

+ Details

Name: pvct_CashPaidForDeferredLoanCosts

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Cash paid for preferred dividend.

+ References

No definition available.

+ Details

Name: pvct_CashPaidForPreferredDividend

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Compensation through issuance of stock.

+ References

No definition available.

+ Details

Name: pvct_CompensationThroughIssuanceOfStock

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Convertible interest.

+ References

No definition available.

+ Details

Name: pvct_ConvertibleInterest

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Gain loss on fair value of warrant liability.

+ References

No definition available.

+ Details

Name: pvct_GainLossOnFairValueOfWarrantLiability

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance of stock for services.

+ References

No definition available.

+ Details

Name: pvct_IssuanceOfStockForServices

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Issuance of warrants for contractual obligations.

+ References

No definition available.

+ Details

Name: pvct_IssuanceOfWarrantsForContractualObligations

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance of warrants for services.

+ References

No definition available.

+ Details

Name: pvct_IssuanceOfWarrantsForServices

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Loss on exercise of warrants.

+ References

No definition available.

+ Details

Name: pvct_LossOnExerciseOfWarrants

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net proceeds from loans from stockholder.

+ References

No definition available.

+ Details

Name: pvct_NetProceedsFromLoansFromStockholder

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net proceeds from sales of common stock and warrants.

+ References

No definition available.

+ Details

Name: pvct_NetProceedsFromSalesOfCommonStockAndWarrants

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net proceeds from sales of preferred stock and warrants.

+ References

No definition available.

+ Details

Name: pvct_NetProceedsFromSalesOfPreferredStockAndWarrants

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Premium paid on extinguishments of debt.

+ References

No definition available.

+ Details

Name: pvct_PremiumPaidOnExtinguishmentsOfDebt

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Proceeds from exercises of warrants and stock options.

+ References

No definition available.

+ Details

Name: pvct_ProceedsFromExercisesOfWarrantsAndStockOptions

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire common stock during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the purchase of all investments (debt, security, other) during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 21 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)
3 Months Ended 6 Months Ended

Mar. 31, 2014

Jun. 30, 2014

2010 Warrants [Member]

Class of Stock [Line Items]

Weighted average term 10 months 24 days 8 months 12 days

Warrant exercise price probability 5.00% 5.00%

Percentage of volatility 187.70%

Risk free interest rate 0.13% 0.09%

2010 Warrants [Member] | Minimum [Member]

Class of Stock [Line Items]

Percentage of volatility 66.50%

2010 Warrants [Member] | Maximum [Member]

Class of Stock [Line Items]

Percentage of volatility 129.70%

2011 Warrants [Member]

Class of Stock [Line Items]

Weighted average term 1 year 9 months 18 days 1 year 6 months

Warrant exercise price probability 5.00% 5.00%

Percentage of volatility 101.80% 132.70%

Risk free interest rate 0.29% 0.29%

2013 Warrants [Member]

Class of Stock [Line Items]

Weighted average term 3 years 10 months 24 days

Warrant exercise price probability 5.00%

Percentage of volatility 84.70%

Warrant Liability 0

2013 Warrants [Member] | Minimum [Member]

Class of Stock [Line Items]

Risk free interest rate 0.77%

2013 Warrants [Member] | Maximum [Member]

Class of Stock [Line Items]

Risk free interest rate 1.32%

X

- Definition

Warrants liability fair value.

+ References

No definition available.

+ Details

Name: pvct_WarrantLiabilityDerivativeInstrumentFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrants liability fair value.

+ References

No definition available.

+ Details

Name: pvct_WarrantLiabilityDerivativeInstrumentFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant liability derivative instrument fair value assumptions warrant exercise price probability rate.

+ References

No definition available.

+ Details

Name: pvct_WarrantLiabilityDerivativeInstrumentFairValueAssumptionsWarrantExercisePriceProbabilityRate

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant liability derivative instrument fair value assumptions weighted average term.

+ References

No definition available.

+ Details

Name: pvct_WarrantLiabilityDerivativeInstrumentFairValueAssumptionsWeightedAverageTerm

Namespace Prefix: pvct_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 22 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) (USD $)
6 Months Ended

Jun. 30, 2014

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Reclassification to APIC due to warrant exercises $ 10,355,619

Recurring [Member] | Level 3 [Member] | Warrants [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Beginning Balance 12,866,572

Issuance of warrants

Change in fair value of warrants included in earnings (1,227,992)

Reclassification to APIC due to warrant exercises (10,335,619)

Ending Balance $ 1,302,961

X

- Definition

Amount reclassified from warrant liability to equity.

+ References

No definition available.

+ Details

Name: pvct_AmountReclassifiedFromWarrantLiabilityToEquity

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 23 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 24 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Basis of Presentation
6 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

Basis of Presentation

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ended December 31, 2014. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Accumulated depreciation on equipment and furnishings $ 432,763 $ 429,331

Amortization on patents 7,796,177 7,460,617

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 25,000,000 25,000,000

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 300,000,000 300,000,000

Common stock, shares issued 176,638,439 159,751,724

Common stock, shares outstanding 176,638,439 159,751,724

Series A 8% Convertible Preferred Stock [Member]

Preferred stock, shares issued 0 33,334

Preferred stock, shares outstanding 0 33,334

Preferred stock, liquidation preference per share $ 0.75 $ 0.75

Aggregate liquidation preference $ 25,001 $ 25,001

Convertible preferred stock 8.00% 8.00%

X

- Definition

Aggregate liquidation preference.

+ References

No definition available.

+ Details

Name: pvct_AggregateLiquidationPreference

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The percentage rate used to calculate dividend payments on preferred stock.

+ References

No definition available.

+ Details

Name: pvct_PreferredStockDividendsRatePercentage

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_PreferredStockLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 26 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Recapitalization and Merger - Additional Information (Detail)
0 Months Ended

Apr. 23, 2002

Business Combinations [Abstract]

Common stock shares issued 6,680,000

X

- Definition

Common stock issued under recapitalization transactions.

+ References

No definition available.

+ Details

Name: pvct_CommonStockIssuedUnderRecapitalizationTransactions

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
6 Months Ended

Jun. 30, 2014

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q2

Entity Registrant Name PROVECTUS BIOPHARMACEUTICALS, INC.

Entity Central Index Key 0000315545

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 176,638,439

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: pvct_DocumentAndEntityInformationAbstract

Namespace Prefix: pvct_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Basic and Diluted Loss Per Common Share - Additional Information (Detail)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Warrants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Common shares excluded from the calculation 58,311,418 50,358,525

Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Common shares excluded from the calculation 13,718,334 15,097,206

8% Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Common shares excluded from the calculation 0 4,881,666

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)
3 Months Ended 6 Months Ended 149 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Revenues

OTC product revenue $ 25,648

Medical device revenue 14,109

Total revenues 39,757

Cost of sales 15,216

Gross profit 24,541

Operating expenses

Research and development 1,025,535 778,349 2,183,418 1,518,865 48,877,826

General and administrative 2,966,569 2,340,706 6,022,513 4,679,109 80,969,666

Amortization 167,780 167,780 335,560 335,560 7,796,177

Total operating loss (4,159,884) (3,286,835) (8,541,491) (6,533,534) (137,619,128)

Gain on sale of fixed assets 55,075

Loss on extinguishment of debt (825,867)

Investment income 1,443 256 2,816 283 657,358

(Loss) gain on change in fair value of warrant liability 3,515,025 909,206 1,227,992 (14,304) (7,530,937)

Net interest expense (8,098,004)

Net loss (643,416) (2,377,373) (7,310,683) (6,547,555) (153,361,503)

Dividends on preferred stock (73,024) (1,149,958) (12,026,710)

Net loss applicable to common shareholders $ (643,416) $ (2,450,397) $ (7,310,683) $ (7,697,513) $ (165,388,213)

Basic and diluted loss per common share $ 0.00 $ (0.02) $ (0.04) $ (0.06)

Weighted average number of common shares outstanding - basic and diluted 175,554,000 127,114,868 172,225,322 123,926,235

X

- Definition

Gain loss on change in fair value of warrant liability.

+ References

No definition available.

+ Details

Name: pvct_GainLossOnChangeInFairValueOfWarrantLiability

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Medical device revenue.

+ References

No definition available.

+ Details

Name: pvct_MedicalDeviceRevenue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a),(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

+ Details

Name: us-gaap_DividendsPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of operating interest income (expense).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.10)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 10

-Article 9

+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SalesRevenueNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 30 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transaction
6 Months Ended

Jun. 30, 2014

Related Party Transactions [Abstract]

Related Party Transaction

6. Related Party Transaction

The Company paid one of the Company’s directors $6,000 as of March 31, 2014, all of which was paid as part of his overall compensation of an aggregate of $85,000 for board and committee service.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation
6 Months Ended

Jun. 30, 2014

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

5. Stock-Based Compensation

One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750, 14,248 options at an exercise price of $0.75 per share of common stock for $10,686 and 600,000 options at an exercise price of $0.93 per share of common stock for $558,000 during the three months ended March 31, 2014. Another employee of the Company exercised 300,000 options at an exercise price of $1.10 per share of common stock for $330,000 during the three months ended March 31, 2014. Another employee of the Company exercised 189,624 options at an exercise price of $1.10 per share of common stock for $208,586 during the three months ended March 31, 2014. One employee of the Company forfeited 300,000 stock options on February 26, 2014.

One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. Another employee of the Company exercised 100,000 options at an exercise price of $1.25 per share of common stock for $125,000 during the three months ended June 30, 2014. A former non-employee member of the board exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. One employee of the Company forfeited 25,000 stock options on May 27, 2014.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments - Warrant Liability Measured at Fair Value on a Recurring Basis (Detail) (Recurring [Member], Warrants [Member], USD $)

Jun. 30, 2014

Dec. 31, 2013

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Warrant liability $ 1,302,961 $ 12,866,572

Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Warrant liability

Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Warrant liability

Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Warrant liability $ 1,302,961 $ 12,866,572

X

- Definition

Warrants liability fair value.

+ References

No definition available.

+ Details

Name: pvct_WarrantsLiabilityFairValueDisclosure

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Equity Transactions - Additional Information (Detail) (USD $)
0 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 149 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended

Jan. 15, 2014

Jan. 31, 2014

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2013

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Network 1 Financial Securities [Member]

Mar. 31, 2014

Series A Warrants [Member]

Mar. 31, 2014

Series C Warrants [Member]

Jun. 30, 2014

Series A and Series C Warrants [Member]

Jun. 30, 2014

Five Year Warrant [Member]

Jun. 30, 2014

Common Stock [Member]

Mar. 31, 2014

Common Stock [Member]

Jun. 30, 2013

Common Stock [Member]

Mar. 31, 2013

Common Stock [Member]

Apr. 30, 2010

8% Convertible Preferred Stock [Member]

Mar. 31, 2010

8% Convertible Preferred Stock [Member]

Jun. 30, 2014

Warrants [Member]

Mar. 31, 2014

Warrants [Member]

Jun. 30, 2013

Warrants [Member]

Mar. 31, 2013

Warrants [Member]

Feb. 28, 2014

Series A 8% Convertible Preferred Stock [Member]

Jun. 30, 2014

Series A 8% Convertible Preferred Stock [Member]

Mar. 31, 2014

Series A 8% Convertible Preferred Stock [Member]

Mar. 31, 2013

Series A 8% Convertible Preferred Stock [Member]

Jun. 30, 2014

Series A 8% Convertible Preferred Stock [Member]

Jun. 30, 2013

Series A 8% Convertible Preferred Stock [Member]

Jun. 30, 2014

Warrant A [Member]

Mar. 31, 2014

Warrant A [Member]

Jun. 30, 2013

Warrant A [Member]

Mar. 31, 2013

Warrant A [Member]

Class of Stock [Line Items]

Issuance of common stock to consultants 75,000 75,000 75,000 75,000

Consulting costs charges $ 140,250 $ 137,500 $ 49,500 $ 48,750

Issuance of warrants to consultants 202,000 733,000 2,605,000 1,924,973

Consulting costs charges related to warrants 450,002 900,317 931,655 409,640

Warrants forfeited 315,000 121,500 1,051,500 859,833

Warrants exercised on cashless basis 1,594,082 12,522,198

Shares issued in cashless exercise 915,467 9,100,824

Warrants exercised 372,000 3,036,218

Exercise price of warrants 372,000 2,672,364

Common stock to be issued on exercise of warrant 372,000 3,036,218 372,000 300,000

Gain (loss) on revaluation of warrants liability 186,262 (1,153,835) 221,149 (311,062) 3,285,793 (211,422) 399,057 (446,698) 42,970 (921,776) 289,000 (165,750)

Warrants series exercised 858,825 697,092

Adjusted fair value of warrants exercised 3,911,370 2,377,133 4,047,116

Convertible preferred stock 8.00% 8.00% 8.00% 8.00%

Issued warrants 133,232 1,756,665 200,000 1,650,000

Fair value of the warrants 1,297,950 1,297,950

Beneficial conversion amount 1,025,950 1,025,950

Dividends on preferred stock 73,024 1,149,958 12,026,710 29,063 0 50,860

Converted preferred stock 0 33,334

Preferred stock converted into shares 33,334

Gross proceeds from private offering of common stock and warrants to accredited investors 5,000,000

Company accepted subscriptions in aggregate 2,000,000

Expiration of warrants 5 years

Number of shares issuable on exercises of warrants issued 2,000,000

Investors received five year warrants 100.00%

Exercise price of common stock $ 3.00 $ 3.00 $ 2.50

Purchase price of common stock with warrants $ 2.50

Payment of fully vested warrants $ 650,000

Percentage of total number of shares of common stock sold to investors 15.00%

X

- Definition

Aggregate exercise price of warrants exercised.

+ References

No definition available.

+ Details

Name: pvct_AggregateExercisePriceOfWarrantsExercised

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Common stock unit beneficial conversion amount.

+ References

No definition available.

+ Details

Name: pvct_CommonStockUnitBeneficialConversionAmount

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Common stock unit fair value of warrants recorded on issuance.

+ References

No definition available.

+ Details

Name: pvct_CommonStockUnitFairValueOfWarrantsRecordedOnIssuance

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Consulting costs.

+ References

No definition available.

+ Details

Name: pvct_ConsultingCosts

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Consulting costs relates to warrant issued.

+ References

No definition available.

+ Details

Name: pvct_ConsultingCostsRelatesToWarrantIssued

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Convertible preferred stock shares to be converted to common stock shares.

+ References

No definition available.

+ Details

Name: pvct_ConvertiblePreferredStockSharesToBeConvertedToCommonStockShares

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gain loss on revaluation of warrants liability.

+ References

No definition available.

+ Details

Name: pvct_GainLossOnRevaluationOfWarrantsLiability

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Gross proceeds from sales of common stock and warrants.

+ References

No definition available.

+ Details

Name: pvct_GrossProceedsFromSalesOfCommonStockAndWarrants

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of shares issuable on exercises of warrants issued.

+ References

No definition available.

+ Details

Name: pvct_NumberOfSharesIssuableOnExercisesOfWarrantsIssued

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of warrants exercised.

+ References

No definition available.

+ Details

Name: pvct_NumberOfWarrantsExercised

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants exercised during period.

+ References

No definition available.

+ Details

Name: pvct_NumberOfWarrantsExercisedDuringPeriod

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of aggregate shares called by warrant.

+ References

No definition available.

+ Details

Name: pvct_PercentageOfAggregateSharesCalledByWarrant

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of common shares issuable on exercise of each warrant.

+ References

No definition available.

+ Details

Name: pvct_PercentageOfCommonSharesIssuableOnExerciseOfEachWarrant

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Period of life of warrants issued.

+ References

No definition available.

+ Details

Name: pvct_PeriodOfLifeOfWarrantsIssued

Namespace Prefix: pvct_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Purchase price of common stock with warrants.

+ References

No definition available.

+ Details

Name: pvct_PurchasePriceOfCommonStockWithWarrants

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Reclassification of adjusted fair value of warrants into additional paid in capital.

+ References

No definition available.

+ Details

Name: pvct_ReclassificationOfAdjustedFairValueOfWarrantsIntoAdditionalPaidInCapital

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Share based goods and nonemployee services transaction quantity of warrants forfeited.

+ References

No definition available.

+ Details

Name: pvct_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share based goods and nonemployee services transaction quantity of warrants issued.

+ References

No definition available.

+ Details

Name: pvct_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares warrants exercised on cashless basis.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesWarrantsExercisedOnCashlessBasis

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrants exercised on a cashless basis.

+ References

No definition available.

+ Details

Name: pvct_WarrantsExercisedOnCashlessBasis

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares issued for each share of convertible preferred stock that is converted.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

+ Details

Name: us-gaap_DividendsPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The percentage rate used to calculate dividend payments on preferred stock.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares or units of entity securities issued in the transaction in which equity securities were issued to pay for goods or nonemployee services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of preferred stock and warrants for common stock issued.

+ References

No definition available.

+ Details

Name: us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued as consideration for cash for development stage entities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 215

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForCash

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 34 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Equity Transactions (Policies)
6 Months Ended

Jun. 30, 2014

Text Block [Abstract]

Derivatives Policies

(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $1,153,835 and $311,062, respectively. During the three months ended March 31, 2014, 858,825 of the Series A Warrants were exercised. During the three months ended March 31, 2014, 697,092 of the Series C Warrants were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $186,262 and $221,149, respectively. The Company determined the fair value of the Series A and Series C Warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the Series A and Series C Warrants exercised in 2014 of $3,911,370 was reclassified into additional paid-in capital.

(d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $211,422 and $446,698, respectively. During the three months ended March 31, 2014, 1,756,665 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $3,285,793 and $399,057, respectively. During the three months ended June 30, 2014, 133,232 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $2,377,133 was reclassified into additional paid-in capital.

(e) In February 2013, the Company had an issuance of Series A 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $921,776 and $165,750, respectively. During the three months ended March 31, 2014, 1,650,000 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $42,970 and $289,000, respectively. During the three months ended June 30, 2014, 200,000 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $4,047,116 was reclassified into additional paid-in capital.

Dividends on the Series A 8% Convertible Preferred Stock accrued at an annual rate of 8% of the original issue price and were payable in either cash or common stock. If the dividend was paid in common stock, the number of shares of common stock equaled the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends were payable quarterly on the 15th day after the quarter-end. The Company paid the dividends in common stock although was required to pay the initial dividends due in cash. The Company had a deficit and, as a result, the dividends were recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In 2014, the Company recognized no dividends because of the full conversion of preferred stock to common stock as of January 15, 2014.

(f) In January 2014 there were 33,334 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 33,334 shares of the Company’s common stock. As of January 15, 2014, there were no shares of Series A 8% Convertible Preferred Stock outstanding.

(g) During the three months ended June 30, 2014 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,000,000. The Company accepted subscriptions, in the aggregate, for 2,000,000 shares of common stock and five year warrants to purchase 2,000,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $3.00 per share. The purchase price for each share of common stock together with the warrants was $2.50. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $650,000 and issued five year fully vested warrants to purchase 300,000 shares of common stock with an exercise price of $2.50 to Network 1 Financial Securities, Inc., which represents 15% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

X

- Definition

Disclosure of accounting policy for its derivative instruments and hedging activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41620-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579245-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579240-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41638-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph n

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41675-113959

+ Details

Name: us-gaap_DerivativesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments
6 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

7. Fair Value of Financial Instruments

The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are measured and reported on a fair value basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. The fair value of certain of the Company’s financial instruments, including Cash and cash equivalents and Accounts payable, approximates the carrying value due to the relatively short maturity of such instruments. The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. The warrant liability is a derivative instrument and is classified as Level 3. The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used at March 31, 2014 for the 2010 warrants include a weighted average term of 0.9 years, a 5% probability that the warrant exercise price would be reset, volatility range of 66.5% to 129.7% and a risk free interest rate of 0.13%. Significant assumptions used at June 30, 2014 for the 2010 warrants include a weighted average term of 0.7 years, a 5% probability that the warrant exercise price would be reset, volatility of 187.7% and a risk free interest rate of 0.09%. Significant assumptions used at March 31, 2014 for the 2011 warrants include a weighted average term of 1.8 years, a 5% probability that the warrant exercise price would be reset, volatility of 101.8% and a risk free interest rate of 0.29%. Significant assumptions used at June 30, 2014 for the 2011 warrants include a weighted average term of 1.5 years, a 5% probability that the warrant exercise price would be reset, volatility of 132.7% and a risk free interest rate of 0.29%. Significant assumptions used at March 31, 2014 for the 2013 warrants include a weighted average term of 3.9 years, a 5% probability that the warrant exercise price would be reset, volatility of 84.7% and a risk free interest rate range of 0.77% to 1.32%. At June 30, 2014 there are no remaining 2013 warrants and therefore no associated warrant liability.

The warrant liability measured at fair value on a recurring basis is as follows:

 Total Level 1 Level 2 Level 3

Derivative instruments:


Warrant liability at June 30, 2014
 $ 1,302,961 $ — $ — $ 1,302,961

Warrant liability at December 31, 2013
 $ 12,866,572 $ — $ — $ 12,866,572

A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2014 to June 30, 2014 follows:

Balance at January 1, 2014
 $ 12,866,572

Issuance of warrants
 —

Change in fair value of warrants included in earnings
 (1,227,992 )

Reclassification to APIC due to warrant exercises
 (10,335,619 )



Balance at June 30, 2014
 $ 1,302,961



X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Litigation
6 Months Ended

Jun. 30, 2014

Commitments And Contingencies Disclosure [Abstract]

Litigation

8. Litigation

Kleba Shareholder Derivative Lawsuit

On January 2, 2013, Glenn Kleba (the “Plaintiff”) derivatively on behalf of the Company, filed a shareholder derivative complaint in the Circuit Court for the State of Tennessee, Knox County (the “Court”), against H. Craig Dees, Timothy C. Scott, Eric A. Wachter, and Peter R. Culpepper (collectively, the “Executives”), Stuart Fuchs, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, together with the Executives, the “Individual Defendants”), and against the Company as a nominal defendant (the “Shareholder Derivative Lawsuit”). The Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties, (ii) waste of corporate assets, and (iii) unjust enrichment, all three claims based on the Plaintiff’s allegations that the defendants authorized and/or accepted stock option awards in violation of the terms of the Company’s 2002 Stock Plan (the “Plan”) by issuing stock options in excess of the amounts authorized under the Plan and delegated to defendant H. Craig Dees the sole authority to grant himself and the other Executives cash bonuses that the Plaintiff alleges to be excessive.

In April 2013, the Company’s Board of Directors appointed a special litigation committee to investigate the allegations of the Shareholder Derivative Complaint and make a determination as to how the matter should be resolved. The special litigation committee conducted its investigation, and proceedings in the case were stayed pending the conclusion of the committee’s investigation. The Company has established a reserve of $100,000 for potential liabilities because such is the amount of the self-insured retention of its insurance policy.

On March 6, 2014, the Company filed a Joint Notice of Settlement (the “Notice of Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company, the parties to the Notice of Settlement are the Plaintiff and the Individual Defendants.

On June 6, 2014, the Company, in its capacity as a nominal defendant, entered into a Stipulated Settlement Agreement and Mutual Release (the “Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company and the Individual Defendants, plaintiffs Glenn Kleba and Don B. Dale are parties to the Settlement.

By entering into the Settlement, the settling parties have resolved the derivative claims to their mutual satisfaction. The Individual Defendants have not admitted the validity of any claims or allegations and the settling plaintiffs have not admitted that any claims or allegations lack merit or foundation. Under the terms of the Settlement, (i) the Executives each agreed (A) to re-pay to the Company $2.24 Million of the cash bonuses they each received in 2010 and 2011, which amount equals 70% of such bonuses or an estimate of the after-tax net proceeds to each Executive; provided, however, that subject to certain terms and conditions set forth in the Settlement, the Executives are entitled to a 2:1 credit such that total actual repayment may be $1.12 Million each; (B) to reimburse the Company for 25% of the actual costs, net of recovery from any other source, incurred by the Company as a result of the Shareholder Derivative Lawsuit; and (C) to grant to the Company a first priority security interest in 1,000,000 shares of the Company’s common stock owned by each such Executive to serve as collateral for the amounts due to the Company under the Settlement; (ii) Drs. Dees and Scott and Mr. Culpepper agreed to retain incentive stock options for 100,000 shares but shall forfeit 50% of the nonqualified stock options granted to each such Executive in both 2010 and 2011. The Settlement also requires that each of the Executives enter into new employment agreements with the Company, which were entered into on April 28, 2014, and that the Company adhere to certain corporate governance principles and processes in the future. Under the Settlement, Messrs. Fuchs and Smith and Dr. McMasters have each agreed to pay the Company $25,000 in cash, subject to reduction by such amount that the Company’s insurance carrier pays to the Company on behalf of such defendant pursuant to such defendant’s directors and officers liability insurance policy. The Settlement also provides for an award to plaintiffs’ counsel of attorneys’ fees and reimbursement of expenses in connection with their role in this litigation, subject to Court approval.

On July 24, 2014, the Court approved the terms of the proposed Settlement and awarded $911,000 to plaintiffs’ counsel for attorneys’ fees and reimbursement of expenses in connection with their role in the Shareholder Derivative Lawsuit.

Class Action Lawsuits

On May 27, 2014, Cary Farrah and James H. Harrison, Jr., individually and on behalf of all others similarly situated (the “Farrah Case”), and on May 29, 2014, each of Paul Jason Chaney, individually and on behalf of all others similarly situated (the “Chaney Case”), and Jayson Dauphinee, individually and on behalf of all others similarly situated (the “Dauphinee Case”) (the plaintiffs in the Farrah Case, the Chaney Case and the Dauphinee Case collectively referred to as the “Plaintiffs”), each filed a class action lawsuit in the United States District Court for the Middle District of Tennessee against the Company, H. Craig Dees, Timothy C. Scott and Peter R. Culpepper (the “Defendants”) alleging violations by the Defendants of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. Specifically, the Plaintiffs in each of the Farrah Case, the Chaney Case and the Dauphinee Case allege that the Defendants are liable for making false statements and failing to disclose adverse facts known to them about the Company, in connection with the Company’s application to the FDA for Breakthrough Therapy Designation (“BTD”) in the Spring of 2014 and the FDA’s subsequent denial of the Company’s application for BTD. The Company intends to defend vigorously against all claims in these complaints. However, in view of the inherent uncertainties of litigation and the early stage of this litigation, the outcome of these cases cannot be predicted at this time. Likewise, the amount of any potential loss cannot be reasonably estimated.

On July 9, 2014, the Plaintiffs and the Defendants filed joint motions in the Farrah Case, the Chaney Case and the Dauphinee Case to consolidate the cases and transfer them to United States District Court for the Eastern District of Tennessee. By order dated July 16, 2014, the United States District Court for the Middle District of Tennessee entered an order consolidating the Farrah Case, the Chaney Case and the Dauphinee Case (collectively and, as consolidated, the “Securities Litigation”) and transferred the Securities Litigation to the United States District Court for the Eastern District of Tennessee.

Hurtado Shareholder Derivative Lawsuit

On June 4, 2014, Karla Hurtado (the “Plaintiff”) derivatively on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the Middle District of Tennessee (the “Court”), against H. Craig Dees, Timothy C. Scott, Jan E. Koe, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, the “Individual Defendants”), and against the Company as a nominal defendant (the “Hurtado Shareholder Derivative Lawsuit”). The Hurtado Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties and (ii) abuse of control, both claims based on the Plaintiff’s allegations that the Individual Defendants recklessly permitted the Company to disclose false and misleading information and failed to implement adequate controls and procedures to ensure the accuracy of the Company’s disclosures.

On July 25, 2014, the court presiding over the Hurtado Shareholder Derivative Lawsuit entered an order transferring the case to the United District Court for the Eastern District of Tennessee. It is anticipated that an order will be entered by agreement that will stay all activity in the Hurtado Shareholder Derivative Lawsuit pending the resolution of an anticipated motion to dismiss the anticipated consolidated amended complaint in the Securities Litigation.

As a nominal defendant, no relief is sought against the Company itself in the Hurtado Shareholder Derivative Lawsuit.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments, contingencies, and guarantees.

+ References

No definition available.

+ Details

Name: us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments (Tables)
6 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Warrant Liability Measured at Fair Value on a Recurring Basis

The warrant liability measured at fair value on a recurring basis is as follows:

 Total Level 1 Level 2 Level 3

Derivative instruments:


Warrant liability at June 30, 2014
 $ 1,302,961 $ — $ — $ 1,302,961

Warrant liability at December 31, 2013
 $ 12,866,572 $ — $ — $ 12,866,572

Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis

A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2014 to June 30, 2014 follows:

Balance at January 1, 2014
 $ 12,866,572

Issuance of warrants
 —

Change in fair value of warrants included in earnings
 (1,227,992 )

Reclassification to APIC due to warrant exercises
 (10,335,619 )



Balance at June 30, 2014
 $ 1,302,961



X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transaction - Additional Information (Detail) (USD $)
1 Months Ended 6 Months Ended

Mar. 31, 2014

Jun. 30, 2014

Directors

Related Party Transactions [Abstract]

Payment for board and committee service $ 6,000 $ 85,000

Number of directors to whom board and committee service paid 1

X

- Definition

Number of non employee to whom consulting services paid.

+ References

No definition available.

+ Details

Name: pvct_NumberOfNonEmployeeToWhomConsultingServicesPaid

Namespace Prefix: pvct_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition

Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) (USD $)

Total

Preferred Stock [Member]

Common Stock [Member]

Paid in Capital [Member]

Accumulated Deficit [Member]

Beginning Balance at Jan. 17, 2002

Issuance to founding shareholders $ 6,000 $ (6,000)

Issuance to founding shareholders, shares 6,000,000

Sale of stock 25,000 50 24,950

Sale of stock, shares 50,000

Issuance of stock to employees 932,000 510 931,490

Issuance of stock to employees, shares 510,000

Issuance of stock for services 360,000 120 359,880

Issuance of stock for services, shares 120,000

Net loss (1,316,198) (1,316,198)

Ending Balance at Apr. 23, 2002 802 6,680 1,310,320 (1,316,198)

Ending Balance, shares at Apr. 23, 2002 6,680,000

Shares issued in reverse merger (3,645) 266 (3,911)

Shares issued in reverse merger, shares 265,763

Purchase and retirement of stock (48,000) (400) (47,600)

Purchase and retirement of stock, shares (400,000)

Stock issued for acquisition of Valley Pharmaceuticals 12,226,320 500 12,225,820

Stock issued for acquisition of Valley Pharmaceuticals, shares 500,007

Exercise of warrants 453 453

Issuance of stock for services 5,144,000 1,900 5,142,100

Exercise of warrants, shares 452,919

Warrants issued in connection with convertible debt 126,587 126,587

Issuance of stock for services, shares 1,900,000

Stock and warrants issued for acquisition of Pure-ific 27,000 25 26,975

Stock and warrants issued for acquisition of Pure-ific, shares 25,000

Net loss (5,749,937) (5,749,937)

Ending Balance at Dec. 31, 2002 11,723,580 9,424 18,780,291 (7,066,135)

Ending Balance, shares at Dec. 31, 2002 9,423,689

Stock to be issued for services 281,500 281,500

Issuance of warrants for services 145,479 145,479

Issuance of common stock pursuant to Regulation S 380,347 680 379,667

Issuance of stock pursuant to Regulation S, shares 679,820

Issuance of stock for services 239,800 764 239,036

Issuance of stock for services, shares 764,000

Employee compensation from stock options 34,659 34,659

Beneficial conversion related to convertible debt 601,000 601,000

Net loss (3,155,313) (3,155,313)

Ending Balance at Dec. 31, 2003 10,251,052 10,868 20,461,632 (10,221,448)

Ending Balance, shares at Dec. 31, 2003 10,867,509

Issuance of warrants for services 495,480 495,480

Issuance of common stock pursuant to Regulation S 793,137 2,469 790,668

Issuance of stock pursuant to Regulation S, shares 2,469,723

Exercise of warrants 5,000 133 4,867

Issuance of stock for services 449,923 734 449,190

Exercise of warrants, shares 132,608

Issuance of stock for services, shares 733,872

Employee compensation from stock options 15,612 15,612

Issuance of convertible debt with warrants 105,250 105,250

Issuance of stock and warrants pursuant to Regulation D 1,288,861 1,930 1,286,930

Issuance of stock and warrants pursuant to Regulation D, shares 1,930,164

Beneficial conversion related to convertible debt 360,256 360,256

Repurchase of beneficial conversion feature (258,345) (258,345)

Net loss (4,344,525) (4,344,525)

Ending Balance at Dec. 31, 2004 9,161,701 16,134 23,711,540 (14,565,973)

Ending Balance, shares at Dec. 31, 2004 16,133,876

Issuance of stock for interest payable 196,031 264 195,767

Issuance of stock for interest payable, shares 263,721

Issuance of warrants for services 1,534,405 1,534,405

Issuance of warrants for contractual obligations 985,010 985,010

Cash proceeds from exercise of warrants and stock options 1,439,795 1,572 1,438,223

Cash proceeds from exercise of warrants and stock options, shares 1,571,849

Issuance of stock for services 152,285 227 152,058

Issuance of stock for services, shares 226,733

Employee compensation from stock options 15,752 15,752

Issuance of convertible debt with warrants 1,574,900 1,574,900

Issuance of stock and warrants pursuant to Regulation D 6,513,176 6,221 6,506,955

Issuance of stock and warrants pursuant to Regulation D, shares 6,221,257

Beneficial conversion related to interest expense 39,529 39,529

Preferred stock conversions into common stock 3,049,362 3,405 3,045,957

Beneficial conversion related to convertible debt 1,633,176 1,633,176

Repurchase of beneficial conversion feature (144,128) (144,128)

Preferred stock/Debt conversions into common stock, shares 3,405,541

Net loss (11,763,853) (11,763,853)

Ending Balance at Dec. 31, 2005 14,387,141 27,823 40,689,144 (26,329,826)

Ending Balance, shares at Dec. 31, 2005 27,822,977

Issuance of stock for interest payable 183,596 195 183,401

Issuance of stock for interest payable, shares 194,327

Issuance of warrants for services 370,023 370,023

Cash proceeds from exercise of warrants and stock options 1,189,816 1,246 1,188,570

Cash proceeds from exercise of warrants and stock options, shares 1,245,809

Issuance of stock for services 676,743 719 676,024

Issuance of stock for services, shares 719,246

Employee compensation from stock options 1,862,456 1,862,456

Issuance of stock and warrants pursuant to Regulation D 4,130,421 10,092 4,120,329

Issuance of stock and warrants pursuant to Regulation D, shares 10,092,495

Beneficial conversion related to interest expense 16,447 16,447

Preferred stock conversions into common stock 1,576,336 2,377 1,573,959

Preferred stock/Debt conversions into common stock, shares 2,377,512

Net loss (8,870,579) (8,870,579)

Ending Balance at Dec. 31, 2006 15,522,400 42,452 50,680,353 (35,200,405)

Ending Balance, shares at Dec. 31, 2006 42,452,366

Issuance of stock for interest payable 1,258 1 1,257

Issuance of stock for interest payable, shares 1,141

Issuance of warrants for services 472,635 472,635

Cash proceeds from exercise of warrants and stock options 3,985,641 3,929 3,981,712

Cash proceeds from exercise of warrants and stock options, shares 3,928,957

Issuance of stock for services 298,950 150 298,800

Issuance of stock for services, shares 150,000

Employee compensation from stock options 2,340,619 2,340,619

Issuance of stock and warrants pursuant to Regulation D 1,848,138 2,377 1,845,761

Issuance of stock and warrants pursuant to Regulation D, shares 2,376,817

Preferred stock conversions into common stock 367,500 490 367,010

Preferred stock/Debt conversions into common stock, shares 490,000

Net loss (10,005,631) (10,005,631)

Ending Balance at Dec. 31, 2007 14,831,510 49,399 59,988,147 (45,206,036)

Ending Balance, shares at Dec. 31, 2007 49,399,281

Issuance of warrants for services 517,820 517,820

Cash proceeds from exercise of warrants and stock options 2,639,711 3,268 2,636,443

Cash proceeds from exercise of warrants and stock options, shares 3,267,795

Issuance of stock for services 390,000 350 389,650

Issuance of stock for services, shares 350,000

Employee compensation from stock options 1,946,066 1,946,066

Net loss (10,269,571) (10,269,571)

Ending Balance at Dec. 31, 2008 10,055,536 53,017 65,478,126 (55,475,607)

Ending Balance, shares at Dec. 31, 2008 53,017,076

Issuance of warrants for services 1,064,210 1,064,210

Cash proceeds from exercise of warrants and stock options 2,524,453 3,480 2,520,973

Cash proceeds from exercise of warrants and stock options, shares 3,480,485

Issuance of stock for services 695,000 796 694,204

Issuance of stock for services, shares 796,012

Employee compensation from stock options 870,937 870,937

Issuance of stock and warrants pursuant to Regulation D 6,518,688 10,117 6,508,571

Issuance of stock and warrants pursuant to Regulation D, shares 10,116,653

Net loss (12,322,314) (12,322,314)

Ending Balance at Dec. 31, 2009 9,406,510 67,410 77,137,021 (67,797,921)

Ending Balance, shares at Dec. 31, 2009 67,410,226

Issuance of warrants for services 1,141,593 1,141,593

Issuance of common stock pursuant to Regulation S 419,250 559 418,691

Issuance of stock pursuant to Regulation S, shares 559,000

Cash proceeds from exercise of warrants and stock options 3,103,680 3,491 3,100,189

Cash proceeds from exercise of warrants and stock options, shares 3,491,014

Issuance of common stock and warrants pursuant to Regulation D 6,346,989 11,169 6,335,820

Issuance of preferred stock and warrants pursuant to Regulation D 4,217,390 13,283 4,204,107

Issuance of common stock and warrants pursuant to Regulation D, shares 11,168,067

Issuance of stock for services 856,613 776 855,837

Issuance of preferred stock and warrants pursuant to Regulation D, shares 13,283,324

Issuance of stock for services, shares 776,250

Employee compensation from stock options 3,759,650 3,759,650

Preferred stock conversions into common stock (7,893) 7,893

Preferred stock/Debt conversions into common stock, shares (7,893,326) 7,893,326

Net loss (18,552,102) (18,552,102)

Ending Balance at Dec. 31, 2010 10,699,573 5,390 91,298 96,952,908 (86,350,023)

Ending Balance, shares at Dec. 31, 2010 5,389,998 91,297,883

Issuance of warrants for services 945,116 945,116

Cash proceeds from exercise of warrants and stock options 6,623,311 7,185 6,616,126

Sale of non-controlling interest in Pure-ific Corporation and warrants 443,500 443,500

Cash proceeds from exercise of warrants and stock options, shares 7,185,522

Issuance of common stock and warrants pursuant to Regulation D 7,041,239 9,905 7,031,334

Issuance of common stock and warrants pursuant to Regulation D, shares 9,905,062

Issuance of stock for services 332,750 350 332,400

Issuance of stock for services, shares 350,000

Employee compensation from stock options 3,368,950 3,368,950

Preferred stock conversions into common stock (1,859) 1,859

Preferred stock/Debt conversions into common stock, shares (1,858,333) 1,858,331

Net loss (19,434,699) (19,434,699)

Ending Balance at Dec. 31, 2011 10,019,740 3,531 110,597 115,690,334 (105,784,722)

Ending Balance, shares at Dec. 31, 2011 3,531,665 110,596,798

Issuance of warrants for services 1,512,026 1,512,026

Issuance of common stock and warrants pursuant to Regulation D 4,790,544 6,228 4,784,316

Issuance of common stock and warrants pursuant to Regulation D, shares 6,227,647

Issuance of stock for services 456,500 550 455,950

Issuance of stock for services, shares 550,000

Employee compensation from stock options 183,028 183,028

Preferred stock conversions into common stock (1,053) 1,053

Preferred stock/Debt conversions into common stock, shares (1,053,480) 1,053,480

Net loss (12,568,354) (12,568,354)

Ending Balance at Dec. 31, 2012 4,393,484 2,478 118,428 122,625,654 (118,353,076)

Ending Balance, shares at Dec. 31, 2012 2,478,185 118,427,925

Issuance of warrants for services 1,786,824 1,786,824

Cash proceeds from exercise of warrants and stock options 7,835,470 6,320 7,829,150

Cash proceeds from exercise of warrants and stock options, shares 6,319,594

Issuance of common stock and warrants pursuant to Regulation D 18,419,335 28,409 18,390,926

Issuance of preferred stock and warrants pursuant to Regulation D 1,252,050 3,400 1,248,650

Issuance of common stock and warrants pursuant to Regulation D, shares 28,409,353

Issuance of stock for services 526,000 750 525,250

Issuance of preferred stock and warrants pursuant to Regulation D, shares 3,400,001

Issuance of stock for services, shares 750,000

Employee compensation from stock options 142,310 142,310

Dividends on preferred stock (29,063) (29,063)

Preferred stock conversions into common stock (5,845) 5,845

Preferred stock/Debt conversions into common stock, shares (5,844,852) 5,844,852

Net loss (27,697,744) (27,697,744)

Ending Balance at Dec. 31, 2013 6,628,666 33 159,752 152,519,701 (146,050,820)

Ending Balance, shares at Dec. 31, 2013 33,334 159,751,724

Reclassification of warrant liability 10,355,619 10,355,619

Issuance of warrants for services 1,350,319 1,350,319

Cash proceeds from exercise of warrants and stock options 4,327,886 14,703 4,313,183

Cash proceeds from exercise of warrants and stock options, shares 14,703,381

Issuance of common stock and warrants pursuant to Regulation D 4,350,000 2,000 4,348,000

Issuance of common stock and warrants pursuant to Regulation D, shares 2,000,000

Issuance of stock for services 277,750 150 277,600

Issuance of stock for services, shares 150,000

Preferred stock conversions into common stock (33) 33

Preferred stock/Debt conversions into common stock, shares (33,334) 33,334

Net loss (7,310,683) (7,310,683)

Ending Balance at Jun. 30, 2014 $ 19,979,557 $ 176,638 $ 173,164,422 $ (153,361,503)

Ending Balance, shares at Jun. 30, 2014 176,638,439

X

- Definition

Adjustments to additional paid in capital beneficial conversion related to interest expense value.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionRelatedToInterestExpenseValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustments to additional paid in capital employee compensation from stock options value.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalEmployeeCompensationFromStockOptionsValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustments to additional paid in capital issuance of convertible debt with warrants value.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertibleDebtWithWarrantsValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustments to additional paid in capital issuance of warrants for contractual.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsForContractualObligationsValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustments to additional paid in capital repurchase of beneficial conversion feature value.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalRepurchaseOfBeneficialConversionFeatureValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Adjustments to additional paid in capital stock to be issued for services value.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalStockToBeIssuedForServicesValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustment to additional paid in capital sale of non controlling interest and warrants.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentToAdditionalPaidInCapitalSaleOfNonControllingInterestAndWarrants

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount reclassified from warrant liability to equity.

+ References

No definition available.

+ Details

Name: pvct_AmountReclassifiedFromWarrantLiabilityToEquity

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance of common stock and warrants pursuant to regulation D.

+ References

No definition available.

+ Details

Name: pvct_IssuanceOfCommonStockAndWarrantsPursuantToRegulationDShares

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance of common stock and warrants pursuant to regulation D value.

+ References

No definition available.

+ Details

Name: pvct_IssuanceOfCommonStockAndWarrantsPursuantToRegulationDValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Preferred stock issued during period pursuant to regulation of value.

+ References

No definition available.

+ Details

Name: pvct_PreferredStockIssuedDuringPeriodPursuantToRegulationOfValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Preferred stock issued during period shares pursuant to regulation of value.

+ References

No definition available.

+ Details

Name: pvct_PreferredStockIssuedDuringPeriodSharesPursuantToRegulationOfValue

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock and warrant issued during period shares.

+ References

No definition available.

+ Details

Name: pvct_StockAndWarrantIssuedDuringPeriodShares

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock and warrant issued during period value.

+ References

No definition available.

+ Details

Name: pvct_StockAndWarrantIssuedDuringPeriodValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period for interest payable value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodForInterestPayableValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period for services value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodForServicesValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period in reverse merger value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodInReverseMergerValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period pursuant to regulation D value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodPursuantToRegulationDValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period pursuant to regulation S value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodPursuantToRegulationSValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period shares for interest payable.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesForInterestPayable

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares for services.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesForServices

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares in reverse merger.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesInReverseMerger

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares pursuant to regulation D.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesPursuantToRegulationD

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares pursuant to regulation S.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesPursuantToRegulationS

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares stock options and warrants exercised.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares to employees.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesToEmployees

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares to founding shareholders.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesToFoundingShareholders

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period to employees value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodToEmployeesValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period to founding shareholders value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodToFoundingShareholdersValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period warrants and stock options exercised value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodWarrantsAndStockOptionsExercisedValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued for acquisition.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedForAcquisition

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued for acquisition shares.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedForAcquisitionShares

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant exercised during period shares.

+ References

No definition available.

+ Details

Name: pvct_WarrantExercisedDuringPeriodShares

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant exercised during period value.

+ References

No definition available.

+ Details

Name: pvct_WarrantExercisedDuringPeriodValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Warrant issued during period for services value.

+ References

No definition available.

+ Details

Name: pvct_WarrantIssuedDuringPeriodForServicesValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 55

-Paragraph 51

-URI http://asc.fasb.org/extlink&oid=32707879&loc=d3e34017-109320

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 25

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28183637&loc=d3e4724-112606

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Warrant

-URI http://asc.fasb.org/extlink&oid=6528364

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

+ Details

Name: us-gaap_DividendsPreferredStockCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The gross value of stock issued during the period upon the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares that have been repurchased and retired during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 40 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Equity Transactions
6 Months Ended

Jun. 30, 2014

Text Block [Abstract]

Equity Transactions

4. Equity Transactions

(a) During the three months ended March 31, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $137,500. During the three months ended March 31, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $48,750.

During the three months ended June 30, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $140,250. During the three months ended June 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $49,500.

(b) During the three months ended March 31, 2014, the Company issued 733,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $900,317. During the three months ended March 31, 2014, 121,500 warrants were forfeited. During the three months ended March 31, 2014, 12,522,198 warrants were exercised on a cashless basis resulting in 9,100,824 common shares being issued. During the three months ended March 31, 2014, 3,036,218 warrants were exercised for $2,672,364 resulting in 3,036,218 common shares issued. During the three months ended March 31, 2013, the Company issued 1,924,973 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $409,640. During the three months ended March 31, 2013, 859,833 warrants were forfeited.

During the three months ended June 30, 2014, the Company issued 202,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $450,002. During the three months ended June 30, 2014, 315,000 warrants were forfeited. During the three months ended June 30, 2014, 1,594,082 warrants were exercised on a cashless basis resulting in 915,467 common shares being issued. During the three months ended June 30, 2014, 372,000 warrants were exercised for $372,000 resulting in 372,000 common shares issued. During the three months ended June 30, 2013, the Company issued 2,605,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $931,655. During the three months ended June 30, 2013, 1,051,500 warrants were forfeited.

As the fair market value of these services was not readily determinable, these services were valued based on the fair market value of the warrants, determined using the Black-Scholes option-pricing model.

(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $1,153,835 and $311,062, respectively. During the three months ended March 31, 2014, 858,825 of the Series A Warrants were exercised. During the three months ended March 31, 2014, 697,092 of the Series C Warrants were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $186,262 and $221,149, respectively. The Company determined the fair value of the Series A and Series C Warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the Series A and Series C Warrants exercised in 2014 of $3,911,370 was reclassified into additional paid-in capital.

(d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $211,422 and $446,698, respectively. During the three months ended March 31, 2014, 1,756,665 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $3,285,793 and $399,057, respectively. During the three months ended June 30, 2014, 133,232 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $2,377,133 was reclassified into additional paid-in capital.

(e) In February 2013, the Company had an issuance of Series A 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $921,776 and $165,750, respectively. During the three months ended March 31, 2014, 1,650,000 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $42,970 and $289,000, respectively. During the three months ended June 30, 2014, 200,000 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $4,047,116 was reclassified into additional paid-in capital.

Dividends on the Series A 8% Convertible Preferred Stock accrued at an annual rate of 8% of the original issue price and were payable in either cash or common stock. If the dividend was paid in common stock, the number of shares of common stock equaled the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends were payable quarterly on the 15th day after the quarter-end. The Company paid the dividends in common stock although was required to pay the initial dividends due in cash. The Company had a deficit and, as a result, the dividends were recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In 2014, the Company recognized no dividends because of the full conversion of preferred stock to common stock as of January 15, 2014.

(f) In January 2014 there were 33,334 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 33,334 shares of the Company’s common stock. As of January 15, 2014, there were no shares of Series A 8% Convertible Preferred Stock outstanding.

(g) During the three months ended June 30, 2014 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,000,000. The Company accepted subscriptions, in the aggregate, for 2,000,000 shares of common stock and five year warrants to purchase 2,000,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $3.00 per share. The purchase price for each share of common stock together with the warrants was $2.50. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $650,000 and issued five year fully vested warrants to purchase 300,000 shares of common stock with an exercise price of $2.50 to Network 1 Financial Securities, Inc., which represents 15% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

X

- Definition

Equity transactions.

+ References

No definition available.

+ Details

Name: pvct_EquityTransactionsTextBlock

Namespace Prefix: pvct_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 209 208 1 false 37 0 false 5 false false R1.htm 101 - Document - Document and Entity Information Sheet http://pvct.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://pvct.com/taxonomy/role/StatementOfFinancialPositionClassified CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://pvct.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://pvct.com/taxonomy/role/StatementOfIncome CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) false false R5.htm 106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://pvct.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) false false R6.htm 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited) Sheet http://pvct.com/taxonomy/role/StatementOfCashFlowsIndirect CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited) false false R7.htm 108 - Disclosure - Basis of Presentation Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation false false R8.htm 109 - Disclosure - Recapitalization and Merger Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Recapitalization and Merger false false R9.htm 110 - Disclosure - Basic and Diluted Loss Per Common Share Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Basic and Diluted Loss Per Common Share false false R10.htm 111 - Disclosure - Equity Transactions Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsEquityTransactionsTextBlock Equity Transactions false false R11.htm 112 - Disclosure - Stock-Based Compensation Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation false false R12.htm 113 - Disclosure - Related Party Transaction Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transaction false false R13.htm 114 - Disclosure - Fair Value of Financial Instruments Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value of Financial Instruments false false R14.htm 115 - Disclosure - Litigation Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsCommitmentsContingenciesAndGuaranteesTextBlock Litigation false false R15.htm 116 - Disclosure - Equity Transactions (Policies) Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsEquityTransactionsTextBlockPolicies Equity Transactions (Policies) false false R16.htm 117 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://pvct.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value of Financial Instruments (Tables) false false R17.htm 118 - Disclosure - Recapitalization and Merger - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureRecapitalizationAndMergerAdditionalInformation Recapitalization and Merger - Additional Information (Detail) false false R18.htm 119 - Disclosure - Basic and Diluted Loss Per Common Share - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureBasicAndDilutedLossPerCommonShareAdditionalInformation Basic and Diluted Loss Per Common Share - Additional Information (Detail) false false R19.htm 120 - Disclosure - Equity Transactions - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureEquityTransactionsAdditionalInformation Equity Transactions - Additional Information (Detail) false false R20.htm 121 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) false false R21.htm 122 - Disclosure - Related Party Transaction - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureRelatedPartyTransactionAdditionalInformation Related Party Transaction - Additional Information (Detail) false false R22.htm 123 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation Fair Value of Financial Instruments - Additional Information (Detail) false false R23.htm 124 - Disclosure - Fair Value of Financial Instruments - Warrant Liability Measured at Fair Value on a Recurring Basis (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsWarrantLiabilityMeasuredAtFairValueOnARecurringBasis Fair Value of Financial Instruments - Warrant Liability Measured at Fair Value on a Recurring Basis (Detail) false false R24.htm 125 - Disclosure - Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsReconciliationOfTheWarrantyLiabilityMeasuredAtFairValueOnARecurringBasis Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) false false R25.htm 126 - Disclosure - Litigation - Additional Information (Detail) Sheet http://pvct.com/taxonomy/role/DisclosureLitigationAdditionalInformation Litigation - Additional Information (Detail) false false All Reports Book All Reports Element us-gaap_LossContingencyReceivable had a mix of decimals attribute values: -4 0. Process Flow-Through: 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: Removing column 'Dec. 31, 2008' Process Flow-Through: Removing column 'Dec. 31, 2007' Process Flow-Through: Removing column 'Dec. 31, 2006' Process Flow-Through: Removing column 'Dec. 31, 2005' Process Flow-Through: Removing column 'Dec. 31, 2004' Process Flow-Through: Removing column 'Dec. 31, 2003' Process Flow-Through: Removing column 'Dec. 31, 2002' Process Flow-Through: Removing column 'Apr. 23, 2002' Process Flow-Through: Removing column 'Jan. 31, 2002' Process Flow-Through: 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Process Flow-Through: Removing column '3 Months Ended Apr. 23, 2002' Process Flow-Through: Removing column '9 Months Ended Dec. 31, 2002' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2013' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2012' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2011' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2010' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2009' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2008' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2007' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2006' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2005' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2004' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2003' Process Flow-Through: Removing column '149 Months Ended Jun. 30, 2014' Process Flow-Through: 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited) Process Flow-Through: Removing column '149 Months Ended Jun. 30, 2014' pvct-20140630.xml pvct-20140630.xsd pvct-20140630_cal.xml pvct-20140630_def.xml pvct-20140630_lab.xml pvct-20140630_pre.xml true true XML 42 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation - Additional Information (Detail) (USD $)
0 Months Ended 3 Months Ended

Feb. 26, 2014

May 27, 2014

Employee One [Member]

Jun. 30, 2014

Employee One [Member]

Mar. 31, 2014

Options Exercised Price One [Member]

Employee One [Member]

Mar. 31, 2014

Options Exercised Price One [Member]

Employee Two [Member]

Jun. 30, 2014

Options Exercised Price One [Member]

Employee Three [Member]

Mar. 31, 2014

Options Exercised Price One [Member]

Employee Three [Member]

Jun. 30, 2014

Options Exercised Price One [Member]

Non Employee [Member]

Mar. 31, 2014

Options Exercised Price Two [Member]

Employee One [Member]

Mar. 31, 2014

Options Exercised Price Three [Member]

Employee One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price 25,000 25,000 300,000 100,000 189,624 25,000 14,248 600,000

Exercise price/share $ 0.95 $ 0.95 $ 1.10 $ 1.25 $ 1.10 $ 0.95 $ 0.75 $ 0.93

Common stock value $ 23,750 $ 23,750 $ 330,000 $ 125,000 $ 208,586 $ 23,750 $ 10,686 $ 558,000

Number of Shares forfeited 300,000 25,000

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Litigation - Additional Information (Detail) (USD $)	0 Months Ended		0 Months Ended		0 Months Ended
Litigation - Additional Information (Detail) (USD $)	Jun. 06, 2014	Apr. 30, 2013	Jun. 06, 2014 Executive Officer [Member]	Jun. 06, 2014 Other Defendants [Member]	Jul. 24, 2014 Subsequent Event [Member]
Loss Contingencies [Line Items]
Reserve for litigation		$ 100,000
Damages sought to be receivable	2,240,000			25,000
Estimated bonus percentage	70.00%
Future payment ratio of contingent consideration	2
Repayment under contingency	1,120,000
Reimbursement cost percentage	25.00%
Number of shares acquired under litigation			1,000,000
Stock option issued to employees			100,000
Share-based compensation forfeiture rate			50.00%
Attorney's fees and reimbursement of expenses					$ 911,000

Basic and Diluted Loss Per Common Share	6 Months Ended
Basic and Diluted Loss Per Common Share	Jun. 30, 2014
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Common Share	3. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation at June 30, 2014 and 2013, respectively, relate to 58,311,418 and 50,358,525 from warrants, 13,718,334 and 15,097,206 from options, and 0 and 4,881,666 from convertible preferred shares.

Recapitalization and Merger	6 Months Ended
Recapitalization and Merger	Jun. 30, 2014
Business Combinations [Abstract]
Recapitalization and Merger	2. Recapitalization and Merger Provectus Biopharmaceuticals, Inc., formerly known as “Provectus Pharmaceuticals, Inc.,” “Provectus Pharmaceutical, Inc.” and “SPM Group, Inc.,” was incorporated under Colorado law on May 1, 1978. SPM Group ceased operations in 1991, and became a development-stage company effective January 1, 1992, with the new corporate purpose of seeking out acquisitions of properties, businesses, or merger candidates, without limitation as to the nature of the business operations or geographic location of the acquisition candidate. On April 1, 2002, SPM Group changed its name to “Provectus Pharmaceutical, Inc.” and reincorporated in Nevada in preparation for a transaction with Provectus Pharmaceuticals, Inc., a privately-held Tennessee corporation (“PPI”). On April 23, 2002, an Agreement and Plan of Reorganization between Provectus Pharmaceutical and PPI was approved by the written consent of a majority of the outstanding shares of Provectus Pharmaceutical. As a result, Provectus Pharmaceuticals, Inc. issued 6,680,000 shares of common stock in exchange for all of the issued and outstanding shares of PPI. As part of the acquisition, Provectus Pharmaceutical changed its name to “Provectus Pharmaceuticals, Inc.” and PPI became a wholly-owned subsidiary of Provectus. This transaction was recorded as a recapitalization of PPI. On November 19, 2002, the Company acquired Valley Pharmaceuticals, Inc., a privately-held Tennessee corporation formerly known as Photogen, Inc., by merging PPI with and into Valley and naming the surviving corporation “Xantech Pharmaceuticals, Inc.” Photogen, Inc. was separated from Photogen Technologies, Inc. in a non-pro-rata split-off to some of its shareholders. The assets of Photogen, Inc. consisted primarily of the equipment and intangibles related to its therapeutic activity and were recorded at their fair value. The majority shareholders of Valley were also the majority shareholders of Provectus. Valley had no revenues prior to the transaction with the Company. By acquiring Valley, the Company acquired its intellectual property, including issued U.S. patents and patentable inventions. On December 16, 2013, Provectus Pharmaceuticals, Inc. was reincorporated in Delaware and changed its name to Provectus Biopharmaceuticals, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets
Cash and cash equivalents	$ 18,126,036	$ 15,696,243
Total Current Assets	18,126,036	15,696,243
Equipment and furnishings, less accumulated depreciation of $432,763 and $429,331, respectively	26,681	30,113
Patents, net of amortization of $7,796,177 and $7,460,617, respectively	3,919,268	4,254,828
Other assets	27,000	27,000
Total Assets	22,098,985	20,008,184
Current Liabilities
Accounts payable - trade	479,857	348,869
Accrued consulting expense	104,042	61,282
Other accrued expenses	232,568	102,795
Total Current Liabilities	816,467	512,946
Long-Term Liability
Warrant liability	1,302,961	12,866,572
Total Liabilities	2,119,428	13,379,518
Stockholders' Equity
Preferred stock; par value $.001 per share; 25,000,000 shares authorized; Series A 8% convertible preferred stock, 0 and 33,334 shares issued and outstanding, respectively, liquidation preference $0.75 (for 2013 in aggregate $25,001)		33
Common stock; par value $.001 per share; 300,000,000 authorized; 176,638,439 and 159,751,724 shares issued and outstanding, respectively	176,638	159,752
Paid-in capital	173,164,422	152,519,701
Deficit accumulated during the development stage	(153,361,503)	(146,050,820)
Total Stockholders' Equity	19,979,557	6,628,666
Total Liabilities and Stockholders' Equity	$ 22,098,985	$ 20,008,184

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited) (USD $)	6 Months Ended		149 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Cash Flows From Operating Activities
Net loss	$ (7,310,683)	$ (6,547,555)	$ (153,361,503)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	3,432	3,100	455,764
Amortization of patents	335,560	335,560	7,796,177
Amortization of original issue discount			3,845,721
Amortization of commitment fee			310,866
Amortization of prepaid consultant expense			1,295,226
Amortization of deferred loan costs			2,261,584
Accretion of United States Treasury Bills			(373,295)
Loss on extinguishment of debt			825,867
Loss on exercise of warrants			236,146
Beneficial conversion of convertible interest			55,976
Convertible interest			389,950
Compensation through issuance of stock options			14,540,039
Compensation through issuance of stock			932,000
Issuance of stock for services	277,750	98,250	9,857,261
Issuance of warrants for services	1,350,319	1,341,295	9,333,712
Issuance of warrants for contractual obligations			985,010
Gain on sale of equipment			(55,075)
Loss (gain) on change in fair value of warrant liability	(1,227,992)	14,304	7,530,937
Change in assets and liabilities
Prepaid expenses and other current assets		(93,034)
Accounts payable	130,988	(178,673)	476,212
Accrued expenses	172,533	81,437	486,240
Net cash used in operating activities	(6,268,093)	(4,945,316)	(92,175,185)
Cash Flows From Investing Activities
Proceeds from sale of fixed assets			180,075
Capital expenditures			(96,570)
Proceeds from sales of investments			37,010,481
Purchases of investments			(36,637,186)
Net cash provided by investing activities			456,800
Cash Flows From Financing Activities
Net proceeds from loans from stockholder			174,000
Proceeds from convertible debt			6,706,795
Net proceeds from sales of preferred stock and warrants		2,550,000	11,458,131
Net proceeds from sales of common stock and warrants	4,350,000	5,817,698	65,583,856
Proceeds from exercises of warrants and stock options	4,347,886	21,000	28,859,292
Cash paid for preferred dividends		(29,063)	(29,063)
Cash paid to retire convertible debt			(2,385,959)
Cash paid for deferred loan costs			(747,612)
Premium paid on extinguishments of debt			(170,519)
Net proceeds from sale of non-controlling interest in Pure-ific Corporation			443,500
Purchase and retirement of common stock			(48,000)
Net cash provided by financing activities	8,697,886	8,359,635	109,844,421
Net change in cash and cash equivalents	2,429,793	3,414,319	18,126,036
Cash and cash equivalents, at beginning of period	15,696,243	1,221,701
Cash and cash equivalents, at end of period	18,126,036	4,636,020	18,126,036
Supplemental Disclosure of Noncash Investing and Financing Activities
Reclassification of warrant liability to equity due to exercise of warrants	$ 10,355,619

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended
	Mar. 31, 2014	Jun. 30, 2014
2010 Warrants [Member]
Class of Stock [Line Items]
Weighted average term	10 months 24 days	8 months 12 days
Warrant exercise price probability	5.00%	5.00%
Percentage of volatility		187.70%
Risk free interest rate	0.13%	0.09%
2010 Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Percentage of volatility	66.50%
2010 Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Percentage of volatility	129.70%
2011 Warrants [Member]
Class of Stock [Line Items]
Weighted average term	1 year 9 months 18 days	1 year 6 months
Warrant exercise price probability	5.00%	5.00%
Percentage of volatility	101.80%	132.70%
Risk free interest rate	0.29%	0.29%
2013 Warrants [Member]
Class of Stock [Line Items]
Weighted average term	3 years 10 months 24 days
Warrant exercise price probability	5.00%
Percentage of volatility	84.70%
Warrant Liability		0
2013 Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Risk free interest rate	0.77%
2013 Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Risk free interest rate	1.32%

Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reclassification to APIC due to warrant exercises	$ 10,355,619
Recurring [Member] \| Level 3 [Member] \| Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	12,866,572
Issuance of warrants
Change in fair value of warrants included in earnings	(1,227,992)
Reclassification to APIC due to warrant exercises	(10,335,619)
Ending Balance	$ 1,302,961

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2014
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ended December 31, 2014. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Accumulated depreciation on equipment and furnishings	$ 432,763	$ 429,331
Amortization on patents	7,796,177	7,460,617
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	176,638,439	159,751,724
Common stock, shares outstanding	176,638,439	159,751,724
Series A 8% Convertible Preferred Stock [Member]
Preferred stock, shares issued	0	33,334
Preferred stock, shares outstanding	0	33,334
Preferred stock, liquidation preference per share	$ 0.75	$ 0.75
Aggregate liquidation preference	$ 25,001	$ 25,001
Convertible preferred stock	8.00%	8.00%

Recapitalization and Merger - Additional Information (Detail)	0 Months Ended
	Apr. 23, 2002
Business Combinations [Abstract]
Common stock shares issued	6,680,000

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	176,638,439

Basic and Diluted Loss Per Common Share - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from the calculation	58,311,418	50,358,525
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from the calculation	13,718,334	15,097,206
8% Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from the calculation	0	4,881,666

Related Party Transaction	6 Months Ended
Related Party Transaction	Jun. 30, 2014
Related Party Transactions [Abstract]
Related Party Transaction	6. Related Party Transaction The Company paid one of the Company’s directors $6,000 as of March 31, 2014, all of which was paid as part of his overall compensation of an aggregate of $85,000 for board and committee service.

Stock-Based Compensation	6 Months Ended
Stock-Based Compensation	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	5. Stock-Based Compensation One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750, 14,248 options at an exercise price of $0.75 per share of common stock for $10,686 and 600,000 options at an exercise price of $0.93 per share of common stock for $558,000 during the three months ended March 31, 2014. Another employee of the Company exercised 300,000 options at an exercise price of $1.10 per share of common stock for $330,000 during the three months ended March 31, 2014. Another employee of the Company exercised 189,624 options at an exercise price of $1.10 per share of common stock for $208,586 during the three months ended March 31, 2014. One employee of the Company forfeited 300,000 stock options on February 26, 2014. One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. Another employee of the Company exercised 100,000 options at an exercise price of $1.25 per share of common stock for $125,000 during the three months ended June 30, 2014. A former non-employee member of the board exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. One employee of the Company forfeited 25,000 stock options on May 27, 2014.

Equity Transactions - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended				6 Months Ended	149 Months Ended	3 Months Ended									1 Months Ended		3 Months Ended				1 Months Ended	3 Months Ended			6 Months Ended		3 Months Ended
	Jan. 15, 2014	Jan. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014 Network 1 Financial Securities [Member]	Mar. 31, 2014 Series A Warrants [Member]	Mar. 31, 2014 Series C Warrants [Member]	Jun. 30, 2014 Series A and Series C Warrants [Member]	Jun. 30, 2014 Five Year Warrant [Member]	Jun. 30, 2014 Common Stock [Member]	Mar. 31, 2014 Common Stock [Member]	Jun. 30, 2013 Common Stock [Member]	Mar. 31, 2013 Common Stock [Member]	Apr. 30, 2010 8% Convertible Preferred Stock [Member]	Mar. 31, 2010 8% Convertible Preferred Stock [Member]	Jun. 30, 2014 Warrants [Member]	Mar. 31, 2014 Warrants [Member]	Jun. 30, 2013 Warrants [Member]	Mar. 31, 2013 Warrants [Member]	Feb. 28, 2014 Series A 8% Convertible Preferred Stock [Member]	Jun. 30, 2014 Series A 8% Convertible Preferred Stock [Member]	Mar. 31, 2014 Series A 8% Convertible Preferred Stock [Member]	Mar. 31, 2013 Series A 8% Convertible Preferred Stock [Member]	Jun. 30, 2014 Series A 8% Convertible Preferred Stock [Member]	Jun. 30, 2013 Series A 8% Convertible Preferred Stock [Member]	Jun. 30, 2014 Warrant A [Member]	Mar. 31, 2014 Warrant A [Member]	Jun. 30, 2013 Warrant A [Member]	Mar. 31, 2013 Warrant A [Member]
Class of Stock [Line Items]
Issuance of common stock to consultants			75,000	75,000	75,000	75,000
Consulting costs charges														$ 140,250	$ 137,500	$ 49,500	$ 48,750
Issuance of warrants to consultants			202,000	733,000	2,605,000	1,924,973
Consulting costs charges related to warrants			450,002	900,317	931,655	409,640
Warrants forfeited			315,000	121,500	1,051,500	859,833
Warrants exercised on cashless basis			1,594,082	12,522,198
Shares issued in cashless exercise			915,467	9,100,824
Warrants exercised			372,000	3,036,218
Exercise price of warrants			372,000	2,672,364
Common stock to be issued on exercise of warrant			372,000	3,036,218				372,000	300,000
Gain (loss) on revaluation of warrants liability			186,262	(1,153,835)	221,149	(311,062)														3,285,793	(211,422)	399,057	(446,698)							42,970	(921,776)	289,000	(165,750)
Warrants series exercised										858,825	697,092
Adjusted fair value of warrants exercised												3,911,370								2,377,133					4,047,116
Convertible preferred stock				8.00%														8.00%	8.00%					8.00%
Issued warrants																				133,232	1,756,665				200,000	1,650,000
Fair value of the warrants					1,297,950		1,297,950
Beneficial conversion amount					1,025,950		1,025,950
Dividends on preferred stock					73,024		1,149,958	12,026,710																			29,063	0	50,860
Converted preferred stock	0	33,334
Preferred stock converted into shares		33,334
Gross proceeds from private offering of common stock and warrants to accredited investors			5,000,000
Company accepted subscriptions in aggregate			2,000,000
Expiration of warrants													5 years
Number of shares issuable on exercises of warrants issued													2,000,000
Investors received five year warrants			100.00%
Exercise price of common stock			$ 3.00					$ 3.00	$ 2.50
Purchase price of common stock with warrants			$ 2.50
Payment of fully vested warrants									$ 650,000
Percentage of total number of shares of common stock sold to investors									15.00%

Equity Transactions (Policies)	6 Months Ended
Equity Transactions (Policies)	Jun. 30, 2014
Text Block [Abstract]
Derivatives Policies	(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $1,153,835 and $311,062, respectively. During the three months ended March 31, 2014, 858,825 of the Series A Warrants were exercised. During the three months ended March 31, 2014, 697,092 of the Series C Warrants were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $186,262 and $221,149, respectively. The Company determined the fair value of the Series A and Series C Warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the Series A and Series C Warrants exercised in 2014 of $3,911,370 was reclassified into additional paid-in capital. (d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $211,422 and $446,698, respectively. During the three months ended March 31, 2014, 1,756,665 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $3,285,793 and $399,057, respectively. During the three months ended June 30, 2014, 133,232 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $2,377,133 was reclassified into additional paid-in capital. (e) In February 2013, the Company had an issuance of Series A 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $921,776 and $165,750, respectively. During the three months ended March 31, 2014, 1,650,000 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $42,970 and $289,000, respectively. During the three months ended June 30, 2014, 200,000 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $4,047,116 was reclassified into additional paid-in capital. Dividends on the Series A 8% Convertible Preferred Stock accrued at an annual rate of 8% of the original issue price and were payable in either cash or common stock. If the dividend was paid in common stock, the number of shares of common stock equaled the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends were payable quarterly on the 15th day after the quarter-end. The Company paid the dividends in common stock although was required to pay the initial dividends due in cash. The Company had a deficit and, as a result, the dividends were recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In 2014, the Company recognized no dividends because of the full conversion of preferred stock to common stock as of January 15, 2014. (f) In January 2014 there were 33,334 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 33,334 shares of the Company’s common stock. As of January 15, 2014, there were no shares of Series A 8% Convertible Preferred Stock outstanding. (g) During the three months ended June 30, 2014 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,000,000. The Company accepted subscriptions, in the aggregate, for 2,000,000 shares of common stock and five year warrants to purchase 2,000,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $3.00 per share. The purchase price for each share of common stock together with the warrants was $2.50. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $650,000 and issued five year fully vested warrants to purchase 300,000 shares of common stock with an exercise price of $2.50 to Network 1 Financial Securities, Inc., which represents 15% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

Litigation	6 Months Ended
Litigation	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]
Litigation	8. Litigation Kleba Shareholder Derivative Lawsuit On January 2, 2013, Glenn Kleba (the “Plaintiff”) derivatively on behalf of the Company, filed a shareholder derivative complaint in the Circuit Court for the State of Tennessee, Knox County (the “Court”), against H. Craig Dees, Timothy C. Scott, Eric A. Wachter, and Peter R. Culpepper (collectively, the “Executives”), Stuart Fuchs, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, together with the Executives, the “Individual Defendants”), and against the Company as a nominal defendant (the “Shareholder Derivative Lawsuit”). The Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties, (ii) waste of corporate assets, and (iii) unjust enrichment, all three claims based on the Plaintiff’s allegations that the defendants authorized and/or accepted stock option awards in violation of the terms of the Company’s 2002 Stock Plan (the “Plan”) by issuing stock options in excess of the amounts authorized under the Plan and delegated to defendant H. Craig Dees the sole authority to grant himself and the other Executives cash bonuses that the Plaintiff alleges to be excessive. In April 2013, the Company’s Board of Directors appointed a special litigation committee to investigate the allegations of the Shareholder Derivative Complaint and make a determination as to how the matter should be resolved. The special litigation committee conducted its investigation, and proceedings in the case were stayed pending the conclusion of the committee’s investigation. The Company has established a reserve of $100,000 for potential liabilities because such is the amount of the self-insured retention of its insurance policy. On March 6, 2014, the Company filed a Joint Notice of Settlement (the “Notice of Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company, the parties to the Notice of Settlement are the Plaintiff and the Individual Defendants. On June 6, 2014, the Company, in its capacity as a nominal defendant, entered into a Stipulated Settlement Agreement and Mutual Release (the “Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company and the Individual Defendants, plaintiffs Glenn Kleba and Don B. Dale are parties to the Settlement. By entering into the Settlement, the settling parties have resolved the derivative claims to their mutual satisfaction. The Individual Defendants have not admitted the validity of any claims or allegations and the settling plaintiffs have not admitted that any claims or allegations lack merit or foundation. Under the terms of the Settlement, (i) the Executives each agreed (A) to re-pay to the Company $2.24 Million of the cash bonuses they each received in 2010 and 2011, which amount equals 70% of such bonuses or an estimate of the after-tax net proceeds to each Executive; provided, however, that subject to certain terms and conditions set forth in the Settlement, the Executives are entitled to a 2:1 credit such that total actual repayment may be $1.12 Million each; (B) to reimburse the Company for 25% of the actual costs, net of recovery from any other source, incurred by the Company as a result of the Shareholder Derivative Lawsuit; and (C) to grant to the Company a first priority security interest in 1,000,000 shares of the Company’s common stock owned by each such Executive to serve as collateral for the amounts due to the Company under the Settlement; (ii) Drs. Dees and Scott and Mr. Culpepper agreed to retain incentive stock options for 100,000 shares but shall forfeit 50% of the nonqualified stock options granted to each such Executive in both 2010 and 2011. The Settlement also requires that each of the Executives enter into new employment agreements with the Company, which were entered into on April 28, 2014, and that the Company adhere to certain corporate governance principles and processes in the future. Under the Settlement, Messrs. Fuchs and Smith and Dr. McMasters have each agreed to pay the Company $25,000 in cash, subject to reduction by such amount that the Company’s insurance carrier pays to the Company on behalf of such defendant pursuant to such defendant’s directors and officers liability insurance policy. The Settlement also provides for an award to plaintiffs’ counsel of attorneys’ fees and reimbursement of expenses in connection with their role in this litigation, subject to Court approval. On July 24, 2014, the Court approved the terms of the proposed Settlement and awarded $911,000 to plaintiffs’ counsel for attorneys’ fees and reimbursement of expenses in connection with their role in the Shareholder Derivative Lawsuit. Class Action Lawsuits On May 27, 2014, Cary Farrah and James H. Harrison, Jr., individually and on behalf of all others similarly situated (the “Farrah Case”), and on May 29, 2014, each of Paul Jason Chaney, individually and on behalf of all others similarly situated (the “Chaney Case”), and Jayson Dauphinee, individually and on behalf of all others similarly situated (the “Dauphinee Case”) (the plaintiffs in the Farrah Case, the Chaney Case and the Dauphinee Case collectively referred to as the “Plaintiffs”), each filed a class action lawsuit in the United States District Court for the Middle District of Tennessee against the Company, H. Craig Dees, Timothy C. Scott and Peter R. Culpepper (the “Defendants”) alleging violations by the Defendants of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. Specifically, the Plaintiffs in each of the Farrah Case, the Chaney Case and the Dauphinee Case allege that the Defendants are liable for making false statements and failing to disclose adverse facts known to them about the Company, in connection with the Company’s application to the FDA for Breakthrough Therapy Designation (“BTD”) in the Spring of 2014 and the FDA’s subsequent denial of the Company’s application for BTD. The Company intends to defend vigorously against all claims in these complaints. However, in view of the inherent uncertainties of litigation and the early stage of this litigation, the outcome of these cases cannot be predicted at this time. Likewise, the amount of any potential loss cannot be reasonably estimated. On July 9, 2014, the Plaintiffs and the Defendants filed joint motions in the Farrah Case, the Chaney Case and the Dauphinee Case to consolidate the cases and transfer them to United States District Court for the Eastern District of Tennessee. By order dated July 16, 2014, the United States District Court for the Middle District of Tennessee entered an order consolidating the Farrah Case, the Chaney Case and the Dauphinee Case (collectively and, as consolidated, the “Securities Litigation”) and transferred the Securities Litigation to the United States District Court for the Eastern District of Tennessee. Hurtado Shareholder Derivative Lawsuit On June 4, 2014, Karla Hurtado (the “Plaintiff”) derivatively on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the Middle District of Tennessee (the “Court”), against H. Craig Dees, Timothy C. Scott, Jan E. Koe, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, the “Individual Defendants”), and against the Company as a nominal defendant (the “Hurtado Shareholder Derivative Lawsuit”). The Hurtado Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties and (ii) abuse of control, both claims based on the Plaintiff’s allegations that the Individual Defendants recklessly permitted the Company to disclose false and misleading information and failed to implement adequate controls and procedures to ensure the accuracy of the Company’s disclosures. On July 25, 2014, the court presiding over the Hurtado Shareholder Derivative Lawsuit entered an order transferring the case to the United District Court for the Eastern District of Tennessee. It is anticipated that an order will be entered by agreement that will stay all activity in the Hurtado Shareholder Derivative Lawsuit pending the resolution of an anticipated motion to dismiss the anticipated consolidated amended complaint in the Securities Litigation. As a nominal defendant, no relief is sought against the Company itself in the Hurtado Shareholder Derivative Lawsuit.

Related Party Transaction - Additional Information (Detail) (USD $)	1 Months Ended	6 Months Ended
	Mar. 31, 2014	Jun. 30, 2014 Directors
Related Party Transactions [Abstract]
Payment for board and committee service	$ 6,000	$ 85,000
Number of directors to whom board and committee service paid		1

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Paid in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Jan. 17, 2002
Issuance to founding shareholders			$ 6,000	$ (6,000)
Issuance to founding shareholders, shares			6,000,000
Sale of stock	25,000		50	24,950
Sale of stock, shares			50,000
Issuance of stock to employees	932,000		510	931,490
Issuance of stock to employees, shares			510,000
Issuance of stock for services	360,000		120	359,880
Issuance of stock for services, shares			120,000
Net loss	(1,316,198)				(1,316,198)
Ending Balance at Apr. 23, 2002	802		6,680	1,310,320	(1,316,198)
Ending Balance, shares at Apr. 23, 2002			6,680,000
Shares issued in reverse merger	(3,645)		266	(3,911)
Shares issued in reverse merger, shares			265,763
Purchase and retirement of stock	(48,000)		(400)	(47,600)
Purchase and retirement of stock, shares			(400,000)
Stock issued for acquisition of Valley Pharmaceuticals	12,226,320		500	12,225,820
Stock issued for acquisition of Valley Pharmaceuticals, shares			500,007
Exercise of warrants	453		453
Issuance of stock for services	5,144,000		1,900	5,142,100
Exercise of warrants, shares			452,919
Warrants issued in connection with convertible debt	126,587			126,587
Issuance of stock for services, shares			1,900,000
Stock and warrants issued for acquisition of Pure-ific	27,000		25	26,975
Stock and warrants issued for acquisition of Pure-ific, shares			25,000
Net loss	(5,749,937)				(5,749,937)
Ending Balance at Dec. 31, 2002	11,723,580		9,424	18,780,291	(7,066,135)
Ending Balance, shares at Dec. 31, 2002			9,423,689
Stock to be issued for services	281,500			281,500
Issuance of warrants for services	145,479			145,479
Issuance of common stock pursuant to Regulation S	380,347		680	379,667
Issuance of stock pursuant to Regulation S, shares			679,820
Issuance of stock for services	239,800		764	239,036
Issuance of stock for services, shares			764,000
Employee compensation from stock options	34,659			34,659
Beneficial conversion related to convertible debt	601,000			601,000
Net loss	(3,155,313)				(3,155,313)
Ending Balance at Dec. 31, 2003	10,251,052		10,868	20,461,632	(10,221,448)
Ending Balance, shares at Dec. 31, 2003			10,867,509
Issuance of warrants for services	495,480			495,480
Issuance of common stock pursuant to Regulation S	793,137		2,469	790,668
Issuance of stock pursuant to Regulation S, shares			2,469,723
Exercise of warrants	5,000		133	4,867
Issuance of stock for services	449,923		734	449,190
Exercise of warrants, shares			132,608
Issuance of stock for services, shares			733,872
Employee compensation from stock options	15,612			15,612
Issuance of convertible debt with warrants	105,250			105,250
Issuance of stock and warrants pursuant to Regulation D	1,288,861		1,930	1,286,930
Issuance of stock and warrants pursuant to Regulation D, shares			1,930,164
Beneficial conversion related to convertible debt	360,256			360,256
Repurchase of beneficial conversion feature	(258,345)			(258,345)
Net loss	(4,344,525)				(4,344,525)
Ending Balance at Dec. 31, 2004	9,161,701		16,134	23,711,540	(14,565,973)
Ending Balance, shares at Dec. 31, 2004			16,133,876
Issuance of stock for interest payable	196,031		264	195,767
Issuance of stock for interest payable, shares			263,721
Issuance of warrants for services	1,534,405			1,534,405
Issuance of warrants for contractual obligations	985,010			985,010
Cash proceeds from exercise of warrants and stock options	1,439,795		1,572	1,438,223
Cash proceeds from exercise of warrants and stock options, shares			1,571,849
Issuance of stock for services	152,285		227	152,058
Issuance of stock for services, shares			226,733
Employee compensation from stock options	15,752			15,752
Issuance of convertible debt with warrants	1,574,900			1,574,900
Issuance of stock and warrants pursuant to Regulation D	6,513,176		6,221	6,506,955
Issuance of stock and warrants pursuant to Regulation D, shares			6,221,257
Beneficial conversion related to interest expense	39,529			39,529
Preferred stock conversions into common stock	3,049,362		3,405	3,045,957
Beneficial conversion related to convertible debt	1,633,176			1,633,176
Repurchase of beneficial conversion feature	(144,128)			(144,128)
Preferred stock/Debt conversions into common stock, shares			3,405,541
Net loss	(11,763,853)				(11,763,853)
Ending Balance at Dec. 31, 2005	14,387,141		27,823	40,689,144	(26,329,826)
Ending Balance, shares at Dec. 31, 2005			27,822,977
Issuance of stock for interest payable	183,596		195	183,401
Issuance of stock for interest payable, shares			194,327
Issuance of warrants for services	370,023			370,023
Cash proceeds from exercise of warrants and stock options	1,189,816		1,246	1,188,570
Cash proceeds from exercise of warrants and stock options, shares			1,245,809
Issuance of stock for services	676,743		719	676,024
Issuance of stock for services, shares			719,246
Employee compensation from stock options	1,862,456			1,862,456
Issuance of stock and warrants pursuant to Regulation D	4,130,421		10,092	4,120,329
Issuance of stock and warrants pursuant to Regulation D, shares			10,092,495
Beneficial conversion related to interest expense	16,447			16,447
Preferred stock conversions into common stock	1,576,336		2,377	1,573,959
Preferred stock/Debt conversions into common stock, shares			2,377,512
Net loss	(8,870,579)				(8,870,579)
Ending Balance at Dec. 31, 2006	15,522,400		42,452	50,680,353	(35,200,405)
Ending Balance, shares at Dec. 31, 2006			42,452,366
Issuance of stock for interest payable	1,258		1	1,257
Issuance of stock for interest payable, shares			1,141
Issuance of warrants for services	472,635			472,635
Cash proceeds from exercise of warrants and stock options	3,985,641		3,929	3,981,712
Cash proceeds from exercise of warrants and stock options, shares			3,928,957
Issuance of stock for services	298,950		150	298,800
Issuance of stock for services, shares			150,000
Employee compensation from stock options	2,340,619			2,340,619
Issuance of stock and warrants pursuant to Regulation D	1,848,138		2,377	1,845,761
Issuance of stock and warrants pursuant to Regulation D, shares			2,376,817
Preferred stock conversions into common stock	367,500		490	367,010
Preferred stock/Debt conversions into common stock, shares			490,000
Net loss	(10,005,631)				(10,005,631)
Ending Balance at Dec. 31, 2007	14,831,510		49,399	59,988,147	(45,206,036)
Ending Balance, shares at Dec. 31, 2007			49,399,281
Issuance of warrants for services	517,820			517,820
Cash proceeds from exercise of warrants and stock options	2,639,711		3,268	2,636,443
Cash proceeds from exercise of warrants and stock options, shares			3,267,795
Issuance of stock for services	390,000		350	389,650
Issuance of stock for services, shares			350,000
Employee compensation from stock options	1,946,066			1,946,066
Net loss	(10,269,571)				(10,269,571)
Ending Balance at Dec. 31, 2008	10,055,536		53,017	65,478,126	(55,475,607)
Ending Balance, shares at Dec. 31, 2008			53,017,076
Issuance of warrants for services	1,064,210			1,064,210
Cash proceeds from exercise of warrants and stock options	2,524,453		3,480	2,520,973
Cash proceeds from exercise of warrants and stock options, shares			3,480,485
Issuance of stock for services	695,000		796	694,204
Issuance of stock for services, shares			796,012
Employee compensation from stock options	870,937			870,937
Issuance of stock and warrants pursuant to Regulation D	6,518,688		10,117	6,508,571
Issuance of stock and warrants pursuant to Regulation D, shares			10,116,653
Net loss	(12,322,314)				(12,322,314)
Ending Balance at Dec. 31, 2009	9,406,510		67,410	77,137,021	(67,797,921)
Ending Balance, shares at Dec. 31, 2009			67,410,226
Issuance of warrants for services	1,141,593			1,141,593
Issuance of common stock pursuant to Regulation S	419,250		559	418,691
Issuance of stock pursuant to Regulation S, shares			559,000
Cash proceeds from exercise of warrants and stock options	3,103,680		3,491	3,100,189
Cash proceeds from exercise of warrants and stock options, shares			3,491,014
Issuance of common stock and warrants pursuant to Regulation D	6,346,989		11,169	6,335,820
Issuance of preferred stock and warrants pursuant to Regulation D	4,217,390	13,283		4,204,107
Issuance of common stock and warrants pursuant to Regulation D, shares			11,168,067
Issuance of stock for services	856,613		776	855,837
Issuance of preferred stock and warrants pursuant to Regulation D, shares		13,283,324
Issuance of stock for services, shares			776,250
Employee compensation from stock options	3,759,650			3,759,650
Preferred stock conversions into common stock		(7,893)	7,893
Preferred stock/Debt conversions into common stock, shares		(7,893,326)	7,893,326
Net loss	(18,552,102)				(18,552,102)
Ending Balance at Dec. 31, 2010	10,699,573	5,390	91,298	96,952,908	(86,350,023)
Ending Balance, shares at Dec. 31, 2010		5,389,998	91,297,883
Issuance of warrants for services	945,116			945,116
Cash proceeds from exercise of warrants and stock options	6,623,311		7,185	6,616,126
Sale of non-controlling interest in Pure-ific Corporation and warrants	443,500			443,500
Cash proceeds from exercise of warrants and stock options, shares			7,185,522
Issuance of common stock and warrants pursuant to Regulation D	7,041,239		9,905	7,031,334
Issuance of common stock and warrants pursuant to Regulation D, shares			9,905,062
Issuance of stock for services	332,750		350	332,400
Issuance of stock for services, shares			350,000
Employee compensation from stock options	3,368,950			3,368,950
Preferred stock conversions into common stock		(1,859)	1,859
Preferred stock/Debt conversions into common stock, shares		(1,858,333)	1,858,331
Net loss	(19,434,699)				(19,434,699)
Ending Balance at Dec. 31, 2011	10,019,740	3,531	110,597	115,690,334	(105,784,722)
Ending Balance, shares at Dec. 31, 2011		3,531,665	110,596,798
Issuance of warrants for services	1,512,026			1,512,026
Issuance of common stock and warrants pursuant to Regulation D	4,790,544		6,228	4,784,316
Issuance of common stock and warrants pursuant to Regulation D, shares			6,227,647
Issuance of stock for services	456,500		550	455,950
Issuance of stock for services, shares			550,000
Employee compensation from stock options	183,028			183,028
Preferred stock conversions into common stock		(1,053)	1,053
Preferred stock/Debt conversions into common stock, shares		(1,053,480)	1,053,480
Net loss	(12,568,354)				(12,568,354)
Ending Balance at Dec. 31, 2012	4,393,484	2,478	118,428	122,625,654	(118,353,076)
Ending Balance, shares at Dec. 31, 2012		2,478,185	118,427,925
Issuance of warrants for services	1,786,824			1,786,824
Cash proceeds from exercise of warrants and stock options	7,835,470		6,320	7,829,150
Cash proceeds from exercise of warrants and stock options, shares			6,319,594
Issuance of common stock and warrants pursuant to Regulation D	18,419,335		28,409	18,390,926
Issuance of preferred stock and warrants pursuant to Regulation D	1,252,050	3,400		1,248,650
Issuance of common stock and warrants pursuant to Regulation D, shares			28,409,353
Issuance of stock for services	526,000		750	525,250
Issuance of preferred stock and warrants pursuant to Regulation D, shares		3,400,001
Issuance of stock for services, shares			750,000
Employee compensation from stock options	142,310			142,310
Dividends on preferred stock	(29,063)			(29,063)
Preferred stock conversions into common stock		(5,845)	5,845
Preferred stock/Debt conversions into common stock, shares		(5,844,852)	5,844,852
Net loss	(27,697,744)				(27,697,744)
Ending Balance at Dec. 31, 2013	6,628,666	33	159,752	152,519,701	(146,050,820)
Ending Balance, shares at Dec. 31, 2013		33,334	159,751,724
Reclassification of warrant liability	10,355,619			10,355,619
Issuance of warrants for services	1,350,319			1,350,319
Cash proceeds from exercise of warrants and stock options	4,327,886		14,703	4,313,183
Cash proceeds from exercise of warrants and stock options, shares			14,703,381
Issuance of common stock and warrants pursuant to Regulation D	4,350,000		2,000	4,348,000
Issuance of common stock and warrants pursuant to Regulation D, shares			2,000,000
Issuance of stock for services	277,750		150	277,600
Issuance of stock for services, shares			150,000
Preferred stock conversions into common stock		(33)	33
Preferred stock/Debt conversions into common stock, shares		(33,334)	33,334
Net loss	(7,310,683)				(7,310,683)
Ending Balance at Jun. 30, 2014	$ 19,979,557		$ 176,638	$ 173,164,422	$ (153,361,503)
Ending Balance, shares at Jun. 30, 2014			176,638,439

Equity Transactions	6 Months Ended
Equity Transactions	Jun. 30, 2014
Text Block [Abstract]
Equity Transactions	4. Equity Transactions (a) During the three months ended March 31, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $137,500. During the three months ended March 31, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $48,750. During the three months ended June 30, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $140,250. During the three months ended June 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $49,500. (b) During the three months ended March 31, 2014, the Company issued 733,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $900,317. During the three months ended March 31, 2014, 121,500 warrants were forfeited. During the three months ended March 31, 2014, 12,522,198 warrants were exercised on a cashless basis resulting in 9,100,824 common shares being issued. During the three months ended March 31, 2014, 3,036,218 warrants were exercised for $2,672,364 resulting in 3,036,218 common shares issued. During the three months ended March 31, 2013, the Company issued 1,924,973 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $409,640. During the three months ended March 31, 2013, 859,833 warrants were forfeited. During the three months ended June 30, 2014, the Company issued 202,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $450,002. During the three months ended June 30, 2014, 315,000 warrants were forfeited. During the three months ended June 30, 2014, 1,594,082 warrants were exercised on a cashless basis resulting in 915,467 common shares being issued. During the three months ended June 30, 2014, 372,000 warrants were exercised for $372,000 resulting in 372,000 common shares issued. During the three months ended June 30, 2013, the Company issued 2,605,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $931,655. During the three months ended June 30, 2013, 1,051,500 warrants were forfeited. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value of the warrants, determined using the Black-Scholes option-pricing model. (c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $1,153,835 and $311,062, respectively. During the three months ended March 31, 2014, 858,825 of the Series A Warrants were exercised. During the three months ended March 31, 2014, 697,092 of the Series C Warrants were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $186,262 and $221,149, respectively. The Company determined the fair value of the Series A and Series C Warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the Series A and Series C Warrants exercised in 2014 of $3,911,370 was reclassified into additional paid-in capital. (d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $211,422 and $446,698, respectively. During the three months ended March 31, 2014, 1,756,665 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $3,285,793 and $399,057, respectively. During the three months ended June 30, 2014, 133,232 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $2,377,133 was reclassified into additional paid-in capital. (e) In February 2013, the Company had an issuance of Series A 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $921,776 and $165,750, respectively. During the three months ended March 31, 2014, 1,650,000 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $42,970 and $289,000, respectively. During the three months ended June 30, 2014, 200,000 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $4,047,116 was reclassified into additional paid-in capital. Dividends on the Series A 8% Convertible Preferred Stock accrued at an annual rate of 8% of the original issue price and were payable in either cash or common stock. If the dividend was paid in common stock, the number of shares of common stock equaled the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends were payable quarterly on the 15th day after the quarter-end. The Company paid the dividends in common stock although was required to pay the initial dividends due in cash. The Company had a deficit and, as a result, the dividends were recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In 2014, the Company recognized no dividends because of the full conversion of preferred stock to common stock as of January 15, 2014. (f) In January 2014 there were 33,334 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 33,334 shares of the Company’s common stock. As of January 15, 2014, there were no shares of Series A 8% Convertible Preferred Stock outstanding. (g) During the three months ended June 30, 2014 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,000,000. The Company accepted subscriptions, in the aggregate, for 2,000,000 shares of common stock and five year warrants to purchase 2,000,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $3.00 per share. The purchase price for each share of common stock together with the warrants was $2.50. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $650,000 and issued five year fully vested warrants to purchase 300,000 shares of common stock with an exercise price of $2.50 to Network 1 Financial Securities, Inc., which represents 15% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

Stock-Based Compensation - Additional Information (Detail) (USD $)	0 Months Ended		3 Months Ended
	Feb. 26, 2014	May 27, 2014 Employee One [Member]	Jun. 30, 2014 Employee One [Member]	Mar. 31, 2014 Options Exercised Price One [Member] Employee One [Member]	Mar. 31, 2014 Options Exercised Price One [Member] Employee Two [Member]	Jun. 30, 2014 Options Exercised Price One [Member] Employee Three [Member]	Mar. 31, 2014 Options Exercised Price One [Member] Employee Three [Member]	Jun. 30, 2014 Options Exercised Price One [Member] Non Employee [Member]	Mar. 31, 2014 Options Exercised Price Two [Member] Employee One [Member]	Mar. 31, 2014 Options Exercised Price Three [Member] Employee One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options exercised at an exercise price			25,000	25,000	300,000	100,000	189,624	25,000	14,248	600,000
Exercise price/share			$ 0.95	$ 0.95	$ 1.10	$ 1.25	$ 1.10	$ 0.95	$ 0.75	$ 0.93
Common stock value			$ 23,750	$ 23,750	$ 330,000	$ 125,000	$ 208,586	$ 23,750	$ 10,686	$ 558,000
Number of Shares forfeited	300,000	25,000